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Abstract 
School of Chemistry 
Doctor of Philosophy 
Novel Multi-Metallic Luminescent Complexes Towards Dual-Functional Cellular and 
Therapeutic Applications by Rebeca Balasingham. 
 
A series of novel multi-metallic luminescent Au(I) and Re(I) complexes have been 
synthesised targeting functionality as cellular imaging and/or therapeutic agents. Both the 
ligands and their complexes have been characterised by a variety of spectroscopic and 
spectrometric techniques. Several complexes were also characterised by X-ray crystal 
diffraction and/or elemental analysis. 
 In both chapters two and three the modulation of the luminescent properties of a series 
of mono- and di-metallic [Re(CO)3(N^N)L]
+
 type complexes bearing functionalised alkyl 
chains by hydrophobically driven, intra- and intermolecular conformational changes is 
reported. Additionally, the first application of di-metallic Re(I) complexes in cellular imaging 
is reported with specific localisation in the nucleoli or ER and Golgi apparatus. 
 In both chapters four and five the synthesis of novel mono- and di-metallic Au(I) 
complexes is reported. Several complexes demonstrated cytotoxicity as well as 
compartemental localisation in cellular imaging demonstrating their potential as dual-
functional cellular imaging and/or therapeutic agents. 
As an extension to the work discussed in Chapters two to five, the synthesis of novel 
multi-metallic luminescent complexes is reported in Chapter six. For the tri-hetero-metallic 
complex incorporating Au(I) and Re(I) units, cytotoxicity towards four cancer cell lines and 
non-specific localization throughout the entire cell is described. 
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Chapter 1.  
1. Introduction 
In recent years there has been increasing interest in the enhancement of the 
luminescence properties of transition metal (TM) complexes.
1,2 
The ability to engineer the 
electronic and so photophysical properties of these complexes through ligand sensitisation can 
help to develop research in several areas, including: employment as photocatalysts, 
luminescent probes or sensors, sensitizers or as luminophores in biological cell 
imaging.
3,4,5
TMs such as Re(I) and Au(I) are among the variety of metals favoured as a result 
of their phosphorescent emission at room temperature. Additionally, heavy TM complexes for 
applications as therapeutic agents are being increasingly investigated. 
1.1. Luminescence spectroscopy 
1.1.1. The Jablonski Diagram 
 
 
Figure 1.1 The Jablonski diagram.  Reproduced from ref. 6.
 
Luminescence is the emission of light in the absence of heat. The luminescent 
behaviour of a molecule is determined by its photophysical properties and the photophysics of 
a complex can be explained using the Jablonski diagram. First the absorption of a photon 
occurs resulting in an electron being promoted from a ground state singlet (S0) to an excited 
state singlet (S1). When in the excited state there are two dominant pathways an excited 
species could follow, (i) photophysical change, this path includes luminescence (radiative) 
and quenching (non-radiative), or, (ii) chemical change (the complex is altered chemically 
forming an entirely new complex), this path includes isomerisation and direct reaction. It is 
the photophysical change of a complex that is the primary focus of the work described herein. 
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Following the excitation by absorption of a photon, the excited state formed is of high 
energy and generally unstable so it must undergo some form of deactivation. The excited state 
singlet initially loses some of its excess energy through internal relaxation to the lowest 
vibrational level of the excited state, this is a non-radiative process and is represented by the 
zig-zag line labelled internal conversion (IC) on Figure 1.1. The molecule is still in the 
excited state so will inevitably lose its remaining excess energy. This excess energy is lost via 
a number of different ways, including, molecular rotations, vibration, heat and light. The 
energy lost as emitted light is referred to as luminescence, and as very little heat is given off 
in this process, it can often be referred to as ‘cold light’. This light can be emitted through one 
of two pathways, fluorescence or phosphorescence, both of which display initial 
intramolecular energy transfer processes where the initial excess energy is lost via a non-
radiative process. As previously mentioned there is a second non-radiative pathway in 
photophysics that could compete with luminescence denoted ‘quenching’ and this involves 
interaction with another molecule or atom, otherwise referred to as a quencher species.  
1.1.1.1.Fluorescence  
Fluorescence involves an immediate emission of light shortly after it is absorbed 
resulting in the electron residing once again in the electronic ground state. This process is fast 
as it is spin- allowed. It has lifetime (the average time a molecule spends in the excited state) 
which ranges from 10
-9
 to 10
-6
 seconds.
7
 As a result of IC the energy emitted differs from that 
which is absorbed, it is generally of lower energy and longer wavelength (red-shifted). This 
difference in the absorbed and emitted wavelength is referred to as the Stokes shift. 
4
  
1.1.1.2.Phosphorescence                                                                                                                                                                    
In this process the energy is absorbed in the same way as fluorescence however, 
emission of the absorbed light does not occur immediately. Phosphorescence involves the 
storage of energy being lost slowly over a long period of time 10
-6 
to 10
-1
 hours
11 
resulting in a 
long lifetime. Once in the excited singlet state intersystem crossing (ISC) occurs, this involves 
the forbidden transition from the excited singlet state (S1) to the excited triplet state (T1). ISC 
is a non- radiative transition brought about by spin-orbit coupling (a process facilitated by the 
heavy atom effect, more common in 2
nd 
and 3
rd 
row TMs). Internal relaxation to the lowest 
level of excited triplet state follows which enables phosphorescence to occur. The 
phosphorescence process is slow (a spin forbidden process); it involves the conversion of a 
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excited triplet (T1) state back to a ground singlet state (So) and light can be detected from the 
sample for some time after the photon irradiation source is removed.  
1.1.2.  Autofluorescence and Stokes Shift 
The application of heavy TM complexes as luminophores (fluorophores) in 
biochemistry is an area receiving considerable attention in the research field however, the 
presence of autofluorescence can be problematic. Autofluorescence is the fluorescence of any 
substance other than the fluorophore of interest
8 
and is typically from the natural species in 
the cell. It tends to have a small Stokes shift, < 50 nm, and a small emission lifetime, < 10 ns. 
Molecules possessing a large Stokes shift and/or a large emission lifetime can allow a clearer 
distinction between the emitted light from the fluorophore and the background emission from 
autofluorescence. For a complex displaying a large Stokes shift an optical filter (a device 
which can selectively transmit light of different wavelength) can be used to filter out the 
autofluorescence.
9,10 
 
Figure 1.2 Spectra illustrating a Stokes Shift. Reproduced from ref. 11.
 
A complex possessing a long emission lifetime allows for a technique called time-
gating to be used to reduce the effect of autofluorescence. Time-gating is a method which 
allows for a snap-shot of the luminescene of the fluorophore to be seen and usually requires 
phosphorescent emitting species.  
1.1.3.  Charge transfer processes 
A charge transfer process involves the transfer of an electron within a molecule upon 
absorption of a photon. The possible excited states for heavy metal complexes include, metal 
to ligand charge transfer (MLCT), ligand to metal charge transfer (LMCT), ligand to ligand 
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charge transfer (LLCT) and intra ligand charge transfer (ILCT). The process is determined by: 
metal centres, chemical structures, triplet state energy levels of ligand, intra- and 
intermolecular interactions and local environments. Although it has proven impossible to 
negate any transfer process completely, it is possible from data accumulated over the years on 
the appearance of emission spectra, energies and lifetimes to predict where each of these 
processes are occurring.
13, 14 
kr                 knr
ISC
1MLCT
3MLCT
 
 
Figure 1.3 Generation and deactivation of a 
3
MLCT
 
state.
 
MLCT is a process which can result in luminescence. For the purpose of this thesis 
when discussing MLCT we refer to a redox process that requires a low oxidation state metal 
and a reducible ligand. Once the electron is transferred to the excited singlet state (S1) it is 
able to undergo ISC, this is a non-radiative process which converts                                              
the excited singlet state (S1) to a triplet excited state (T1). Once the electron resides in T1, the 
lowest spin forbidden level, emission occurs. The 
3
MLCT in a complex is a phosphorescent 
process.
14
                  
1.1.4.   FRET- Förster resonance energy transfer
 
FRET consists of a non-radiative transfer of energy between an initially excited donor 
molecule and an acceptor molecule. FRET efficiency is dependant on: the degree of spectral 
overlap of donor emission and acceptor absorption, the orientation of chromophores and the 
distance between the chromophores.
15 
In bichromophoric molecules additional consideration 
of the choice of ligands can efficiently tune the emission towards different parts of the UV-vis 
region. The photophysical properties of fluorophores such as quantum dots, lanthanide and 
TM complexes are being increasingly investigated for applications using FRET as they 
overcome some of the problems associated with the more common organic chromophores 
used (small Stokes shift/short lifetimes).  
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1.2.    Ligands 
A ligand is an ion or molecule that bonds to a metal centre to form a co-ordination 
complex. Ligands, in a simple crystal-field model, can be thought of as negative charges that 
perturb the energy levels of the metal ion when co-ordinated. This is referred to as d-d 
splitting. The magnitude and order of the d-orbitals in the splitting are dependent on: the 
number of d electrons on the metal, the metal oxidation state, the arrangement of ligands and 
the nature of the ligand (i.e. geometry and symmetry).  
1.2.1.    Spectrochemical series 
The spectrochemical series of ligands is an ordering of ligands based on their co-
ordination strength, it is somewhat independent of the metal ion but the ordering is not 
absolute. The general trend is: 
 
Br
-
 < Cl
-
 < F
-
 < OH
-
 < H2O < CH3CN < Py < NH3 < Bipy < Phen < PPh3 < CN
-
 = CO 
Weak-field ligands                                                                        Strong-field ligands 
     π donors                                                                                           π acceptors 
         Δo                                                     Δo                                                    Δo 
Figure 1.4 A Spectrochemical series and the ligands effects on Δo. 
The π-acceptor ligands / π-acids are ligands which accept electron density from the 
metal through π-bonding. π-acceptors can be found on the right hand side of the series; these 
ligands result in much larger splitting. The π-donor ligands / π-bases can be found on the left 
hand side of the series and result in much smaller splitting. Pyridine is found in an 
intermediate position of the spectrochemical series, and it is one of the most versatile ligands 
in photochemistry. 
1.2.2.   Dewar-Chatt Duncanson Model: 
This is potentially one of the more useful bonding models for explaining metal-ligand 
interactions in TM complexes. It describes the bonding between an unsaturated ligand 
(carbonyls or alkenes) and a metal ion. There are two types of bonding, σ-donation from the 
ligand to the metal, and π bonding from the filled d-orbital on the metal to an empty π* orbital 
on the ligand. The latter form of bonding is referred to as back bonding. As both types of 
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bonding leads to a strengthening of the bond, the bonding can be defined as synergic. 
 
 
 
Figure 1.5 Dewar-Chatt-Duncanson Model. Reproduced from ref. 16.
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1.3.   Biological imaging 
Biological imaging techniques are used primarily in diagnostics and treatment. X-rays, 
magnetic resonance imaging (MRI), ultrasound and tomography
17
 are the more commonly 
used imaging techniques, each specialising in the imaging of a certain area in the body 
(bones, heart and blood flow). None of the techniques mentioned have the ability to provide 
high resolution images
17
 and so, despite lacking the ability to view large objects in great 
detail, confocal fluorescence microscopy has found its niche in biological imaging. Confocal 
fluorescence microscopy can produce high quality images of minute sample sizes with 
relative ease and is thus able to produce individual images of cells and smaller cellular 
components.
18
 
1.3.1. Confocal fluorescence microscopy 
Luminescence is the light which is emitted by a substance; emission of light is 
necessary if a sample is to be viewed using confocal fluorescence microscopy. If light is not 
emitted by a cell, a fluorescent dye can be used as a ‘stain’. There are a vast number of 
commercially available dyes, including dyes specific in the targeting of organelles. If 
required, more than one dye can be used at any one
 
time to allow for a more detailed analysis.  
Confocal microscopy produces increased optical resolution in comparison to other 
wide-field microscopes. The pin hole situated beneath the light source produces a narrow 
beam of light, eliminating reflected or out of focus light,
19 
this increases the sensitivity and the 
resolution of the image. The narrow light beam then passes through the beam splitter and one 
small, thin region of the cell. The fluorescent light emitted from sample is then reflected by 
the beam splitter toward the detector to produce an accurate well-defined image of that region. 
A three-dimensional image is constructed through combining each small thin segment 
imaged.      
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Figure 1.6 Confocal Microscope with the key features highlighted. Reproduced from ref. 20.
 
1.3.2. Ideal properties of cellular imaging agents  
In order for a compound to be useful for bioimaging there are several characteristics 
that it must possess including the previously discussed photophysical attributes (large Stokes 
shift and long lifetime).
 23
 These are: 
 
(i) Photostability. Photobleaching is the permanent loss of fluorescence. Compounds that 
are easily photobleached, for example many organic flurophores, are not ideal luminescent 
probes for bioimaging. 
 
(ii) Toxicity.  Compounds must be non-toxic. Cytotoxicity of phosphorescent heavy metal 
compounds is dependent on structure. The lipophilicity of a compound can sometimes be 
correlated with their cytotoxicity, generally the more lipophilic a compound is, the more 
cytotoxic it is.
21  
 
(iii) Uptake. To be a successful bioimaging agent it is necessary for the compound to pass, 
without the aid of a chemical agent, through the cell membrane into the cell. The cell 
membrane consists of a phospholipid bilayer and numerous protein channels so although 
water soluble complexes are ideal, a balance between the hydrophobic and hydrophilic 
characteristics of a molecule need to be maintained. The negative surface on the cell indicates 
that positively charged molecules are preferred.
21,22
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 There are two different routes a molecule can take to enter the cell, energy-dependent 
or energy-independent. An energy-dependent process, for example endocytosis (being 
encapsulated in an endosome) or active transport, occurs at temperatures around 37 ˚C (for 
mammalian cells at least) and so using low incubation temperatures (such as 4 ˚C) it is 
possible to reduce this uptake mechanism. Energy independent processes include passive 
diffusion through channel proteins or directly through lipid bilayer.
21 
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1.4.   Metals in cellular imaging 
 
Figure 1.7 A detailed structure of a cell highlighting the localisation patterns of varying d
6 
metals. 
Reproduced from ref. 23.
 
A cell consists of several organelles, each with their own function. With the number of 
complexes reported for cellular imaging agents increasing, a preference for localisation in a 
specific organelle is ideal. A brief summary of the different localisation patterns of different d
6
 
metal complexes can be seen in figure 1.7.
23
 Further examples of metals in imaging are 
discussed in the following sections. 
1.4.1. Lanthanides in imaging 
Lanthanide complexes display characteristics that would enable them to be efficient 
luminophores for cell imaging; they have Stokes shifts greater than 200 nm and emission 
lifetimes in the range of 0.2-1.5 m.
24 
The sharp emission intervals exhibited by complexes of 
this type enable all other signals to be removed, allowing optimum sensitivity to be achieved. 
However, despite lanthanide complexes exhibiting the ideal properties for use as a lumophore, 
there are certain drawbacks to using them in research areas such as biological cell imaging 
and these drawbacks result from their electronic configuration. Exciting an electron from the 
ground state is extremely difficult in lanthanide complexes due to excitation involving a ff 
transition which is Laporte forbidden. To overcome this obstacle a sensitizing chromophore or 
‘antenna’ for indirect excitation is required.25 The requirement for an antenna makes this 
process for lanthanides more complicated (Figure 1.8). 
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Figure 1.8 The antenna effect for sensitization of the luminescence in some lanthanide cations. 
Reproduced from ref. 25. 
Despite the drawbacks associated with using lanthanides in imaging, a DO3A-type Eu
III 
complex has been shown to target exposed Ca
2+
 ions, binding to scratched/damaged bone 
surface.
25b
 
 
 
Figure 1.9 A polycarboxylate terminated Eu
III
 complex (LHS) and microscopy images of bone sample 
immersed in 10
-3
 M solution of the complex. (a) reflected light image: 0 h; (b) control; (c) 4 h; (d) 24 h. 
Reproduced from ref. 25b. 
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1.4.2.   TM complexes in imaging 
The useful photophysical properties of some TMs have resulted in them being heavily 
investigated for applications as cell imaging agents.
21,22 
TM residing in the 2
nd 
and 3
rd
 row of 
the periodic table, with d
6
, d
8
, and d
10 
electronic configurations, result in more effective ISC 
than 1
st 
row complexes leading to highly intense phosphorescent emission. Heavy TMs with a 
d
6 
configuration such as Ru(II), Re(I), Ir(III) and Os(II), when bonded to one or more 
aromatic bidentate ligands show the ideal photophysical and redox properties required to be 
useful luminophores. Additionally, the cationic charges associated with metals of this nature 
increase the likelihood of them being able to interact with the negative surface of the cell
26
 
and therefore enter the cells. 
The photophysical properties of a TM complex are reliant on the ligands attached, in 
the case of MLCT systems, the ligand attached acting as an electron acceptor.
27
Having both a 
high degree of stability and tunability, diimine ligands (specifically polypyridines) are 
generally employed for this role. The diimines, 1,10’-phenanthroline and 2,2’-bipyridine have 
attracted the greatest attention due to the suitable energy of their lowest occupied molecular 
orbital (π*). If the level of the π* orbital is too low it can result in an increase in the rate of 
non-radiative decay. If the level of the π* orbital is too high the rate of both the 3MLCT and 
non-radiative decay decrease. Both extremes can render a complex a poor luminophore.
4,23,28 
It is possible to have more than one diimine ligand attached to the TM and to also have 
variation in the diimine ligand structure. Variation of the diimine ligand structure can allow 
for the electronic properties of the complex to be finely tuned.
23
 The reducible properties of 
the diimine ligand make them fitting candidates for allowing the dππ* MLCT to occur. The 
synthetic versatility of both the TM and diimine ligands in a complex allow for research into 
the expansion of lifetimes, the deactivation processes and the alteration in energy.
14 
1.4.2.1.Iridium in imaging
 
There have been several investigations into the cellular distribution of highly 
lipophilic Ir(III) biscyclometallated complexes of the type [Ir(C^N)2(N^N)]
+
 (where C^N is a 
monoanionic ligand).
23,29,30
 Complexes of this type can have tunable luminescence 
(redblue) with lifetimes in the order of μs and quantum yields that reach values of up to 70 
% in organic solvents.
23,29 
The majority of biscyclometallated Ir(III) complexes reported have 
demonstrated non-specific localisation in the cytoplasm of Hela cells.
23,29,30
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The first example of a cell imaging application of a complex of this type was reported 
by Li et al.
29
 in 2008 with complexes 1 and 2.  
N
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Figure 1.10 Iridium complexes 1 and 2 (varying in the diimine unit) were the first iridium 
complexes reported with cellular imaging properties.
29 
Complex 1 and 2 both displayed low toxicity with staining of the cytoplasm (Figure 
1.10). Shortly after reporting complexes 1 and 2, Lo et al.
31
 reported a second series of Ir(III) 
biscyclometallated complexes which demonstrated the structure-function relationship for 
complexes of this type. The nine complexes in the series varied in the cyclometallated unit 
and/or the alkyl chain length, thus varying the lipophilicity of the complexes (Figure 1.11). 
For compounds a-c the lipophilic nature of the complex was shown to increase with the chain 
length, C18>C10>C2, however the cellular uptake properties did not follow the same linear 
fashion, but followed the trend C10>C2>C18 (Figure 1.11). The increased lipophilicity but 
minimal cellular uptake efficiency of the complex with chain length C18 is suggestive of the 
formation of aggregates; the lipophilic compound arranged in a conformation to minimise any 
contact with the aqueous media hindering cellular uptake. 
 The cytotoxic properties of the compounds displayed dependency on the 
cyclometallated unit and followed the trend 5>4>3.
31 
The increased lipophilic nature of 
compound 5c (C18), when compared to complexes 3-4, resulted in nuclear as well as 
cytoplasm staining being observed in the Hela cells but the accumulation of this complex was 
only observed at temperatures > 4 ˚C which indicate that uptake occurred via energy 
dependent processes.
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Figure 1.11 Iridium complexes 3-5(a-c) were the second series of iridium complexes reported 
by Lo et al. exhibiting cellular imaging properties.
31 
The variation of the different properties within this series of complexes 
demonstrates the need of a balance in the lipophilic nature of a compound. If a compound is 
too lipophilic it is unlikely to be taken up into the cell; an aqueous media is used to ‘transport’ 
the compound into the cell, if the compound is too lipophilic it will aggregate and will have 
limited uptake. If the compound is not lipophilic enough, the compound will not sufficiently 
cross the outer/inner cell membranes and so specific localisation will not be achieved. 
 Following Lo’s report, collaborative work between Lo and Lam et al. in 201032 led to 
a series of Ir(III) dipyridoquinoxaline complexes, varying again via the cyclometallated 
substituents and the alkyl spacers (Figure 1.12). These dipyridoquinoxaline complexes were 
shown to stain the nucleoli of MCDK cells (Figure 1.13). Localisation in the nucleoli was 
only visible after long incubation times > 90 mins and was attributed to the complexes 
residing in hydrophobic pockets of proteins (intercalated into the base-pairs of double 
stranded DNA).  
2
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Figure 1.12 Iridium complexes 6-12 reported by Lo and Lam et al. each exhibited specific 
organelle staining with nucleoli localisation.
32 
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Figure 1.13 Fluorescence laser-scanning confocal microscopy images of fixed MDCK cells 
treated successfully with fibrillarin antibody (20 μL mL-1, 1 h), Alexa 633 antirabbit IgG antibody (20 μL 
mL
-1
, 30 min), and [Ir(ppy)2(R=H)]
+
. Reproduced from ref. 32.
 
 Both the Li and Lo groups have reported more than twenty iridium complexes 
exhibiting cytoplasmic staining. Some of the complexes reported are inclusive of 
bioconjugated complexes; there are several complexes conjugated with a specific molecule 
for receptor targeting bioimaging applications, for example, indoles or estradiol.
23,31,32 
Complexes of this type have shown suitability for applications as bioimaging agents,
29
 
OLEDS,
33 
sensors
34,35 
and switches.
36 
An interesting report by Velders et al.
30
 described the 
suitability of an Ir(III) tris diimine complex as a biomarker in diagnostics. The successful 
incorporation of 1/2/3 peptides onto the phen unit in the [Ir(phen)3]
3+
 complex resulted in the 
increased uptake of the compound into the cell. Once inside the cell, the successful 
visualisation of the chemokine receptor 4 (CXCR4) using FLIM and confocal microscopy 
was observed. CXCR4 is over expressed in twenty three types of cancer cells.  
 There have been a huge number of examples of Ir(III) luminophores where good cell 
uptake and low cytotoxicity with cytoplasmic staining was observed. Occasionally, nuclear 
staining has been reported which seems dependent on hydrophobic interactions with the cell. 
However, despite a large number of examples existing, it is still difficult to predict how 
changes in structure will relate to cell localisation and so further research is required.  
1.4.2.2.Ruthenium in cell imaging 
The most studied luminescent Ru(II) system is based around a tris-diimine complex, 
for example a [Ru(N^N)2(N^N)]
2+
.
 
With the tris-diimine system, variation in the nature of 
substituents on the diimines can ‘tune’ the luminescence of the compound. Ruthenium 
polypyridyls tend to have lifetimes in the order of μs and quantum yields that reach the values 
of 60 % in organic solvents.
1,23
 Despite the favourable photophysical properties of complexes 
of this type, when compared to the number of Ru-based complexes investigated for 
applications as O2 sensors or DNA intercalators, there are few examples of Ru-based 
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complexes reported as suitable cellular imaging agents.
37-41 
A report by Musatkina et al.
42
 demonstrated how the uptake of Ru(II)-polypyridyl type 
complexes is dependent on the nature of the diimines with compounds 13-16 (Figure 1.14).  
The bipy analogues show poor cell uptake, whereas the extended hydrocarbon system of 
bathophenanthroline shows nuclear staining. 
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Figure 1.14 Ruthenium complexes 13-16 reported by Musatkina et al.
42 
highlight the effect of 
diimines on cell uptake. 
Uptake of a complex of the type [Ru(N^N)2(N^N)]
2+ 
can be problematic, but there 
have been several reports where-by the formation of a bioconjugate molecule via the addition 
of estradiol/biotin/peptide to the diimine, has resulted in an increase in uptake and has shown 
cell department localisation.
43-46
 Puckett et al.
44
 demonstrated how the inclusion of a peptide 
can improve the uptake efficiency of a Ru(II) tris-diimine complex; [Ru(bipy)2(dppz)]
2+ 
showed poor cellular uptake, however, when conjugated with octarginine, staining of the 
endosomes was observed and when conjugated with fluorescein, nuclear staining was 
observed. The difference in localisation of the two complexes was attributed to the differences 
in their lipophilicity.
 
The difference in their lipophilicity was later confirmed with the 
synthesis of two [Ru(Phen)(bipy)(dppz)]
2+
 type complexes inclusive of octarginine. The first 
of the two complexes was inclusive of octarginine only and displayed cytoplasmic staining; 
the second complex was inclusive of octarginine, but also incorporated a fluorescein 
conjugate and staining of the cystol, nuclei and nucleoli of HeLa cells was observed (Figure 
1.15).
47 
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Figure 1.15 [Ru(Phen)(bipy)(dppz)]2+ type complexes 17 and 18 inclusive of octarginine (LHS) 
and octarginine and fluorescein (RHS). Reproduced from reference 47.
 
An interesting report by Zhang et al.
48
demonstrated a Ru(II) complex as a sensor of 
NO. In absence of NO, the diaminophenyl-substituted Ru(II) compound, compound 19, was 
non-emissive. In the presence of NO, compound 19 reacts forming compound 19b, an 
emissive complex (Figure 1.16). Incubation of compound 19 with Gardenia cells resulted in 
staining of the nucleus and membranes only (Figure 1.17). However, similarly to the Ir 
complexes discussed, there are unexplored areas of research into this type of compounds with 
regards to cellular imaging.
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Figure 1.16 Rutheium complexes19 and 19b.
48 
 
Figure 1.17 Luminescence images of Gardenia cells incubated with complex 19 at different                     
incubation times, 1 h (LHS) and 5 h (RHS). Reproduced from ref. 48.
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1.4.2.3. Rhenium in cell imaging 
Fac-[Re(CO)3(N^N)L]
+
 type complexes permit a simpler system for exploring 
modifications in structure and charge on the lipophilicity and toxicity of a complex in 
comparison to the Ir(III) and Ru(II) complexes discussed above. Many studies involving Re(I) 
have focused on the fac-[Re(CO)3(N^N)L]
+
 type complexes due to the advancement in their 
photophysical and photochemical properties as well as their inter- and intramolecular 
processes.
4,20,21 
Neutral complexes of this type (e.g. L=Cl, Br) tend to have lifetimes in the 
order of ns and quantum yields that reach the values of 0.1 % in organic solvents. Cationic 
complexes of this type tend to have lifetimes in the order of μs and quantum yields that can 
reach exceptional values of 80 % in organic solvents.
23 
  
 The majority of complexes of this type use a halide or an acetonitrile complex as a 
precursor for introducing the desired axial ligand.
23
 The axial ligand will determine the 
stability of the complex towards substitution. The axial ligand also affects the energy 
difference between the highest occupied molecular orbital and the lowest unoccupied 
molecular orbital which has an impact on the predominant charge transfer process that can 
occur.
 
The main effect of this is seen in the emission and adsorption energies. The stabilisation 
of the metal dπ using a π accepting ligand results in a blue-shift in excitation and emission 
wavelengths due to the increased excited state lifetime and decreased rate of non-radiative 
decay.
25 
Numerous investigations have been carried out where the axial ligands or their 
substituents are π-acceptors, π-neutral or weak π-donors  and the same conclusions were 
drawn; little change in the electronic nature of a complex is seen when altering the axial 
ligand in comparison to the changes seen with varying the diimine ligand,
23 
these changes 
however, are essential in developing the photophysics of a molecule.  
The first example of Re(I) in cell imaging was reported by Zubieta et al. in 2004
28
 
with the bisquinoline based complex, complex 20 (Figure 1.18). Complex 20 was observed to 
accumulate in the periphery of the leukocytes. Since this report, our group has taken the 
leading role in the research of complexes of the type fac-[Re(CO)3(N^N)L]
+
 reporting the first 
example of a fac-[Re(CO)3(N^N)L]
+
 species in cell imaging in 2007 with complexes 21-27 
(Figure 1.19).
20 
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Figure 1.18 Compounds 20-27.
28,57 
 
 
Figure 1.19 Rhenium complex 24 in MCF7 showing cytoplasmic and perinuclear staining. 
Reproduced from ref. 57.
 
Similarly to the Ir(III) complexes discussed previously (complexes 1-5
31
), complexes 
21-27 demonstrated the structure-function relationship for complexes of this type. Again, the 
complexes varied in the cyclometallated unit and/or the alkyl chain length or functional 
group, thus varying the lipophilicity of the complexes (Figure 1.18). The toxicity of the 
complex was shown to increase with the lipophilicity of the complex; cell lysis was observed 
with complex 25 (C18 alkyl chain length) only. The shorter chained complexes showed good 
uptake and low toxicity with accumulation in the membrane and membrane structures of the 
cytoplasm.
49
 Small changes in a complex was shown to lead to variation in the localisation 
pattern observed. For complex 22, the hydroxyl derivative, accumulation in the membrane 
was observed; following chlorination of the hydroxyl group, specific-staining was observed 
via staining of the mitochondria (Figure 1.20).
50 
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Figure 1.20 Rhenium complexes 22 (LHS) and 23 (RHS) in MCF7 showing different staining. 
Reproduced for ref. 49 and 50.
 
1.4.2.4.Gold in imaging 
Gold chemistry is of increasing interest due to gold’s ability to form luminescent 
materials.
51,52 
The favourable photophysical properties of gold complexes can be attributed to 
a number of factors including: the nature of the ligands; M-M interactions; and the geometry 
around the metal centre. The M-M interactions (also referred to as aurophilic interactions) are 
proposed as key in governing the unique photophysical properties of Au(I) complexes.
51,53 
Unlike the aforementioned d
6 
heavy TMs, research into luminescent gold complexes for 
applications as cellular imaging agents is relatively new and thus understudied compared to 
the Re(I), Ru(II), Ir(III). There are few examples of gold complexes as imaging agents. One of 
the more interesting examples to date is a gold alkynyl species which was reported by Dyson 
et al.
53 
which combined imaging capability with therapeutic activity. The incorporation of a 
water soluble phosphine ligand, PTA, resulted in a luminescent Au(I) complex which was 
shown to permeate throughout the entire cell (Figure 1.21).
53
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Figure 1.21 An Au(I)-alkyl complex incorporating a water soluble PTA ligand shows non specific 
cell localisation throughout an entire cell. Cell images reproduced from ref. 53.
 
 
Gold is highly researched for its therapeutic potential with applications of both Au(I) 
and Au(III) based complexes having been studied for many years. Despite the number of 
studies into gold as a therapeutic agent, its mechanistic details are poorly understood. Gold 
has a higher affinity for thiolates when compared to nitrogen or oxygen and so binds to DNA 
weakly, this suggests DNA-based cytotoxic-mechanism is unlikely and promotes as a target.
51
 
Further discussion of Au(I) based complexes in therapeutics and cellular imaging can be 
found in Chapter 5.  
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1.5.     TM complexes in therapeutics 
 The cytotoxicity of a complex can be efficiently tuned through modification of its 
composition. This was previously discussed with Ir(II) and Re(I) complexes where-by 
increasing the lipophilic nature of the complex resulted in an increased cytotoxic effect. The 
ease of modifying the structure and so properties of a TM complex has led to their cytotoxic 
effects being heavily investigated for applications in therapeutics. To be a successful 
therapeutic agent, a compound must be able to cross the cell membranes, this is critical for 
useful cytotoxic properties. Once inside the cell, cytotoxicity can arise from the inhibition of 
cellular function/activity and or the distribution of structures. To date there are a wide range of 
metals used in therapeutics, some of which are discussed in detail below. 
1.5.1. Platinum in therapeutics 
 Platinum is now one of the more widely used metals in therapeutics for the treatment 
of cancer, with several complexes already in clinical use (Figure 1.22).
51 
The most common 
platinum-based compound is cisplatin. Cisplatin is a neutral complex that passes with ease 
into the cell. Once inside the cell the neutral compound undergoes intracellular hydrolysis to 
the more reactive complex [Pt(NH3)2(H2O)2]
2+
. The interaction of cisplatin with both DNA 
and RNA has been extensively studied and cisplatin-DNA interaction is now known to be 
responsible for cell death.
51,52 
A number of cisplatin-DNA compounds have been formed and 
their crystal structures have shown irreversible binding of the platinum compound to two 
adjacent N donors on the same DNA strand. This interaction is thought to inhibit replication, 
transcription and repair functions of the DNA, resulting in apoptosis (programmed cell death). 
This interaction with DNA can also account for the limited activity of the trans complex when 
compared to the cis.
51,52 
Despite there being ample evidence suggesting a cisplatin-DNA 
interaction there have been reports questioning  the exact mechanism of interaction.
51
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Figure 1.22 Cisplatin (LHS), carboplatin (centre) and 254-S (RHS).
51 
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1.5.2. Ruthenium in therapeutics 
 Similarly to Pt, Ru based complexes have been extensively studied for applications as 
therapeutic agents. When compared to the previously discussed Pt-based complexes, Ru-type 
complexes have more synthetic versatility; a higher number of ligands can be situated around 
the octahedral ruthenium atom when compared to the square planar Pt(II) complex. 
Additionally, a higher number of different bonds can be formed using a Ru unit when 
compared to Pt, therefore mechanistically, Ru-based complexes are not restricted to DNA-
binding. The suggested route for uptake into cells for Ru-based complexes is via uptake with 
iron using transferrin apoprotein.
54 
 The first ruthenium compounds to enter clinical trials were KP1010 and NAMI-A 
(Figure 1.23). For the two structurally similar Ru(III) complexes, different anticancer activity 
was observed. KP1019 displayed higher activity towards primary cancers (main tumour mass) 
whereas activity towards secondary cancers was observed with NAMI-A. RAPTA compounds 
displayed similar characteristics as the structurally dissimilar NAMI-A compound with 
activity against secondary cancers being observed (Figure 1.23); RAPTA has since been 
considered as the most successful Ru-based anticancer complex. Again, despite the high level 
of research that has been conducted with Ru-based complexes for application in therapeutics 
there is still a requirement for understanding the mechanism of action.
54 
 
Figure 1.23 NAMI-A (LHS), KP1019 (centre) and RAPTA (RHS)
51 
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1.6.    Aims 
   The work within this thesis aims to: further understand the solvent dependent 
photophysical properties of Re(I)-based complexes; explore the photophysical and cytotoxic 
properties of Au(I)-based complexes with a view to biological imaging and/or therapeutic 
potentials; and finally, explore the potential applications of hetero-metallic complexes based 
on Re(I)/Ru(II)/Ir(III) with Au(I) as dual-functioning cellular and therapeutic agents.  
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1.7. General measurements 
1.7.1. Photophysical data 
All starting materials, reagents and solvents were purchased from commercial 
suppliers and used as supplied unless otherwise stated. 
1
H-NMR and 
13
C-NMR spectra were 
recorded at 400 and 100 MHz respectively on a Bruker Avance DPX, or 250 MHz and 62 
MHz respectively on a Bruker Avance DPX 250. 
31
P-NMR were recorded on a Jeol Eclipse 
300MHz at 121 MHz. All NMR spectra were referenced to residual solvent peaks unless 
otherwise reported. IR spectra were recorded on a Perkin Elmer 1600 FT IR as thin films or 
nujol mulls and are reported in wavenumbers (cm
-1
). UV-vis data were recorded as solutions 
on a Jasco 570 spectrophotometer. Mass spectra were recorded on a VG Fisons Platform II or 
at the EPSRC national mass spectrometry service, Swansea (HRMS). Elemental analyses 
were performed by Warwick Analytical Services (University of Warwick). All photophysical 
data were obtained on a JobinYvon-Horiba Fluorolog spectrometer fitted with a JY TBX 
picosecond photodetection module. Luminescence lifetimes were obtained using either 295 
nm or 372 nm nanoLEDs operating at 1 MHz. All lifetime data were collected using the JY-
Horiba FluoroHub single photon counting module in multi-channel scaler mode. Lifetimes 
were obtained using the provided software, DAS6. Estimated errors are τem ± 10% and 
excitation and emission maxima are limited in accuracy to the monochromator slit width of 5 
nm. 
 
1.7.2. Method for cytotoxicity analysis 
Anti-tumour evaluation in MCF7, LoVo, A549 and PC3 cell lines was performed by 
MTT assay. Compounds were prepared as 0.1–100 mM stock solutions dissolved in DMSO 
and stored at -20 °C. Cells were seeded into 96-well microtitre plates at a density of 5 × 10
3
 
cells per well and allowed 24 h to adhere. Decimal compound dilutions were prepared in 
medium immediately prior to each assay (final concentration 0.1–100 µM). Experimental 
medium was DMEM +10% FCS (PC3 and Lovo) or RPMI +10% heat inactivated FCS (A549 
and MCF7). Following 96 h compound exposure at 37 °C, 5% CO2, MTT reagent (Sigma 
Aldrich) was added to each well (final concentration 0.5 mg/ml). Incubation at 37 °C for 4 h 
allowed reduction of MTT by viable cells to an insoluble formazan product. MTT was 
removed and formazan solubilised by addition of 10% Triton X-100 in PBS.  Absorbance was 
read on a Tecan Sunrise spectrophotometer at 540 nm as a measure of cell viability; thus 
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inhibition relative to control was determined (IC50). 
 
1.7.2. Method for cellular imaging 
Human adenocarcinoma cells (MCF-7), obtained from the European Collection of Cell 
Cultures, Porton Down, Wiltshire, U.K., were maintained in Hepes modified minimum 
essential medium (HMEM) supplemented with 10% fetal bovine serum, penicillin, and 
streptomycin. Cells were detached from the plastic flask using trypsin−EDTA solution, and 
suspended in an excess volume of growth medium. The homogeneous cell suspension was 
then distributed into 1 mL aliquots with each aliquot being subject to incubation with the 
complexes final concentration 50 μg mL−1, at 4 °C for 30 min. Cells were finally washed 
three times in phosphate buffer saline (PBS, pH 7.2), harvested by centrifugation (5 min, 800 
g), and mounted on a slide for imaging. Preparations were viewed using a Leica TCS SP2 
AOBS confocal laser microscope using X63 objective, with excitation at 405 nm and 
detection at 510−580 nm. Z-plane slices were used to record multiple single-plane views cell 
populations to estimate percentage uptake of lumophores. 
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2.1.    Introduction 
The first half of this chapter reports the synthesis of a series of novel long-chained 
ligands bearing a terminal chromophore moiety or methyl group coordinated to a fac- 
[Re(CO)3(N^N)]
+ 
core for investigations into solvent-dependent  luminescent properties. The 
second half of the chapter reports the synthesis of novel
 
[Re(CO)3(bipy)]
+ 
complexes and 
coumarin-based ligands appended with a biotin moiety to investigate their avidin-biotin 
binding properties and to further understand the solvent-dependent  luminescent properties of 
all the complexes reported herein.  
2.1.1.   fac-[Re(CO)3(N^N)L] 
 Many studies involving d
6
, low spin Re(I) have focused on fac-[Re(CO)3(N^N)L] type 
complexes due to their stability, redox properties and luminescent characteristics, with bipy 
and phen diimines being the more commonly investigated. Useful properties of complexes of 
this type include: the ability to add ligands step-wise, the presence of only one diimine ligand 
(which allows for the charge transfer process to be controlled) and the ability to synthesise a 
huge range of diimine and axial pyridines or derivatives. The latter property allows for the 
electronic and photophysical properties of the complex to be ‘tuned’. This best achieved 
through the variation of the diimine unit, however, variation of the axial ligand has proven 
vital for investigations into cell imaging, lipophilicity etc. 
1,2,3
   
 With excitation around 340-420 nm and their well-known 
3
MLCT emission around 
530-600 nm (allowing visible detection) fac-[Re(CO)3(N^N)L] complexes display the 
desirable large Stokes shifts  required to be effective luminophores. Additionally, cationic 
derivatives of this type of complex typically show an extension in the emission lifetime from 
100’s of ns to μs. 4-8 
2.1.2.   Solvent-dependant photophysical properties 
The photophysical and photochemical properties of a fac-[Re(CO)3(N^N)L] type 
complexes can be tuned through variation in the co-ordinating ligands and the solvent 
properties. The latter has been less exploited in the investigation into the enhancement of 
luminescence properties of TM complexes, despite solvatochromic studies being routinely 
used to identify the charge transfer nature of excited state.  
The first investigation into the effect that water solvent has on the emission properties 
of fac-[Re(CO)3(N^N)L]
+
 type complexes was reported by our group in 2009
9
 as an extension 
of the report discussing the first application of a fac-[Re(CO)3(N^N)L]
+
 complex in cellular 
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imaging.
2
 In the investigation, a series of ligands equipped with varying lengths of aliphatic 
chain, C2, C6 and C12 were synthesised and co-ordinated to a [Re(CO)3(bipy)]
+
 unit. The 
luminescent properties of all three complexes were then measured in both acetonitrile and 
water. The biggest effect of the change of solvent was seen with the C12 aliphatic chain 
(Figure 2.1). 
Re
+
CO
OC
OC
N
+
O
O
CH3
N
+
N
+
BF
4
-
11
 
Figure 2.1 The photophysical properties of fac-[Re(CO)3(bipy)L(C12)]
+
 was greatest effected when the 
solvent was changed from acetonitrile to water.
9 
When measured in acetonitrile the expected emission properties were observed, λem = 
555 nm and τ = 176 nm. However, in water the emission was blue-shifted, λem = 523 nm, and 
the lifetime dramatically extended, τ = 688 ns. These results are contrary to what are predicted 
in the simple solvation model (in which very polar solvent can stabilise dipolar excited state), 
which therefore suggests a partial shielding of the central [Re(CO)3(bipy)]
+
 unit from the 
solvent.
9  
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Figure 2.2 Cartoon diagram depicting the orientation of the alkyl chaing in different solvents. 
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When the complex equipped with a C12 chain was introduced to an aqueous media, in 
the presence of lipid membranes, the same photophysical data for MeCN was observed 
(Figure 2.2). This observation, along with the observed emission and lifetime of complex in 
H2O being similar to that in hexane (Figure 2.3), led to the proposed hypothesis that 
intramolecular hydrophobically driven interactions were occurring.  
 
Figure 2.3 Reproduced steady state emission spectra for [Re(CO)3(bipy)L(C12)]
+
 recorded in different 
media (λ exc 345 nm).
9 
 2.1.3.  Hydrophobic interactions 
A hydrophobic molecule is one that does not have a favourable interaction with polar 
environments such as water and so will tend to arrange itself into a conformation that 
minimises its contact with that solvent. There are several conformations known, some more 
energy favourable than others. If a complex contains a hydrophilic region (head) attached to a 
hydrophobic region (tail) when in a polar solution, it simultaneously forms aggregates. These 
aggregates tend to be either a micelle or a bilayered structure and are formed as a result of a 
process referred to as the hydrophobic effect (Figure 2.4). 
 
 
 
Micelle                                                                        Bilayered structure 
 
 
Figure 2.4 The arrangements of both the micelle and bilayered structure. 
15 
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The aggregate structure is dependent on both the length of the hydrophobic region 
(hydrocarbon chain), and size of the hydrophilic region. In complexes where a sufficiently 
sized aliphatic chain is attached to a polar group it may be energetically unfavourable for one 
of the two aggregates discussed above to form, but more favourable for chain wrapping or 
fold-back to occur.
16 
2.1.4.   Resonance Energy Transfer (RET) 
Resonance energy transfer (RET) was discussed briefly in Chapter 1. It describes the 
process where the energy that is absorbed by one molecule (donor) is transferred non-
radiatively to a second molecule (acceptor) (Figure 2.5). RET can occur between intra- and 
intermolecular chromophores but is dependent on the orientation and distance between the 
chromophores. When investigating intramolecular hydrophobic interactions, in particular the 
mechanisms by which they occur (e.g. chain wrapping/ fold back) RET can be a useful 
technique to probe conformation. 
 
Figure 2.5 Acceptor emitting energy transferred from the donor.
10 
There are two mechanisms by which non-radiative energy transfer can occur; Förster 
and Dexter energy transfer. The main difference between these two transfer processes is the 
distance over which they can occur. Förster energy transfer results from Coulombic 
interactions (dipole-dipole interactions) between the donor and acceptor, it can occur over a 
large distance 10-100 Å, and is strongly dependent on spectral overlap. This process is most 
efficient for singlet-singlet transitions as multiplicity-conserving transitions have large 
transition dipoles (Figure 2.6). The rate of energy transfer is shown in Figure 2.7.
11,12 
1D*             1A                                      1D               1A*
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Figure 2.6 Förster energy transfer, singlet-singlet 
K= 1/ τD(R0/r)6 
Figure 2.7 Förster energy transfer. (K= rate of energy transfer, τD = decay time of donor excited state, R0 = 
Förster distance (distance where energy transfer is 50 %, around 20-60 Å ) and r = donor-acceptor 
distance. 
Dexter energy transfer is a shorter range process and can only occur for distances less 
than 10 Å. It is dependant on temperature and orbital overlap and its efficiency decreases 
exponentially with distance. The donor and acceptor exchange an electron, the exchanged 
electron occupies the vacant orbital of the acceptor, thus Dexter energy transfer can be applied 
to produce the triplet state of the molecule of interest (acceptor).
11-14  
1D*             1A                                      1D               1A*
 
Figure 2.8 Dexter energy transfer, singlet-singlet 
Whenever the R0 (Fӧrster distance) is smaller than the molecular contact distances, 
electron exchange (Dexter) is dominant. The rate of electron transfer is dependent on the 
following equation. 
kET = exp (-2r/L) J 
Figure 2.9 Dexter energy transfer. Rate of Dexter electron transfer (r = donor to acceptor distcance, L = 
constant related to orbital radii of donor and acceptor, J= extent of spectral overlap). 
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2.1.5.   Biotinylation in exploring RET 
To understand any RET processes which may be occurring between two 
chromophores on the same molecule (thus exploring any intramolecular hydrophobic 
interactions) the effects of intermolecular interactions between the two chromophores should 
also be known. The binding of up to four biotins to avidin can result in fluorophores being 
brought within their Förster distances. For many organic fluorophores, where Stokes shifts are 
small, this can result in self quenching through RET.  Biotin-avidin binding is an area of 
research that can allow the exploration into RET between two chromophores on separate 
molecules. 
Avidin is a tetrameric glycoprotein found in chicken egg whites with a molecular 
weight of ca. 4 × 15000.
17,18 
It has four substrate binding sites each with a depth of ca. 15 Å 
specific for the binding of a small molecule of biotin, otherwise known as vitamin H (Figure 
2.10),
19
 (Biotin is a water soluble molecule often found in the biochemical pathway of fat 
metabolism). 
 
The affinity between avidin and biotin is the strongest known non-covalent 
bond between a protein and a ligand with a dissociation constant / Kd = 10
-15 
M. The 
numerous hydrogen bonds and VDW interactions which are formed when biotin binds to the 
hydrophobic avidin pocket result in avidin: biotin binding being irreversible (high eq 
constant) and thus the biotinylation of molecules is widely used in diagnostics which require 
the use of irreversible bonds with specific linkages between biological macromolecules.
17-19  
 
Figure 2.10 Tetrameric structure of streptavidin (homologous protein of avidin) with two bound biotins.
18 
2.1.6.   Biotinylation of TM 
The biotinylation of fluorophores can aid in cellular uptake as biotinylated species can 
be actively transported into cells by some of the existing mechanisms for biotin uptake.
17,19-21 
The conjugation of TM complexes to biotin seems a promising route for delivery of TM 
complexes into cells. The Lo group have taken the leading role inr research into biotinylated 
complexes reporting both Ir(III)
 
and Re(I) 
 
biotinylated complexes. Both types of biotinylated 
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complexes have reported show photophysical properties identical to that of the parent 
complexes. Several examples of both TM complexes (Ir(III)/Re(I)) exist where biotin is 
appended to pendant chains of varying length and incorporating different linking units 
(ester/amide).
22-29   
2.1.6.1. Biotinylated Ir(III) complexes 
The binding pockets of avidin are small and hydrophobic in nature and so when 
biotinylated complexes are bound to avidin an increase in emission intensity can sometimes 
be seen. Lo et al.
26
 highlighted the effect of different chain lengths on the emission intensity 
of biotinylated Ir(III) complexes when bound to avidin (Figure 2.11).
26 
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Figure 2.11 Ir(III)-biotin complexes reported by Lo et al.
26
 
For the smaller chain lengths (C2 chain, 1a and 1c) a two-fold increase in emission 
intensity was observed. This increase in emission was attributed to the increased rigidity of 
the complex and the shielding nature of the hydrophobic pocket, however, the presence of the 
shorter chain led to higher Kd values (less efficient binding). Kd values are a lot smaller with 
1a (C2 chain with methyl substituent) when compared to 1c (C2 chain with phen substituent) 
which suggests the substituent (as well as chain length) has some effect on binding properties 
of the complex. Further research by this group reported the length of the spacer had the 
greater effect on the binding efficiency of biotinylated complexes to avidin.
26 
The reports by the Lo et al group can be summarised with the need for a compromise; 
too short a chain will lead to a poor binding efficiency where as too long a chain leads to 
diminished emission enhancement;‘C6 appears to be a reasonable compromise’.
1 
 
Chapter 1. 
 
38 
 
2.1.6.2.Biotinylated Re(I) complexes 
Lo et al.
27-29
 have also dominated research in this area having reported several 
successful variations in the biotinylation of Re(I) complexes in addition to reporting the first 
class of luminescent biotinylation reagents derived from [Re(CO)3(N^N)]
+
 type complexes. In 
2005 analogous results to those of the iridium complex were reported. Through the 
employment of different spacer arms (ethyl and hexyl), different linking groups between the 
Re(I) luminophore and biotin group (Figure 2.12), and the variation of diimines (phen, Me4-
phen, Me2-Ph2-phen, and dpq), a catalogue of twelve Re(I)-biotin complexes were 
synthesised. The luminescence data reported an increase in both the emission intensity and the 
lifetimes when Re(I)-biotin complexes were bound to avidin. As the spacer arms were 
increased, a smaller increase in emission enhancement was observed, this was attributed to 
the increased exposure of the complex to the solvent. Variations in the substituent position of 
pyridine to which the biotin was bound found that the meta-substituted variant had a longer 
emission lifetime than the para-substituted.
27 
Further examples by the group showed an 
increased emission enhancement factor of ca. 3.05-8.05 for the C6 and C2 spacer arms.
28 
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Figure 2.12 The different biotin ligands which were attached to Re(I). Each complex showed enhanced 
emission intensity when bound to avidin
27 
There is only one example of cellular imaging with Re(I)-biotin to date and this again 
was reported by the Lo et al.
29
 group (Figure 2.13). The following Re(I)-biotin isothiocynate 
complex showed intense cytoplasmic staining of the cell with partial organelle staining and 
also presented cytotoxicity values similar to the anticancer drug cisplatin.
29 
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Figure 2.13 Re(I)-biotin isothiocyanate complex found to localise in cytoplasm.
29 
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2.2     Overview 
It is possible that different ligands can impose a greater influence on both the 
structural and photophysical properties of a complex. In light of the unusual photophysical 
observations for varying aliphatic chained complexes seen for the C12 aliphatic chain length, 
the aims of the work described in this chapter was to further analyse the solvent effect on 
hydrophobically driven inter- or intramolecular interactions. Two different series of novel 
luminescent complexes were synthesised. The first series of Re(I) complexes was synthesised 
to investigate the effect of variations in aliphatic chain lengths, linker units and diimine 
groups on the hydrophobic interactions. The second series of Re(I) complexes was 
synthesised to investigate the effect of a fluorescent chromophore moiety on these interactions 
when appended to the terminal position of varying lengths of aliphatic chain. Avidin: biotin 
binding was also investigated to evaluate the effect of intermolecular energy transfer 
processes between the chromophores. This latter scenario affords the possibility of 
photophysical studies on the distance dependent (and therefore indicative of molecular 
conformation) energy transfer processes that are possible between donor and acceptor 
components in luminescent systems. 
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2.3.   Results and discussion (part 1) 
2.3.1.  Synthesis of long aliphatic chained complexes 
 
 
 
 
 
 
Figure 2.14  Structure of ligands with varying aliphatic chain length, L
1
-L
6
. 
L
1
-L
3
 were isolated following a reaction of 3-amino methyl pyridine with the 
appropriate long chain acid chloride. The analogous ligands, L
4
-L
6
, were isolated using 
hydroxyl methyl pyridine as a substitute for 3-amino methyl pyridine, n = C6, C12, C18 
respectively. 
1
H NMR spectra were obtained in CDCl3 where the synthesis of each ligand was 
confirmed by the appearance of new CH2 linker environments between +3.97 and +4.85 ppm 
(Figure 2.14).  
The synthesis of the cationic complexes [Re(CO)3(bipy)L
1-6
]
+
, [Re(CO)3(phen)L
1-6
]
+
 
and
 
[Re(CO)3(neoc)L
1-6
]
+
, was achieved following literature precedent.
30
 Each complex was 
reacted with L
1-6 
in a 1:1.1 ratio in chloroform over 12 hours. Column chromatography was 
used to isolate the pure complexes as their tetrafluoroborate salts in modest yields of 13 % to 
58 % (Figure 2.15). 
1
H NMR spectra were obtained for each complex in CDCl3 confirming 
the presence of the ligand and were consistent with what was expected for the desired 
product. MS (ES) and HRMS analysis for each of the complexes was carried out which gave 
good mass ions in all cases; peaks associated with the parent cation [M-BF4]
+ 
with the correct 
isotope distribution was observed in all cases. Solid state IR studies were also carried out for 
all complexes which showed subtle changes in the ν(CO) in comparison to the ligands and the 
[Re(CO)3(N^N)]
+ 
precursors. All the complexes studied showed two carbonyl stretching 
frequencies at around 2030 and 1921 cm
-1 
with very slight variation in wavenumbers directly 
relating to the electron density available at the Re(I) centre.   
 
N NH
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n
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Figure 2.15 Structures of complexes discussed herein. 
2.3.2.   UV-Vis absorption spectroscopy 
The electronic absorption spectra for the complexes [Re(CO)3(N^N)L
1-6
]
+ 
were 
obtained in acetonitrile solution at room temperature. For each of the complexes an intense 
absorption band in the high energy region of the spectrum (< 330 nm) was typically assigned 
to spin-allowed intra ligand (
1
IL)(ππ*) transitions. A structureless shoulder peak is expected 
in the region of 340-400 nm for the spin-allowed metal to ligand charge transfer transition 
(
1MLCT) (Re(I) dπ π* NN), but this peak was not apparent in any of the complexes. The 
absence of the 
1
MLCT peak is assumed to be the result of the broad IL peak (Table 2.1). 
2.3.3.   Luminescence spectroscopy 
Luminescence spectra were obtained in acetonitrile solution at room temperature. 
Following excitation at 345 nm, [Re(CO)3(N^N)L
1-6
]
+ 
displayed the expected broad 
structureless emission band around 550 nm, corresponding to the 
3
MLCT transition. With 
excitation of 345 nm and detection at 550 nm respectively, time-resolved lifetime 
measurements in acetonitrile detected single exponential lifetimes over 132-292 ns 
corresponding to the expected values for the varying diimines (Table 1 and 2). When the 
solvent was changed from acetonitrile to water a slight blue-shift in emission wavelength was 
occassionally seen, accompanied with an increase in emission lifetime for some complexes. 
The C12 chain length demonstrated, in all three sets of analogous complexes, to have the more 
consistent, predictable luminescent properties when the solvent was changed. 
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Table 2.1 The absorption and emission data for rhenium based complexes of L1-6 in both acetonitrile and 
water.  λexc = 345 nm. 
Compounds Abs 
(nm) 
Em(MeCN) 
(nm) 
 Lifetime MeCN 
(ns) 
Em (H2O) 
(nm) 
Lifetime H2O 
(ns) 
 
       
Re-bipy-L
1
 273 553 132 551 136  
Re-phen-L
1
 276 547 257 542 486  
Re-neoc-L
1
 277 529 292 532 357  
 
Re-bipy-L
2
 
 
274 
 
556 
 
128 
 
554 
 
137 
 
Re-phen-L
2
 270 547 216 541 489  
Re-neoc-L
2
 280 528 226 532 307  
       
Re-bipy-L
3
 275 554 125 552 141  
Re-phen-L
3
 273 544 247 546 437  
Re-neoc-L
3
 275 532 271 532 301  
       
Re-phen-L
4
 273 541 248 539 486  
Re-neoc-L
4
 221 530 292 530 325  
       
Re-phen-L
5
 274 546 257 536 312  
Re-neoc-L
5
 280 542 153 539 270  
       
Re-phen-L
6
 273 544 247 546 437  
Re-neoc-L
6
 275 532 271 532 301  
2.3.3.1. Luminescent properties of [Re(CO)3(bipy)(L
1
-L
3
)]
+
  
  For the ester complexes of [Re(CO)3(bipy)(L
1
-L
3
)]
+
 (discussed in the introduction) a 
blue shift in emission maxima and an increase in emission lifetime was observed however, for 
the amide comples, when the solvent was changed from acetonitrile to water, this was not the 
case. The amide complexes of bipy L
1
-L
3
 showed no dramatic increase in either emission 
wavelength or lifetime when the solvent was changed suggesting the nature of the linker 
(amide/ester) governs the degree of any intramolecular hydrophobic chain wrapping. This 
conclusion, although apparent for the bipyridine complexes was not consistently observed for 
the other diimine complexes in this study. 
2.3.3.2. Luminescent properties of [Re(CO)3(neoc)(L
1
-L
6
)]
+
  
The [Re(CO)3(neoc)(L
1
-L
6
)]
+
 complexes each  displayed an increase in the emission 
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lifetime upon changing from acetonitrile to water. For the complex of L
5
 (C12 chain, ester 
linker), this increase in lifetime was accompanied by a small blue shift in emission maxima of 
3 nm, from 542 nm in MeCN to 539 nm in H2O. This was the only complex to exhibit a shift 
in emission maxima, however, the shift was too small to be considered relevant.  
2.3.3.3. Luminescent properties of [Re(CO)3(phen)(L
1
-L
6
)]
+
  
Similarly to the neoc complexes, the [Re(CO)3(phen)(L
3,6
)]
+
 (C18 ester and amide) 
complexes showed a dramatic increase in emission lifetime with no significant change in 
emission maxima. For [Re(CO)3(phen)(L
1,2,4,5
)]
+
 (the C2 and C12 ester and amide) both a blue 
shift in emission maxima and a dramatic change in emission lifetime was observed. The 
biggest shift in emission maxima was seen with L
5
 (C12) with a shift 10 nm, from 546 nm in 
MeCN to 536 nm in H2O, this result however was accompanied by the smallest increase in 
emission lifetime, 55 ns. The analogous complex, L
2
, showed the second biggest blue shift in 
emission maxima of 6 nm and was accompanied by a lifetime increase of 273 ns.  
2.3.3.4.Variable temperature measurements 
To further probe the extent of chain wrapping, variable temperature luminescence 
measurements were carried out for the [Re(CO)3(phen)(L
2
and L
5
)]
+
 in water (Figure 2.16). 
An increase in the intensity of the emission maxima was seen as the temperature decreased. 
This increase was attributed to an enhancement in the shielding of the excited state. As the 
temperature is lowered the conformation of the chain is more rigid (less freedom to move). 
The increase in emission intensity suggests the average conformation for the chain resides 
around the [Re(CO)3(N^N)]
+
 centre resulting in the enhancement of luminescence. As the 
temperature is elevated there is more degrees of freedom within the chain thus a decrease in 
emission intensity is viewed. 
 
Figure 2.16 Variable temperature measurements of [Re(CO)3(phen)(L
2
)]
+ 
(LHS) and [Re(CO)3(phen)(L
5
)]
+
 
(RHS) (λexc 345 nm). 
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2.4.    Conclusion 
From the photophysical data reported, no universal model describing the behaviour of 
all of the complexes can be derived. The results show that for bipyridine complexes the nature 
of the linker group governs the degree of chain-wrapping; ester linkers appear to facilitate 
better chain-wrapping than amides. When looking at the alternative diimines, phen/neoc, not 
all data was complimenting of the bipy findings, however, both sets of complexes provide 
evidence to suggest the C12 chain is the optimum chain length for chain-wrapping to occur 
with the ester linkers displaying, for C12 chains, the greatest blue-shift for emission maxima.  
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2.5. The incorporation of a fluorescent chromophore to investigate 
hydrophobic interactions 
To further probe the effect of hydrophobic interactions on the C12 alkyl chain with an 
ester linker, the syntheses of ligands incorporating a sensitizer (coumarin) or quencher 
(anthracene) moiety were attempted. The addition of a photoactive component onto the 
terminus of the aliphatic chain should potentially allow for a better understanding of the 
orientation of the chain when coordinated to a [Re(CO)3(N^N)]
+ 
 unit, and help to deduce 
whether intramolecular hydrophobic interactions are occurring. Anthracence and coumarin 
units can have very different effects on the photophysics of a complex.
31  
Anthracene (Figure 2.17) is highly luminescent in nature. It is able to participate in 
photo-induced energy transfer processes as either an electron donor or acceptor depending on 
its photophysical ‘partners’.32-35When partnered with a [Re(CO)3(N^N)]
+ 
type  species,
 
the
 
excited triplet energy of anthracence is typically lower than the 
3
MLCT energetic state. The 
anthracence moiety can therefore efficiently quench the luminescence of the 
3
MLCT state. 
The low oxidation potential of the anthracence also results in a higher quenching rate 
constant.
36 
O O
O
OH
    
Figure 2.17 Anthracene (LHS), coumarin (RHS) 
In contrast, coumarin (Figure 2.17) is a highly fluorescent chromophore whose excited 
singlet and triplet energy is typically higher than Re(I) based 
3
MLCT potentially leading to 
energy transfer and sensitization of MLCT. In this manner, the fluorescence intensity of the 
coumarin fluorophore should therefore be quenched. Through the analysis of the intra 
molecular energy transfer efficiency, information on the orientation of the coumarin (and 
hence aliphatic chain) with respect to the excited states situated on the diimine ligand and/or 
the metal centre can be obtained.
35
The quantum yield of coumarin is in the range of 35-71 
%.
35b 
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2.6.    Results and discussion (part 2) 
2.6.1.   Synthesis of dual functionalised ligand precursors 
The most convenient pathway for synthesising a bi-functional alkyl chain was to 
proceed via the formation of amide and ester linking units and the most convenient way to 
form these functionalities was via the use of acid chlorides. An acid chloride enables 
‘activation’ of a carbon promoting more facile nucleophillic substitution. The position of the 
1
H NMR peak for the CH2 adjacent to OH/COOH/NH2 in the precursor can be used in most 
cases to distinguish products from their SM. 
The ligand chosen for synthesising the precursor ligand had to be adaptable for the 
addition of different functional groups. A number of attempts were made to synthesise a 
bifunctional C12 chain using 1,12-dodecandiol and a tert-butyloxycarbonyl (BOC) / t-butyl 
carbamate protecting group, however low yields of the desired product were obtained (Figure 
2.18). Different ratios of the BOC group were trialled as well as a mono de-protection of the 
di-phthalimide structure. Both proved unsuccessful and an alternative route was sought. 
    i ii
iii
iv
    
40 %                           14 %                                        44 %
9N
O
O
N
O
O
OH
OH 9
Cl
Cl 9
NH2
NH2
9
NH
NH2
O
O
t
Bu
NH
NH
O
t
Bu
O
O
O
t
Bu
9
NH2
NH2
9
9
 
Figure 2.18 Attempted ligand synthesis. Reagents: i) SOCl2; ii) potassium pthalimide, DMF, Δ; iii) 
hydrazine, methoxyethanol; iv) BOC, CHCl3. 
An alternative precursor, 1,12-dibromodecane was used in an attempt to increase the 
yield of a dual functionalised ligand. 1,12-dibromodecane and 1 equivalent of potassium 
phthalimide were reacted to form the mono protected product. The 
1
H NMR spectra initially 
suggested formation of the product due to the presence of signals corresponding to both a 
bromo-subsituted and a phthalimide-substituted chain. However, on further analysis it was 
discovered that these signals had resulted from the presence of both the unreacted 1,12-
dibromodecane and the bis-substituted product in a 1:1 ratio. The reaction was repeated using 
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different ratios of SM with and without the presence of a KI catalysts and varying the 
solvents, but unfortunately the same results were observed.  
A pleasing result was eventually found with a reaction of 1,12-dodecandiol and 
nicotinoyl chloride (Figure 2.19). To a dilute solution of the diol (5 eq) in chloroform, was 
added nicotinoyl chloride (1 eq) and TEA. Following an aqueous work-up a new ligand, L
7
, 
was produced with a 50 % yield. It was also possible to recover the majority of 1,12-
dodecandiol that was used in an 80 % excess. The formation of the mono-substituted, L
7 
from 
the symmetrical 1,12 dodecandiol was a welcomed breakthrough in this area of work.  
 
N
O
Cl + OH
OH
N
O
O
OH
    1                      :                5
 
 Figure 2.19 Reaction scheme for ligand precursor A. 
2.6.2. Addition of a chromophoric moiety 
L
7 
can be utilised as a ligand precursor allowing the addition of a chromophore moiety 
via the unreacted terminal hydroxyl group. Initially, anthracene-9-acid chloride was chosen as 
the chromophore moiety but when reacted with L
7 
the 
1
H
 
NMR spectrum gave evidence to 
suggest hydrolysis of the anthracene-reactant. The reaction was repeated under anhydrous 
conditions and pure product was obatained in a low yield. As a result of the low yielding 
nature of this reaction a second chromophore moiety, coumarin, was reacted with L
7
 which 
gave the desired product, L
10
 in a 48 % yield (Figure 2.20). L
8/9
 with varying chain lengths of 
C2 and C6 respectively, were synthesised following the same procedure as L
7 
and L
10
; L
8-10
, n 
= C2, C6, C12 respectively. 
N
O
OH
ON
Cl
O
OH OH
n
+
N
O
O
O
O
OO
n
n
                                             L8    n = C2
                                  L9    n = C6
                                               L10  n = C12 
 
Figure 2.20 Ligand syntheses. 
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2.6.3.   Synthesis of complexes 
  L
8-10
 were coordinated to [Re(CO)3(bipy)]
+ 
and [Re(CO)3(phen)]
+
 following literatre 
precedent. The six complexes were formed in yields ranging from 18-43% (Figure 2.21). 
n
Re
+
OC
OC
N
+
O
O
O
O
O O
CO
N
+
N
+
BF
4
-
Re
+
OC
OC
CO
N
+
O
O
O
O
O O
N
+
N
+
BF
4
-
n
                          L8    n = C2
     L9    n = C6
                                 L10  n = C12
 
Figure 2.21 [Re(CO)3(bipy)L
8-10
]
+
and [Re(CO)3(phen)L
8-10
]
+
. 
2.6.3.1. UV-Vis absorption and luminescence spectroscopy 
The photophysical properties of [Re(CO)3(bipy)(L
8-10
)]
+
 
 
and [Re(CO)3(phen)(L
8-10
)]
+
  
were studied and are summarised in Table 2. The emission spectra of complexes of L
8-10 
in 
acetonitrile and water are shown in Figures 2.22-2.24. The electronic absorption spectra 
obtained for the complexes generally show absorption < 330 nm. The intense absorption 
bands around 222-290 nm was assigned to the spin allowed 
1
IL
 (ππ*) (coumarin/NN) 
transitions and the broad shoulder displayed by the majority of spectra at lower energy 
typically around 320 to 330 nm was assigned to the spin allowed 
1MLCT transition of dπ 
(Re(I))π* (N^N). 
The incorporation of the coumarin moiety onto the chain resulted in dual-emissive 
species. Upon photoexcitation at 340 nm all of the complexes exhibit two emission maxima 
centred on 420 nm and 540 nm. The emission band around 420 nm was assigned as the 
3
IL 
(ππ*) of the coumarin and the structureless emission band at about 535-550 nm was 
assigned as the 
3MLCT transition of dπ (Re(I))π* (NN). Through comparing the intensity of 
emission maxima, IL:
3
MLCT, it was hoped to be possible to determine the proximity of the 
coumarin to the [Re(CO)3(N^N)]
+
 unit; if the coumarin moiety is in close proximity to the 
central [Re(CO)3(N^N)]
+
 unit an increase in 
3
MLCT intensity would be expected, this coupled 
with the lifetime data (an increase is expected if the excited state is shielded from solvent) 
will allow for the amount of hydrophobic interaction to be assessed.  
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Table 2.2 The absorption and emission data for L8-10, [Re(CO)3(bipy)L
8-10
]
+
and [Re(CO)3(phen)L
8-10
]
+
. 
Spectra recorded in both acetonitrile and water. λexc = 345 nm. 
Compounds Abs 
(nm) 
Em(MeCN) 
(nm) 
Lifetime MeCN 
(ns) 
Em (H2O) 
(nm) 
Lifetime H2O 
(ns) 
L
8
 290 
331 
417 - 421 
 
- 
L
9
 291 
330 
416 - 420 - 
L
10
 289 
335 
415 - 417 - 
Re-bipy-L
8
 223 
288 
419 
549 
150 422 
549 
108 
Re-bipy-L
9
 251 
288 
320 
414 
547 
146  151 
Re-bipy-L
10
 268 
320 
416 
548 
147 413 152 
Re-Phen-L
8
 277 
328 
412 
539 
321 408 
386 
183 
Re-Phen-L
9
 278 
331 
420 
540 
290 418 
536 
403 
Re-Phen-L
10
 273 
435 
410 
536 
218 421 
538 
177 
Through a comparison of both the emission intensities of  
3
MLCT-based emission at 
550 nm with coumarin-based emission at 420 nm and the lifetimes of the complexes, we can 
attempt to differentiate between the complex conformations (whether the coumarin unit is 
close to or further away from the [Re(CO)3(N^N)]
+
 unit). These comparisons are discussed in 
detail in the following sections. 
2.6.3.2. Luminescent properties of [Re(CO)3(bipy)L
8-10
]
+ 
In acetonitrile dual emission profiles were observed for all three complexes. The 
spectra of [Re(CO)3(bipy)L
8
]
+ 
(C2) (Figure 2.22) depicts how energy transfer is dependent on 
distance; [Re(CO)3(bipy)L
8
]
+
 (C2) is the shortest chain length and in both acetonitrile and 
water 
3
MLCT-based signal intensity was greater than the coumarin-based emission intensity. 
In acetonitrile, for complexes [Re(CO)3(bipy)L
9/10
]
+
, the C6 and C12 chain length respectively, 
coumarin-based emission was dominant for [Re(CO)3(bipy)L
9
]
+
 (C6) and 
3
MLCT-based 
emission was dominant for [Re(CO)3(bipy)3L
10
]
+
 (C12).  It is unlikely that chain ‘wrapping’ 
occurred for [Re(CO)3(bipy)L
10
]
+
 (C12) in the organic solvent and so it is assumed that the 
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chain ‘folds’ into a conformation that brought the coumarin unit  into closer contact to the 
[Re(CO)3(bipy)]
+
 unit. 
Literature reports have shown that coumarin can act as a sensitizer of 
[Re(CO)3(N^N)]
+
 based emission;
34
 coumarin-based emission energy can be ‘transferred’ to 
rhenium thus coumarin emission is quenched. However, in water, two out of the three 
complexes show coumarin-based fluorescence only; there is no evidence for the 
3
MLCT-
based emission for the C6 and C12 chain. Earlier examples of [Re(CO)3(N^N)L]
+
complexes 
(discussed in part 1), in the absence of a coumarin chromophore, reported observed 
3
MLCT-
based emission in water, which suggests quenching of the 
3
MLCT-based emission is 
occurring for the C6 and C12 chained [Re(CO)3(bipy)]
+
complexes (Figure 2.19).  
 
Figure 2.22 Spectra displaying emission of [Re(CO)3(bipy)L
8-10
]
+ 
in acetonitrile (LHS) and water (RHS). 
(λexc 340 nm). 
2.6.3.3.Luminescent properties of [Re(CO)3(phen)L
8-10
]
+
 
Unlike the [Re(CO)3(bipy)L
8-10
]
+
, the [Re(CO)3(phen)L
8-10
]
+
 complexes showed dual 
emission profiles when in both MeCN and H2O with more pronounced changes in the 
emission intensity being observed. In acetonitrile, the 
3
MLCT-based emission was dominating 
over that of coumarin-based emission for all three chain lengths, the effect was maximised for 
[Re(CO)3(phen)L
9
]
+ 
(C6). The difference in the 
3
MLCT:coumarin ratio of emission intensities 
for the different chain lengths followed C6 > C2 > C12. Coumarin has a much greater quantum 
yield when compared to [Re(CO)3(N^N)]
+
,
1,34b
 and so the presence of a dominating 
3
MLCT-
based emission peak illustrated efficient energy transfer from the coumarin to the Re(I) unit 
(Figure 2.23). Efficient energy transfer suggests the orientation of the coumarin chromophore 
was in close proximity to the [Re(CO)3(N^N)]
+ 
central unit, however, these spectra were 
recorded in acetonitrile so can assume chain wrapping is not causing the closeness.  
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Figure 2.23 Spectra displaying emission of [Re(CO)3(phen)L
8-10
]
+ 
in acetonitrile. (λexc 340 nm) 
When the solvent was changed to water the 
3
MLCT-based emission was still more 
dominating than the coumarin-based emission, but the effect was maximised for the 
[Re(CO)3(phen)L
10
]
+ 
(C12), following the trend C12 > C2 / C6 for the different chain lengths. 
The C12 chain showed the most efficient energy transfer (Figure 2.24) suggesting hydrophobic 
interactions were occurring bringing the coumarin and the [Re(CO)3(phen)]
+ 
unit into closer 
proximity than the C2 chain.  
 
Figure 2.24 Spectra displaying emission of [Re(CO)3(phen)L
8-10
]
+ 
in water. (λexc 340 nm) 
2.6.3.4. Variable temperature measurements 
 
Variable temperature measurements were carried out for [Re(CO)3(phen)L
10
]
+
, (Figure 
2.25). The data showed that as the temperature was decreased, the 
3
MLCT:coumarin intensity 
ratio increased. The increase in 
3
MLCT-based emission intensity suggests the favoured 
conformation brings the coumarin unit into closer proximity of the [Re(CO)3(phen)]
+ 
unit.  
The absence of both a blue-shift in emission maxima and an increase in lifetime, as the 
solvent was changed from acetonitrile to water for the C12 species, suggests that chain-
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wrapping around the central unit was not responsible for the proximity of coumarin to 
[Re(CO)3(phen)]
+ 
unit.  
 
Figure 2.25 VT emission spectra for [Re(CO)3(phen)L
10
]
+ 
recorded in water. (λexc 340 nm). 
It was hoped that the inclusion of a the coumarin chromophore moiety would allow 
greater insight into the conformation of the aliphatic chain with respect to the 
[Re(CO)3(N^N)]
+ 
central unit, however, not all the results obtained herein are conclusive; for 
the [Re(CO)3(bipy)L
8-10
]
+
 complexes 
3
MLCT based emission was shown to dominate the 
coumarin based emission in acetonitrile only but for the phen based complexes, 
[Re(CO)3(phen)L
8-10
]
+
, 
3
MLCT based emission was shown to dominate the coumarin based 
emission in both solvent systems. These results suggest that the [Re(CO)3(phen)]
+
 based 
complexes are more sensitive to the effects of solvent than [Re(CO)3(bipy)]
+
 based complexes 
but further research is required to determine the orientation of the aliphatic chain in polar 
solvent. 
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2.7.    Biotinylation of the complexes 
To further probe the phenomenon of energy transfer which occurs via the 
aforementioned intramolecular hydrophobic interactions, application of the avidin-biotin 
binding model was investigated. Avidin can bind up to four biotin units in a 1:4 ratio and so 
any intermolecular hydrophobic interactions can lead to energy transfer between biotinylated 
photoactive units. In this case a [Re(CO)3(bipy)L(biotin)]
+ 
species and a coumarin-biotin 
species, were to be bound to the surface of avidin, allowing investigation of any inherent 
energy transfer processes. As already discussed, C6 is the optimum chain length for linkers to 
biotin. [Re(CO)3(bipy)L(biotin)]
+ 
and biotin-coumarin compounds were synthesised with the 
units linked by a C6 chain, and for comparison, [Re(CO)3(bipy)L(biotin)]
+
 linked by a C12 
chain was  also synthesised.  The increase in chain length, from the optimised C6 chain to the 
longer C12 chain, was expected to bring the hydrophobic [Re(CO)3(bipy)]
+
 unit into closer 
contact to the avidin, which could also result in closer contact to the coumarin allowing 
energy transfer to occur more efficiently. 
2.7.1. Ligand design 
Conveniently, there are commercially available, functionalised biotin compounds, 
such as biotinyl-N-hydroxysuccinimydyl ester, but herein the more cost effective, unmodified 
biotin is used (Figure 2.26). The presence of the carboxylic acid group at the terminal position 
of the biotin chain allows the stepwise addition of a ligand to biotin via a condensation 
reaction (seen in the ligand synthesis for part 1). The starting material for ligand synthesis 
should include a C6 or C12 chain appended with an OH/NH2 terminal functional group for 
ester or amide linkages. Any ligand chosen should also be suitable for Re(I) co-ordination and 
thus include a pyridine donor for this purpose.  
O
S
NH
O
NH
OH
HH
 
Figure 2.26 Biotin 
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2.8.    Results and discussion (part 3) 
2.8.1.   Synthesis and reactivity of biotin chloride 
Literature precedent was followed for the formation of biotin chloride.
37
 Biotin was 
added to a small Schlenk flask followed by freshly distilled oxalyl chloride and the reaction 
mixture was stirred at room temperature until complete dissolution of biotin. The excess 
oxalyl chloride was then removed in vacuo and the solid residue was washed with dried 
toluene. When reacted with 6-amino-1-hexanol in the presence of triethylamine TEA (Figure 
2.27) a poorly soluble product was recovered. The absence of a peak in the 
1
H NMR spectrum 
corresponding to the formation of an amide/ester group indicated that the reaction was 
unsuccessful. Additionally, poorly resolved integration for the biotin species in the 
1
H NMR 
spectrum suggests possible breakdown of the biotin species.  
NH2
OH
+
O
S
NH
O
NH
Cl
HH
5
ii+
O
S
NH
O
NH
NH
HH
OH
6
O
S
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O
NH
OH
HH
i
 
Figure 2.27 Attempted synthesis of functionalised biotin. Reagents; i) oxalyl chloride, toluene; ii) 6-amino-
1-hexanol, TEA, CHCl3, Δ. 
2.8.2.   Synthesis and reactivity of a biotin ester  
As the use of biotin chloride had been unsuccessful, an alternative method was used to 
form a ‘reactive’ biotin moiety via an activated biotin ester.38 Biotin was dissolved in warm, 
anhydrous DMF and after the solution was cooled to room temperature, TEA was added 
followed by drop wise addition of tetrafluorophenyl trifluoroactate (Figure 2.28). The 
reactivity of the activated biotin ester was tested using both octanol and 1,6-di-amino hexane. 
The reactants were heated to 50 ˚C in a small amount of DMF in the presence of TEA for 3 
days. No reaction was seen using octanol with only starting materials observed in the 
1
H NMR 
spectrum. 
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Figure 2.28 The formation of biotin ester (i), pro-ligand 11 (ii) and L
11 (iii). Reagents; DMF, TEA, Δ. 
When using1,6-di-amino hexane, evidence of an amide group was observed in the 
1
H 
NMR spectrum with a peak at +3.51 ppm. This led to an attempted reaction using 6-amino-
hexan-1-ol, intended to give pro-ligand 11 (Figure 2.28).  The successful formation of pro-
ligand 11 was confirmed using 
1 
H NMR spectroscopy in which the signal corresponding to 
the CH2NH2 was shifted to higher frequency from +2.51 ppm to +3.49 ppm. Additional 
characterisation was carried out using MS (ES) and HRMS analysis, with observed peaks 
corresponding to the parent ion, [M+Na
+
] and [M+K
+
]. Pro-ligand 11 was formed with a 
good yield of 76 % and when added to a solution of coumarin acid chloride in chloroform in 
the presence of TEA, following an aqueous work up, it afforded the pure product L
11 
in a 68 
% yield (Figure 2.28). This successful synthesis of a biotin–coumarin conjugate suggested 
that the use of an activated ester of biotin could lead to mixed ester and amide linked 
biotinylated ligands and/or fluorophores. 
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2.8.2.1. Synthesis of L
12,13 
using the biotin ester 
N
O
O
OH
O
NH N
O
OO
N
5 55
NH2OH
O
 i                                                                               ii                                                                                                             
                                                iii
NH NH2
O
N
5
iv
         Pro-ligand 12
 
Figure 2.29 Synthesis of pro-ligand 12. Reagents (i) pthalic anhydride, Δ; (ii) SOCl2; (iii) 3-aminomethyl 
pyridine; (v) hydrazine hydrate, Δ. 
Pro-ligand 12 is a ligand precursor similar in nature to that of L
7
 (pyridine-spacer-
OH) and was synthesised using 6-amino-caproic acid. 6-amino-caproic acid was heated in the 
presence of phthalic anhydride producing the phalimido-acid X. The acyl chloride of the 
phthalimide protected amino acid was formed by treatment of phalimido-acid X with thionyl 
chloride. Acid chloride X, was then reacted with 3-amino methyl pyridine in chloroform and 
in the presence of TEA to form the starting material for pro-ligand 12. The phthalimide 
protecting group of the starting material
 
was cleaved using hydrazine in ethoxyethanol 
producing the bi-product phthalazine and the desired primary amine, pro-ligand 12
  
in a 68 % 
yield (Figure 2.29). Pro-ligand 13 was synthesised following the same methodology but 
using 12-aminolauric acid. L
12,13 
were then synthesised from their pro-ligands by reacting 
with biotin activated ester  following the same procedure as L
11
 in yields of 65 % and 56 % 
respectively (Figure 2.30).   
N
NH
O
NH
O
S
NH
O
NH
H H
n
L12     n = 5
L13    n = 10
 
                                                                             Figure 2.30 L
12/13
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2.8.3.   Synthesis of [Re(CO)3(bipy)L
12/13
]
+ 
 
 
Due to the limited solubility of biotin-based ligands, bipyridine was chosen as the 
diimine for the rhenium-precursor as the [Re(CO)3(bipy)]
+
 analogues are notably more 
soluble than their phen/neoc analogues. The synthesis of the cationic rhenium complexes, 
[Re(CO)3(bipy)L
12/13
]
+
, was achieved following literature precedent; 1.1 equivalent of the 
ligand was reacted with [Re(CO)3(bipy)MeCN]
+
 in DMF at 75 ˚C for 7 days. The solution 
was filtered to yield an orange precipitate. Following additional purification by precipitation, 
the pure [Re(CO)3(bipy)L
12/13
]
+ 
complexes were isolated as their tetrafluoroborate salts in low 
yields of 18 % and 19 % respectively (Figure 2.31).
 1
H NMR spectra were obtained for each 
complex and comparison of the spectra to the free ligand confirmed the successful co-
ordination of the ligands to the [Re(CO)3(bipy)]
+ 
units.  
n
L12     n = 5
L13    n = 10
N
+
NH
O
NH
O
S
NH
O
NH
H
H
Re
3-
N
N
OC
OC
CO
+
 
Figure 2.31 [Re(CO)3(bipy)L
12/13
]
+ 
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2.8.4.  Avidin:biotin binding properties of L
11 
and [Re(CO)3(bipy)L
12
]
+
 
2.8.4.1.HABA Assay 
The avidin:binding activity of both L
11 
and [Re(CO)3(bipy)L
12
]
+
 were studied by 2-(4'-
hydroxyazobenzene) benzoic acid (HABA) assays. HABA when bound to avidin has an 
absorption feature at 500 nm and a binding constant of Kd = 6 x10
-6 
M.
25
 Due to the stronger 
binding affinity of biotin (Kd = 10
-15 
M)
25
 biotin should displace the HABA resulting in a 
decrease in the absorbance at 500 nm. Solutions of unmodified biotin, L
11 
and 
[Re(CO)3(bipy)L
12
]
+ 
of known concentrations were prepared and UV-vis titrations of each 
with avidin-HABA solutions were carried out. Avidin-unmodified biotin binding is known 
and well documented; the titrations using unmodified biotin not only act as a control for the 
modified biotin species but also ensure the standard of the avidin starting material is good. 
For the three UV-vis titrations a decrease in the absorbance at 500 nm was observed which 
indicates successful avidin-boitin binding in all three samples. A plot of -ΔAbs500 nm versus 
the [biotin] : [avidin] can be seen in Figure 2.32. The equivalence point is show at three-four 
in all three plots; [biotin] : [avidin] 4:1 which suggests that both the modified and unmodified 
biotin compounds  bind to the avidin with a stoichiometry of 4:1. Figure 2.32 depicts 
modified biotin, L
11
, displacing HABA more efficiently than the unmodified biotin. This 
would suggest coumarin-biotin, L
11
, binds to avidin more strongly than pure biotin (although 
the difference in binding strength is small).  
 
Figure 2.32 Absorption titration curves for the titration of biotin / L11/ [Re(CO)3(bipy)L
12
]
+ 
with avidin-
HABA. 
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2.8.4.2. Luminescent spectroscopy titrations 
The avidin-binding activity of a molecule can also be investigated using luminescence 
spectroscopy titrations. This analytical technique is of particular interest when exploring any  
intermolecular energy tranfer between compounds L
11
 and [Re(CO)3(bipy)L
12
]
+ 
as avidin can 
bind up to four biotin molecules at one given time. The HABA-titrations of both compounds 
showed adequate binding to avidin (seperately) with equivalence points of four being 
observed. When both compounds are added to avidin in solution simultaneously, it is possible 
to have the two different compounds bound to one molecule of avidin. Although a method to 
control the binding ratio of the two compounds is unknown, if the two compounds are bound 
to avidin, any intermolecular energy transfer occuring is expected to be viewed in the 
luminescence spectra with a difference in the intensity between coumarin-based and 
3
MLCT-
based emissions.  
Emission titrations of compounds L
11
 and [Re(CO)3(bipy)L
12
]
+ 
were carried out 
seperately as well as together (as a 50:50 mix) to allow any changes seen in the mixture to be 
efficiently analysed. Following a similar procedure to the HABA titrations, solutions of i) a 
blank solution of PBS (no avidin) and ii) avidin containing solution, was titrated into a known 
concentration and volume of L
11
. This was repeated for both and [Re(bipy)(CO)3L
12
]
+ 
and 
then a mixture of L
11
 and [Re(bipy)(CO)3L
12
]
+ 
. 
2.8.4.2.1.  Solvent effect/ hydrophobic interactions 
The first part of this chapter discusses the effect of different solvents on the 
photophysical properties of complexes with long aliphatic chains, taking the effect of the 
solvent into consideration, when attempting to analyse energy transfer between long chained 
aliphatics, the nature of the solvent needs to be analysed and so titrations of  blank solutions 
of PBS were included in the analysis.  
Due to the limited solubility of the compounds in aqueous media initial titrations (UV-
vis and fluorescence) were carried out using a solvent system of MeOH:PBS (1:1). The data 
obtained for the UV-vis spectra was as expected, with a decrease in absorbance at 500 nm 
indicative of the successful biotin-avidin binding. However, the data obtained from the 
fluorescence titrations showed little change between the standard (blank solution of 
PBS:MeOH) and avidin for all three compounds (unmodified biotin, L
11
 and 
[Re(CO)3(bipy)L
12
]
+
. The titrations were repeated using minimal MeOH in PBS in a ratio of 
0.1:3 and more pronounced changes in the luminescence were observed; these changes are 
discussed in detail in the following sections. 
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2.8.4.2.2. Emission titrations of L
11
 
An enhancement in the emission intensity at 420 nm was seen for the coumarin-biotin 
compound, L
11
, when known quantities of avidin were added to the sample (Figure 2.33). 
This enhancement was not present in the control (the addition of pure PBS only) and so it is 
attributed to avidin-biotin binding. The increased emission intensity suggests L
11
 is shielded 
from the solvent within the hydrophobic  avidin pocket and so any quenching effects that are 
occuring within the PBS titration are minimised. No blue-shift was observed in the emission 
maxima when L
11
 binds to avidin.  
 
Figure 2.33 Emission titration curves for the titration of i) blank pbs solution with L
11
 [0.3mM] & ii) 
[0.075mM] aliquots of avidin with L
11
 [0.3 mM]. (λ em = 420 nm). RHS steady state emission of L
11
. (λ exc = 
310 nm). 
2.8.4.2.3. Emission titrations of [Re(CO)3(bipy)L
12
]
+  
For both the control, PBS [Re(CO)3(bipy)L
12
]
+ 
and avidin [Re(CO)3(bipy)L
12
]
+
,
 
the 
same change in emission intensity at 552 nm was observed; no change in the luminescence 
for avidin : [Re(CO)3(bipy)L
12
]
+ 
(Figure 2.34). The binding of [Re(CO)3(bipy)L
12
]
+ 
(modified 
biotin) to avidin was confirmed via UV-vis avidin-HABA titrations and so the the absence of 
an increase in emission intensity, the lack of blue-shift in the emission maxima, and the 
absence of an extension in emission lifetime (Table 3) suggests there is little or no protection 
of the [Re(CO)3(bipy)L
12
]
+
 unit when it is bound to avidin.  
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Table 2.3 Lifetimes of [Re(CO)3(bipy)L
12
]
+ 
in different media 
 Lifetime (ns) 
Re(I)-L
12
 101 
Re(I)-L
12 
PBS 108 
Re(I)-L
12 
Avidin 104 
 
   
 
Figure 2.34 LHS; Emission titration curves for the titration of i) blank PBS solution with 
[Re(CO)3(bipy)L
12
]
+ 
[0.3mM] & ii) [0.075mM] aliquots of avidin with [Re(CO)3(bipy)L
12
]
+ [0.3 mM]. (λ em 
= 552 nm). RHS steady state emission of [Re(CO)3(bipy)L
12
]
+ 
. (λ exc = 310 nm). 
 
2.8.4.2.4. Emission titrations of mixed L
11
 and [Re(CO)3(bipy)L
12
]
+  
Despite no effect of avidin-binding being observed for [Re(CO)3(bipy)L
12
]
+
, titrations 
were carried out using a 50:50 mixture of L
11
 and [Re(CO)3(bipy)L
12
]
+ 
and avidin/PBS to 
examine the possibility of intermolecular energy transfer. The intensities of the bands at 420 
nm and 552 nm, which correspond to ligand based and 
3
MLCT-based emission respectively, 
were analysised at different quantities of avidin/PBS (Figure 2.35). At 420 nm, no 
enhancement in emission intensity was seen for the ligand based emission when compared to 
the standard (PBS), this observation is dis-similar to that of the isolated L
11
 seen above 
(Figure 2.33). At 552 nm no change in emission intensity from the standard to the avidin-
bound compound was observed, similarly to the behaviour of isolated [Re(CO)3(bipy)L
12
]
+ 
seen above (Figure 2.34). 
The absence of an increase in ligand based-emission intensity for avidin-bound 
coumarin-biotin compound, L
11
, in the presence of [Re(CO)3(bipy)L
12
]
+
 (Figure 2.35), 
suggests that the enhancement in coumarin-based emission previously seen for this compound 
(Figure 2.33) was being quenched and so it is likely that energy transfer was occuring. The 
lack of an increase in emission at 552 nm (which would be expected for efficient transfer of 
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ligand based energy) suggests that the energy transferred is not re-emitted, and so overall the 
enhancement of coumarin emission which occurs upon avidin binding is simply being 
quenched by the presence of the rhenium complex in the avidin macromolecule, with no 
associated extra emission at a different wavelength. The emissivity of the 
3
MLCT state will 
be dictated by those processes that dominate quenching of that specific excited state. 
 
 
Figure 2.35 Emission titration curves for the titration of i) blank pbs solution with (L
11
 and 
[Re(CO)3(bipy)L
12
]
+
) [0.3mM] & ii) [0.075mM] aliquots of avidin with (L
11
 and [Re(CO)3(bipy)L
12
]
+
) [0.3 
mM]. LHS, (λ em = 420 nm); RHS  (λ em = 552 nm). (λ exc = 310 nm). 
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2.9.   Conclusion 
L
11
-L
13
 were successfully synthesised via the activated biotin esters and the formation 
of [Re(CO)3(bipy)L
12/13
]
+ 
was achieved following literature precedent.
30
 Avidin-biotin binding 
of coumarin-biotin, L
11
 and [Re(CO)3(bipy)L
12
]
+ 
was confirmed using UV-vis titrations; the 
Uv-vis data reported that both compounds have efficient binding to avidin. The flourescence 
data, acccumulated from the emission titrations, indicate an enhancement in the emission 
intensity for coumarin-biotin, L
11
, when bound to avidin. This increase in emission was 
absent in a mixed system of coumarin-biotin, L
11
 and [Re(CO)3(bipy)L
12
]
+ 
which is 
suggestive of the occurance of energy transfer/quenching. Any effect of Re(I)-biotin avidin 
binding and/or energy transfer was not observed in the intensity of 
3
MLCT-based emission 
which could suggest that any increase in the fluorescence as a result of avidin binding and/or 
energy transfer was being quenched. To prove this further investigation into the lifetimes of 
the coumarin and rhenium species is required. If energy transfer is occuring, the lifetime of 
coumarin in the presence of Re(I) should decrease, additionally, if the lifetime of rhenium 
decreases in the presesence of the coumarin, quenching would be implied. As coumarin 
lifetime is short this would be a lot of work, and as the desired result (enhancement of Re(I)) 
was not observed, no further investigations were carried out. 
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2.10. Experimental 
2.10.1. Synthesis of complexes Re(I)-L
1-6
 
fac-[Re(CO)3(bipy)L
1
]
+ 
To a round bottom flask  L
1
 (43 mg, 1.8  10-4 mol) and 
[Re(CO)3(bipy)MeCN]
+ 
(50 mg, 1.07  10-4 mol) in toluene (10 mL) were added and heated 
to 100 ˚C for 24 hours. The solution was filtered through Celite and column chormatography 
was used to purify the crude product (silica, DCM:MeOH 95:5). Yield: 27 mg, 38 %. 
1
H 
NMR (CDCl3, 400 MHz, 298 K) δH:  0.82 (3H, t, 
3
JHH  = 6.8 Hz, (H13)), 1.15-1.18 (8H, m, 
(H9-H12)), 1.57-1.62 (2H, m, (H8)) 2.01-2.04 (2H, m, (H7)), 4.10 (2H, d, 
3
JHH  = 5.9 Hz, 
(H5)), 7.02-7.07 (1H, m, (H3)) , 7.45 (1H, t,
 3
JHH  = 6 Hz, (H6)), 7.65-7.74 (4H, m (H16, 
H17)), 7.76 (1H, d, 
3
JHH  = 7.9 Hz, (H4)), 8.13-8.21 (2H, m, (H1, H2)), 8.42-8.48 (2H, m, 
(H15)),  9.0-9.08 (2H, m, (H14)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 12.0, 
20.0, 23.5, 26.6, 28.7, 29.2, 33.9, 38.0, 123.5, 124.5, 127.0, 137.5, 138.0, 139.0, 140.1, 148.5, 
150.9, 153.8, 172.1 ppm. MS (ES
+
) m/z: 661.26 [M-BF4
-
]
+
, HRMS (ES
+
) found m/z 659.1784; 
[
185
ReC27H30O4N4
10
BF4]
+  
requires 659.1791. IR (nujol) υ: 1670 (CO), 1934 (CO), 2036 (CO) 
cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 273 (7874) nm.  
fac-[Re(CO)3(bipy)L
2
]
+
 To a round bottom flask L
2
 (38 mg, 1.18  10-4 mol) and 
[Re(CO)3(bipy)MeCN] (50 mg, 1.07  10
-4 mol) were added and heated to 100 ˚C for 24 
hours. Worked up as before. Yield: 36 mg, 45 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 
0.81-0.85 (3H, m, (H19)), 1.14-1.27 (20H, m, (H9-H18)), 1.42-1.51 (2H, m, (H8)), 2.01 (2H, 
t, (H7)), 4.10 (2H, d, (H5)), 7.15 (1H, t, (H3)) , 7.52-7.56 (1H, m, (H6)), 7.62-7.69 (4H, m, 
(H22,H23)), 7.72 (1H, d, (H4)), 8.15-8.19 (2H, m, (H1,H2)), 8.49-8.52 (2H, m, (H21)),  9.01-
9.05 (2H, m, (H20)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 14.9, 22.3, 25.2, 28.9, 
29.0, 31.1, 32.6, 36.5, 40.8, 126.8, 129.0, 139.8, 140.1, 141.0, 150.0, 150.8, 153.8, 154.2, 
156.1, 174.8 ppm. MS (ES
+
) m/z: 745.34 [M-BF4
-
]
+
, HRMS (ES
+
) found m/z 743.2728; 
[
185
ReC33H42O4N4
10
BF4]
+  
requires 743.2730. IR (nujol) υ: 1560 (CO), 1926 (CO) 2036 (CO) 
cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 274 (3953) nm.  
fac-[ Re(CO)3(bipy)L
3
]
+
 To a round bottom flask L
3
 (44 mg, 1.18  10-4 mol) and 
[Re(CO)3(bipy)MeCN] (50 mg, 1.07  10
-4 
mol) in toluene (10 mL) were added and heated to 
100 ˚C for 24 hours. Work up same as before. Yield: 43 mg, 54 %. 1H NMR (CDCl3, 400 
MHz, 298 K) δH: 0.82 (3H, t, 
3
JHH =3.5 Hz, (H23)), 1.12-1.29 (28H, m, (H9-H22)), 1.43-1.49 
(2H, m, (H8)) 1.99 (2H, t, (H7)), 4.11 (2H, d, 
3
JHH = 6 Hz, (H5)), 7.12 (1H, t, (H3)) , 7.41 
(1H, t, (H6)), 7.61-7.81 (5H, m, (H4, H26, H27)), 8.16-8.21 (2H, m, (H1, H2)), 8.48-8.52 
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(2H, m, (H25)), 9.05 (2H, d, 
3
JHH = 5.4 Hz (H24)) ppm. MS (ES
+
) m/z: 745.27 [M-2CO-
BF4]
+
, HRMS (ES
+
) found m/z 745.2744 [M-2CO]
+
; [
185
ReC35H50O2N4
10
BF4]]
+  
requires 
745.3486. IR (nujol) υ: 1603 (CO), 1928 (CO), 2036 (CO) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 275 (8548) nm.  
fac-[Re(CO)3(phen)L
1
]
+
  To a round bottom flask encased in foil, L
1
 (44
 
mg, 1.89  10-4 
mol), [Re(CO)3(phen)Br] (50
 
mg, 9.43  10-5 mol) and silver tetrafluoroborate (28 mg, 1.44  
10
-4 
mol) in toluene (10 mL) were added and heated to 100 C for 24 hours. The solution was 
filtered through Celite and washed repeatedly with acetonitrile. The removal of the solvent 
under high vacuum afforded a yellow solid. Column chromotography was then used to purify 
the crude product (silica, DCM:MeOH, 95:5). Yield: 14 mg, 22 %. 
1
H NMR (CDCl3, 400 
MHz, 298 K) δH: 0.8 (3H, t, (H13)), 1.08-1.21 (8H, m, (H9-H12)), 1.45 (2H, t, 
3
JHH = 7.1 Hz, 
(H8)), 2.01 (2H, t, 
3
JHH =7 Hz, (H7)), 4.01 (2H, s, (H5)), 7.11-7.15 (1H, m, (H3)), 7.58-7.61 
(1H, m, (H4)) , 8.10-8.19 (4H, m, (H14, H15)), 8.21-8.26 (1H, m, (H2)), 8.25 (1H, s, (H1)), 
8.85 (2H, d, (H16)), 9.05 (2H, d, (H17)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 
13.8, 22.2, 25.0, 29.0, 28.9, 31.5, 36.0, 40.0, 125.0, 124.9, 127.5, 128.0, 131.2, 138.0, 141.1, 
146.5, 149.3, 151.9, 153.1, 154.2 ppm. MS (ES
+
) m/z: 685.2 [M-BF4
-
]
+
. HRMS (ES
+
) found 
m/z 683.1749 [M]]
+
; [
185
ReC29H30O4N4
10
BF4]]
+  
requires 683.1791. IR (nujol) υ: 1598 (CO), 
2024 (CO), 2036 (CO) cm
-1
. UV-vis (ε / M-1cm-1) (MeCN) λmax: 223 (1673), 276 (643) nm.  
fac-[Re(CO)3(phen)L
2
]
+
  To a round bottom flask encased in foil, L
2 
(60 mg, 1.89  10-4 
mol), [Re(CO)3(phen)Br] (50 mg, 9.43  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  
10
-4 
mol) in toluene (10 mL) were added and set to sub reflux at 100 C for 24 hours. Work-
up was as described above. Yield: 18 mg, 25 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.81 
(3H, t, (H19)), 1.11-1.23 (22H, m, (H8-H18)), 2.01 (2H, t, (H7)), 4.01 (2H, s, (H5)), 7.12-
7.15 (1H, m, (H3)), 7.49 (1H, d, (H4)), 8.08-815 (4H, m, (H22, H23)), 8.17-8.23 (1H, m, 
(H2)), 8.25 (1H, s, (H1)), 8.82 (2H, d, (H21)), 9.59 (2H, d, (H20)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δC: 12.2, 21.1, 22.3, 23.0, 24.1, 27.9, 28.0, 28.5, 29.2, 31.0, 33.2, 
37.1, 49.0, 27.8, 124.5, 126.1, 127.1, 130.1, 138.9, 139.5, 145.4, 148.0, 150.8, 153.0, 173.1, 
206.0  ppm. MS (ES
+
) m/z: 769.25 [M-BF4
-
]
+
, 319.26 [M-Re(CO)3PhenBF4+H]
+
. HRMS 
(ES
+
) found m/z 769.2757; [
185
ReC35H42O4N4
10
BF4]]
+ 
requires 767.2730. IR (nujol) υ: 1599 
(CO), 1926 (CO), 2036 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax:  206 (923), 270 (153) 
nm.  
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fac-Re(CO)3(phen)L
3
]
+
  To a round bottom flask encased in foil L
3
 (71
 
mg, 1.89  10-4 mol), 
[Re(CO)3(phen)Br] (50 mg, 9.43  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C for 24 hours. Work-up as before. 
Yield: 27 mg, 35%. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.82 (3H, t, 
3
JHH = 6.8 Hz, 
(H23)), 1.01-1.24 (28H, m, (H19-H22)), 1.38-1.42 (2H, m, (H8)), 1.97 (2H, t, 
3
JHH = 7.7 Hz, 
(H7)), 4.05 (2H, d, 
3
JHH =6.1 Hz, (H5)), 7.01-7.09 (1H, m, (H3)), 7.18 (1H, t, (H6)), 7.65 (1H, 
d, (H4)), 8.04-8.08 (1H, m, (H2)), 8.11-8.15 (4H, m, (H26,H27)), 8.25 (1H, s, (H1)), 8.69 
(2H, d, (H25)), 9.57 (2H, d, (H24)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 14.0, 
22.8, 25.8, 29.1, 32.0, 36.0, 40.9, 126.0, 128.2, 129.4, 131.7, 139.2, 146.5, 146.8, 149.9, 
152.0, 155.1, 174.5, 195.6 ppm. MS (ES
+
) m/z: 825.33 [M-BF4
-
]
+
, 375.33 [M-
Re(CO)3PhenBF4]+H]
+
. HRMS (ES
+
) found m/z 825.3381; [
185
ReC39H50O4N4
10
BF4]
+  
requires 
823.3356. IR (nujol) υ: 1668 (CO), 1923 (CO), 2034 (CO) cm-1. UV-vis (ε / M-1cm-1) 
(MeCN) λmax: 214 (1628), 273 (785) nm.  
fac-[Re(CO)3(phen)L
4
]
+
  To a round bottom flask encased in foil L
4
 (45 mg, 1.89  10-4 
mol), [Re(CO)3(phen)Br] (50 mg, 9.43  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  
10
-4 
mol) in toluene (10 mL) were added and heated to 100 C for 24 hours. Work-up as 
before. Yield 37 mg, 58 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.75 (3H, t, 
3
JHH = 6.2 Hz, 
(H12)), 1.15-1.28 (8H, m, (H8-H11)), 1.42 (2H, t, 
3
JHH = 6.9 Hz, (H7)), 2.14 (2H, t, 
3
JHH = 
7.6 Hz, (H6)), 4.85 (2H, s, (H5)), 7.29 (1H, t, 
3
JHH = 4.5 Hz, (H3)), 7.61 (1H, d, 
3
JHH = 7.9 
Hz, (H4)), 8.10 (2H, s, (H16)), 8.12-8.26 (3H, m, (H2, H15)), 8.33 (1H, s, (H1)), 8.75-8.78 
(2H, m, (H14)),  9.57 (2H, d, 
3
JHH = 4.9 Hz, (H13)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 
298 K) δC: 22.0, 22.9, 24.2, 27.0, 29.8, 30.2, 33.0, 61.0, 126.2, 126.9, 129.8, 130.0, 134.5, 
138.2, 139.1, 144.7, 150.0, 152.5, 171.5, 193.5 ppm. MS (ES
+
) m/z: 686.15 [M-BF4
-
]
+
. HRMS 
(ES
+
) found m/z 684.1361; [
185
ReC29H29O5N3
10
BF4]
+  
requires 684.1631. IR (nujol) υ: 1740 
(CO), 2024 (CO), 2037 (CO) cm
-1
. UV-vis (ε / M
-1
cm
-1
) (MeCN) λmax: 221 (6308) 273 (5096) 
nm.  
fac-[Re(CO)3(phen)L
5
]
+
   To a round bottom flask encased in foil L
5
 (47 mg, 1.89  10-4 
mol), [Re(CO)3(phen)Br] (50 mg, 9.43  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  
10
-4 
mol) in toluene (10 mL) were added and heated to 100 C for 24 hours. Work-up as 
before. Yield: 15 mg, 21 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.79 (3H, t, 
3
JHH
 
= 6.6 
Hz, (H18)), 1.15-1.33 (20H, m, (H8-H17)), 1.49 (2H, t, (H7)) 2.13 (2H, t, (H6)), 4.85 (2H, s, 
(H5)), 7.23-7.29 (1H, m, (H3)), 7.62 (1H, d, (H4)) , 8.03-8.17 (5H, m, (H2, H21, H22)) 8.30 
(1H, s, (H1)), 8.75 (2H, d, 
3
JHH = 8.2 Hz, (H20)), 9.53 (2H, d, 
3
JHH = 4.7 Hz, (H1)) ppm. 
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13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 13.8, 23.0, 25.2, 28.9, 32.2, 34.1, 62.2, 127.0, 
127.5, 128.3, 130.8, 135.7, 139.5, 140.7, 146.6, 151.8, 154.4, 173.5, 195.2 ppm. MS (ES
+
) 
m/z: 770.23 [M-BF4]
+
. HRMS (ES
+
) found m/z  768.2521; [
185
ReC35H41O5N3
10
BF4]
+  
requires 
768.2570. IR (nujol) υ: 1735 (CO), 1935 (CO), 2035 (CO) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 216 (3063), 274 (2093) nm.  
fac-[Re(CO)3(phen)L
6
]
+
  To a round bottom flask encased in foil L
6
 (71 mg 1.89  10-4 mol), 
[Re(CO)3(phen)Br] (50 mg, 9.43  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C for 24 hours. Work-up as before. 
Yield: 10 mg, 13 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.83 (3H, t, (H22)), 1.08-1.24 
(28H, m, (H8-H21)), 1.45 (2H. t, (H7)), 2.24 (2H, t, (H6)), 4.2 (2H, s, (H5)), 7.13 (1H, t, 
(H3)), 7.37 (1H, d, (H4)), 7.92-7.97 (2H, m, (H24)), 8.21 (2H, s, (H26)), 8.78-8.83 (2H, m, 
(H1, H2)), 8.88-8.91 (2H, m, (H25)), 9.55 (2H, d, ((H23)) ppm. MS (ES
+
) m/z: 826.29 [M-
BF4]
+
. IR (nujol) υ: 1795 (CO), 2013 (CO), 2039 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) 
λmax: 207 (1408), 262 (483) nm.  
fac-[Re(CO)3(neoc)L
1
]
+
  To a round bottom flask encased in foil L
1
 (41 mg, 1.78  10-4 mol), 
[Re(CO)3(neoc)Br] (50 mg, 8.9  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C for 24 hours. Work-up as before. 
Yield: 19 mg, 30 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.74-0.78 (3H, m, (H13)), 1.19-
1.26 (8H, m, (H9-H12)), 1.47 (2H, t, 
3
JHH = 7.3 Hz, (H8)), 1.95 (2H, t, 
3
JHH = 7.7 Hz, (H7)), 
3.29 (6H, s, (H14)), 3.97 (2H, d, (H5)), 6.92 (1H, t, (H3)) , 7.05 (1H, t, (H6)), 7.48-7.55 (1H, 
m, (H4)), 7.63-7.66 (2H, m, (H16)), 7.80 (2H, s, (H17)), 7.91 (2H, d, 
3
JHH = 8.3 Hz, (H15)),  
8.37-8.41 (2H, m, (H1,H2)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 13.0, 21.5, 
24.2, 27.8, 28.7, 30.0, 30.9, 34.8, 124.8, 124.9, 126.0, 126.9, 128.1, 138.1, 139.0, 146.0, 
149.1, 150.2, 163.5, 172.8 ppm. MS (ES
+
) m/z: 713.15[M-BF4]
+
. HRMS (ES
+
) found m/z 
713.2129 [M]
+
; [
185
ReC31H34O4N4
10
BF4]
+  
requires 711.2099. IR (nujol) υ: 1598 (CO), 1970 
(CO), 2023 (CO) cm
-1
.UV-vis (ε / M-1 cm-1) (MeCN) λmax: 277 (6528) nm.  
fac-[Re(CO)3(neoc)L
2
]
+
  To a round bottom flask encased in foil L
2
 (57 mg, 1.71  10-4 mol), 
[Re(CO)3(neoc)Br] (50 mg, 8.9  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C 24 hours. Work-up as before. 
Yield: 28 mg, 39 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.78 (3H, t, 
3
JHH = 6.5 Hz, 
(H19)), 1.17-1.29 (20H, m, (H9-H18)), 1.45-1.49 (2H, m, (H8)), 1.97-1.99 (2H, m, (H7)), 
3.29 (6H, s, (H20)), 4.02 (2H, s, (H5)), 6.90-6.95 (1H, m, (H3)), 7.51-7.56 (1H, m, (H6)), 
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7.60-7.68 (1H, m, (H4)), 7.75 (2H, s, (H23)), 7.93-7.97 (2H, m, (H22)), 8.28 (2H, d, 
3
JHH = 
8.2 Hz, (H21)), 8.44-8.47 (2H, m, (H1,H2)) ppm. MS (ES
+
) m/z: 797.77 [M-BF4]
+
. HRMS 
(ES
+
) found m/z 797.3065; [
185
ReC37H46O4N4
10
BF4]
+  
requires 795.3043. IR (nujol) υ:1589 
(CO), 1961 (CO), 2034 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 275 (7447) nm. 
fac-[Re(CO)3(neoc)L
3
]
+
  To a round bottom flask encased in foil L
3 
(67 mg,  10-4 mol), 
[Re(CO)3(neoc)Br] (50 mg, 8.9  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C 24 hours. Work-up as before. 
Yield: 17 mg, 22 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH:  0.82 (3H, t, (H23)), 1.12-1.28 
(30H, m, (H8-H22)), 1.91-1.95 (2H, m, (H7)), 3.31 (6H, s, (H24)), 3.97 (2H, s, (H5)), 6.89-
6.93 (1H, m, (H3)) , 7.19 (1H, s, (H6)), 7.43-7.49 (1H, m, (H4)), 7.56-7.61 (2H, m, (H25)), 
7.75-7.79 (2H, m, (H26)), 8.88 (2H, s, (H27)), 8.42-8.47 (2H, m, (H1,H2)) ppm.
13
C{
1
H} 
NMR (CDCl3, 101 MHz, 298 K) δC: 12.7, 15.1, 16.0, 16.4, 16.5, 17.1, 17.7, 18.3, 20.5, 24.8, 
27.4, 27.9, 28.6, 29.8, 30.8, 54.1, 61.8, 134.0, 139.8, 145.5, 147.1, 149.6, 150.6, 153.2, 162.7, 
173.4 ppm. MS (ES
+
) m/z: 853.43 [M-BF4]
+
. HRMS (ES
+
) found m/z 853.3700; 
[
185
ReC41H54O4N4
10
BF4]
+  
requires 851.3669. IR (nujol) υ: 1597 (CO), 1932 (CO), 2035 (CO) 
cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 275 (7447) nm.  
fac-[Re(CO)3(neoc)L
4
]
+
  To a round bottom flask encased in foil L
4
 (42 mg, 1.79  10-4 mol), 
[Re(CO)3(neoc)Br] (50 mg, 8.9  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C 24 hours. Work-up as before. 
Yield: 14 mg, 23 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.80 (3H, t, 
3
JHH = 6.2 Hz, 
(H12)), 1.11-1.28 (8H, m, (H8-H11)), 1.49 (2H, t, (H7)) 2.15 (2H, t, 
3
JHH = 7.6 Hz, (H6)), 
3.25 (6H, s, (H13)), 4.73 (2H, s, (H5)), 7.55-7.61 (1H, m, (H3)), 7.65 (1H, d, 
3
JHH = 8 Hz, 
(H4)) , 7.89 (2H, 
3
JHH = 8.3 Hz, (H14)), 7.92 (2H, s, (H16)), 8.25 (2H, d, 
3
JHH = 8.3 Hz, 
(H15)), 8.48-8.52 (2H, m, (H1,H2)) ppm.
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC:14.5, 
22.0, 25.1, 29.2, 29.3, 30.7, 31.5, 34.2, 62.0, 126.4, 126.5, 127, 127.5, 127.5, 128.7, 129.5, 
135.2, 138.0, 139.9, 140.0, 147.1, 151.8, 152.1, 164.0, 164.8, 174.1, 196.2 ppm. MS (ES
+
) 
m/z: 714.13 [M-BF4]
+
. HRMS (ES
+
) found m/z 714.1996; [
185
ReC31H33O5N4
10
BF4]
+  
requires 
712.1944. IR (nujol) υ: 1740 (CO), 1935 (CO), 2036 (CO) cm-1.UV-vis (ε / M-1 cm -1) 
(MeCN) λmax: 221 (1691), 280 (1049) nm. 
fac-[Re(CO)3(neoc)L
5
]
+ 
To a round bottom flask encased in foil L
5
 (57 mg, 1.74  10-4 mol), 
[Re(CO)3(neoc)Br] (50 mg, 8.9  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C 24 hours. Work-up as before. 
Chapter 1. 
 
70 
 
Yield: 28 mg, 39 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.78 (3H, t, 
3
JHH = 7.3 Hz, 
(H18)), 1.10-1.28 (18H, m, (H9-H17)), 1.46 (2H, t, (H8)), 2.12 (2H, t, (H7)), 3.28 (6H, s, 
(H19)), 4.73 (2H, s, (H6)), 7.16-7.21 (1H, m, (H3)), 7.54 (1H, d, (H4)), 7.61 (2H, s, (H22)), 
8.30-8.37 (2H, m, (H21)), 7.90 (2H, d, 
3
JHH = 8.4 Hz, (H20)), 8.51-8.53 (2H, m, (H1, H2)) 
ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 2.0, 13.1, 21.9, 23.8, 28.0, 28.0, 28.1, 
28.5, 28.5, 28.7, 28.8, 30.0, 31.1, 33.1, 116.2, 124.0, 124.9, 125.8, 126.0, 126.0, 126.2, 128.7, 
134.0, 137.5, 137.5, 138.5, 139.7, 145.4, 150.5, 157.5, 163.5, 172.1 ppm. MS (ES
+
) m/z: 
798.38 [M-BF4]
+
. HRMS (ES
+
) found m/z 798.2902  [M]
+
; [
185
ReC37H45O5N3
10
BF4]
+ 
requires 
796.2883. IR (nujol) υ: 1739 (CO), 1936 (CO), 2036 (CO) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax:  229 (10440), 272 (8240) nm.  
fac-[Re(CO)3(neoc)L
6
]
+ 
To a round bottom flask encased in foil L
6
 (66 mg, 1.78  10-4 mol), 
[Re(CO)3(neoc)Br] (50 mg, 8.9  10
-5 
mol) and silver tetrafluoroborate (28 mg, 1.44  10-4 
mol) in toluene (10 mL) were added and heated to 100 C 24 hours. Work-up as before. 
Yield: 29 mg, 38 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.78 (3H, m, (H22)), 1.13-1.31 ( 
28H, m, (H8-H21)), 1.48-1.54 (2H, m, (H7)) 2.12 (2H, t, (H6)), 3.22 (6H, s, (H23)), 4.22 (2H, 
s, (H5)), 7.12-7.16 (1H, m, (H3)), 7.55 (1H, d, (H4)) , 7.62 (2H, d, (H25)), 7.83 (2H, s, 
(H26)), 7.89 (2H, d, (H24)), 8.48-8.51 (2H, m, (H1, H2)) ppm.  
13
C{
1
H} NMR (CDCl3, 101 
MHz, 298 K) δC: 14.0, 22.2, 24.8, 29.0, 29.0, 29.0, 29.1, 29.1, 29.1, 29.1, 29.1, 29.2, 29.2, 
30.8, 31.9, 34.2, 62.0, 125.8, 125.9, 126.0, 126.9, 126.9, 127.8, 130.0, 135.4, 135.5, 139.0, 
140.5, 141.3, 147.7, 151.9, 153.5, 164.5, 173.6 ppm. MS (ES
+
) m/z: 854.33 [M-BF4]
+
. HRMS 
(ES
+
) found m/z 854.3537; [
187
ReC41H53O5N4
10
BF4]
+  
requires 854.3509 IR (nujol) υ: 1597 
(CO), 1924 (CO), 2036 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 228 (1041), 277 
(725.8) nm.  
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2.10.2. Synthesis of ligand and [Re(CO)3(N^N)L
8-10
]
+ 
L
7
 1,12 dodecandiol (10 g, 4.99 × 10
-2
 mol) in chloroform was added slowly to a solution of 
nicotinyl chloride (1 g, 7.07 × 10
-3
 mol) and TEA (3.23 mL, 2.2× 10
-2
 mol) in chloroform (50 
mL). The solution mixture was left to stir at 60 °C for 3 hours. The solution was washed with 
water (3 × 10 mL) and sat. aq. Ammonium chloride (10 mL). The organic layer was dried and 
the solvent evaporated to dryness, yielding a cream solid. Yield: 0.940 g, 43 %. 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 1.49-1.32 (16H, m, (H7-H14)), 1.50-1.55 (2H, m, (H15)), 1.62-
1.69 (2H, m, (H6)), 3.58 (2H, t, 
3
JHH =6.6 Hz , (H16)), 4.75 (2H, t, 
3
JHH =6.6 Hz, (H5)), 7.39-
7.43 (1H, m, (H3)), 8.18-8.22 (1H, m, (H4)), 8.67 (1H, d, 
3
JHH =3.3 Hz, (H2)), 9.10 (1H, s, 
(H13)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δc: 24.7, 25.0, 27.6, 28.2, 28.4, 28.5, 
28.5, 31.8, 61.9, 64.6, 122.3, 125.4, 136.1, 149.7, 152.2, 164.3 ppm. MS (ES
+
) m/z: 308.23 
[M+H]
+
, HRMS (ES
+
) found m/z 308.2218; [C18H30O3N]
+  
requires 308.2220. IR (nujol) υ: 
1711 (CO) cm
-1
.
 
UV-vis (ε / M-1 cm-1) (MeCN) λmax: 264 (3096) nm. 
Pro-L
8  Ethylene glycol (2.8 mL, 4.9 × 10
-2
 mol) in chloroform was added slowly to a 
solution of nicotinyl chloride (1 g, 7.07 × 10
-3
 mol) and TEA (3.23 mL, 2.2 × 10
-2
 mol) in 
chloroform (40 mL). The solution was left to stir at 60 °C for 3 h. Work-up as before. Yield: 
0.350 g,  30 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 3.82 (2H, t, 
3
JHH = 4.7 Hz, (H6)), 4.32 
(2H, t, 
3
JHH = 4.5 Hz, (H5)), 7.31-7.36 (1H, m, (H3)), 8.13 (1H, d, 
3
JHH = 7.6 Hz, (H4)), 8.58-
8.64 (1H, m, (H2)), 9.22 (1H, s, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δc: 
60.4, 67.1, 137.4, 150.5, 153.0, 165.3 ppm. MS (ES
+
) m/z: 168 [M+H]
+
, 124.03 [M-
C2H5O+H)]
+
. IR (nujol) υ:1734 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 230 (2331), 
250 (2023), 268 (1940) nm. L
8 
Coumarin acid chloride (0.412 g, 1.98× 10
-3
 mol) was 
dissolved in chloroform (10 mL) and TEA (0.5 mL, 3.96 × 10
-3
 mol) and added slowly to pro-
L
8
 (0.300 g, 1.8 × 10
-3
 mol) in chloroform (25 mL). The solution was left to stir at 60 °C for 3 
hours. The solution was washed using sat. aq. sodium bicarbonate (3 × 10 mL) and sat. aq. 
ammonium chloride (2 x 10 mL) and the organic layer dried and solution evaporated. The 
crude product was purified using column chromatography eluting with DCM:MeOH (90:10). 
Yield: 0.100 g, 16 %. 
1
H NMR (CDCl3, 400MHz, 298K) δH: 4.59-4.68 (4H, m, (H5, H6)), 
7.27-7.33 (2H, m, (H9, H10)), 7.42-7.45 (1H, m, (H3)), 7.52-7.62 (2H, m, (H8, H11)), 8.24 
(1H, d, (H4)), 8.49 (1H, s, (H7)), 8.22 (1H, s, (H2)), 9.18 (1H, s, (H1)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298K) δc: 61.9, 62.3, 115.8, 116.6, 116.7, 123.9, 128.7, 133.6, 136.3, 
148.1, 149.9, 152.5, 154.2, 156.0, 161.8, 164.0 ppm. MS (ES
+
) m/z: 362 [M+Na]
+
, 378 
[M+K]
+
, 403 [M+MeCNNa]
+
, HRMS (ES
+
) found m/z 340.0820 [M+H]
+
; [C18H14O6N]
+  
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requires 340.0816. IR (nujol) υ: 1642 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 330 
(2953) nm.  
fac-[Re(CO)3(bipy)L
8
]
+ 
 To a round bottom flask, L
8
 (35 mg, 1.03 × 10
-4
 mol)  and 
[Re(CO)3(bipy)MeCN] (48 mg, 1.03 × 10
-4
 mol) in chloroform (2 mL) were added and heated 
at 60 °C for 24 hours. Work up as before. Yield: 25 mg, 32 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 4.53-4.62 (4H, m, (H5, H6)), 7.28-7.32 (2H, m, (H9, H10)), 7.51 (1H, t, 
3
JHH = 4.5 
Hz, (H3)), 7.56-7.63 (2H, m, (H8, H11)), 7.75 (2H, t, 
3
JHH = 4.5 Hz, (H15)), 8.22 (2H, t, 
(H14)), 8.30-8.38 (2H, m, (H7, H4)), 8.52-8.56 (3H, m, (H2, H13)), 8.65 (1H, s, (H1)). 9.18 
(2H, d, 
3
JHH =5 Hz, (H12)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δc: 29.9, 52.5, 
61.8, 115.7, 116.0, 116.5, 124.1, 124.6, 126.5, 127.3, 128.2, 129.0, 133.8, 139.6, 140.8, 148.7, 
151.9, 152.2, 153.5, 153.5, 154.6, 156.1, 162.0 ppm. MS (ES
+
) m/z: 766.05 [M-BF4
-
]
+
,  
HRMS (ES
+
) found m/z 766.0840 [M]
+
; [
187
ReC31H21O9N3
10
BF4]
+ 
requires 766.0809. IR 
(nujol) υ: 1609 (CO), 1732.73 (CO), 1916.41 (CO), 2033.09 (CO) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 223 (4492.5), 288 (5342.5), 345 (3615) nm.  
fac-[Re(CO)3(phen)L
8
]
+ 
 To a round bottom flask, L
8
 (43 mg, 1.23 × 10
-4
 mol) and 
[Re(CO)3(phen)MeCN] (60 mg, 1.1 × 10
-4
 mol) in chloroform (2 mL) were added and heated 
at 60 °C for 24 hours. Work up as before. Yield: 16 mg, 18 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 4.52-4.68 (4H, m, (H5, H6)), 7.28-7.39 (2H, m, (H9, H10)), 7.44-7.47 (1H, m, 
(H3)), 7.60-7.73 (2H, m, (H8, H11)), 8.09-8.18 (2H, m, (H7, H4)), 8.21-8.32 (3H, m, (H2, 
H14)), 8.48-8.53 (2H, m, (H15)), 8.77-8.90 (3H, m, (H1, H13)), 9.65 (2H, d, (H12)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δc: 77.2, 116.7, 124.2, 127.9, 128.6, 131.3, 135.2, 
140.7, 146.3, 149.9, 154.6 ppm. MS (ES
+
) m/z: 790.09 [M-BF4
-
]
+
. HRMS (ES
+
) found m/z 
790.0824; [
187
ReC33H21O9N3
10
BF4]
+  
requires 790.0809. IR (nujol) υ: 1653 (CO). 1733 (CO), 
1761 (CO), 1916 (CO), 2031 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 277 (5048), 328 
(1821) nm.  
Pro-L
9 
1,6 hexandiol (4.1 g, 3.4 × 10
-2
 mol) in chloroform was added slowly to a solution of 
nicotinyl chloride (1 g, 7.07 × 10
-3
 mol) and TEA (3.23 mL, 2.2 × 10
-2
 mol) in chloroform (40 
mL). The solution mixture was left to stir at 60 °C for 3 hours. Work up as before. Yield: 0.93 
g, 59 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.32-1.46 (4H, m, (H7, H8)), 1.7 (2H, t, 
(H9)), 2.42-2.46 (2H, m, (H6)), 3.61 (2H, t, (H10)), 4.34 (2H, t, (H5)), 7.39-7.41 (1H, m, 
(H3)), 8.28 (1H, dd, (H4)). 8.72-8.75 (1H, m, (H2)). 9.11-9.17 (1H, m, ((H1)) ppm. L
9
 
Coumarin acid chloride (0.250 g, 1.2 × 10
-3
 mol) was dissolved in chloroform (10 mL) and 
TEA (0.37 mL, 2.6 × 10
-3
 mol) and added slowly to pro-L
9
 (0.225 g, 1.01 × 10
-3
 mol) in 
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chloroform (25 mL). Work up as before. Yield: 0.375 g, 94 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.42-1.50 (4H, m, (H7, H8)), 1.69-1.79 (4H, m, (H6, H9)), 4.25-4.34 (4H, m, (H5, 
H10)), 7.17-7.20 (3H, m, (H3, H13, H14)), 7.52-7.61 (2H, m, (H12, H15)), 8.23 (1H, d, 
(H4)), 8.47 (1H, s, (H11)). 8.68-8.74 (1H, m, (H2)), 9.21 (1H, s, (H1)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δc: 25.6, 25.7, 28.5, 28.5, 65.6, 65.8, 116.7, 117.9, 123.2, 124.9, 
129.7, 134.4, 137.2, 148.7, 150.7, 153.2, 155.1, 156.7, 163.2, 163.3 ppm. MS (ES
+
) m/z: 
396.13 [M+H]
+
, 418.12 [M+Na]
+
, 434 [M+K]
+
. HRMS (ES
+
) found m/z 396.1440; 
[C22H22O6N]
+  
requires 396.1442.  IR (nujol) υ: 1608.82 (CO), 1721.16 (CO), 1763.58 (CO) 
cm
-1
.
 
UV-vis (ε / M-1 cm-1) (MeCN) λmax:  292 (30632) nm.  
fac-[Re(CO)3(bipy)L
9
]
+ 
To a round bottom flask, L
9
 (52 mg, 1.25 × 10
-4
 mol) and 
[Re(CO)3(bipy)MeCN]
+
 (45 mg, 9.6 × 10
-5
 mol)  in chloroform (2 mL) were added and heated 
at at 60 °C for 24 hours. Work up as before. Yield: 28 mg, 35 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.38-1.51 (4H, m, (H7, H8)), 1.59-1.71 (4H, m, (H6, H9)), 4.24-4.36 (4H, m, (H5, 
H10)), 7.29-7.33 (2H, m, (H19)), 7.49 (1H, t, (H13)), 7.53-7.59 (2H, m, (H3, H14)), 7.75 (2H, 
t, 
3
JHH = 6.5 Hz, (H17)), 8.21-8.32 (3H, m, (H4, H18)), 8.39-6.44 (2H, m, (H12,H15)), 8.48-
8.53 (1H, m, (H2)), 8.61-8.65 (2H, m, (H1, H11)). 9.09 (2H, d, (H16)) ppm. 
13
C {
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δc: 14.5, 22.8, 23.0, 25.9, 28.8, 29.5, 31.4, 34.5, 66.1, 66.8, 117.2, 
118.0, 118.5, 125.4, 126.5, 128.7, 129.3, 129.5, 130.1, 134.9, 141.7, 142.4, 152.6, 149.0, 
149.3, 153.0, 153.2, 156.2, 157.4, 163.1, 165.0 ppm. MS (ES
+
) m/z: 822.09 [M-BF4
-
]
+
.  
HRMS (ES
+
) found m/z 822.1437; [
187
ReC35H29O9N3
10
BF4]
+  
requires 822.458. IR (nujol) 
υ:1608.82 (CO), 1717.78 (CO),  1817.86 (CO), 2031.64 (CO) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 251 (1095), 288 (1706), 320 (1027) nm. 
fac-[Re(phen)(CO)3L
9
]
+ 
To a round bottom flask, L
9
 (36 mg, 8.7 × 10
-5
 mol) and 
[Re(CO)3(phen)MeCN] (45 mg, 7.9 × 10
-5
 mol) in chloroform (2 mL) were added and heated 
at 60 °C for 24 hours. Work up as before. Yield: 29 mg, 43 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.18-125 (4H, m, (H7, H8)), 1.50-1.59 (4H, m, (H6, H9)), 4.25 (2H, t, (H5)), 4.35 
(2H, t, (H10)), 7.28-7.34 (2H, m, (H12, H15)), 7.54-7.68 (1H, m, (H3)), 7.62-7.68 (2H, m, 
(H13, H14)), 8.03-8.22 (5H, m, (H2, H4, H11, H17)), 8.51-8.56 (2H, m, (H19)), 8.80-8.91 
(3H, m (H1,H18)), 9.59 (2H, d, (H16)) ppm. MS (ES
+
) m/z: 846.1 [M-BF4
-
]
+ 
. HRMS (ES
+
) 
found m/z 846.1450; [
187
ReC37H29O9N3
10
BF4]
+  
requires 846.1428. IR (nujol) υ: 1632 (CO), 
1688 (CO), 1767 (CO), 1987 (CO), 2031.2 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax:  
274 (28123), 318 (30932) nm.  
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L
10
Coumarin acid chloride (0.112 g, 5.37 × 10
-4
 mol) was dissolved in chloroform (10 mL) 
and TEA (0.137 mL, 9.8 × 10
-4
 mol) and added slowly to L
7
 (0.150 g, 4.88 × 10
-4
 mol) in 
chloroform (25 mL), then heated at 60 °C for 3 hours. Work up as before. The crude product 
was purified using column chromatography eluting with DCM. Yield: 0.118 g, 50 %.  
1
H 
NMR (CDCl3, 400 MHz, 298 K) δH: 1.17-1.32 (12H, m, (H8-H13)), 1.42-1.49 (4H, m, (H7, 
H14)), 1.68-1.75 (4H, m, (H6, H15)), 4.29-4.36 (4H, m, (H5, H16)), 7.23-7.27 (2H, m, (H18, 
H21)), 7.36-7.43 (1H, m, (H3)), 7.54-7.59 (2H, m, (H19, H20)), 8.29-8.35 (1H, m, (H4)), 8.48 
(1H, s, (H17)), 8.52-8.57 (1H, m, (H2)), 9.12-9.18 (1H, m, (H1)) ppm. 
13
C {
1
H}NMR 
(CDCl3, 101 MHz, 298 K): δc: 24.9, 25.0, 27.6, 27.6, 28.2, 28.5, 64.6, 65.1, 115.8, 116.9, 
117.4, 123.8, 128.5, 133.3, 136.1, 147.4, 154.0, 155.3, 162.2 ppm. MS (ES
+
) m/z: 480 
[M+H]
+
, 502 [M+Na]
+
, 518 [M+K]
+
, 543 [M+MeCNNa]
+. IR (nujol) υ: 1706 (CO), 1717 
(CO), 1759 (CO) cm
-1
.UV-vis (ε / M-1 cm-1) (MeCN) λmax: 289 (1410), 334.9 (6829) nm.  
fac-[Re(bipy)(CO)3L
10
]
+ 
To a round bottom flask, L
10
 (33 mg, 6.82 x 10
-4 
mol) and 
[Re(CO)3(bipy)]MeCN (29 mg, 4.07 × 10
-5
 mol) in chloroform (2 mL) were added and heated 
at 60 °C for 24 hours. Work up as before. Yield: 14 mg, 38 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.18-1.42 (16H, m, (H7- H14)), 1.59-1.73 (4H, m, (H6, H15)), 4.19-4.30 (4H, m, 
(H5, H16)), 7.25-7.31 (2H, m, (H19, H20)), 7.49-7.63 (3H, m, (H3, H18, H21)), 7.79 (2H, t, 
(H25)), 8.19-8.32 (3H, m, (H2, H24)), 8.46-8.49 (2H, m (H4, H17)), 8.73-8.76 (2H, m, 
(H23)), 8.84 (1H, s, (H1)). 9.12 (2H, d, (H22)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 
K) δc: 24.1, 26.7, 26.8, 27.4, 27.5, 27.5, 27.8, 28.0, 30.2, 51.8, 64.4, 64.9, 115.0, 116.2, 121.6, 
123.2, 124.3, 125.5, 125.9, 127.3, 127.6, 127.9, 132.7, 137.5, 138.5, 140.0, 147.1, 151.0, 
151.0, 151.4, 153.1, 153.9, 154.1, 155.1, 160.9, 161.5 ppm. MS (ES
+
) m/z: 906.24 [M-BF4
-
]
+
.  
HRMS (ES
+
) found m/z 906.2387; [
187
ReC41H41O9N3]
+  
requires 906.2353. IR (nujol) υ:  
1609.31 (CO), 1732.73 (CO), 1760.59 (CO), 1916.9 (CO), 2033.57 (CO) cm
-1
. UV-vis (ε / M-
1 
cm
-1
) (MeCN) λmax: 290 (14193), 317 (8666), 335 (5949), 350 (3707) nm.  
fac-[Re(CO)3(phen)L
10
]
+ 
 To a round bottom flask, L
10
 (22 mg, 4.58 × 10
-5
 mol) and 
[Re(CO)3(phen)MeCN] (20 mg, 4.16 × 10
-5
 mol) in chloroform (2 mL) were added and 
heated at  60 °C for 24 hours. Work up as before. Yield: 10 mg, 26 %. 
1
H NMR (CDCl3, 400 
MHz, 298 K) δH: 1.17-1.33 (16H, m, (H7-H14)), 1.51-1.54 (2H, m, (H15)), 1.71 (2H, m, 
(H6)), 4.14-4.17 (2H, m, (H16)), 4.25-4.31 (2H, m, (H5)), 7.21-7.24 (1H, m, (H3)), 7.39-7.44 
(2H, m, (H19, H20)), 7.56-7.68 (2H, m, (H18, H21)), 7.81-7.94 (3H, m, (H24, H4)), 8.02-
8.09 (3H, m, (H25, H17)), 8.68 (2H, d, (H23)), 8.71 (1H, d, (H2)), 9.21 (2H, d, (H22)). 9.49-
9.55 (1H, m, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 24.9, 26.4, 26.7, 26.9, 
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27.0, 27.1, 27.2, 28.9, 30.5, 51.8, 64.5, 64.9, 65.0, 116.7, 125.0, 125.8, 127.9, 128.1, 131.8, 
141.7, 146.6, 150.7, 156.2, 161.0 ppm. MS (ES
+
) m/z: 930.25 [M-BF4
-
]
+
. HRMS (ES
+
) found 
m/z 928.2366; [
185
ReC43H41O9N3
10
BF4]
+  
requires 928.2367. IR (nujol) υ: 1730 (CO), 1912 
(CO), 2034 (CO) cm
-1
.UV-vis (ε / M
-1
cm
-1
) (MeCN) λmax : 273 (4148), 435 (1667) nm.  
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2.10.3. Experimental-Biotin 
HABA-assay of modified and unmodified biotin 
Typically, to a mixture of  HABA (300 Μm) and avidin (0.0075 mM) in 50 mM potassium 
phosphate buffer pH 7.4 were added 5 μL aliquots of the biotin/modified biotin compounds 
(0.3 mM) in 1-min intervals. The formation of biotin-avidin adduct was indicated by a 
decrease in the absorbance at 500 nm due to the displacement of HABA from the avidin. By 
plotting –ΔA500 nm versus [biotin]:[avidin], the binding stoichiometry of the biotin compounds 
was determined 
Emission titrations 
In a typical procedure, avidin (0.0075 mM) in 50 μM PBS buffer pH 7.4 was titrated with the 
modified biotin compounds (0.3 mM) by accumulative additions of 5 μL aliquots at 1-min 
intervals. The solutions were excited at 310 nm, and the emission intensity was monitored at 
the emission maxima of the compounds. 
Pro-L
11
 To a solution of biotin-ester (150 mg, 0.383 mmol)  in DMF (2 mL) was added  6-
amino-1-hexanol (58 mg, 0.497 mmol) and TEA (0.01 mL). The solution was heated at 50 ˚C 
for 3 days. Yield: 95 mg, 73 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.2-1.62 (14H, m, 
(H2-H5, H8-H10)), 2.09 (2H, t, 
3
JHH = 7.3 Hz, (H1)), 2.61 (1H, d, 
3
JHH = 12.3 Hz,  (H12a)), 
2.83 (1H, dd, (H12b)), 3.05 (2H, t, (H7)), 3.49 (2H, t, 
3
JHH = 6.6 Hz, (H6)), 4.12-4.18 (1H, m, 
(H14)), 4.30-4.39 (1H, m, (H13)) ppm. 
13
C NMR ((CDCl3) 400 MHz, 298K) δc: 25.3, 25.6, 
26.5, 28.5, 29.1, 32.3, 35.5, 39, 39.7, 55.7, 60.3, 61.6, 62.1, 78.2 ppm. MS (ES
+
) m/z: 344.25  
[M+H]
+
, 366.23 [M+Na]
+
, 367.24 [M+K]
+
. HRMS (ES
+
) found m/z 344.1995 [M+H]
+
; 
[C16H30O3N3S1]
+ 
requires 344.2002, HRMS (ES
+
) found m/z 366.1812 [M+Na]
+
; 
[C16H29O3N3S1Na]
+  
requires 366.1822. IR (nujol) υ: 1636 (CO), 1675 (CO), 1698 (CO) cm-1. 
UV-vis (ε / M-1 cm-1) (MeCN) λmax: 208 (30895), 234 (14683) nm. L
11
 Pro-L
11
 (125 mg, 
0.364 mmol) was added to a solution of coumarin acid chloride (76 mg, 0.4 mmol) in 
chloroform (15 mL) followed by TEA (0.1 mL, 0.56 mmol) and reaction left stirring at RT for 
4 days. The solution was washed with water (3 × 5 mL) and sat. aq. Ammonium chloride (10 
mL). The organic layer was dried and the solvent evaporated to dryness, yielding a cream 
solid. Yield: 127 mg, 68 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.1-1.82 (14H, m, (H2-
H5, H8-H10)), 2.18 (2H, t, (H7)), 2.61-2.64 (1H, m, (H12b)), 2.87-2.95 (1H, m, (H12a)), 
3.08-3.12 (1H, m, (H11)), 3.21-3.26 (2H, m, (H1)), 4.27-4.36 (3H, m, (H14, H6)), 4.49-4.55 
(2H, m, (H13)), 6.12-6.18 (2H, m, (NH)), 7.20-7.27 (2H, m, (H17)), 7.58-7.63 (2H, m, 
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(H16)), 8.49 (1H, s, (H15)) ppm. MS (ES
+
) m/z: 516 [M+H]
+
, 538 [M+Na]
+
, 554 [M+K]
+
. 
HRMS (ES
+
) found m/z  516.2157 [M+H]
+
; [C26H34O6N3S1]
+  
requires 516.2163. IR (nujol) υ: 
1640 (CO), 1708 (CO), 1755 (CO), 1798 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 290 
(1719), 330 (9252.57) nm.  
Pro-L
12
 6-amino caproic acid (1.5 g, 11.43 mmol) and phthalic anhydride (1.7 g, 11.43 
mmol) were added to a shlenk and heated until no more vapour was seen to be given off. 
Yield: 2.1 g, 67 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.39-1.42 (4H, m, (H6, H5)), 
1.62-1.66 (4H, m, (H4,H7)), 2.32-2.35 (2H, m, (H3)), 3.61-3.66 (2H, m, (H8)), 7.80-7.83 (2H, 
m, (H2)), 7.91-7.97 (2H, m, (H1)) ppm.
 
The acyl chloride (700 mg, 2.54 mmol) was dissolved 
in chloroform (10 mL) and TEA (0.54 mL, 3.82 mmol) then added to 3-amino methyl 
pyridine (0.26 mL 2.54 mmol) in chloroform (10 mL). The solution was left to stir at 61 ˚C 
for 3 h. The solution was washed with water (3 × 5 mL) and sat. aq. Ammonium chloride (10 
mL). The organic layer was dried and the solvent evaporated to dryness. The crude product 
was purified using column chromatography eluting with DCM:MeOH (90:10). Yield: 0.78 g, 
84 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.28-1.32 (4H, m, (H5, H6)), 1.68-1.71 (4H, m, 
(H4, H7)), 2.21 (2H, t, 
3
JHH=7.55 Hz, (H3)), 3.62 (2H, t, 
3
JHH=7.42 Hz, (H8)), 4.39 ((2H, d, 
3
JHH=5.94 Hz, (H9)), 6.2 (1H, m, (NH)), 7.15-7.19 (1H, m, (H13)), 7.59 (1H, d, 
3
JHH=8.13 
Hz, (H13)), 7.61-7.66 (2H, m, (H2)), 7.73-7.76 (2H, m, (H1)), 8.42-8.47 (2H, m, (H1, H2)) 
ppm. 
13
C NMR ((CDCl3) 400 MHz, 298K) δc: 25, 26.4, 28.2, 36.3, 37.7, 121, 123.2, 132.1, 
134, 135.8, 168.5, 172.8 ppm. IR (nujol) υ: 1715 (CO), 1772 (CO) cm-1.UV-vis (ε / M-1 cm-1) 
(MeCN) λmax:  257 (5744) nm. Hydrazine (0.18 mL, 3.9 mmol) was added and solution left at 
70 ˚C overnight. 1H NMR (CDCl3, 400 MHz, 298 K) δH: 1.18-1.25 (8H, m, (H7, H10)), 2.12 
(2H, t, (H11)), 2.54 (2H, t, (H6)), 4.22 (2H, d, (H5)), 7.05-7.13 (1H, m, (H3)), 7.56 (1H, d, 
(H4)), 8.25-8.33 (2H, m, (H1, H2)) ppm. 
13
C NMR ((CDCl3) 400 MHz, 298K) δc: 25.4, 26.4, 
29.7, 36.4, 40.9, 134.9, 184.3, 173.1 ppm. IR (nujol) υ: 1647.9 (CO) cm-1. L12 Biotin-ester 
(125 mg, 0.319 mmol) in DMF (2 mL) was added to a solution of pro-L
12
 (98 mg, 0.415 
mmol) and TEA (0.01 mL). The solution was stirred at 50 ˚C for 5 days. (95 mg, 65 %) 1H 
NMR (CDCl3, 400 MHz, 298 K) δH: 1.25-1.41 (8H, m, (H8- H11)), 1.47-1.56 (6H, m, (H15-
H17)), 2-2.08 (2H, m, (H14)), 2.23-3.01 (2H, m, (H7)), 2.6 (1H, s, (H19a)), 2.65 (1H, s, 
(H19b)), 2.82-2.85 (2H, m, (H12)), 3.05 (1H, s, (H18)), 4.12-4.15 (1H, m, (H20)), 4.31-4.36 
(3H, m, (H5, H21)), 6.32 (1H, s, (H23)), 6.49 (1H, s, (H22)), 7.36-7.40 ( 1H, m, (H3)), 7.62 
(1H, d, (H4)), 7.78 (1H, s, (H6)), 8.42-8.49 (2H, m, (H1, H2)) ppm. 
13
C NMR ((CDCl3) 400 
MHz, 298K) δc: 25.3, 26, 26.3, 28.2, 28.5, 28.6, 35.5, 38.8, 39.6, 39.9, 55.7, 60.3, 62.1, 135.4, 
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147, 147.5, 163.2 ppm. IR (nujol) υ: 1633.4 (CO), 1697 (CO), 2057.7 (CO) cm-1. UV-vis (ε / 
M
-1 
cm
-1
) (MeCN) λmax: 260 (3002) nm.  
[Re(CO)3(bipy)L
12
] [Re(CO)3BipyMeCN] (50 mg, 0.107 mmol) and L
12
 (49 mg, 0.107 
mmol) in DMF (2 mL) was heated at 50 ˚C 7 days. The solution was filtered and the filtrate 
evaporated yielding an orange precipitate. Yield: 17 mg, 18 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH:  1.15-1.67 (12H, m, (H7-H10, H13,H14)), 2.02-2.2 (4H, m, (H6, H12)), 3-3.17 
(4H, m, (H11, H17)), 3.48-3.55 (1H, m, (H16)), 4.12 (2H, s, (H5)), 4.41-4.62 (2H, m, (H18, 
H19)), 7.21-7.24 (1H, m, (H3)), 7.63-7.81 (3H, m, (H4, H24)), 8.14-8.32 (4H, m, (H1, H2, 
H22)), 8.53 (2H, d, (H21)), 9.22 (2H, d, (H20)) ppm. 
13
C NMR ((CDCl3) 400 MHz, 298K) δc: 
25 (x2), 25.1, 26, 29, 34, 34.1, 34.5, 38.4, 38.9, 39.5, 54, 56.5, 58, 58.2, 70, 124.2, 126, 128.8, 
138.6, 141, 150, 150.5, 153.5, 155.3, 184.8, 185.1 ppm. MS (ES) m/z: 890.24 [M]
+
. 
L
13 
 Biotin-ester (125 mg, 0.319 mmol)  in DMF (2 mL) was added to a solution of Pro-L
13 
(126 mg, 0.415 mmol) and TEA (0.01 ml). The solution was left to stir at 50 ˚C for 5 days. 
Yield: 95 mg, 56 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.18-1.29 (20H, m, (H8- H17)), 
1.37-1.43 (6H, m, (H21-H23)), 2.04-2.08 (2H, m, (H20)), 2.18 (2H, t, (H7)), 2.55 (1H, s, 
(H25a)), 2.60 (1H, s, (H25a)), 3.01-3.04 (2H, m, (H18)), 3.32 (1H, s, (H24)), 4.13 (1H, s, 
(H26)), 4.28-4.36 (3H, m, (H5, H27)), 6.32 (1H, s, (H29)), 6.46 (1H, s, (H28)), 7.36-7.39 ( 
1H, m, (H3)), 7.62 (1H, d, (H4)), 7.65 (1H, s, (H6)), 8.42-8.49 (3H, m, (H1, H2, H19)) ppm. 
13
C NMR ((CDCl3) 400 MHz, 298K) δc: 27.4, 28.4, 29.9, 30.2, 30.7, 30.9, 31, 37.3, 37.4, 
40.8, 41.5, 41.9, 49.2, 49.4, 49.6, 49.9, 50.1, 55.3, 57.5, 62, 63.8, 125.7, 138.1, 149.2, 149.8, 
176.4 ppm. MS (ES): 531.33 [M+H]
+
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 229 (3316), 259 
(910) nm. 
[Re(CO)3(bipy)L
13
]
  
[Re(CO)3bipyMeCN] (50 mg, 0.107 mmol) amd L
13
 (57 mg, 0.107 
mmol) in DMF (2 mL) was heated at 50 ˚C 7 days. The solution was filtered and filtrate 
evaporated yielding an orange precipitate. Yield: 19 mg, 19 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.22-1.6 (24H, m, (H8-H16, H21-H23)), 1.9-2.05 (4H, m, (H7, H20)), 2.53-2.56 
(1H, m, (H25a)), 2.79-2.85 (1H, m, (H25b)), 3.02-3.07 (2H, m, (H17)), 3.99 (2H, d, (H5)), 
4.08-4.10 (1H, m, (H27)), 4.78-4.82 (1H, m, (H26)), 7.08-7.11 (1H, m, (H3)), 7.55 (2H, d, 
(H4)), 7.61.7.64 (2H, m, (H31)), 7.92-8.03 (2H, m, (H1, H2)), 8.12-8.19 (2H, m, (H30)), 8.2-
8.23 (2H, m, (H29)), 9.12-9.17 (2H, m, (H28)) ppm. 
13
C NMR ((CDCl3) 400 MHz, 298K) δc: 
24.2, 25.5, 29, 34, 34.2, 48.2, 48.8, 53.1, 66, 67, 70, 124.1, 125.8, 137.9, 138, 138.2, 140.8, 
149.5, 152, 154 ppm. MS (ES) m/z: 974.34 [M+NH3]
+
. HRMS (ES
+
) found m/z 974.3270 
[M+NH3]
+
; [ReC41H53O7N7]
+  
requires 974.3280. 
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Chapter 3. Hydrophobic Modulation of Emission Lifetimes For 
Both Mono- and Di-Metallic Re(I) Complexes Linked Through 
Functionalized Alkyl Chains Towards Cellular Imaging 
Applications. 
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3.1.    Introduction 
In Chapter 2 the effect of the chain length, linking units and varying diimines on the 
photophysical properties of a Re(I) species in different media were reported. Continuing with 
the same objective, Chapter 3 focuses on the hydrophobic modulation of emission lifetimes 
for a novel series of both mono- and di-metallic Re(I) complexes, additionally, reported 
herein is the first application of di-metallic rhenium complexes in cellular imaging. For the 
complexes described in this chapter, a series of monomeric ligands with varying 
chromophoric ‘linking’ units, along with a series of dimeric ligands suitable for the co-
ordination to two metal ions, were synthesised.  
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Figure 3.1 Ligands discussed herein. 
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3.2.   Ligand Design 
For the complexes described in this chapter, the ligand design will take into account 
variables such as chain length, the nature of linking units and the incorporation of 
chromophores into, or at, the terminus of the chain.  
3.2.1.   Variations in the alkyl chain length 
The photophysical findings for the fifteen analogous Re(I) diimine complexes reported 
in Chapter 2, suggests that when the solvent is changed from acetonitrile to water, the C12 
chain is the optimum chain length for chain-wrapping / fold-back to occur. This data 
complements the findings from the original investigation into the effect of solvent on the 
photophysical properties of a luminescenct rhenium complex reported in 2009 (Figure 3.2).
1,2 
Chapter 2 also highlighted how the nature of the linker functionality to pyridine (amide/ester), 
in the case of bipyridine-based complexes had an effect on the degree of intramolecular 
hydrophobic chain wrapping. Therefore, when looking to further probe the hydrophobic 
modulation of emission lifetimes it is logical to include the C12 alkyl chain and vary the linker 
units used. 
  
Re
+
CO
OC
OC
N
+
O
O
CH3
N
+
N
+
BF
4
-
11
 
Figure 3.2 Preliminary results discussed in Chapter 2. 
1,2 
3.2.2.    Variations in the chromophore unit 
  The addition of a chromophore unit to an aliphatic chain could, potentially, allow for a 
better understanding of the chain wrapping phenomena helping to deduce the extent of 
hydrophobic interactions. The proximity of the chromophore to the 
3
MLCT-based excited 
state may be detectable through the photophysical observations; the variation in emission 
intensity and lifetimes for the two luminescent centres will be dependent on the quenching 
processes and energy transfer mechanisms, which in turn will be dependent on the nature, 
position and number of chromophore units employed. 
 λ max / nm τ  / ns 
MeCN 555 176 
H2O 523 688 
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Figure 3.3 Ligand precursor A 
The incorporation of a chromophoric unit requires a ligand precursor adaptable for the 
stepwise addition of functional groups providing easy variation in the ligand design. The 
synthesis of ligand precursor A (Fig. 3.3), from 1,12-dodecandiol, was described in Chapter 2, 
and provided a small degree of control in the ligand synthesis. This allowed six analogous 
coumarin-appended complexes, which varied in both the diimine (phen/bipy) and in chain 
lengths (C2/6/12), to be synthesised (Fig 3.4).    
   
    n = C 2 / 6 / 12 
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Figure 3.4 [Re(CO)3(bipy/phen)L
8-10]
+ 
 
Although a conclusive model of the interaction of the chain/chromophore unit with the 
3
MLCT excited state could not be drawn from the photophysical data of the complexes, the 
emission intensities were shown to vary in different media. The varying intensities 
demonstrated that a chromophoric unit within a complex does provide some additional insight 
into the position of the chain and so perhaps variation in the chromophore unit could allow 
further insight into the chain wrapping phenomena. The electronic nature of the 
choromophoric moiety (e.g. a sensitizer or quencher or excited states) and its spatial position 
within the complex are areas that require further investigation. The phthalimide unit was 
selected as a chromophore for additional study in this way (Figure 3.5).  
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3.2.2.1. Phthalimide 
O
O
NH
 
Figure 3.5 Phthalimide 
Phthalimides are a group of compounds described as imides; a functional group with 
two acyl groups bound to a nitrogen centre, and are generally synthesised from a 
condensation reaction with a dianhydride. The best known example of phthalimide is the well 
documented thalidomide. Thalidomide is well documented for the adverse effects 
encountered during its use in the treatment of morning sickness. Thalidomide was prescribed 
without any clinical trials (and so without being teratogenically tested) which resulted in a 
huge number of babies being born with birth defects. In vivo the R-thalidomide, prescribed for 
the treatment of morning sickness, racemises forming S-thalidomide which has since been 
shown to be responsible for the teratogenic effects. The adverse effects of thalidomide 
resulted in much stricter testing for drug and pesticide licencing and nowadays it is used 
safely for the treatment of cancers (bone marrow), leprosy and used as an anti-inflammatory.
3-
5 
      
N
O
O
S P
(OCH3)2
S
N
O
O
S
CCl3
N
O
O
N
H
O
O*
     
Figure 3.6 Thalidomide with chiral centre marked (LHS), Imidan (centre) and Folpet (RHS). 
Phthalimide is used in the synthesis of a range of important products including: 
pharmaceuticals (discussed above); pesticides; fungicides
 
and dyes. For instance, Imidan 
(Figure 3.6) is an insecticide derived from phthalimide, it is a cholinesterase inhibitor that 
kills insect pests on crops whilst having low toxicity for humans; another phthalimide 
derivative, Folpet (Figure 3.6) is a leaf fungicide;
6 
phthalimide is also used as a chromophore 
in photochemistry and for many synthetic applications, some of which are shown below.
7 
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O
O
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+ NH2 CH3 N
O
O
CH3
 
Figure 3.7 An example of phthalimide used as a protecting group; phthalic anhydride used as a protecting 
group for an amine or amino acid.
 
Potassium phthalimide is a precursor used in the preparation of primary amines using 
Gabriel synthesis. Gabriel synthesis is limited to the formation of primary amines from 
primary alkyl halides.
8,9
 There are few gentle deprotection methods for cleaving the ‘amide’ 
bond with the more common methods using hydrazine or 2 eq. NaOH (Figure 3.8).
10 
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Figure 3.8 An example of Gabriel synthesis
 
3.2.2.2. Pyromellitic centre 
O
O
O
O
O
O  
Figure 3.9 PMDA Unit 
Polyimides are polymers of the imide monomer. Following the same synthetic 
approach described in Figure 3.7, a polyimide can be incorporated into the centre of two 
aliphatic chains. Benzol 1,2,4,5-benzenetetracarboxylicdianhydride otherwise known as 
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pyromellitic dianhydride and herein referred to as PMDA (Figure 3.9) is a well-known, cheap, 
commercially available dianhydride. It is used in the production of thermostable polyimides 
(PI’s), for example, Kapton.10-15 The rigid backbone and strong inter-chain interactions of 
PMDA have been reported to have an effect on both the solubility and the charge transfer 
fluorescence intensity within a compound.
16,17 
 
3.2.2.3. Di-metallic rhenium complexes  
Although the number of complexes reporting the effect of solvent on the 
photophysical properties of a complex is increasing,
1,2,18
 no statement on the specific 
interaction of the aliphatic chain with the excited state species can be made. The incorporation 
of an additional rhenium unit to the terminal position of the alkyl chain, synthesising a di-
metallic rhenium complex (Re(I)-spacer-Re(I)), may provide further insight as to how the 
chain interacts. 
  If the two rhenium centres are brought within close proximity, shielding each other 
from the effect of the aqueous solvent, a blue shift in emission maxima along with an increase 
in emission lifetime and intensity should be seen. It is possible, in an aqueous environment, 
that the two different rhenium centres within a complex will have different degrees of 
shielding from the quenching effect of a solvent, essentially resulting in two inequivalent 
emitting states, and therefore two different emission lifetimes would be expected. If it is in 
fact only the initial carbons in the chain involved in the ‘wrapping’ of the excited state (this 
was a suggestion made in Chapter 1), the two rhenium centres should be in the same 
environments and so no difference in lifetimes would be expected. 
Chapter 1. 
 
88 
 
3.3.   Results and discussion 
3.3.1.  Ligand synthesis 
3.3.1.1. Synthesis of symmetrical ligands equipped to form di-metallic complexes 
The simplest ligands, which allow the co-ordination of two rhenium units to an alkyl 
chain (one at each end) can be synthesised by reacting symmetrical functionalised aliphatic 
chains, such as 1,12-dodecandiol, with acid chlorides, such as nicotinoyl chloride. An acid 
chloride enables ‘activation’ of a carbon promoting more facile nucleophillic substitution. In a 
1
H NMR spectrum, the frequency of the CH2 group adjacent to the functional group (e.g. OH 
or NH2) on the aliphatic chain can be used, in most cases, to distinguish the products from 
starting material. 
N
O
O
O
O
N
                                                                                                  
n
      
n = 1 / 11
N
O
NH
NH
O
N
 11         
 
Figure 3.10 Symmetrical ligands,  L
1,2 
(LHS) and L
3 
(RHS). 
The synthesis of the symmetrical esters, L
1,2
, and the symmetrical amide, L
3
, was 
achieved using an excess of commercially available nicotinic acid which was converted to the 
derived nicotinoyl chloride by stirring at 70 ˚C in thionyl chloride for 1 hour (Figure 3.10). 
Nicotinoyl chloride was then reacted with either commercially available 1,12-dodecandiol, 
ethylene glycol, or the synthesised 1,12-diaminododecane (for its synthesis see Chapter 2). 
The observation of a shift to higher frequency for the CH2OCO / CH2NHCO in the 
1
H NMR 
spectra confirms the formation of the ether/amide units, which were achieved in low to 
excellent yields; L
1
 68 %, L
2
 93 %, L
3
 27%. The lowest yield was for the C12 chained di-
amide based ligand, L
3
, this was the only ligand that required purification by column 
chromatography recovering: starting material, mono (in very low yield) and di-substituted 
products. The difference in the reactivity of L
1
-L
3
 was attributed to the presence of different 
functional groups (ester vs. amide); the presence of an NH functional group in the precursor 
of L
3 
can promote intra- and intermolecular hydrogen bonding which could potentially inhibit 
the reactivity of the terminal groups.  
An alternative route for the synthesis of symmetrical ligands equipped to co-ordinate 
to two rhenium di-imine units was taken via a reaction with oxalyl chloride. The di-ester 
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ligands, L
4
 and L
5 
were formed by reacting hydroxymethyl pyridine or ligand precursor A (in 
a slight excess) with oxalyl chloride (Figure 3.11). The reaction was left to stir at room temp 
for 30 minutes. L
4
, the di-ester equipped with a C1 aliphatic chain, was formed in a 53 % yield 
requiring no further purification; however L
5
, the di-ester equipped with a C12 aliphatic chain, 
required purification via column chromatography which resulted in a low yield of 12 %. The 
low yield of L
5 
was attributed to the change in chain length (C1 vs. C12), again, the increased 
chain length can allow intra- as well as intermolecular hydrophobic interactions whilst the C1 
chain length omits intramolecular interactions completely.  
N
O
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N
n n
   n = 1
n
   n = 12
N
O
O
N
O
O O
O
O
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n
 
Figure 3.11 Symmetrical ligands, L
4 
(LHS) and L
5 
(RHS). 
 
The use of symmetrical ligand precursors limits the variation of (and within) the 
possible ligands which can be produced with the majority of symmetrical starting materials 
forming only symmetrical products (di-alcohols seem to be one of the few exceptions to this 
trend).  
3.3.1.2. Synthesis of unsymmetrical ligands derived from laurolactam 
A dual functional starting material which allowed variation in both the symmetry and 
functionality within the ligands it synthesised was laurolactam. Laurolactam otherwise known 
as 12-aminododecanolactam, is a cheap, commercially available starting material which has 
been reported to readily undergo acid or base promoted ring opening hydrolysis to produce 
12-aminolauric acid. Both routes (acid/base) were attempted; HCl (6 M) displayed enhanced 
reactivity with the better yield of 73 %, as opposed to the lower yield of 35 % with the base. 
The two different functional groups (amine and carboxylic acid) in 12-aminolauric acid 
allowed the stepwise addition of functional groups allowing a variety of ligands to be 
produced. 
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Figure 3.12 Reagents (i) 6M HCl; (ii) phthalic anhydride, Δ; (iii) SOCl2; (iv) 3-aminomethyl pyridine; (v) 
hydrazine hydrate, Δ; (vi) nicotinyl chloride; (vii) pyromellitic dianhydride, Δ. 
3.3.1.2.1. Synthesis of L
6- 8 
 
 The incorporation of a phthalimide unit to one end of the 12-aminolauric acid allowed 
greater control in reactivity and led to the formation of the chromophore appended ligand, L
6
, 
in an excellent yield of 95 %. L
6 
was formed from a series of reactions; 12-aminolauric acid 
was heated (neat) with phthalic anhydride until no further vapour was given off producing the 
phalimido-acid. The acyl chloride of the phthalimide appended chain was formed by 
treatment of phalimido-acid with thionyl chloride. The acid chloride was then reacted with 3-
amino methyl pyridine, in chloroform and TEA to form the amide L
6
 (Figure 3.12). 
The phthalimide protecting group of L
6 
was cleaved using hydrazine in ethoxyethanol to 
produce the bi-product phthalazine and the desired primary amine, ligand precursor B
 
in a 58 
% yield. Finally, ligand precursor B was reacted with an excess of nicotinoyl chloride in 
chloroform in the presence of TEA to produce L
7
, the first unsymmetrical dimer accessed in 
this work.  L
7
 was distinguished from its precursor
 
by the expected downfield shift of the 
signal corresponding to the CH2 adjacent to NH2 from +2.55ppm to +3.35ppm in the 
1
H NMR 
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spectrum. Additionally, two separate singlet peaks integrating to one proton each, at +6.1ppm 
and +6.48ppm, were displayed for the two inequivalent NH’s. L7 was formed in an excellent 
yield of 93 % (Figure 3.12).  
3.3.1.3. Synthesis of a symmetrical chromophore centred dimer 
 The bi-functional analogue of phthalic anhydride, PMDA, can provide a central 
chromophore to link two C11 alkyl chains;
 
PMDA, when reacted with an excess of ligand 
precursor B produces a dimeric ligand, L
8
, in an excellent yield of 98 %. Again, the 
characteristic change in chemical shift of the CH2 adjacent to NH2 was observed (Figure 
3.12).  
NH N
O
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N
10
NH
O
N
NH N
O
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Figure 3.13  L
6
 (LHS), L
8 
(RHS). 
 L
8
 is structurally related to the previously discussed phthalimide appended pyridine 
C11 ligand, L
6
 (differing in the additional anhydride unit and a C11 chain) (Figure 3.13). The 
structural relationship between the ligands, L
6 
and L
8
, allowed a comparison of the effects of 
the chromophore unit on the photophysical properties of the molecule. 
 Following the successful preparation of L
8 
the synthesis of a range of ligands which 
incorporated the PMDA centre and could add additional functionality within the aliphatic 
chain was attempted following the same solvent-free method discussed above. The 
incorporation of a C3 chain to the chromophore, using 1-amino-3-propanol, resulted in a 
product of low solubility which inhibited ease of characterisation. The reaction of a C6 chain 
(using 1-amino-6-hexanol with PMDA) produced a product with a mixture of amide and ester 
bonds as indicated in the 
1
H NMR spectrum. In an attempt to initiate some control in the 
reaction (slow the reaction so the more kinetically favourable product would form) a solvent 
was introduced; 1-amino-6-hexanol and PMDA were heated in DMF at 160 ˚C for 6 hours. 
The solution was cooled and poured into ice water and the white precipitate that formed was 
filtered and recrystallized using methanol giving L
9
 in a good yield of 84 % (Figure 3.14).    
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Figure 3.14 L
9
 formed using PMDA centre and 1-amino-6-hexanol. 
 
 As with other PMDI derivatives, the limited solubility of L
9
 in common organic 
solvents required any reactions using it as a starting material to be carried out in DMF at high 
temperatures. Following a succession of unsuccessful reactions using the di-chloro alkyl of L
9
 
in the presence of a phthalimide unit and catalytic amounts of KI at 150 ˚C, the reaction time 
was extended to 3 weeks. The extension of reaction time resulted in a single phthalimide unit 
being appended to L
9 
forming L
10
 in low yield (Figure 3.15). This limited reactivity meant 
that no further work on this set of compounds was attempted and an alternative route was 
sought for the synthesis of unsymmetrical chromophore centred ligands. 
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Figure 3.15 Formation of L10. Reagents: (i) DMF; (ii) thionyl chloride, Δ; (iii) potassium phthalimide, KI, 
DMF, Δ. 
 3.3.1.4. Synthesis of unsymmetrical chromophore centred ligands 
A bi-functionalised centred chromophore presents an alternative route to introduce 
more variation within the ligand design. Through the synthesis of ligands with varying 
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terminal functional groups appended to the aliphatic chain, a wider scope of bi-functionalised 
chromophores could be included.  
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Figure 3.16 Ligand Precursors A (LHS), B (centre) and C
 
(RHS). 
An additional ligand precursor to ligand precursor A (with a terminal hydroxy group), 
and ligand precursor B (with a terminal amine group), which have both been well documented 
herein, was synthesised from the reaction of dried 12-amino lauric acid with nicotinoyl 
chloride. Precursor ligand C, equipped with a terminal acid group was synthesised in a 55 % 
yield. 
3.3.1.4.1. 3-hydroxy, 2-napthoic acid 
OH
O
OH  
Figure 3.17 3-hydroxy, 2-naphtoic acid 
3-hydroxy, 2-naphthoic acid (3-HNA) is a commercially available, bi-functionalised 
chromophore whose photophysical properties have been well documented.
19-24
It has two 
different functional groups and thus represents an ideal ligand precursor to allow the synthesis 
of an unsymmetrical, chromophore centred ligand. When the acyl chloride of 3-hydroxy, 2-
naphthoic acid was reacted with ligand precursor B (following same procedure as above) 
there was little evidence of product formation. The absence of naphthol aromatic protons in 
the final 
1
H NMR spectrum indicated that either the reaction was unfavourable or the 
chromophore/final product was soluble in water.  
O
O
O
H
H
O
O
OH
H
 
Figure 3.18 Two ground state conformers known for 3-HNA, R (left) and P (right).
19 
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There are several observations which could account for the limited reactivity between 
the two starting materials, including; the presence of two groups on the chromophore moiety 
which can become chlorinated providing additional reaction/intermediate forming pathways 
than those predicted; the presence of an amide bond within ligand precursor B which could 
allow hydrogen bonding to the chromophore, slowing the reaction; or, the more likely, 
intramolecular interactions between the hydroxyl group and the assumed chlorinated 
carboxylic acid in the chromophore. The latter is a well-known photophysically observed 
interaction that is deemed responsible for excited state intramolecular proton transfer 
(ESIPT). 3-HNA has a large Stokes shift resulting from the translocation of the hydroxyl 
proton to the carboxylic acid group (Figure 3.18) which leads to ESIPT.
19 
TEA is a proton 
acceptor thus promotes ESIPT,
24
 the reaction between 3-HNA and ligand precursor B was 
repeated varying conditions such as the concentration of TEA used, omitting the TEA 
completely and changing the chlorinating reagent from thionyl chloride to the less aggressive 
oxalyl chloride, but only starting material was recovered (no shift in the resonance of 
CH2NH2). The strong interactions between the hydroxy and the carboxylic acid groups are 
believed to have hindered the reaction and thus an alternative type of chromophore was 
subsequently investigated.   
3.3.1.4.2. Methyl anthranilate 
O
O
CH3
NH2  
Figure 3.19 Methyl anthranilate 
Methyl anthranilate (MA) is a naturally occurring compound that is found in cocoa, 
coffee and a variety of fruits such as grapes and limes, and is a well-known chromophore. It 
contains both an ester and amine functional group at the 1,2-position. The two different 
functional groups can potentially allow control in the reactivity of the bi-functionalised 
chromophore unit (MA) when compared to the previously investigated 3-HNA, and although 
there is still the possibility of hydrogen bonding within the MA chromophore, it is weaker.  
Methyl anthranilate was reacted with the acyl chloride of ligand precursor C to produce L
11
 in 
a moderate yield of 37 % (Figure 3.20).   
To further functionalise the central unit of L
11
, an attempt was made to form a six 
membered heterocyclic moiety (via an imine formation) using hydrazine in ethanol in a one 
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pot synthesis (Figure 3.20). The 
1
H NMR spectrum of the product showed the absence of the 
methyl group, but with further characterisation (MS and IR) it was evident that hydrolysis of 
the ester bond had occurred with no evidence to suggest the presence of hydrazine unit within 
the ligand. The incorporation of an acid (i.e. catalytic HCl) can, in some cases, accelerate 
reactions of this type,
25
however, although the predicted product was not produced, the 
hydrolysis of L
11
 presents an alternative route for the synthesis of an unsymmetrical dimer 
unit with a chromophore centre.   
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Figure 3.20 Synthesis of L
11
 and hydrolysed L
11b
. Reagents: (i) 6M HCl; (ii) nicotinoyl chloride; (iii) 
SOCl2, Δ; (iv) methyl anthranilate; (v) hydrazine hydrate, Δ. 
3.3.1.4.3.  Ring Opening 
Following the unpredicted synthesis of hydrolysed L
11
 (Figure 3.20) a simpler, 
alternative synthetic route that resulted in a similar end product was carried out using partial 
ring opening chemistry. Ring opening reactions of phthalic anhydride and PMDA in the 
presence of various metal salts
29,30
 and Lewis acids
26-28
 have been well documented with the 
latter being more common. Ring opening of phthalic anhydride with different alcohols in the 
presence of a Lewis acid leads to the mono-ester of the alcohol forming under mild 
conditions.
31 
The Lewis acid acts as a catalyst and accelerates the reaction by co-ordinating to 
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the carbonyl oxygen, the partially positive charge located on a carbon accelerates the 
likelihood of a nucleophilic attack which will proceed to open the ring.
 
  Ligand precursor A was reacted with phthalic anhydride in DMF and in the presence 
of acid. Through trial and error it was found that the acid catalyst chosen should be such that 
is unlikely to react with the cleaved CO or COO, for example, trifluoroacetic acid (TFA). 
When acetic acid was used the formation of methyl ester was observed; the presence of the 
singlet peak at +2 ppm accurately integrating to three protons in the 
1
H NMR spectrum was 
primary evidence for this formation, confirmed with the mass spectrum displaying a dominant 
m/z peak for the [M+H]
+
 acetyl ester. In the presence of TFA the desired product was formed 
with the 
1
H and 
13
C NMR spectra, as well as the mass spectrum results all in agreement. The 
formation of the symmetrical dimeric ligand proved kinetically un-favourable, however, the 
low and limiting yield of this reaction has led to no further reactions having taken place to 
date.  
N
O
O
OH
N
O
O
O
O
OH
O
i
11
11
 
Figure 3.21 L12. Reagents (i) phthalic anhydride, TFA, Δ. 
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3.3.2.   Synthesis and characterisation of the complexes 
With a variety of novel ligands having been synthesised, the formation of the 
corresponding rhenium complexes was attempted. From the data reported in Chapter 2 it was 
noted that the choice of diimine is crucial for the photophysical properties. The 
phenanthroline diimine consistently exhibits more pronounced changes in the photophysical 
properties of a complex when the solvent is changed from acetonitrile to water in comparison 
to its analogues and therefore this diimine was to be used in further investigations. The 
synthesis of the following cationic rhenium complexes was achieved following literature 
precedent, with 1.1 equivalents of the ligand reacted with [Re(CO)3PhenBr] (1 eq per pyridine 
present in ligand)) in the presence of silver tetrafluoroborate (1.2 eq) in chloroform at 55 ˚C 
for 12 hours. The solution was filtered through Celite and the filtrate dried in vacuo. 
Following additional purification by column chromatography the pure mono- and di-metallic 
complexes were isolated as their tetrafluoroborate/hexafluoroborate salts in low to moderate 
yields of 16% to 65 % (Figure 3.22). 
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Figure 3.22 The complexes discussed herein. 
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1
H NMR spectra were obtained for each complex and comparison of the spectra to the 
free ligand confirmed the successful co-ordination of the ligands to the Re(I) units e.g. For 
[Re(CO)3(phen)L
6
]
+ 
a shift of the CH2NH
 
to a lower frequency, +4.32 ppm to +4.09 ppm was 
displayed.  
Solid state IR studies were carried out for all complexes which show subtle changes in 
the ν(CO) in comparison to the rhenium precursor. Complexes show two carbonyl stretching 
frequencies at around 2030 and 1921 cm
-1 
with very slight variation in wavenumbers directly 
relating to the electron density available at the metal centre.   
MS and HRMS analysis for each of the complexes was carried out and gave good 
mass ions in all cases. For the dimeric complexes, fragmentation occurred in all three 
complexes which resulted in a loss of the [Re(CO)3Phen]
+ 
unit. The dimeric complex ion was 
visible only in {[Re(CO)3(phen)]2L
8
}
2+
, in the spectra the dominant mass ion was that of [M-
Re(CO)3Phen]
+
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3.3.3.   UV-Vis absorption spectroscopy 
The electronic absorption spectra were obtained in acetonitrile for the Re(I) complexes 
and their ligands are the data shown in Table 3.1 and are discussed in the following sections. 
Table 3.1 UV-vis data for the ligands and their complexes 
Compound λabs / nm (ε) 
L
A 
264 (30960) 
Re-phen-L
A
 367 (1711), 324 (3191), 273 (14639) 
L
6
 294 (6394), 259 (14699) 
Re-phen-L
6
 365 (3421), 275 (29552) 
L
11a
 311 (4442), 252 (14839) 
Re-Phen-L
11a
 348 (1253), 272 (2911), 252 (8949) 
L
11b
 255 (9260) 
Re-Phen-L
11b
 255 (11424) 
[[Re(phen)]2-L
2
 377 (2946) 
L
7
 260 (9859) 
[Re(phen)]2-L
7
 324 (5760), 272 (5520) 
L
8
 234 (17545) 
[Re(phen)]2L
8
 375 (5085), 274 (17451) 
The high energy band (below 330nm) was visible for all complexes and is typically 
assigned to spin-allowed intra ligand (IL) (ππ*) transitions. The transitions in the region of 
340-400nm are assigned to the spin allowed charge transfer (
1MLCT) (d ππ*). As the 
conjugation within a ligands increases the energy required to promote an electron into the 
excited state is decreased (the π* orbital energy is lowered.). This accounts for the additional 
adsorption peaks seen within the ligands with more than one chromophore moiety.  
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Figure 3.23 UV-vis graph, each displaying ligand (--) and their complex (--). 
 
The high energy absorption of  complex [Re(CO)3(phen)L
6
]
+
 displayed a red-shifted, 
less structured profile in comparison to the phthalimide-appended-free ligand, with an 
additional peak at 365 nm, which was assigned to the addition of the rhenium unit (
1
MLCT). 
A prominantly structured peak at 310 nm in the unsymmetrical dimer, L
11a
 indicated the 
presence of a chromophore moiety, 
1
IL (ππ*). A less structured profile was displayed by the 
[Re(CO)3(phen)L
11a
] complex with a broad shoulder at 377 nm indicating a 
1
MLCT transition 
(Figure 3.23).  
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3.3.4.  Luminescence spectroscopy 
Luminescence spectra were obtained in aerated acetonitrile solutions following 
irradiation at λexc 340 nm. Complexes displayed the expected broad, structureless emission 
band around 536-546 nm that corresponds to 
3
MLCT emission (Table 3.2). With excitation at 
345 nm and detection at 540 nm respectively, time-resolved lifetime measurements detected 
lifetimes in the range of 46-248 ns corresponding to the expected values for the varying 
diimines. When the solvent was changed from acetonitrile to water, a slight blue shift in 
emission wavelength was seen in most cases, this was accompanied with an increase in 
emission lifetime for all complexes with some complexes showing an increase of more than 
100 %. The luminescence data for the Re(I) complexes are shown in Table 3.2 and are 
discussed in detail in the following section. 
Table 3.2 Luminescence data for complexes discussed in Chapter 3 recorded in both water and 
acetonitrile. λexc = 340 nm. 
Compound λem MeCN 
    (nm) 
τ/ns MeCN ɸ MeCN λem H2O 
   (nm) 
τ/ns H2O 
Re-phen-L
A 
532 248 0.02 531 623 
Re-phen-L
6 
546 248 0.08 543 338 
Re-phen-L
11a 
536 221 0.06 538 318 
Re-phen-L
11b 
395,543 122 0.01 385, 539 383 
[Re-phen]2-L
2 
541 248 0.064 546 444 
[Re-phen]2-L
7 
547 215 0.048 540 510 
[Re-phen]2-L
8 
405,541 46,202 0.050 415,537 27,332 
  
3.3.4.1. Luminescence properties of {[Re(CO)3(phen]2L
2/7
]
2+ 
and [Re(CO)3(phen)L
A
]
+ 
 Upon excitation at 340nm, in acetonitrile, [Re(CO)3(phen)L
A
]
+
 (monomeric complex 
of ligand precursor A, C12 chain with a terminal OH group) displayed a single broad emission 
band around 532 nm, which is blue-shifted emission when compared to the emission maxima 
of the di-metallic ester and amide complexes, {[Re(CO)3(phen)]2L
2/7
}
2+
, at 541 nm and 547 
nm respectively. When the solvent was changed to water, a blue-shift in emission maxima 
was observed for the unsymmetrical di-amide, {[Re(CO)3(phen)]2L
7
}
2+
 only. All three 
complexes displayed dramatic extensions in lifetime with increases from 79 % for the 
unsymmetrical di-amide di-rhenium, {[Re(CO)3(phen)]2L
7
}
2+
, to 151 % for the monomeric 
rhenium complex, [Re(CO)3(phen)L
A
]
+
.   
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Figure 3.24 Lifetime graphs of {[Re(CO)3(phen)]2L
2
}
2+ 
in MeCN (LHS) and H2O (RHS).   
          
Figure 3.25 Lifetime graphs of [Re(CO)3(phen)]L
A
}
+ 
in MeCN (LHS) and H2O (RHS). 
 These extensions in lifetime were similar to those displayed in the preliminary studies 
with a C12, ester linker chain, suggesting that the excited state, localised on the 
[Re(CO)3Phen]
+
 central unit, is shielded from the quenching effect of the water solvent.
1,2 
With the effect for the mono-rhenium complex mimicking the effects of the dimers it is 
assumed that the additional rhenium moiety had little or no effect on the change in the 
photophysical properties of these complexes. The lifetimes, which best fit to a single 
exponential decay, suggested that both the [Re(CO)3(phen)]
+
 moieties are in the same excited 
state environment. These findings imply that the ‘start’ of the chain (the methylene units in 
the chain closest to rhenium) is responsible for the shielding of the excited state from the 
solvent. These findings are in agreement with the behaviour of the coumarin complexes 
studied in Chapter 1.  
 Variable temperature measurements were carried out on the symmetrical ester, 
{[Re(CO)3(phen)]2L
2
}
2+
 (Figure 3.26). An increase in the intensity of the emission maximum 
was seen as the temperature decreased which was attributed to an enhancement in the 
shielding of the excited state. As the temperature is lowered the conformations of the chain is 
more restricted (less freedom to move) and the average conformation resides around the 
[Re(CO)3(phen)]
+
 centre resulting in the enhancement of the emission intensity.  
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Figure 3.26 Steady state emission spectra for {[Re(CO)3(phen)]2L
2
}
2+ recorded in water (λ exc 345 nm). 
3.3.4.2. Luminescence properties of [Re(CO)3(phen)L
6
]
+ 
and {[Re(CO)3(phen)]2L
8
}
2+
 
 
 {[Re(CO)3(phen)]2L
8
}
2+
 is a symmetrical di-metallic compound incorporating a 
chromophoric centre. The presence of the additional chromophore moiety results in a dual 
emissive compound exhibiting two emission bands; in acetonitrile, the emission band at 405 
nm is attributed to the PMDA fluorophore with a wavelength which is very similar to that of 
the free ligand, the second, more broader emission band, at 541 nm  is attributed to the 
3
MLCT. The decay profile for {[Re(CO)3(phen)]2L
8
}
2+
 was best fit to a bi-exponential decay 
giving two distinct lifetimes; 46 and 202 ns which were assigned to PMDA-based 
fluorescence and 
3
MLCT-based phosphorescence respectively. The 
3
MLCT-based emission 
for {[Re(CO)3(phen)]2L
8
}
2+
 followed the same trend as {[Re(CO)3(phen)]2L
2/7
}
2+
 and 
[Re(CO)3(phen)L
A
]
+
; when the solvent is changed from acetonitrile to water a slight blue-shift 
in emission maxima and an increase in lifetime of 65 %  was observed (Figure 3.27). 
  The PMDA-based fluorescence presents the opposite trend to the 
3
MLCT based 
emission. For the PMDA-based fluorescence, the results depict those predicted by a simple 
solvation model (the lowering of the π* orbital and the decrease in the ππ* energy gap with 
more polar solvent). When the solvent was changed from acetonitrile to water a red-shift of 
10 nm of the emission maxima was viewed, this bathochromic shift was presented in the 
emission lifetime data with a decrease 41 % in the more polar solvent.  
 
                                               Figure 3.27 {[Re(CO)3(phen)]2L
8
}
2+ in different solvents.                    
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 Further evaluation of the lifetime data in acetonitrile showed the fluorescence 
lifetime of the PMDA-based emission in the free ligand to be longer than the PMDA-based 
emission in the complex (2.6 vs 4.9 ns) suggesting some quenching of PMDA-based emission 
had occurred in the presence of the rhenium units. When the lifetime and the quantum yield 
values for {[Re(CO)3(phen)]2L
8
}
2+
 and the structurally similar reference complex 
[Re(CO)3(phen)L
6
]
+
 for acetonitrile were compared, the data suggest quenching of the 
rhenium emission via the PMDA centre. The lifetimes of both, chromophore (PMDA) and 
rhenium in the complex, decreased in comparison to the starting materials or structural 
isomers. 
 The PMDA centred 
3ππ* state of L8 (recorded at 77 K; 1:1, EtOH : MeOH 
glass) showed structured emission at 467 nm (21400 cm
-1
) and at 490 nm (20400 cm
-1
), these 
values are higher that the reported PMDA triplet state energy of 19700 cm
-1 32
 suggesting that 
the PMDA-based emission in the complex may have some spectral overlap with the 
3
MLCT-
based emission profile which could account for the decrease in both the lifetime attributed to 
3
MLCT emission and the shorter PMDA-based lifetime when compared to its free ligand.  
 Variable temperature measurements were carried out for the symmetrical complex, 
{[Re(CO)3(phen)]2L
8
}
2+
. Again, an increase in the intensity of the 
3
MLCT emission 
maximum was seen as the temperature was decreased indicative of increased shielding of the 
excited state at lower temperatures (Figure 3.28). 
 
Figure 3.28 Steady state emission spectra for {[Re(CO)3(phen)]2L
8
}
2+ 
recorded in water (λ exc 345 nm). 
3.3.4.3. Luminescence properties of [Re(CO)3(phen)L
11a
]
+ 
and [[Re(CO)3(phen)]L
11b
]
+ 
 L
11a 
and L
11b 
differ only in the functional group appended to the aromatic 
chromophore, be it an ester or carboxylic acid, respectively. When co-ordinated to the 
[Re(CO)3(phen)]
+
 unit, in acetonitrile, (although the data reported in Table 3.2 shows little 
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change in the standard emission in comparison to [Re(CO)3(phen)L
11a
], [Re(CO)3(phen)L
11b
]
+ 
showed an increase in the ratio of intensity of the ligand based emission to 
3
MLCT emission. 
This increase was accompanied by a decrease in the emission lifetime in comparison to the 
complexes previously reported. The difference was observed in acetonitrile only and so, 
similarly to the unpredictable photophysical properties of the Re(I)-coumarin type complexes 
discussed in Chapter 2, no conclusive statement concerning the difference in the 
photophysical properties of the analogous complexes [Re(CO)3(phen)L
11a/11b
]
+ 
could be made.     
 
Figure 3.29 Steady state emission of [Re(CO)3(phen)L
11a/11b
]
+
 in different solvents & lifetime graphs of 
[Re(CO)3(phen)L
11b
]
+
. 
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3.4.   Cellular imaging 
  The photophysical studies show that for all the complexes
 
reported each 
possess suitable excitation and emission characteristics for cellular imaging applications. The 
cellular imaging properties of [Re(CO)3(phen)L
6
]
+ 
and {[Re(CO)3(phen)]2L
2,7,8
]
2+ 
were 
investigated and are discussed below. 
 Cationic, highly lipophilic complexes are known to accumulate in cells due to passive 
diffusion across a lipid membrane assisted by the membrane potential (the inside of the cell is 
negative compared to the outside). The favourable photophysical properties (Stokes 
shift/lifetime) and tuneable properties (lipophilicity/charge) of [Re(CO)3(N^N)pyridine]
+
 type 
complexes have resulted in complexes of this type being heavily investigated for applications 
as luminophores in cellular imaging. A catalogue of complexes based around the 
[Re(CO)3(N^N)]
0/+
 central unit, suitable for roles as cellular imaging agents, have already 
been reported (Chapter 1/2), however, the application of fac-{[Re(CO)3(phen)]2L]
2+
 (di-
metallic) type species in this role has yet to be explored.  
 Rhenium complexes functionalised with a long chain aliphatic have reported enhanced 
lipophilicity thus a high degree of cellular uptake.
1,2 
Both the di-cationic charge and the 
aliphatic chain length situated on {[Re(CO)3phen]2-L
2,7,8
]
2+ 
present characteristics, such as 
favourable concentration gradient/ lipophilicity to promote an increase in the uptake of the 
complexes through the outer cell membrane and possibly uptake through the inner cell 
membranes leading to more specific localisation in organelles. (Note: In some cases an 
increase in lipophilicity has led to an increase in toxicity). To test the viability of these 
complexes as cellular imaging agents the selected complexes were incubated with the MCF-7 
cell line and then the cells examined by confocal fluorescence microscopy. 
 The mono-metallic [Re(CO)3(phen)L
6
]
+
 and di-metallic {[Re(CO)3(phen)]2-L
2,7,8
}
2+ 
were each incubated with MCF-7 cells over a 30 minute period at 4 ˚C. The low temperature 
allows energy-dependent uptake processes, such as endocytosis, to be repressed.
33,34 
Following the removal of excess agent, the cells were allowed to warm to room temperature. 
At room temperature the cells functions normalise; energy-dependent pathways are no longer 
repressed allowing the accumulation and toxicity of the investigated complexes to be viewed.  
 The samples were imaged by confocal microscopy using an excitation wavelength of 
405 nm (providing effective sensitisation of the 
1
MLCT band) and a detection range between 
530-580 nm in accordance to the 
3
MLCT emission reported in Table 3.2 thus effectively 
eliminating autofluorescence. All four of the complexes viewed showed successful uptake 
with > 80 % of cells showing rhenium based emission for complexes 
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{[Re(CO)3(phen)]2L
7,8
}
2+
,[Re(CO)3(phen)L
6
]
+ 
and > 90 % of cells showing rhenium based 
emission for {[Re(CO)3(phen)]2L
2
}
2+
. Good cell morphology was maintained for each of the 
four samples. Further localisation details are discussed in detail in the following sections. 
 
 
3.4.1.   Cell imaging with [Re(CO)3(phen)]L
6
]
+ 
 The mono-metallic complex, [Re(CO)3(phen)L
6
]
+
, equipped with a phthalimide 
moiety showed invariable rhenium based emission. The absence of intense spots (seen in later 
examples) confirms non-specific localisation within the cell. Non-specific localisation was 
displayed with the plasma membrane, internal membrane and the perinuclear region of the 
cytoplasm all showing strong emission (Figure 3.30). 
 
Figure 3.30 [Re(CO)3(phen)L
6
]
+ 
uptake (left, scale bar = 48 μm) and localization (right, scale bar = 5 μm). 
3.4.2. Cell imaging with {[Re(CO)3(phen)]2L
8
}
2+  
 Unlike the monometallic complex, [Re(CO)3(phen)L
6
]
+
 (Figure 3.30) the emission 
intensity of the chromophore-centred, di-rhenium complex was variable from cell to cell; 
general background emission from the membrane and cytoplasm was observed along with 
distinct bright spots, which are indicative of specific localisation. The increase in the 
specificity of localisation from the monomer to the dimer can be attributed to the increase in 
lipophilicity and charge on the {[Re(CO)3(phen)]2L
8
}
2+ 
complex allowing the dimer to diffuse 
across inner-membranes to accumulate within the organelles. The diffuse nature of the bright 
spots argues against specific mitochondrial staining but can be attributed to ER and Golgi 
apparatus staining (Figure 3.31).  
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Figure 3.31 {[Re(CO)3(phen)]2L
8
}
2+ uptake (left, scale bar = 48 μm) and localization (right, scale bar = 10 
μm). 
3.4.3. Cell imaging with {[Re(CO)3(phen)]2L
7
}
2+  
 Similarly to the previous example, {[Re(CO)3(phen)]2L
8
}
2+
 (Figure 3.31), this non-
symmetrical, di-rhenium complex showed variable emission intensity from cell to cell, 
however, unlike the chromophore, centred dimer, {[Re(CO)3(phen)]2L
7
}
2+ 
showed a decrease 
in the intensity of the rhenium based emission with visible staining of the cytoplasm only 
(Figure 3.32). The absence of bright spots is indicative of non-specific localisation.  
 
 
 
Figure 3.32 {[Re(CO)3(phen)]2L
7
}
2+ 
 Uptake Uptake (left, scale bar = 48 μm) and localization (right, scale 
bar = 10 μm). 
                                                          
3.4.4. Cell imaging with {[Re(CO)3(phen)]2L
2
}
2+  
 The symmetrical, di-rhenium ester species, {[Re(CO)3(phen)]2L
2
}
2+
, displayed 
invariable intensity with non-specific, diffuse cytoplasmic and membrane staining of higher 
intensity than the unsymmetrical amide analogue, {[Re(CO)3(phen)]2L
7
}
2+
. Additionally, 
intense spots could be viewed from the centre of a small number of cells; this emission is 
attributed to specific staining of the nucleolar.  Z-stacks were taken confirming the presence 
of intra-nuclear staining as oppose to cell surface staining. The increased lipophilic nature of 
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this complex in comparison to previous mono and di-rhenium complexes herein is evident in 
the accumulation of the ester in the nucleolar via permeation of the nuclear membrane (Figure 
3.33).  This increased lipophilicity is attributed to the linker unit (amides show lower uptake 
than esters, see Chapter 1).  
 
 
 
Figure 3.33 {[Re(CO)3(phen)]2L
2
}
2+
 uptake (left, scale bar = 14 μm) and localization (right, scale bar = 10 
μm). 
 
3.4.4.1.  SYTORNASelect (SRS) 
 The low number of cells displaying nucleolar staining made confirmation of the 
specific organelle staining via co-localization experiments impossible. To demonstrate the 
accumulation of the di-rhenium ester in the nucleolei, SRS was used (Figure 3.34). SRS is a 
cell permeable nucleic acid known to selectively stain the nucleolei, but more specifically it 
stains the RNA found in the nucleolei. When incubated with MCF-7s SRS displayed emission 
distribution very similar to that shown in Figure 3.33. Both the Z stacks and SRS localisation 
indicate the assignment for the bright emissive spot to nucleolar staining is highly probable.  
 
 
Figure 3.34 Localization of SRS (scale bar = 9 μm) in MCF7s 
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3.5.   Cytotoxicity investigation 
Propidium iodide (PI) is a cell impermeable fluorophore that can only be taken up into 
cells with damaged membranes and it is commonly used to test the number of dead cells in a 
given sample and thus can be used to test the toxicity of the complexes after incubation. 
Following incubation of MCF-7’s with {[Re(CO)3(phen)]2L
2/7
}
2+ 
and [Re(CO)3(phen)L
6
]
+
, the 
cells were incubated with PI. The results are shown in Table 3.3. 
A control made up of MCF-7 cells, PI and DMSO showed 3 % of cells took up the PI 
indicator. The symmetrical, di-rhenium ester species, {[Re(CO)3(phen)]2L
2
}
2+
, gave the 
highest toxicity value of 7 % indicating a relationship between toxicity and lipophilicity  as 
reported previously. Despite the increase in toxicity of the dimer ester in comparison to the 
control all three complexes tested showed low-cytotoxicity with 1-7% of samples taking up 
the PI indicator. The low toxicity values of all four complexes favour their use as cellular 
imaging agents. 
Table 3.3 Cytotoxicity data for{[Re(CO)3(phen)]2L
2/7
}
2+ 
and [Re(CO)3(phen)L
6
]
+
 
Compound  % of dead cells 
Control 3 ± 2.92 
[Re-phen-L
51b
]
+
 4 ± 3.51  
[[Re-phen]2-L
42
]
2+
 7 ± 4.66 
[[Re-phen]2-L
62
]
2+
 1 ± 1.79 
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3.6.    Conclusion 
 From the photophysical data discussed it was clear that each of the complexes reported 
herein are sensitive to the nature of the solvent environment. The inclusion of an additional 
rhenium moiety in complexes {[Re(CO)3(phen)]2L
2/7/8
}
2+
, showed an appreciable difference 
in the photophysical results of the complex when the solvent is changed from acetonitrile to 
water with both a dramatic increase in emission intensity and lifetime seen in the majority of 
compounds investigated. The monomer species, [Re(CO)3(phen)L
A
]
+
, mimics the 
photophysical changes with solvent seen in both the di-metallic complexes and the mono-
rhenium complex reported in the preliminary studies. The monomers, [Re(CO)3(phen)L
6 
/11a/11b
]
+ 
showed a much smaller increase in lifetime when the solvent was changed in 
comparison to [Re(CO)3(phen)L
A
]
+ 
thus linker units and functional groups appended to the 
end of the chains must have an effect on the extent of chain wrapping. 
 Similar to the results in Chapter 2, the inclusion of a chromophore moiety to the centre 
and end of a ligand chain does show an effect on the solvent-dependent photophysical 
properties with changes in emission intensities. As only a small number of complexes have 
been investigated no conclusive statement on the role of the chromophore in hydrophobic 
interactions can be drawn.
 
Four complexes were investigated for their suitability as cellular imaging agents, the 
monomer [Re(CO)3(phen)L
6
]
+
, and the di-metallic complexes {[Re(CO)3(phen)]2L
2/7/8
]
2+
. All 
four complexes displayed low toxicity and good cellular uptake. More specific localisation 
was viewed for the di-rhenium, di-ester complex, {[Re(CO)3(phen)]2L
2
]
2+ 
with specific 
localisation in the nucleolar and for the di-rhenium chromophore centred complex, 
{[Re(CO)3(phen)]2L
8
]
2+
, with probable ER and Golgi apparatus localisation. 
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3.7. Experimental 
3.7.1. Synthesis of ligands 
L
1
 Nicotinoyl chloride (0.5 g, 3.5 mmol) in chloroform was added slowly to a solution of 
ethylene glycol (4 mL, 7 mmol) and TEA (1.6 mL, 11 mml) in chloroform (40 mL) and the 
solution was left to stir at 60 C for 5 h. The solution was washed with water (3  10 mL) and 
sat. aq. ammonium chloride (10 mL). The organic layer was dried and solvent evaporated to 
dryness, yielding a cream solid. Yield: 1.3 g, 68 %. 
1
H NMR (CDCl3, 400 MHz, 298K) δH: 
4.61 (4H, s, (H5)), 7.32-7.35 (2H, m, (H3)), 8.21-8.26 (2H, m, (H4)), 8.68-8.73 (2H, m, 
(H2)), 9.13 (2H, s, (H12)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298K) δc: 61.9, 122.4, 
136.2, 149.9, 152.6, 164 ppm. MS (ES
+
) m/z: 272 [M+H]
+
. HRMS (ES
+
) found m/z  273.0872 
[M+H]
+
; [C14H13O4N2]
+  
requires 273.0791. IR (nujol ) υ: 1651 (CO) cm-1. UV-vis (ε / M-1 cm-
1
) (MeCN) λmax: 261 (3488), 332 (558) nm. Mp= 112-115. 
L
2
 Nicotinoyl chloride (1.77 g, 12.48 mmol) in chloroform was added slowly to a solution of 
1,12-dodeacanediol (1 g, 4.99 mmol) and TEA (2.1 mL, 14.97 mml) in chloroform (40 mL) 
and the solution was left to stir at 60 C for 5 h. Same work up as above. Yield: 1.90 g, 93 %. 
1
H NMR (CDCl3, 400 MHz, 298K) δH: 1.13 (12H, s, (H8-H10)), 1.43-1.48 (4H, m, (H7)), 
1.69-1.79 (4H, m, (H6)), 4.75 (4H, t, 
3
JHH = 6.7 Hz, (H5)), 7.30-7.36 (2H, m, (H3)), 8.21-8.27 
(2H, m, (H4)), 8.68-8.72 (2H, m, (H2)), 9.12 (2H, s, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 
MHz, 298K) δc: 24.9, 27.6, 28.2, 28.5, 28.9, 64.6, 122.3, 125.4, 136.2, 149.7, 152.1, 164.2 
ppm. MS (ES
+
) m/z: 413.2 [M+H]
+
. 
L
4
 To a solution of hydroxy methyl pyridine (0.8 mL, 92 mmol) in DCM (30 mL) was added  
oxalyl chloride (0.3 mL, 3.7 mmol) dropwise at room temperature. The reaction was left to 
stir for 30 mins. The white precipitate formed was filtered and dried under reduced pressure. 
Yield 800 mg, 53 %. 
1
H NMR (CDCl3, 400 MHz, 298K) δH: 5.31 (4H, s, (H5)), 7.29-7.36 
(2H, m, (H3)), 7.71-7.75 (2H, m, (H4)), 8.78-8.80 (2H, m, (H2)), 8.62 (2H, s, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298K) δc: 66.2, 110, 123.7, 129.7, 136.7, 150, 150.3, 157 
ppm. MS (ES
+
): 273 [M+H]
+
. HRMS (ES
+
) found m/z 273.08 [M+H]
+
; [C14H13O4N2]
+  
requires 273. IR (nujol) υ: 1732.7 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) λmax:  209 (367), 
224 (681), 250nm, (1090) nm.  
L
5 
To a solution of ligand precursor A (1 g, 3.26 mmol) and TEA (0.69 mL, 4.89 mmol) in 
DCM (30 mL) was added oxalyl chloride (0.201 g, 1.63 mmol) dropwise at room 
temperature. The reaction was left to stir for 30 mins. The crude product was purified 
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using column chromatography, eluting with dichloromethane:methanol (96:4).  Yield: 
0.136 mg, 12 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.15-1.29 (28H, m, (H8-H14)), 
1.29-1.41 (4H, m, (H7)), 1.53-1.62 (4H, m, (H15)), 1.68-1.77 (4H, m, (H6)), 4.08 (4H, t, 
3
JHH = 6.8 Hz, (H16)), 4.29 (4H, t, 
3
JHH = 6.7 Hz, (H5)), 7.27-7.36 (2H, m, (H3)), 8.18 (2H, 
dd, (H4)), 8.13-8.25 (2H, m, (H2)), 9.11-9.19 (2H, m, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 
101 MHz, 298 K) δc: 25.6, 25.8, 26.2, 26.8, 27.1, 28.5, 28.9, 28.6, 29, 29.3, 29.6, 42.3, 
65.7, 123.3, 137.1, 151.2, 153.4, 164.6 ppm. MS (ES
+
) m/z: 682.41 [M]
+
. HRMS (ES
+
) 
found m/z 682.4181 [M]
+
; [C30H58O8N2]
+ 
requires 682.4188. IR (nujol) υ: 1751 (CO), 
1756 (CO) cm
-1
. UV-vis (ε / M-1cm-1) (MeCN) λmax : 261 (6067), 363 (610) nm.  
L
6 
12-aminolauric acid (1 g, 3.98 mmol) and phthalic anhydride (0.589 mg, 3.98 mmol) were 
added to a shlenk and heated until no vapour was given off. 
1
H NMR (MeOD, 400 MHz, 298 
K) δH: 1.25 (12H, s, (H5-H10)), 1.5-1.62 (4H, m, (H4,H11)), 2.23 (2H, t, 
3
JHH = 6.8 Hz, 
(H12)), 3.26 (2H, m, (H3)), 3.63 (2H, t, 
3
JHH = 6.3 Hz, (H13)),  7.7-7.82 (4H, m, (H1,H2)) 
ppm. Thionyl chloride (2 mL) was added and solution was left at 71 C for 1 h. The excess 
thionyl chloride was removed under vacuum and chloroform (20 mL), TEA (1.14 mL, 11.14 
mmol) and amino-methyl pyridine (0.76 mL, 7.43 mmol) were added and mixture heated to 
59 ˚C for 3 h. The product was washed with sat. aq. ammonium chloride (3  10 mL), the 
organic layer dried and solution evaporated. Yield: 1.48 g, 95 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.21 (14H, s, (H5-H11)), 1.58-1.65 (4H, m, (H4, H12)), 2.19 (2H, t, 
3
JHH = 7.3 Hz, 
(H3)), 3.58 (2H, t, 
3
JHH = 7.5 Hz, (H13)), 4.32 (2H, d, 
3
JHH = 4.3 Hz, (H14)), 6.47 (1H, s, 
(NH)), 7.13-7.18 (1H, m, (H17)), 7.50-7.53 (1H, m, (H16)), 7.61-7.64 (2H, m, (H2)), 7.72-
7.76 (2H, m, (H1)), 8.46-8.49 (2H, m, (H15,H18)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 
298K) δc: 25.7, 26.8, 28.6, 29.1, 29.2, 29.4, 36.7, 38.1, 40.9, 123.1, 123.5, 132.2, 133.9, 
134.2, 135.6, 148.7, 149, 168.5, 173.3 ppm. MS (ES
+
) m/z: 435.33 [M+H]
+
. HRMS (ES
+
) 
found m/z 436.2588 [M+H]
+
; [C26H33O3N3]
+ 
requires 436.2695. IR (nujol) υ: 1715 (CO), 
1772 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 259 (14699), 294 (6394) nm.  
Ligand precursor B: L
6 
(1.2 g, 2.84 mmol) was dissolved in methoxyethanol (20 mL), 
hydrazine (0.41 mL, 0.854 mmol) was added and the solution left at 115 ˚C for 12 h. The 
solution cooled and the white precipitate was filtered and filtrate evaporated. Yield: 0.5 g, 58 
%. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.21 (14H, s, (H8-H15)), 1.59 (2H, t, 
3
JHH = 6.2 
Hz, (H16)),1.63 (2H, t, 
3
JHH = 7.5 Hz, (H7)), 2.55 (2H, t,
 3
JHH = 12.5 Hz, (H17)), 4.44 (2H, d, 
3
JNH = 5 Hz, (H5)), 7.1-7.19 (1H, m, (H3)), 7.53 (1H, d, 
3
JHH = 7.5 Hz, (H4)), 8.44-8.49 (2H, 
m, (H1,H2)) ppm.
 13
C{
1
H} NMR (CDCl3, 101 MHz, 298K) δc: 24.5, 24.7, 25.8, 28.2, 28.3, 
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28.4, 28.5, 32.5, 33.5, 35.6, 39.9, 41.1, 122.6, 134.6, 147.7, 148.1 ppm. MS (ES
+
) m/z: 306.26 
[M+H]
+
, HRMS (ES
+
) found m/z 306.2537 [M+H]
+
; [C18H32ON3]
+ 
requires 306.2540. IR 
(nujol) υ: 3292 (NH), 1632 (CO) cm-1. UV-vis. (ε / M-1 cm-1) (MeCN) λmax: 259 (759) nm.  
L
7 
: To nicotinoyl chloride (55 mg, 0.39 mmol) was added  Ligand precursor B (100 mg, 0.38 
mmol) and TEA (0.14 mL, 0.93 mmol) in chloroform (30 mL) and the solution heated to 59 
˚C for 3 h. Work-up was the same as above. Yield: 125 mg, 93 %. 1H NMR (CDCl3, 
400MHz, 298K) δH: 1.22-1.45 (12H, m, (H9-H15)), 1.49-1.62 (4H, m, (H8,H16)), 2.15 (2H, t, 
3
JHH = 7.6 Hz, (H17)), 3.36-3.41 (2H, m, (H7)), 4.45 (2H, d, 
3
JHH = 5.9 Hz, (H5)), 6.1 (1H, s, 
(NH)), 6.48 (1H, s, (NH)), 7.12-7.15 (1H, m, (H21)), 7.21-7.27 (1H, m, (H3)), 7.50 (1H, d, 
3
JHH = 7.8 Hz, (H20)), 8.00 (1H, d, (H4)), 8.32-8.39 (2H, m, (H2,H22)), 8.49-8.55 (1H, m, 
(H19)), 8.82-8.96 (1H, m, (H1)) ppm. 
13
C NMR (CDCl3, 400 MHz, 298K) δc: 25.7, 26.9, 
29.2, 29.3, 29.5, 36.7, 40.1, 49, 65.2, 123.6, 123.7, 135.3, 135.9, 147.8, 148.8, 149.1, 156.8 
ppm. MS (ES
+
) m/z: 411.3 [M+H]
+
, 433.3 [M+Na]
+
. HRMS (ES
+
) found m/z 411.2749 
[M+H]
+
; [C24H35O2N4]
+ requires 411.2755. IR (nujol) υ:1633 (CO) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 260 (9859) nm. Mp=74-82 
L
8
: Ligand precursor B (200 mg, 0.655 mmol) and benzol-1,2,4,5 benzenetetracarboxylic- 
dianhydride (71 mg, 0.323 mmol) were heated together in a Schlenk until no vapour was 
given off producing a brown solid. Yield: 251 mg, 98 %. 
1
H NMR (MeOD, 250 MHz, 298 K) 
δH: 1.11-1.42 (32H, m, (H9-H16)), 1.49-1.62 (8H, m,  (H17,H18)), 2.18 (4H, t,
 3
JHH = 15 Hz, 
(H7)), 3.17 (4H, t, 
3
JHH = 1.5 Hz, (H18)), 4.41 (4H, d, 
3
JNH = 6.3 Hz, (H5)), 7.2-7.24 (2H, m, 
(H3)), 7.57 (2H, d, 
3
JHH = 7.5 Hz, (H4)), 8.22 (2H, d, (H19)), 8.41-8.61 (4H, m, (H1,H2)) 
ppm. 
13
C{
1
H} NMR (MeOD, 101 MHz, 298K) δc: 24.7, 25.7, 27.4, 28, 28.2, 28.3, 28.4, 35.6, 
37.7, 38.7, 39.9, 117.1, 117.4, 122.7, 122.8, 133.4, 134.9, 135.8, 135.9, 136.2, 136.4, 147.5, 
147.8, 148.5, 149, 164.7, 165.1, 165.3, 172.3 ppm. MS (ES
+
) m/z: 793.5 [M+H]
+
, 815.5 
[M+Na]
+
. HRMS (ES
+
) found m/z 793.4634 [M+H]
+
; [C46H61O6N6]
+ 
requires 793.4647. IR 
(nujol) 1696 (CO), 1740 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 234 (17545) nm. 
L
9 
6-amino, 1-hexanol (1.07 g) was added drop wise to a solution of benzol-1,2,4,5 
benzenetetracarboxylicaciddianhydride (1 g) in DMF (4.5 mL) The mixture was set to sub 
reflux at 160 ˚C. After 6 h the solution was cooled and poured into ice water. The white 
precipitate that formed was filtered and recrystallized using methanol. Yield: 1.6 g, 84 %.  
1
H 
NMR (CDCl3, 400MHz, 298K) δH: 0.82-0.88 (8H, m, (H3,H4)), 1.52-1.57 (4H, m,
 
(H2)), 
1.68-1.71 (4H, m, (H5)), 3.52 (4H, t, 
3
JHH =  Hz, (H1)), 3.69 (4H, t, 
3
JHH =  Hz, (H6)), 8.15 
(2H, s, (H7)) ppm. MS (ES) m/z:  855.31 [2M+Na
+
]. L
10
 The white precipitate (1 g) thionyl 
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chloride (2 mL) was added and the reaction was left at 71 ˚C for 4 h. The excess thionyl 
chloride was then removed using a second vacuum chamber. 
1
H NMR (CDCl3, 400MHz, 
298K) δH: 1.42-1.48 (4H, m, (H3)), 1.49-1.57 (4H, m,
 
(H4)), 1.75-1.80 (8H, m, (H2, H5)), 
3.48 (4H, t, 
3
JHH =6.6 Hz, (H1)), 3.72 (4H, t, 
3
JHH = 7.3 Hz, (H6)), 8.19 (2H, s, (H7)) ppm. To 
the precursor (100 mg, 0.22 mmol) in DMF (20 mL) was added potassium pthalimide (101 
mg, 0.56 mmol) in DMF (10 mL) drop wise followed by catalytic amount of KI. The reaction 
was left at 150 ˚C for 3 weeks. The resulting solution was evaporated to yield a orange oil. 
Recrystalised using chloroform and petrol. 
1
H NMR (CDCl3, 400MHz, 298K) δH: 1.43-1.46 
(8H, m, (H3, H4, H12, H13)), 1.65-1.75 (8H, m, (H2, H5, H11, H15)), 3.51 (2H, t, (H15)), 
3.59 (2H, t, (H6)), 3.68-3.72 (4H, m, (H1, H10)), 7.62-7.66 (2H, m, (H7)), 7.79-7.84 (2H, m,  
(H8)), 8.15-8.19 (2H, m, (H9)) ppm. 
13
C NMR (CDCl3, 400 MHz, 298K) δc: 36.1, 41.2, 44.1, 
44.4, 44.8, 45, 45.7, 55.8, 127.9, 138.7 ppm. MS (ES
+
) m/z: 545.22 [M]. IR (solid) υ: 1661.86 
(CO), 1716.82 (CO), 1769.85 (CO), 3414.83 (OH), cm
-1
.
 
UV-vis (ε / M-1 cm -1) (MeCN) λmax: 
237 (5377) nm.  
Ligand precursor C: Nicotinoyl chloride (1.96 g, 15.9 mmol) in chloroform (10 mL) was 
added slowly to a solution of 12-amino lauric acid (2 g, 7.95 mmol) and TEA (5.6 ml, 39.8 
mmol) in chloroform (20 mL) and the solution was left to stir at 60 C for 5 h. The solution 
was washed with water (3  10 mL) and sat. aq. ammonium chloride (10 mL). The organic 
layer was dried and solvent evaporated to dryness, yielding a cream solid Yield: 1.6 g, 55 %. 
1
H NMR (MeOD, 400 MHz, 298 K) δH: 1.17-1.25 (14H, m, (H7-H13)), 1.55-1.58 (4H, m, 
(H6,H14)), 2.22 (2H, t, 
3
JHH = 7.4 Hz, (H5)), 3.34 (2H, t, 
3
JHH = 7.2 Hz, (H15)), 7.49-7.54 
(1H, m, (H3)), 8.18-8.21 (1H, m, (H4)), 8.62-8.68 (1H, m, (H2)), 8.91-8.93 (1H, m, (H1)) 
ppm. 
13
C{
1
H} NMR (MeOD, 101 MHz, 298K) δc: 26, 28.1, 30, 30.1, 35, 41.2, 48, 49.7, 50.1, 
125.2, 132.3, 137.2, 148.9, 152.4, 167.7, 177.7 ppm. MS (ES
+
) m/z: 321.33 [M+H]
+
, 343.20 
[M+Na
+
], 359.18 [M+K
+
], 384.22 [M+MeCNNa
+
]. HRMS (ES
+
) found m/z 319.2035 [M-H]
+
; 
[C18H27O3N2]
+  
requires 319.2035. IR (nujol) υ: 1650 (CO),  1807 (CO), 3306 (NH) cm-1. UV-
vis (ε / M-1 cm-1) (MeCN) λmax: 213 nm (10891), 257 (16758) nm.  
L
11a
: Ligand precursor C (1.2 g, 3.75 mmol) was dissolved thionyl chloride (2 mL and left at 
71 ˚C for 1 h. The excess thionyl chloride was removed under vacuum. Methyl anthranilate 
(1.45 mL, 11.25 mmol) in chloroform (30 mL) was added and reaction left at 59 ˚C for 3 h. 
The precipitate in solution was filtered. The solution was concentrated and petrol added to 
precipitate out a cream solid. Yield: 600 mg, 37 %.
 1
H NMR (CDCl3, 400 MHz, 298 K) δH: 
1.12-1.37 (16H, m, (H7-H14)), 1.52 (2H, t,
 3
JHH = 7.4 Hz, (H15)), 1.67 (2H, t, 
3
JHH = 7.1 Hz, 
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(H6)), 2.35 (2H, t, 
3
JHH = 7.3 Hz, (H5)), 3.31-3.38 (2H, m, (H15)), 3.82 (3H, s, (H20)), 6.12 
(1H, s, (NH)), 6.92 (1H, t,
 3
JHH = 7.5 Hz, (H19)), 7.22-7.27 (1H, m, (H3)), 7.42 (1H, t,
 3
JHH = 
7.3 Hz, (H18)), 7.79 (1H, d, 
3
JHH = 7.5 Hz (H4)), 8.00 (1H, d, 
3
JHH=8 Hz, (H20)), 8.49-8.51 
(2H, m, (H1,H2)), 8.81-8.87 (1H, m, (H17)) ppm. 
13
C{
1
H} NMR CDCl3, 101 MHz, 298 K) 
δc: 25.5, 27, 29.2, 29.3, 29.4, 29.6, 38.7, 40.3, 52.3, 114.8, 120.2, 122.3, 130.8, 134.7, 135.3, 
141.7, 147.7, 151.8, 168.8, 172.4 ppm. MS (ES
+
) m/z: 454.28 [M+H]
+
, 476.35 [M+Na
+
], 
493.23 [M+K
+
], HRMS (ES
+
) found m/z 454.2692 [M+H]
+
; [C26H36O4N3]
+ 
requires 454.2700. 
IR (nujol) ν: 1650 (CO), 1683 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 223 (31383) 
252.4 (14839), 310.5 (4442) nm.   
L
l1b
: 11a (600 mg, 1.38 mmol) was dissolved in ethanol (30 mL) and hydrazine (0.05 mL, 
1.65 mmol) was added drop-wise. The reaction mixture was left to heat at 70 ˚C for 3 h. 
Water was then added to the mixture and product was extracted using chloroform and ethyl 
acetate. Organic layer dried and solution evaporated to yield a dark cream ppt. Yield: 400 mg, 
66 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH:  1.19-1.35 (14H, m, (H8-H14)), 1.48-1.52 (2H, 
m, (H15)), 1.57-1.63 (2H, m, (H7)), 2.30 (2H, t, 
3
JHH = 7.5 Hz, (H16)), 3.41 (2H, t, 
3
JHH = 7.2 
Hz, (H6)), 6.94 (1H, t, 
3
JHH = 7.6 Hz, (H20)), 7.29 (1H, dt, (H19)), 7.42-7.46 (1H, m, (H3)), 
8.0 (1H, d, 
3
JHH = 7.6 Hz , (H4)), 8.11 (1H, d, 
3
JHH = 8 Hz, (H21)), 8.40 (1H, d, 
3
JHH = 8.3 Hz, 
(H18)), 8.51-8.55 (1H, m, (H2)), 8.79-8.83 (1H, m, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 
MHz, 298 K) δc: 25.1, 26.4, 26.8, 28.9, 29, 29.2, 29.3, 38.7, 41.2, 119.4, 122.2, 131.6, 135.6, 
166.2, 172.9 ppm. IR (nujol) ν: 1656 (CO), 3440 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) 
λmax: 254.5 (926) nm.  
L
12
: Ligand precursor A (150 mg, 0.488 mmol) and phthalic anhydride (72 mg, 0.488 mmol) 
were dissolved in chloroform (20 mL) and added to RBF where they were heated to 56 ˚C. 
TFA was added drop wise until pH was acidic and reaction left to heat and stir at room 
temperature for 48 h. The resulting solution was washed with NaH(CO)3 (2 × 5 mL), dried 
and solution evaporated. Yield: 39 mg, 18 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.21 
(16H, m, (H7-H14)), 1.54-1.71 (4H, m, (H6,H15)), 4.21 (2H, t, 
3
JHH = 6.7 Hz, (H5)), 4.31 
(2H, t, 
3
JHH = 6.7 Hz, (H16)), 7.78 (2H, m, (H18)), 7.91 (2H, m, (H17)), 8.72 (1H, d, 
3
JHH = 
7.3 Hz, (H4)), 8.89 (1H, m, (H2)), 9.31 (1H, s, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 
298 K) δc: 20.9, 25.4, 25.8, 28, 28.4, 29, 29.1, 29.3, 29.4, 65, 67.4, 68.4, 125.7, 127.1, 131.2, 
136.1, 143.7, 145.4, 145.6, 161.7, 162.8 ppm. MS (ES
+
) m/z: 456.25 [M+H]
+
. HRMS (ES
+
) 
found m/z 456.2378 [M+H]
+
; [C26H34O6N]
+  
requires 456.2378. IR (nujol) ν: 1687 (CO), 1732 
(CO), 1810 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 264 (2212) nm.  
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3.7.2. Synthesis of Complexes 
[Re(CO)3(phen)L
A 
]
+
 To a round bottom flask encased in foil ligand precursor A (36 mg, 
1.25  10-4 mol), [Re(CO)3(phen)Br] (60 mg, 1.1  10
-4 
mol), and silver tetrafluoroborate (33 
mg, 1.7  10-4 mol) in toluene (10 mL) were added and heated to 100 ˚C for 24 h. The 
solution was filtered through Celite and washed repeatedly with acetonitrile. The removal of 
the solvent under high vacuum afforded a yellow solid. Column chromatography was then 
used to purify the crude product. Yield: 22 mg, 27 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 
1.17-1.21 (14H, s, (H12-H18)), 1.40-1.43 (2H, m, (H11)), 1.55-1.57 (2H, m, (H19)), 2.12-
2.17 (2H, m, (H10)), 3.39 (2H, t, 
3
JHH = 6.6 Hz, (H20)), 4.08 (2H, t, 
3
JHH = 6.6 Hz, (H9)), 
7.24-7.26 (1H, m, (H7)), 7.99-8.04 (2H, m, (H3)), 8.05-8.09 (1H, m, (H8)), 8.17 (2H, s, 
(H4)), 8.79-8.86 (3H, m, (H2,H6)), 9.32-9.40 (2H, m, (H1)), 9.51-9.57 (1H, m, (H5)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δc: 6.96, 23.8, 24, 26.4, 26.7, 27.3, 27.5, 30.9, 45.5, 
61.1, 65.6, 120.5, 124.9, 125.7, 126.4, 126.8, 129.4, 129.5, 138.3, 138.9, 144.4, 144.9, 152, 
191.3 ppm. MS (ES
+
) m/z: 758.23 [M+H]
+
. HRMS (ES
+
) found m/z 758.2132 [M+H]
+
; 
[ReC33H37O6N3]
+  
requires 758.22. IR (nujol) υ: 1765 (COO), 1924 (CO), 2025.85 (CO), 3404 
(OH) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 251.2 (12228), 273.4 (14639), 323.6 
(3191),366.7 (1711) nm.  
[Re(CO)3(phen)L
6 
]
+
 To a round bottom flask encased in foil L
6 
1(50 mg, 0.12 mmol), 
[Re(CO)3(phen)Br] (57 mg, 0.1 mmol) and silver tetrafluoroborate (31 mg, 0.14 mmol) in 
toluene (10 mL) were added and heated to 100 ˚C for 24 h. Work-up as before. Yield 29 mg, 
33 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.11-1.17 (16H, m, (H12-H19)), 1.36-1.46 
(2H, m, (H12)), 1.53-1.64 (2H, m, (H20)), 1.96 (2H, t, 
3
JHH = 7.7 Hz , (H11)), 3.59 (2H, t, 
3
JHH = 7.3 Hz, (H21)), 4.09 (2H, t, 
3
JHH = 6 Hz, (H9)), 6.88-6.91 (1H, m, (H7)), 7.56-7.59 
(4H, m, (H3, H23)), 7.69-7.71 (2H, m, (H22)), 8.0 (2H, s, (H4)), 8.01-8.09 (1H, m, (H8)), 
8.06-8.13 (2H, m, (H2)), 8.60-8.64 (2H, m, (H5, H6)), 9.51-9.54 (2H, m, (H1)) ppm. 
13
C 
NMR ((CDCl3) , 101 MHz, 298K): δc: 22.8, 23, 25.9, 26.1, 27.3, 29, 29.6, 29.8, 29.9, 34.5, 
36.4, 38.5, 40.6, 53.9, 123.6, 124.1, 126.5, 128.1, 128.8, 131.5, 131.8, 132.5, 134.3, 135.1, 
139.9, 140.5, 146.8, 150, 152, 154.6, 168.9, 174.6 ppm. MS (ES
+
) m/z: 886.40, HRMS (ES
+
) 
found m/z 884.2570 [M-BF4
-
]
+
; [
185
ReC41H41O6N5]
+  requires 884.2581. IR (nujol) ν: 1711 
(CO), 1781 (CO), 1921 (CO), 2032 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 275.3 
(29552), 365 (3421) nm.   
[Re(CO)3(phen)L
11a
]
+
 To a round bottom flask encased in foil L
11a 
(50 mg, 0.11 mmol), 
[Re(CO)3(phen)Br] (50 mg, 0.09 mmol) and silver tetrafluoroborate (30 mg, 0.15 mmol) in 
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toluene (10 mL) were added and heated to 100 ˚C for 24 h. Work-up as before. Yield: 21 mg, 
26 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.17-1.40 (14H, m, (H8-H14)), 1.41-1.47 (2H, 
m, (H15)), 1.62-1.69 (2H, m, (H7)), 2.48 (2H, t, (H16)), 3.19-3.25 (2H, m, (H6)), 4.38 (3H, s, 
(H21)), 6.68 (1H, t, (H19)), 7.32-7.38 (1H, m, (H3)), 7.41-7.49 (1H, m, (H18)), 7.91-8.03 
(2H, m, (H24)), 8.04 (2H, s, (H25)), 8.02-8.09 (1H, m, (H20)), 8.31 (1H, d, (H4)), 8.51 (1H, 
s, (H1)), 8.67-8.92 (3H, m, (H2, H23)), 9.29 (1H, d, (H17)), 9.48-9.53 (2H, m, (H22)) ppm. 
MS (ES
+
) m/z: found 903.33 [M-BF4
-
]
+
, HRMS (ES
+
) found m/z 902.2675 [M-BF4
-
]
+
; 
[
185
ReC41H43O7N5]
+  
requires 902.2665. IR (nujol) ν: 1710 (CO), 1921 (CO), 2034 (CO) cm-1. 
UV-vis λmax (ε / M
-1 
cm
-1
) (MeCN): 252.4 (8949), 272.32 (7911), 348 (12536) nm.  
[Re(CO)3(phen)L
11b 
]
+
 To a round bottom flask encased in foil L
11b 
(50 mg, 0.11 mmol), 
[Re(CO)3(phen)Br] (50 mg, 0.09 mmol), and silver tetrafluoroborate (30 mg, 0.15 mmol) in 
toluene (10 mL) were added and heated to 100 ˚C for 24 h. Work-up as before. Yield: 14 mg, 
18 mg. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.09-1.42 (14H, m, (H8-H14)), 1.44 (2H, t, 
3
JHH = 6.7 Hz, (H15)), 1.68 (2H, t, 
3
JHH = 6.9 Hz, (H7)), 2.32 (2H, t, 
3
JHH = 7.1 Hz, (H16)), 
3.18-3.25 (2H, m, (H6)), 6.73 (1H, t, 
3
JHH = 7.5 Hz, (H5)), 7.11-7.13 (1H, m, (H3)), 7.22 (1H, 
t, 
3
JHH = 7 Hz, (H18)), 7.72 (1H, d, 
3
JHH = 6.8 Hz, (H20)), 7.91 (2H, s, (H24)), 8.04-8.07 (3H, 
m, (H19, H23)), 8.21 (1H, d, 
3
JHH = 5.6 Hz, (H4)), 8.45-8.56 (4H, m, (H2, H17, H22)), 8.86 
(1H, s, (H1)), 9.2 (2H, d, 
3
JHH = 5.2Hz, (H21)) ppm. MS (ES
+
) m/z: found 890.26 [M-BF4
-
]
+
.
 
IR (nujol) ν: 1690 (CO), 1895 (CO), 1920 (CO), 2049 (CO) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 239 (18984), 255 (11424) nm.  
{[Re(CO)3(phen)]2L
2 
}
2+
 To a round bottom flask encased in foil L
2 
(14 mg, 3.69 × 10
−5
 mol), 
[Re(CO)3PhenBr] (30 mg, 7.39  10
-5 
mol),  and silver tetrafluoroborate (8.5 mg, 4.4  10-5 
mol) in toluene (10 mL) ) were added and heated to 100 ˚C for 24 h. Work-up as before. 
Yield: 19 mg, 26 %. 
1
H NMR (CD3CN, 400 MHz, 298 K) δH: 1.13-1.31 (12H, s, (H12-H14)), 
1.50-1.58 (4H, m, (H11)), 1.92- 2.05 (4H, m, (H10)), 4.04 (4H, t, 
3
JHH = 6.6 Hz, (H9)), 7.23-
7.42 (2H, m, (H7)), 7.97-7.99 (4H, m, (H3)), 8.02-8.06 (6H, m, (H4, H8)), 8.31 (2H, d, (H6)), 
8.48 (2H, s,  (H5)), 8.72 (4H, d, (H2)), 9.51-9.54 (4H, m, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 
400 MHz, 298K) δc: 28.1, 29.4, 29.9, 66, 126.7, 127.2, 128.3, 129.2, 131.4, 140.4, 140.6, 
146.7, 152, 154.6, 155.6, 162.9 ppm. MS (ES
+
) m/z: 863.3 [M-(Re(CO)3Phen)+H]
+
. HRMS 
(ES
+
) found m/z 861.2404 [M-(Re(CO)3Phen)]
+
; [
185
ReC39H40O7N4]
+  
requires 861.2421. IR 
(nujol) ν: 1722 (CO), 1917 (CO), 2034 (CO) cm-1. UV−vis (ε / M−1 cm−1) (MeCN) λmax: 252 
(24400), 275 (26600), 377 (2900) nm. Anal. calcd (%) for B2C54F8H48N6O10Re2·0.75CH2Cl2: 
C, 42.40; H, 3.22; N, 5.42. Found (%): C, 42.13; H, 3.87; N, 5.80. 
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{[Re(CO)3(phen)]2L
7 
}
2+
 To a round bottom flask encased in foil L
7
(27 mg, 0.06 mmol), 
[Re(CO)3PhenBr] (70 mg, 0.13 mmol), and silver tetrafluoroborate (40 mg, 0.2 mmol) in 
toluene (10 mL) ) were added and heated to 100 ˚C for 24 h. Work-up as before. Yield: 21 
mg, 24 %. 
1
H NMR (CD3CN, 400 MHz, 298 K) δH: 1.18-1.35 (16H, m, (H7-H14)), 1.36-1.42 
(2H, m, (H15)), 1.51-1.55 (2H, m, (H6)), 3.90-3.92 (2H, m, (H16)), 4.31 (2H, d, (H5)), 6.61 
(1H, s, (NH)), 6.92 (1H, s, (NH)),  7.02-7.09 (1H, m,  (H19)), 7.11-7.17 (1H, m, (H3)), 7.52 
(1H, d, (H18)), 7.60-7.65 (1H, m, (H4)), 8.01-8.09 (8H, m, (H23, H24, H27, H28)), 8.20-8.25 
(1H, m, (H20)), 8.44-8.49 (1H, m, (H2)), 8.71-8.78 (5H, m, (H17, H22, H26)), 9.49-9.53 (5H, 
m, (H1, H21, H25)) ppm. MS (ES
+
) m/z: 861.29 [M-Re(CO)3(phen)]
+
. HRMS (ES
+
) found 
m/z 859.2743 [
185
ReC39H42O5N6]
+
; [
185
ReC39H42O5N6]
+  
requires 859.2741
+
. IR (nujol) υ: 
1675 (CO), 1910 (CO), 2031 (CO) cm
-1
. UV-vis (ε / M-1cm-1) (MeCN) λmax: 252.4 (5760), 
272 (5520) nm. Anal. calcd (%) for B2C54F8H50N8O8Re2·3CH2Cl2 C, 39.35; H, 3.24; N, 6.44. 
Found (%): C, 39.24; H, 3.60; N, 6.69. 
 
{[Re(CO)3(phen)]2L
8
}
2+
 To a round bottom flask L
8 
(40 mg, 0.05 mmol), 
[Re(CO)3PhenMeCN] (50 mg, 0.1 mmol) in chloroform (10 mL) ) were added and heated to 
59 ˚C for 12 h. The removal of the solvent under high vacuum afforded an orange colored 
solid. The crude product was purified using column chromatography, eluting with 
dichloromethane:methanol (96:4). Yield: 16 mg, 14%. 
1
H NMR (CD3CN, 400 MHz, 298 K) 
δH: 0.98-1.13 (32H, m, (H8-H15)), 1.37 (4H, t, 
3
JHH = 7 Hz, (H7)), 1.65 (4H, t, 
3
JHH = 6.7 Hz, 
(H16)), 3.57 (4H, t, 
3
JHH = 7.2 Hz , (H6)), 3.93 (4H, d, 
3
JHH = 6 Hz, (H5)), 6.62 (2H, s, (NH)), 
7.01-7.03 (2H, m, (H3)), 7.49 (2H, d, 
3
JHH = 7.9 Hz, (H4)), 8.0-8.08 (12H, m, (H2, H17, H20, 
H21)), 8.1 (2H, s, (H1)), 8.72 (4H, d, (H19)), 9.46-9.49 (4H, m, (H18)) ppm. MS (ES
+
) m/z: 
846.2 ([M]
2+
, 1243.5 [M-(Re(CO)3Phen)]
+
, 1779.5 [M+BF4]
+
. HRMS (ES
+
) found m/z 
845.2345 [M-2BF4
-
]
2+
; [
185
Re2C76H76012N10]
2+  
requires 845.2346. IR (nujol) υ: 2032 (CO), 
1917 (CO), 1717 (CO) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 274 (17451) nm, 375 (5085) 
nm. Anal. Calcd (%) for the corresponding hexafluorophosphate salt, C76F12-
H76N10O12P2Re2·1.5CH2Cl2: C, 44.08; H, 3.78; N, 6.64. Found (%): C, 44.06; H, 3.80; N, 
6.38. 
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Chapter 4. Luminescent Di-metallic Au(I) Complexes Bearing 
Functionalised Alkyl Chains Towards Therapeutic Applications. 
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4.1.    Introduction 
Therapeutics is an area of growing interest due to the rising resistance of diseases to 
known therapeutics such as chloroquinone and cisplatin (Figure 4.1). Cisplatin is a therapeutic 
agent inclusive of the metal platinum and has been used in the treatment of cancer for over 30 
years, but due to the increase of cellular resistance cisplatin has become ineffective in its role 
as an antitumor agent. With this rise in resistance, the development of new compounds for 
effective use in the treatment of diseases is needed and so different types of metal-based 
compounds are now being studied. Through comparing IC50 values of a given complex to a 
standard, such as
 
cisplatin (IC50 = 2 μM), the potential of a given complex for applications as a 
therapeutic agent can be assessed. IC50 values represent the concentration at which the ‘agent’ 
reduces cell survival to 50 % of the control value.
1 
The design of metal-based therapeutics is a 
promising area in this field.  
NCl
NH
CH3
N
CH3
CH3
Pt
Cl
Cl
NH3
+
NH3
+
  Chloroquinone                                                                                 Cisplatin
 
Figure 4.1 Structure of chloroquinone (LHS) and cisplatim (RHS). 
 
Gold complexes tend to form aggregates through metal-metal interactions, these weak 
intra- and intermolecular interactions present between gold centres have attracted increasing 
interest since they were first reported by Schmidbaur et al. in 1988.
2 
The rich photophysical 
properties associated with aurophilic interactions make Au(I) complexes an interesting class 
of luminescent materials. Additionally, the number of Au(I)-based complexes in therapeutics 
is increasing. 
The design of gold complexes as therapeutic agents has primarily focused on gold 
analogues of cisplatin and/or the addition of Au(I) or Au (III) to known antitumor agents to 
form new compounds with enhanced activity.
3,4
There have been several cases where gold 
complexes have been synthesised for a specific role but have shown enhanced suitability for 
another. Herein, the synthesis of two different series of di-metallic Au(I) complexes are 
reported and their photophysical and potential therapeutic properties are discussed. 
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4.1.1.   Aurophilic Interactions 
Aurophilicity describes the intra- and intermolecular attractive forces between gold 
centres. Due to relativistic effects, the strength of these attractive forces are comparable to 
those of hydrogen bonding. Relativistic effects are caused by the presence of a heavy atom, in 
this case gold. As the charge on the gold increases (Au(0)Au(I)) an acceleration in the 
average velocity of electrons is observed; the high speed electrons lead to an increase in the 
effective nuclear charge.
 
Both s and p, the less diffuse orbitals contract, increasing the 
shielding effect, which leads to the expansion of the more diffuse orbitals, d and f. Au(I) has a 
filled 5d orbital thus exhibits the maximum impact of the relativistic effect.
5,6
 Weak bonding 
interactions can be used to explain the interactions between Au(I) closed shell d
10
 metal 
centres of the same charge. Metal-metal interactions destabilise the filled 5dz
2 
orbital. The 
filled 5d orbitals are stabilised by configuration mixing with the empty molecular orbitals of 
correct symmetry 6s and 6p orbitals.
  
This lowers the energy difference between the filled d 
orbital and the empty s and p, leading to a more effective nuclear overlap and stronger metal-
metal interactions. Thus these forces are deemed responsible for the structural and so 
photophysical properties of a complex. Aurophillic interactions are generally observed with a 
bond distance of 3 Å and a bond energy of 5-10 kcal mol
-1
.
3
  
Energy
6p
6s
5d
6p
6s
5d
 
Figure 4.2 Energy-level diagram showing the effect of relativistic effect on the energy of atomic orbitals. 
7 
The heavy metal effect (gold in this case) enhances spin orbit coupling which aids in 
the forbidden transition of singlet to triplet excited state via intersystem crossing, which often 
results in phosphorescence. Emission can arise from intra-ligand (IL), metal centred (MC), 
[5d(Au)6p(Au)], and ligand-metal (LM) charge transfer transitions. LMCT can be modified 
by the presence of Au-Au interactions (intra- and intermolecular) which can lead to a ligand-
metal-metal charge transfer (LMMCT) transition. It is not always possible to assign 
luminescence to one particular charge transfer process.
8 
The following sections discuss how 
the distances vary for intra- and intermolecular molecular interactions and the outcome of 
these variations. 
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4.1.2.   Au(I) co-ordination chemistry 
The most common coordination geometry of Au(I) is a two coordinate, linear 
geometry (as a result of relativistic effects), however, trigonal planar and tetrahedral have also 
been reported.
3
 Au(I) is a soft Lewis acid and thus prefers to bind to soft Lewis bases such as 
phosphines and thiolates, although examples of Au(I) bound to pyridines, alkynes and 
carbenes are also known.
8-13 
 
4.1.3.   Au(I) phosphine co-ordination chemistry 
Phosphines, PR3, are tuneable ligands; they can be strong σ-donors with easily 
adjustable electronic and steric factors (they can be π-acids or π-bases depending on the R-
substituent). Phosphines have a low charge and are highly polarizable, they tend to form 
stable complexes with low valent, electron rich metal ion’s, for example gold.  
The electronic and steric factors of phosphine’s were determined by Tolman through the use 
of Ni(CO)3(PR3) type complexes. Through the monitoring of the stretching frequency of CO 
(using infrared spectroscopy) the electronic properties of phosphines could be determined.
14
 
For example: 
 
F3P-M
-
-C≡O+ > PH3P-M=C=O > Cy3-P-M
+≡C-O- 
 
The steric properties for PR3 type ligands are determined using the Tolman cone angle, 
θ. The Tolman cone angle is the standard parameter used when discussing ligand size. The 
sterics for PR3 are based on the R group and can be determined through the angle of the cone 
where the metal atom is situated on the apex, centred 2.28 Å from the centre of the P atom, 
which touches the van der Waals radii of the outermost atoms of the molecule. 
14-16 
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Figure 4.3 Tolman Cone Angle. Reproduced from ref. 14.
 
Au(I) phosphine chemistry has been well researched with examples of both, mono and 
bis-chelated phosphine Au(I) complexes and mono- and di-metallic Au(I) phosphine 
complexes displaying rich luminescent properties and potential as therapeutic agents.
17,18 
4.1.4.  Au(I) phosphines in therapeutics 
The cytotoxic activity of Au(I) and Au(III) phosphine based complexes was 
highlighted by Berners-Price et al.
11
 with reports on auranofin, bis[1,2-bis (diphenyl-
phosphino)ethane] gold(I) chloride and bis[1,2-bis(di-n-pyridylphosphino)ethane] gold(I) 
chloride (Figure 4.4). All three of the complexes were shown to exhibit antitumor activity in 
murine tumour models in vivo. In 2007 this group went on to provide evidence to suggest that 
the cytotoxic properties of complexes of this type are a result of mitochondrial interaction, 
more particularly, the triggering of cytochrome C that induces apoptosis. Although the exact 
mechanism for the triggering of apoptosis is un-known, the inhibition of selenocysteine 
residues of thioredoxin reductase (TrxR) is believed to be key. TRxR (found in the 
mitochondria) has been identified as the most relevant target for gold inhibitors.
19
  
 
O
OAc
OAc
OAc
S
OAc
Au P(Et)3
Au
Ph2P PPh2
PPh2Ph2P
+
Cl
-
Au
PR2 PR2
PR2PR2
+
Cl
-
 
Figure 4.4 Au(I)-complexes 1-3. Auranofin (LHS), bis(1,2-bis(diphenylphosphino)ethane]gold(I)chloride 
(centre) and bis[1,2-bis(di-n-pyridylphosphino)ethane]gold(I)chloride (RHS); R = pyridine.
11 
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Collaborative work between Berners-Price and McKeage
20
 on complexes of the type 
[Au(dppe)2]
+
 showed the selectivity of a cytotoxic complex for cancer cells over healthy cells 
could be tuned by adjustments in the complexes liphophilic and hydrophilic properties.  
However, despite the complex [Au(dppe)2Cl] showing potential as an antitumor agent with 
increased cytotoxic activity against cisplatin resistant cell lines, the observation of 
hepatotoxicity in vivo means complexes of this type require further understanding before they 
can be of use as an antitumor agent in therapeutics.
8,19,20. 
 
The luminescent properties of complexes inclusive of Au(I) phosphines are generally 
dominated by metal perturbed ligand-based emission and/or aurophillic interactions (mainly 
in the solid state) examples of which are discussed both herein and in Chapter 5. Although 
intensely studied, we are a long way from realising the true potential of Au(I) phosphine 
chemistry with reports recently emerging 40 years after originally discussing the antitumor 
properties of Au(I).
 
The potent reproducible cytotoxic properties of Au(I) phosphines have 
resulted in them being considered as one of the more promising candidates for 
therapeutics.
21,22   
4.1.5.   Au(I) thiolates 
Au(I) thiolates have been the main compounds used in chrysotherapy.
3,22 
Since the 
first report in 1935 displaying the anti-inflammatory properties of Au(I) salts, Au(I) 
complexes have been well documented for the treatment of arthritis. Au(I) thiolates such as 
sodium aurothiomalate (Myocrisin) and aurothioglucose (Solganol), which are intramuscular 
injected, as well as auranofin (Ridaura) which is orally ingested, are the more commonly used 
Au(I) complexes for the treatment of rheumatoid arthritis (Figure 4.5),
 
however, the exact 
anti-arthritic mechanism is un-known.
11 
Auranofin, although commonly used in the treatment 
of arthritis, has also shown potential in the treatment of AIDS
23
 and malaria
24 
and thus 
research into applications of known therapeutics for the treatment of different diseases is also 
under investigation. 
 
O
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OAc
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OAc
Au
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P(Et)3
H2O
O
OH
OH
OH
S
OH
Au
n
ONa
ONa
O
O
S
Au
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Figure 4.5 Au(I)-complexes 4-6, complexes commonly used in the treatment of arthritis. Sodium 
aurothiomalate (LHS), Aurothioglucose (centre) and Auranofin (RHS). 
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The dependency of the luminescent properties of Au(I) thiolate compounds on the Au-
Au interactions can be exemplified by reports by Fackler et al.
24
 and Eisenberg et al.
24b
 Both 
groups reported the dependence of the luminescence properties of mono- and di-metallic 
Au(I) thiolate compounds on the intermolecular Au-Au interactions.
 
Einsburg et al.
24b
 
reported the more interesting luminescent properties with the di-metallic Au(I) compound, 
[Au2{S2CN(C5H11)2}2].DMSO. Recrystallization of [Au2{S2CN(C5H11)2}2].DMSO produced 
orange crystals with a λem = 631 nm, however, when the crystals were dried in vacuo, 
colourless, non-emissive crystals resulted. The orange and the colourless compounds reported 
intramolecular Au-Au distances of 2.9617 Å and 2.7653 Å respectively, however, the 
intermolecular separation of the Au centres (for the orange and colourless compounds) were 
2.7690 Å and 8.135 Å, respectively. This data suggests the orange colour and hence 
luminescence properties are dependent on the intermolecular distances more so than the 
intramolecular distances. Drying the orange compound removes any solvent present, and this 
in turn increases the Au-Au intermolecular distance suggesting an effect of the solvent on the 
Au-Au aggregate.
 
 
Interestingly, on/off aurophillic based luminescent properties dependent on ion sensing 
was displayed by Yam et al.
25
 with a di-metallic-Au(I) phosphine thiolate complex. In 
absence of K
+ 
ions, the Au-Au distance was such that no aurophillic interactions were present. 
On binding of K
+ 
the two Au(I) centres were brought into closer proximity and a new, red-
shifted emission peak at 720 nm was observed (Figure 4.6). The proximity of the two Au(I) 
centres resulted in LMMCT emission.
25
  
 
Figure 4.6 Complex 7 (LHS) with its ion sensing capability (RHS). Reproduced from ref. 25. 
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4.1.6.   Au(I) alkynes in therapeutics and luminescence 
Au(I) alkyne complexes display linear coordination geometry with the potential to 
form short Au-Au contacts.
3,27
 Both mono and di-metallic alkyne complexes have been 
reported. The Au(I) centre can bind to two unsaturated alkyne units, one bound via a σ bond 
whereas the second is via a π bond. These two types of bonding, coupled with the potential of 
intermolecular aurophilic interactions between Au(I) centres, can lead to the formation of 
interesting Au(I)-alkynyl complexes.
4 
There exists to date few examples of alkynyl gold 
complexes as therapeutics. 
  The synthesis of a novel series of mono-Au(I)-alkyne complexes was reported by 
Mohr et al.
27
 (Figure 4.7). These complexes were synthesised primarily for investigation into 
their activity against malaria; low activity against the malaria parasite strains 3D7 
(chloroquine sensitive) and KI (chloroqine resistant) was reported. Their low activity was 
attributed to the strength of the C-Au bond and the increased lipophilic nature of the complex 
(when compared to chloroquinone) which is suspected to hinder the complex reaching the 
target site.
27
    
N
O
Au(PPh3)
Cl
O
Au(PPh3)
O O
Au(PPh3)
                             8                                                        9                                                            10
 
Figure 4.7 Structure of complexes 8-10. 
Although limited success against chloroquinone sensitive strains was observed, 
complexes 8-10 was tested against four tumour cell lines. The results show increased anti-
cancer activity of complex 10 (in comparison to 8 and 9) with activity similar to that of 
cisplatin in ovarian and colon cancer cell lines (Table 4.1). Despite complex 10 showing 
enhanced activity, the similar nature of all three results suggest that the cytotoxic activity is 
governed/dominated by the [Au(PPh3)-alkyne] moiety as oppose to the variable ligands 
attached.
27 
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Table 4.1 In vitro cytotoxicity results
27 
Compound CH1 ovarian cancer cell line SW480 colon cancer cell line 
10 0.4   ± 0.1 4.5 ± 0.7 
Cisplatin 0.16 ± 0.03 3.5 ± 0.3 
 
4.17.  Au(I) pyridines 
Despite pyridine ligands being considered as one of the more versatile ligands in co-
ordination chemistry, there are very few reports of Au(I)-pyridine based complexes when 
compared to the previously mentioned Au(I)-thiolate or Au(I)-phosphine based 
complexes.
28,29
 The stability of the Au(I)-N unit is dependent on the electronics and sterics of 
the complex formed. 
Schmidbaur et al.
30
 reported the first Au(I)-pyridine complexes with [PPh3Au-
pyridine]
+
 and [PPh3Au-2-hydroxypyridine]
+
. The crystal structures of the two complexes 
provided evidence that suggested the incorporation of the hydroxyl group in the 2 position of 
the pyridine had no effect on the donating ability of the nitrogen; N-Au bond length was 
unchanged for the two complexes reported.
30 
The successful synthesis of six novel complexes incorporating planar aromatic 
pyridine N-Au(I) bonds in good yields, 49 % to 88 %, was reported by Pope et al.
13
. The 
nature of the fluorophore unit and its position on the pyridine, as well as the spacer length, 
were varied (Figure 4.8). The luminescent properties of the directly bound phthalimides 
reported a red-shifted emission which was attributed to increased conjugation within the 
ligands bound to the -AuPPh3 unit; the lifetimes were short for all complexes reported.
13 
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Figure 4.8 Ligands 11-16 reported by Pope et al.13
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4.1.8.   Au(I) azolates 
An azolate is a 5-membered heterocyclic ring inclusive of a nitrogen, it is included 
herein due to similar nature of the Au(I)-N bond for pyridine. The cytotoxic analysis of nine 
novel (PPh3 / TPA)-Au-(pyrazolates / imindazolates) type complexes was reported by 
Marzano et al.
31
 Two out of the nine complexes reported (Figure 4.9) show potent cytotoxic 
activity with IC50 values exceeding those of cisplatin (Table 4.2). The triphenylphosphine 
based complexes showed increasing cytotoxic activity when compared to the TPA based 
complexes. With the Trx having been reported as the most relevant molecular target for gold 
complexes (previously discussed in reports by Berners-Price et al.),
19,20
 the inhibitor activity 
of these compounds, compounds 17 and 18 were investigated for TrxR1 and TrxR2 forms of 
Trx. Compounds 17 and 18 displayed increasing inhibitor potential in TrxR1 in comparison to 
TrxR2 (Table 4.2). TrxR inhibition was then evaluated in 2008 with complexes 17 and 18 
which showed a decrease in cellular activity of TrxR by 85 %.
6,31 
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Figure 4.9 Complex 17 (LHS) and 18 (RHS), both exhibit cytotoxic values > cisplatin
31 
 
Table 4.2 In vitro cytotoxicity results for complex 17 and 18 for TrxR1/R2, MCF-7, A549 and LoVo cell 
lines.
 
Compound MCF-7 A549 LoVo TrxR1 TrxR2 
17 1.03  ± 0.59 0.96   ± 0.34 0.90   ± 0.52 3.50 38.12 
18 0.53  ± 0.35 0.49   ± 0.21 0.73   ± 0.30 15.80 48.12 
Cisplatin 10.31 ± 1.36 13.42 ± 1.96 8.03   ± 1.23 - - 
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4.2.    Overview 
The first part of this chapter discusses the attempts to synthesise a series of di-metallic 
Au(I)-pyridyl complexes, {[Au(PPh3)]2L}
2+
, with varying aliphatic chain lengths. The 
synthesis and photophysical properties of the structurally related di-metallic Re(I)-based 
complexes have been reported in Chapter 3. The second half of this chapter reports a novel 
series of di-metallic Au(I)-alkyne complexes, based around a malonate centre, inclusive of 
both aliphatics and/or aromatics. The synthesis, photophysical properties and the application 
of these complexes as therapeutic agents is discussed herein. 
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4.3.    Results and discussion (part 1) 
4.3.1.   Syntheses of L
1-3 
The synthesis of symmetrical ligands suitable for the co-ordination of two metal ions 
was initially discussed in Chapter 3. Continuing with the same ligand system, three 
symmetrical pyridyl based ligands with varying aliphatic chain lengths were synthesised for 
the co-ordination of two gold units. The symmetrical esters, L
1-3
, varying in chain lengths 
C2/C6/C12 respectively, were synthesised using an excess of commercially available nicotinic 
acid which was converted to the derived nicotinoyl chloride by stirring at 70 ˚C in thionyl 
chloride for 1 hour. Nicotinoyl chloride was then reacted with either commercially available 
1,12-dodecandiol, 1,6 hexanol or ethylene glycol. The observation of a shift to higher 
frequency for the signal corresponding to the ester methylene unit CH2OCO in the 
1 
H NMR 
spectrum from +3.35 ppm to +4.5 ppm confirmed the formation of the ester units, which were 
achieved in good yields of 68 %, 78 % and 46 % respectively.  
 
4.3.2.  Syntheses of {[Au(PPh3)]2L
1-3
}
2+ 
 n = 2 / 6 / 12
 n  n
 n = 2       Au(I)-L1
 n = 6       Au(I)-L2
 n = 12     Au(I)-L3
N
O
O O
O
N N
O
O O
O
N
Au(PPh3) Au(PPh3)
 
Figure 4.10 Synthesis of [Au(PPh3)L
1-3 
]. Reagents: AgOTf, [AuClPPh3], DCM, N2(g) 
Having achieved the synthesis of L
1-3
 in good yields the synthesis of {[Au(PPh3)]2L
1-
3
}
2+ 
was attempted. [AuClPPh3] was chosen as the gold precursor complex as work within the 
group had shown successful bonding of the gold unit to the pyridine nitrogen.
13
 The synthesis 
of the gold complexes was carried out using literature precedent. In the absence of light, due 
to the sensitive nature of the gold precursor, at 0 ˚C, [AuClPPh3] and silver triflate were 
stirred in DCM for 20 minutes. Silver triflate was necessary to remove the chloride ion. 
Following the addition of the symmetrical ligand, L
1-3
, (0.5 eq) the reaction was left to reach 
room temperature and was stirred for an additional 16 hours. After the removal AgCl via 
filtration, the product was purified via re-precipitation using diethyl ether. Principal 
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characterisation using 
1
H and 
31
P
 
NMR spectroscopies suggested the presence of the predicted 
products, however there was also the presence of [Au(PPh3)2](OTf) (δ31P = +45 ppm) and or 
the presence of the gold starting material.  
Recrystallizations were carried in an attempt to obtain pure products of all three 
products, {[Au(PPh3)]2L
1-3
}
2+
. Crystals suitable for XRD were obtained for all three reactions 
however the recrystallized products were not consistent with the proposed products. For both 
{[Au(PPh3)]2L
1
}
2+ 
and {[Au(PPh3)]2L
2
}
2+
 an unexpected gold trimer cluster biproduct (Figure 
4.11) resulted from the recrystallisations.  This biproduct was formed as a result, presumably, 
of ligand dissociation. Structures of this nature have been previously reported
32-34
 and so no 
further data was collected. The driving forces for the formation of these clusters have not been 
investigated and so are not fully understood.  
For {[Au(PPh3)]2L
1
}
2+
, the expected product
 
was observed as a linear C12 alkyl, di-
pyridyl-Au(I) complex. There was no evidence of intra- or intermolecular Au-Au aurophillic 
interactions in the solid state IR of this complexl. The absence of these interactions can be 
attributed to the linearity and the sterics of the bulky substituents of the complex. The co-
ordination of the gold unit was linear with the N-Au-P bond angle of 177 ˚, the Au-N and Au-
P bond distances of 2.069 Å and 2.25 Å are in accordance with related compounds.
11 
The 
presence of crystalline starting material, [AuClPPh3], within the sample (which was not 
present in the initial characterisation via 
31
P NMR spectroscopy) indicated that decomposition 
of the product in solution had occured, this resulted in incomplete characterisation. These 
findings are reported further in the following section. 
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4.3.3.   Single crystal X-ray diffraction studies 
Re-crystallisation of complexes {[Au(PPh3)]2L
1-3
}
2+ 
yielded pale orange crystals 
suitable for X-ray diffraction studies. The crystals were obtained via vapour diffusion of 
diethyl ether into a concentrated THF solution (Figure 4.11). 
 
 
 
Figure 4.11 Structural representations of the bi-product of {[Au(PPh3)]2L
1
 and L
2
}
2+
 (bottom) and 
{[Au(PPh3)]2L
3
}
2+
 (top) (H atoms omitted for clarity). 
 
The parameters associated with the data collections of the novel complex 
{[Au(PPh3)]2L
3
}
2+ 
and the gold trimer cluster
 
biproduct
 
(Table 4.3) and the selected bond 
lengths and bond angles (Table 4.4) are shown below. 
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Table 4.3 Crystal data collection and refinement details for the crystal structures of                             
{[Au(PPh3)]2L
3
}
2+
 and the gold trimer cluster biproduct.     
 
                                                                    {[Au(PPh3)]2L
3
}
2+
                   Cluster 
 
 
 
Empirical formula C62H62Au2F6N2O10P2S2 C56H47Au3Cl2F3O4P3S 
Formula weight 1629.13 1627.71 
Temperature 293 K 150 K 
Wavelength 0.71013Å 0.71013Å 
Crystal system Monocyclic Triclinic 
Space group P2(1)/n P-1(2) 
Unit cell dimensions a = 12.0014 (15) Å 
α = 90.00 ˚ 
b = 27.888 (4) Å 
β = 104.048˚ 
c = 19.133 (2) 
ϒ =90.00˚ 
a = 12.7242 (2) Å 
α = 63.8380 (10) ˚ 
b = 14.5427 (2) Å 
β = 81.6950 (10)˚ 
c = 16.2111 (3) Å 
ϒ =89.6090 (10)˚ 
Volume 6212.2  Å
3 
2658.75 Å
3
 
Z 4 2 
Density (calculated) 
F(000) 
1.742 g/cm
3 
3208 
2.033 g/cm
3 
1548 
Crystal size 0.10 × 0.04 × 0.04 0.12 × 0.10 × 0.10 
Theta range for data 
collection 
38 55 
All reflections 9107 17979 
Independent reflections 4906 12118 
Observed reflections 3666 10074 
Goodness-of-fit-on F 
Rint 
1.353 
0.0864 
1.033 
0.0367 
Final R indices 
[I>2sigma(I)] 
R1 = 0.1565 
wR2 = 0.3030 
R1 = 0.0453 
wR2 = 0.1065 
R indices (all data)   
 
Table 4.4 Selected bond lengths and bond angles for the complexes: {[Au(PPh3)]2L
3
}
2+
 and the gold trimer 
cluster biproduct. 
                                            {[Au(PPh3)]2L
3
}
2+
                                            Cluster                    
C62H62Au2F6N2O10P2S2 C56H47Au3Cl2F3O4P3S 
                                        Bond Lengths (Å) 
Au-N             2.069 (3)                    Au1-Au2      3.184 (3)                    
Au-P             2.25    (1) Au1-Au3      2.967 (4) 
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  The labile nature of Au(I)-pyridyls can be rationalised in terms of the donating 
properties of the pyridine unit. Pyridine is a ‘borderline’ soft donor and therefore is less well 
matched to the soft Au(I) ion than sulfur or phosphine donors. This mismatch, coupled with 
the electron-withdrawing ester functional group reducing the donor ability of the pyridine, 
decreases the stability of the complex; the donating ability of the pyridyl nitrogen is reduced 
and the Au(I)-N bond becomes increasing labile. The most stable Au(I) complexes are seen 
when ‘softer’ donors such as thiolates, phosphines or even alkynes are used.35,36A new di-
metallic Au(I) complex series based around Au(I) alkynes was synthesised to further probe 
the potential of Au(I) complexes as both therapeutic and cellular imaging agents. 
Additionally, the effect of aurophilic interactions on the luminescent properties of Au(I) are 
explored. 
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4.4.    Results and discussion (part 2) 
4.4.1.   Ligand Design 
Having shown the labile nature of the Au(I)-N unit, an alternative approach to the 
synthesis of di-metallic Au(I) complexes for investigation into their photophysical and 
therapeutic properties was made. There have been an increasing number of reports on the 
syntheses of Au(I)-alkyne units and for this reason these units were investigated. Several 
commercially available functionalised alkynes exist, including propargyl alcohol and 
propargyl bromide, both of which are equipped to act as ‘building blocks’ providing 
additional functionality to the compound.  
4.4.1.1.Malonates 
Malonate is a commercially available compound. It is also a known competitive 
inhibitor of the enzyme succinate dehydrogenase; an enzyme that is bound to the inner 
mitochondrial membrane. The incorporation of a malonate unit within a di-metallic Au(I) 
alkyne complex allows additional functionality within the compound and also offers the 
potential to allow cellular functions to be monitored via imaging. 
Cl Cl
O O
Acidic
 
Figure 4.12 Malonyl chloride 
 
Malonyl chloride is an organic compound with an acidic α carbon. This carbon 
provides a second, alternative route for the addition of functionality to the compound. A 
reaction of the acyl unit of the compound with propargyl alcohols allows the addition of two 
alkyne units suitable for the co-ordination of gold units, the presence of the acidic α carbon 
allows the synthesis of more complicated ligand systems, for example, the addition of an 
aromatic group. 
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4.4.2  Ligand synthesis 
4.4.2.1.Synthesis of L
4 
 
O O
O O
CHCH
Cl Cl
O O
 
Figure 4.13 Synthesis of L
4
(RHS). Reagents: propargyl chloride, TEA and DCM. 
 
The addition of two alkyne units to a malonyl chloride precursor resulted in the 
formation of L
4 
(Figure 4.13). L
4 
was synthesised via the drop-wise addition of malonyl 
choride to a solution of propargyl alcohol and TEA in DCM. After stirring at room 
temperature for 15 minutes, following an aqueous work up, L
4 
was produced in a moderate 
yield 41 %. The acidic nature of the central CH2 in L
4 
was a suggested route to further 
functionalise the compound whilst keeping the alkynes ‘intact’ for the co-ordination of two 
Au(I) units. The ‘removal’ of the acidic proton on L4, using a base, produces a carbanion 
suitable to undergo nucleophilc substitution with an alkyl halide. The presence of excess base 
in this reaction can lead to both mono- and di-substitution reactions taking place. The addition 
of a di-halide species can lead to the synthesis of an alicyclic compound.  
4.4.2.2. Synthesis of L
5-6
 
To further functionalise L
4
, it was reacted with benzaldehyde following literature 
precedent using ammonium acetate
37 
and/or potassium tertiary butoxide
38
 however, in both 
cases no reaction was evident with only starting material  observed in the 
1
H NMR spectra. 
An alternative base is proline; proline is a zwitterionic, α amino acid (Figure 4.14). The lack 
of a proton on the amide group means it cannot act as a proton donor, only as a hydrogen 
bond acceptor, thus can be used as a base for the removal of the acidic proton. 
 
N
H O
OH
*
 
Figure 4.14 Proline 
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L
4 
was reacted with both benzaldehyde and anisaldehyde in the presence of proline in 
DMSO at room temperature for 24 hours to produce L
5 
and L
6 
in low to moderate yields of 21 
% and 33 % respectively (Figure 4.15). Nitro-benzaldehyde was also reacted with L
4 
following the same procedure, however, only starting material was recovered. 
CH
O
O
O
O
CH
MeO
CH
O
O
O
O
CH  
Figure 4.15 L
5 
(LHS) and L
6 
(RHS), 
The unsuccessful formation of a ligand inclusive of nitro-benzaldehyde resulted in an 
alternative synthetic route being attempted. Benzaldehyde was reacted with malonoic acid (as 
opposed to L
4
), following the same reaction conditions as above, to form ligand precursor 2 
with a very low yield of 3.5 %. For the synthesis of compounds of this type, the nature of the 
substituent in the para position of the benzaldehyde was shown to dictate the reaction yield / 
outcome; EDG > H > EWG. The limited reactivity of L
4
 resulted in an alternative synthetic 
approach being taken where the alkyne units were situated on the acidic CH2 and the 
compounds further functionalised via the terminal positions of the malonate. 
4.4.2.3. Synthesis of L
7-15 
CH3
O O
O
O CH3
CH
CH
CH3
O O
O
O CH3
 
Figure 4.16 Synthesis of L
7
. Reagents: propargyl bromide, potassium tertiary butoxide, ethanol. 
Diethyl malonate (DEM) is the most common malonic ester. Following literature 
precedent propargyl bromide was added to a solution of diethyl malonate and potassium 
tertiary butoxide in ethanol, to form L
7  
with an 82 % yield (Figure 4.16).
39
 Continuing with 
the same reaction conditions used for both L
4 
and L
7
, a novel series of alkyne based ligands 
with varying aliphatic chain lengths and aromatic substituents were synthesised; L
8
-L
15
 
precursors were synthesised following the same procedure as L
4
 using ethyl malonyl chloride 
or malonyl chloride resulting in yields ranging from 12 % to 78 %.  The addition of the 
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alkynes to the ligand precursors via nucleophilic substitution reactions (following the same 
procedure used for L
4
) resulted in the formation of L
8
-L
15 
in yields ranging from 5 % to 59 %.  
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Figure 4.17 Ligands L
7
-L
15
 discussed herein. 
4.4.2.4.Synthesis of L
8-10 
Ligand precursors of L
9 
and L
10
 were formed from the addition of octanol to the 
unsymmetrical starting material ethyl malanoate and the symmetrical starting material 
malonate respectively and purified via distillation with a Kugelrohr apparatus (removing 
excess butanol). The shift in the 
1
H NMR spectra of the octanol CH2OH to the higher 
frequencies of +4.01ppm or +4.18 ppm was attributed to product formation in ligand 
precursors L
9 
and L
10 
respectively. The addition of the alkyne units was achieved using 
propargyl bromide. Purification of L
9
 via chromatography isolated both unsymmetrical mono- 
and di-alkyne ligands, L
8 
and L
9 
respectively. For L
9
, the absence of the peak at +3.32 ppm 
(acidic CH2 in the ligand precursor) and the appearance of two new peaks, a triplet at +2.08 
ppm and a doublet at +2.98 ppm in the 
1
H NMR spectrum, both with intensities fitting the 
addition of two alkyne units, confirmed its formation. In the 
1
HNMR spectrum of L
8
, a 
multiplet peak at +2.72 ppm, at lower frequency when compared to that of the CH2 peak in the 
ligand precursor was observed as-well as peaks similar in frequency to those of the di-alkyne 
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L
9
. MS analyses confirmed the addition of one alkyne unit only for L
8
. The symmetrical, di-
alkyne ligand, L
10 
was formed in a 59 % yield with peaks in the 
1
H NMR spectrum similar in 
nature to the unsymmetrical di-alkyne ligand, L
9
. No bi-products were isolated.
 
4.4.2.5. Synthesis of L
11-13 
Ligand precursor A was documented in both Chapters 2 and 3 and consists of a 
pyridine-spacer-OH. When reacted with ethyl malonyl chloride, following the same procedure 
as L
7
 and purification via column chromatography, the ligand precursor L
12
 was formed in a 
good yield of 69 %. The number of signals in the 
1
H NMR spectrum and their intensities fit 
well for the predicted product, characterization by MS (ES
+
) showed the presence of [M+H]
+ 
at 422.25, [M+Na]
+ 
at 444.23 and [M+K]
+ 
at 460.21. Despite the high yielding nature of its 
ligand precursor, L
12 
was formed in a very low yield; following purification of L
12 
via column 
chromatography isolated both L
7 
, L
12
 and  bi-product L
11
 (Figure 4.18). The bi-product L
11
 
was fully characterized and similarly to the bi-product, L
8
, in the 
1
H NMR spectrum, a 
multiplet peak at +2.72 ppm was observed. 
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Figure 4.18 Synthesis of ligand L
12
 with bi-products L
11 
and L
7
. Reagents: (i) ligand precursor A, ethyl 
malonoate, TEA, DCM, RT; (ii) Propargyl bromide, K
+ t
BuO, EtOH, N2(g). 
The isolation of the two bi-products, L
8 
and L
11
, indicated the breakdown of the ligand 
precursor and/or L
12 
during their reactions. Intra- or intermolecular breakdown of ligand 
precursor A has not been seen previous chapters, but it is possible that with the additional 
ester groups present on the ligand precursor, and in the presence of potassium tertiary 
butoxide, intra- or intermolecular breakdown of the product was promoted. The low yield of 
the unsymmetrical, di-alkyne pyridine ligand, L
12
, resulted in the synthesis of the analogous 
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symmetrical di-alkyne pyridine L
13
 in a more favorable yield of 37 % (Figure 4.19). L
13 
was 
again purified via column chromatography with no isolation of bi-products. 
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Figure 4.19 Synthesis of ligand L
13
. Reagents: (i) ligand precursor A, malonyl chloride, TEA, DCM, RT; 
(ii) propargyl bromide, K
t
BuO, EtOH, N2(g). 
4.4.2.6. Synthesis of L
14-15 
Having synthesized a series of di-alkyne ligands with varying aliphatic chained 
ligands, aromatic di-alkyne ligands were synthesized to add additional functionality to ligands 
of this type. Benzyl-alcohol and naphthyl alcohol were reacted with malonyl chloride and 
then propargyl bromide following the same procedures as above to produce L
14 
and L
15 
 in 
yields of 37 % and 16 % respectively (Figure 4.20).  
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Figure 4.20 L
14 
(LHS) and L
15 
(RHS). 
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4.4.3.   Complex synthesis 
The gold precursor [AuClPPh3] was synthesised via literature methodology from 
H[AuCl4], as this is known to be useful in the synthesis of gold alkynes.
40 
Omitting the bi-
products formed during the ligand synthesis, the di-alkyne ligands, L
7
, L
9,10 
and L
12-15 
, were 
reacted with [AuClPPh3] (1.2 eq of gold per alkyne present in ligand) in the absence of light 
under a N2 atmosphere and in the presence of potassium tertiary butoxide in ethanol. The 
reaction mixture was left to stir at room temperature for 16 hours. Due to the production of 
potassium chloride salt; the filtrate was dried under reduced pressure, re-dissolved in 
chloroform and filtered. The work up was slightly modified in the cases where precipitate was 
visible in the reaction mixture; the precipitate was filtered, dissolved in DCM and re-filtered 
to remove the salt. Each complex was purified by recrystallization using vapour diffusion of 
diethyl ether into a concentrated THF solution. The use of THF proved necessary as 
prolonged exposure to chlorinated solvents resulted in the breakdown of complexes to the 
Au(I)- starting material [AuClPPh3]. The complexes, {[Au(PPh3)]2L
7
}, {[Au(PPh3)]2L
9
}, 
{[Au(PPh3)]2L
10
}, {[Au(PPh3)]2L
15
}, were isolated in yields ranging from 57 % to 87 %.  
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Figure 4.21 Complexes discussed herein. 
1
H NMR spectra for all complexes were obtained in CDCl3. For each complex there 
was an absence of the CH2CCH peak seen in the free ligand and a characteristic shift of the 
H2CC- to higher frequency from around +2.92 ppm in the free ligand to around +3.21 ppm in 
the complexes. The addition of the phenyl ligands was also apparent in all four NMR spectra. 
For the aliphatic based, di-alkyne Au(I)2 complexes, {[Au(PPh3)]2L
7
}, {[Au(PPh3)]2L
9
}, 
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{[Au(PPh3)]2L
10
}, a broad proton resonance in the region of 7.21-7.62 ppm integrating to 30H 
for the triphenyl phosphine proton resonances was observed. For the aromatic based, di-
alkyne Au(I)2 complex, {[Au(PPh3)]2L
15
}, the triphenyl phosphine proton resonances were 
typically broad and super imposed with co-ordinated ligand aromatic protons in the region of 
7.22-7.52 ppm.  
The
 31
P{
1
H} NMR spectra for complexes{[Au(PPh3)]2L
7/9/10/15
} gave a signal in a 
range with agreement to literature around +42.8 ppm.
 
All of the complexes gave a single peak 
in the 
31
P NMR which indicated the di-metallic complexes were symmetrical. Solid state IR 
studies were carried out for all complexes which showed subtle changes in the ν(CC) in 
comparison to ligand. The ligands displayed an IR stretch similar to the precursors, propargyl 
alcohol and propargyl bromide with a shift at 2120 cm
-1 
whereas the complexes displayed a 
weaker IR absorption band ranging from 2168-2329 cm
-1 
for the alkyl stretch; for the 
aliphatic, di-alkyne Au(I)2 complexes the lower stretching frequency was observed. This 
slight shift to a higher frequency for the aromatic, di-Alkyne Au(I)2 complex, 
{[Au(PPh3)]2L
15
}, corresponds to a stronger CC bond. MS analysis for each of the complexes 
gave a peak at 721 only which is attributed to the breakdown of the complex within the mass 
spectrometer and then recombination to form [Au(PPh3)2]
+
. 
The synthesis of {[Au(PPh3)]2L
12-14
} was attempted, but in all three cases, despite 
evidence in the 
1
H NMR and 
31
P NMR spectra to support product formation, when 
purification via recrystallization was attempted breakdown of the product was observed; 
starting materials were observed in both 
1
H NMR and 
31
P NMR spectra following 
recrystallization.  
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4.4.3.1. Single crystal X-ray diffraction studies 
Re-crystallisation of complexes {[Au(PPh3)]2L
7
}, {[Au(PPh3)]2L
9
} and 
{[Au(PPh3)]2L
15
}
 
yielded pale  crystals suitable for X-ray diffraction studies. The crystals 
were obtained via vapour diffusion of diethyl ether into a concentrated THF solution. 
 
 
 
 
Figure 4.22 Structural representations of complexes {[Au(PPh3)]2L
7
}, {[Au(PPh3)]2L
9
} and 
{[Au(PPh3)]2L
15
}, (H atoms omitted for clarity). 
 
The parameters associated with the data collection of the novel complexes 
{[Au(PPh3)]2L
7
}, {[Au(P Ph3)]2L
9
}
 
and {[Au(PPh3)]2L
15
},
 
(Table 4.5) and the selected 
bond lengths and bond angles (Table 4.6) are shown below. 
For the diethyl malonate based di-alkyne Au(I)2 structure of {[Au(PPh3)]2L
7
}, the C-
Au-P bond angle did not show substantial deviations from linearity, 176 ˚. The Au-P bond 
lengths have an average length of 2.28 Å and the Au-C bond lengths, 2.00 Å, which are both 
consistent with other gold(I)-acetylide complexes reported, additionally, both bond lengths 
are longer than those of the [AuClPPh3] starting material, consistent with the stronger trans 
influence of the acetylene group when compared to the chloride.
41-43
 The C≡C bond lengths in 
the complex have an average length of 1.19 Å, and are again normal for complexes of this 
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type. There was no evidence of intra- or intermolecular contacts between the Au(I) units. 
Similarly to the {[Au(PPh3)]2L
7
}, both the unsymmetrical and symmetrical di-alkyne Au(I)2 
structures of {[Au(PPh3)]2L
9
} and of {[Au(PPh3)]2L
15
}, respectively,
 
showed no deviation 
from the expected literature values for gold(I)-acteylide complexes and again no intra- or 
intermolecular contacts between the Au(I) units were observed.
18,44  
Both complexes however 
did display dis-ordered structures; for {[Au(PPh3)]2L
9
} disorder was modelled with in the C7 
alkyl chain; for {[Au(PPh3)]2L
15
} disorder modelled in one napthyl ring (C10 to C19). All 
atoms refined as split over two sites with occupancies refined to 0.60(2) and 0.40(2) for the 
two components.  
Table 4.5 Crystal data collection and refinement details for the crystal structures of {[Au(PPh3)]2L
7
} and 
{[Au(PPh3)]2L
9
} and {[Au(PPh3)]2L
15
}. 
                                                       {[Au(PPh)3]2L
7
}         {[Au(PPh)3]2L
9
}              {[Au(PPh3)]2L
15
} 
 
 
  
Empirical formula C49H44Au2O4P2 C55H56Au2O4P2 C67H52Au2O4P2 
Formula weight 1152.71 1236.87 1376.96 
Temperature 150(2)K 293(2)K 120(2)K 
Wavelength 0.71013Å 0.71013Å 0.71013Å 
Crystal system Monoclinic Monoclinic Triclinic 
Space group P2(1)/a P2(1)/a P-1 
Unit cell dimensions a = 18.3922 (7) Å 
α = 90.00 ˚ 
b = 12.7687 (4) Å 
β = 112.362˚ 
c = 22.6554 (8) 
ϒ =90.00˚ 
a = 18.6917 (16) Å 
α = 90.00 ˚ 
b = 12.9506 (13) Å 
β = 110.571˚ 
c = 22.7648 (12) 
ϒ =90.00˚ 
a = 13.2177 (12) Å 
α = 72.055 ˚ 
b = 13.2371 (11) Å 
β = 77.650 ˚ 
c = 17.0686 (18) 
ϒ =83.635 ˚ 
Volume 4920.39 (3) Å
3 
5159.23 () Å
3 
2772.1 (4) Å
3 
Z 4 4 2 
Density (calculated) F(000) 1.556 g/cm
3 
1.592 g/cm
3 
1.650 Mg/m
3 
Crystal size 0.40 × 0.28 × 0.122 0.25 × 0.15 × 0.02 0.53 × 0.34 × 0.02 
Theta range for data collection   3.11  27.46 ° 
All reflections 14715 9411 29975 
Independent reflections 8086 5271 11299 
Observed reflections 5461 2885  
Goodness-of-fit on F 1.035 1.394 0.975 
Rint 0.067 0.1260 0.1704 
Final R indices [I>2sigma(I)] R1 = 0.1107 
wR2 = 0.2657 
R1 = 0.1535 
wR2 = 0.3603 
R1 = 0.1424 
wR2 = 0.2173 
R indices (all data)    
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Table 4.6 Selected bond lengths and bond angles for the complexes: {[Au(PPh3)]2L
7
} and {[Au(PPh3)]2L
9
} 
and {[Au(PPh)3]2L
15
}. 
 
                   {[Au(PPh)3]2L
7
}                     {[Au(PPh)3]2L
9
}                   {[Au(PPh)3]2L
15
} 
C49H44Au2O4P2 C55H56Au2O4P2 C67H52Au2O4P2 
                                                  Av. Bond Lengths (Å) 
Au-P           2.28 (6) Au-P       2.2  (2) Au-P       2.28 (3) 
Au-C           2.00 (2) Au-C      1.94 (2) Au-C      1.9  (13) 
C-C             1.19 (3) C-C        1.23 (8) C-C        1.20 (15) 
4.4.3.2. Promoting aurophilic interactions 
Following the successful crystallisation of the three complexes, {[Au(PPh3)]2L
7/9/15
}, a 
better insight into the solid state interactions of the Au(I) centres was gained. In all three 
complexes the Au(I) centres were orientated away from each-other and there was no evidence 
to suggest intra- or even intermolecular interactions were occurring. An attempt was made to 
bring the two Au(I) centres into a closer proximity to each-other, i.e. ‘lock’ the two Au(I) 
centres in a position that could result in aurophillic interactions. Both dppm and  dppe were 
used in an attempt to lock the Au(I) centres and to promote and investigate any aurophillic 
interactions that may be occurring.   
4.4.3.2.1. Synthesis of [Au(I)2-dppm-L
7
] 
Dppm was reacted with {[Au(PPh3)]2L
7
}; to a solution of {[Au(PPh3)]2L
7
} in toluene, 
under nitrogen, was added dppm. After 12 hours, the resulting solution was dried in vacuo.
45
 
In the 
31
P NMR spectra, peaks at +21.7 ppm, +33.1 ppm and +43.4 ppm were observed which 
were attributed to oxidised dppm, gold
 
starting material and potential product respectively. 
The presence of the gold starting material [AuClPPh3] in the spectra indicated breakdown of 
the complex, {[Au(PPh3)]2L
7
}. A second synthetic approach was taken to synthesise the same 
product. [(Au-dppm)2] was reacted with L
7 
following literature precedent,
46
 however, peaks 
attributed to oxidised phosphines were observed in the 
31
P NMR spectra only (Figure 4.23). 
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Figure 4.23 Attempted synthesis of [Au(I)2-dppm-L
4
] 
The oxidation of the phosphine units, even in an inert atmosphere, indicated the 
stability of the product and/or the intermediate (where one dppe unit is bound) was poor. The 
distance required to ‘lock’ the two Au(I) centres, whilst attached to the alkynes, may also 
have been a hindering factor in these reactions.   
4.4.3.2.2 Synthesis of [Au(I)2-dppe-L
7
] 
In an attempt to overcome the issues discussed above, dppe was reacted following the 
same reaction pathways as previous; {[Au(PPh3)]2L
7
} with dppe and [(Au-dppe)2] with L
7
, 
using completely anhydrous, deoxygenated conditions. The reaction of [(Au-dppe)2] with L
7 
resulted in starting material and oxidised dppe being recovered only. The reaction of 
{[Au(PPh3)]2L
7
} with dppe produced the desired product. In the 
31
P NMR spectrum peaks at 
+21.3 ppm and +39.7 ppm were observed for the oxidised dppe and product respectively. The 
1
H NMR spectra revealed the CH2 dppe peak at a higher frequency, from +2.02 ppm to +2.55 
ppm, which is attributed to its successful co-ordination to the Au(I) unit. The absence of 
peaks at a lower frequency in the 
1
H NMR spectrum suggests, firstly, that the two CH2 groups 
on dppe are equivalent, and both are bonded to a Au(I) unit, and secondly, with one peak 
present at +3.25 ppm for the CH2 alkyne, the Au(I) units remain co-ordinated to the alkynes.  
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                               Figure 4.24 Attempted synthesis of [Au(I)2-dppe-L
4
]. Reagents: (i) toluene.
Chapter 1. 
 
149 
 
4.4.4    UV-Vis absorption spectroscopy  
 The UV-Vis data are summarised in Table 4.7. The high energy transitions around 250 
nm are attributed to 
1IL (ππ*) or metal perturbed 1IL transitions. The low energy 
absorptions in the regions of 330 nm are indicative of ligand to ligand charge transfer 
(
1LLCT) transitions from the π orbital on the alkyne ligands.  
4.4.5.   Luminescence spectroscopy 
There have been a number of reports discussing the luminescent properties of Au(I) 
complexes resulting from aurophilic interactions. To investigate the potential aurophilic 
interactions of the malonate, di-alkyne Au(I)  both solution and solid state spectra were 
recorded with irradiation at λexc 340 nm. The results of these measurements can be seen in 
Table 4.7 and are discussed in the following sections. 
Table 4.7 Solid and solution photophysical data for {[Au(PPh3)]2L
7/9/10/15
} and [Au2–dppe L
7
] complexes, 
λexc 340 nm and solid state IR data. 
Compound Abs ε dm3 mol-1  cm-1 Em(MeCN) Em(Solid) CC (Cm-1) 
      
{[Au(PPh3)]2L
7
} 250 
271 
297 
14608 
4939 
1497 
 
403-420 
 
405-438 
 
2168 
 
      
{[Au(PPh3)]2L
9
} 250 
271 
297 
14608 
4939 
1497 
 
407-429 
 
414-448 
 
2168 
 
      
{[Au(PPh3)]2L
10
} 251 
306 
326 
20779 
5000 
4429 
 
 
383-415 
 
405-453 
 
 
2182 
 
{[Au(PPh3)]2L
15
} 253 
273 
 
 
1076 
831 
407-438 410-458 2329 
[Au2–dppe L
7
] 241 
285 
315 
11788 
6100 
1246 
 
403-455 
 
404-440 
500-540 
 
2166 
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4.4.5.1. Luminescent properties of {[Au(PPh3)]2L
7/9/10/15
}
 
Upon excitation at 340nm all four complexes, {[Au(PPh3)]2L
7/9/10/15
} displayed a very 
similar, single, broad emission band ranging between 403 nm and 438 nm. The luminescence 
lifetimes of the three aliphatic based, di-alkyne Au(I)2-complexes, {[Au(PPh3)]2L
7/9/10
} were 
< 2 ns, which is suggestive of emission of a singlet excited state, and is attributed to 
1
IL/
1LLCT with possible mixed character of CC (ππ*) and Au-P (σπ*)CC (the π* may be 
localised on the alkyne/aryl group). As the conjugation within the ligands is increased, 
{[Au(PPh3)]2L
7/9/10
}
 
to [[Au(PPh3)]2L
15
]
 
a small red-shift in the emission maxima is observed 
(Figure 4.25). The variation in the emission maxima of the naphthalene-based, di-alkyne 
Au(I) complex was compared to the emission maxima of the free ligand, L
15
 (Figure 4.25).  
  
 
Figure 4.25 Emission spectra of L
15
, {[Au(PPh3)]2L
10
}
 
and {[Au(PPh3)]2L
15
} (λexc = 340 nm). 
  The more extensively conjugated, {[Au(PPh3)]2L
15
} displayed a more structured, red- 
shifted emission profile when compared to that of L
15
, 407-438 nm and 395-426 nm 
respectively. The red-shifted emission in {[Au(PPh3)]2L
15
} was attributed to the effect of the 
[AuPPh3]
+
 unit. The luminescence lifetimes of {[Au(PPh3)]2L
15
} was < 2 ns and so again is 
suggestive of emission singlet in origin; the emission is attributed to 
1
IL/
1
LLCT possibly with 
mixed character of CC (ππ*) and Au-P σπ*CC.  
4.4.5.2. Aurophillic Interactions 
Au-Au interactions have been reported to lead to the observation of a red-shift in the 
emission maxima in the solid state emission when compared to the solution state. The solid 
and solution state emission for the Au(I) malonate complexes are compared in the following 
sections. 
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4.4.5.3. Luminescent properties of both the solid and solution state of 
{[Au(PPh3)]2L
10/15
}. 
In both the solution and solid state spectra the same emission maxima were observed 
for {[Au(PPh3)]2L
15
} (Figure 4.26) however, for the symmetrical, aliphatic based complex 
[[Au(PPh3)]2L
10
] a more dramatic difference was seen. When changing from solution to solid 
state measurements, a red-shifted, more-structured emission spectra was observed; 383-415 
nm in solution to 405-453 nm. The tail of the emission profile in the solid state is more 
structured than that in solution; this increased resolution could suggest the presence of 
aurophilic interactions between Au-Au centres. The absence of an increase in emission 
lifetime make the MMLCT dσ (Au-Au)π* PPh3/CC transition unlikely.  
   
Figure 4.26 Solution and solid state emission spectra of {Au(PPh3)]2L
10
} (LHS) and {Au(PPh3)]2L
15
} (RHS) 
(λexc = 340 nm). 
4.4.5.4. Luminescent properties of both the solid and solution state of {[Au(PPh3)]2L
7
} & 
[Au2-dppe-L
7
] 
In both the solid and solution state spectra the same emission maxima were observed 
for {[Au(PPh3)]2L
7
} (Figure 4.27). More interesting results are seen when changing to the 
dppe-linked complex [Au2-dppe-L
7
]. A red-shifted emission maximum in the was observed 
when compared to the spectra ran in solution with a shift of ca. 100 nm (404-440 nm in 
solution to 500-540 nm in the solid state) (Figure 4.27). This red-shift may be indicative of 
aurophilic interactions occurring. The absence of a red-shift in emission maxima of [Au2-
dppe-L
7
]  in the solution state suggests the  red-shifted emission seen in the solid state is a 
result of intermolecular interactions only, however, the lack of an increase in the emission 
lifetime suggest the emission is singlet state in origin as opposed to the suggested triplet state. 
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Figure 4.27 Steady state emission spectra of {Au(PPh3)]2L
7
} and [Au2-dppe-L
7
] in solid and solution (λexc = 
340 nm). 
Chapter 1. 
 
153 
 
4.5. Cytotoxicity investigation 
A preliminary study of the cytotoxicity was undertaken for L
15
 and {[Au(PPh3)]2L
15
} 
using the MTT assay with four different cancer cell lines: MCF-7 (breast adenocarcinoma), 
A549 (lung adenocarcinoma), PC3 (prostate adenocarcinoma) and LOVO (colon 
adenocarcinoma). For the MTT assay, the compounds were initially dissolved in DMSO, and 
doses of 0.1, 1, 10 and 100 μm were tested to analyse the activity of different concentrations 
and then compared to a control medium with no treatment. The approximate IC50 values for 
these compounds are shown in table 4.8.  
 
Table 4.8 Cytotoxicity data for L
15 
and {[Au(PPh3)]2L
15
}  
Ligand / Complex IC50 MCF-7 IC50 PC3 IC50 A549 IC50 Lovo 
L
15
 >100 >100 >100 >100 
[Au(PPh3)]2L
15
] 5 >100 >100 >100 
 
A comparison of the IC50 values in Table 4.8, showed that the Au(I) complex of 
{[Au(PPh3)]2L
15
} is significantly more toxic than the corresponding free ligand towards the 
MCF-7 cell line and so the increase in the cytotoxicity of the complex is attributed to the 
presence of the Au(I) alkynyl unit, as opposed to the presence of the naphthalene unit. The 
MCF-7 cell line is the most sensitive cell line to this complex with an IC50 value of 5 μM. For 
the other three cell lines (A549, PC3 and LOVO) no sensitivity to the complex is observed. 
Despite the increased sensitive nature of the MCF-7 cell line, when compared to the IC50 
value of cis-platin (IC50 = 2.0 μM) these values are not sufficiently active to suggest 
applications solely as a therapeutic agent. The cellular imaging application of 
{[Au(PPh3)]2L
15
} could not be assessed as the excitation wavelength for this complex is too 
high in energy and cellular damage would be expected.   
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4.6. Conclusion 
A novel series of mono-and di-alkyne malonate ligands were synthesized followed by 
their {[Au(PPh3)]2}
+
 complexes. Crystal structures were obtained for {[Au(PPh3)]2L
7
}, 
{[Au(PPh3)]2L
9
} and {[Au(PPh3)]2L
15
}, but no intra- or intermolecular Au-Au interactions 
were observed in the solid state of these structures. A novel dppe containing complex was 
synthesized using dppe and {[Au(PPh3)]2L
7
}, which ‘locked’ the Au(I) units in a fixed 
position. Luminescence measurements were recorded for all five complexes in both solution 
and solid state to investigate the presence of aurophilic interactions. There was no evidence of 
Au-Au interactions for {[Au(PPh3)]2L
7
}, {[Au(PPh3)]2L
9
} or {[Au(PPh3)]2L
15
} with the same 
emission maxima being observed for both solution and solid state. More interestingly, for 
{[Au(PPh3)]2L
10
} and {[Au2-dppe-L
7
}, when changing from the solution to solid state, a red-
shifted, more structured emission profile is viewed. The red-shift is more dramatic for [Au2-
dppe-L
7
] with a shift of ca.100 nm. The absence of an increase in lifetime suggests that the 
luminescent transitions occurring in {[Au(PPh3)]2L
10
} and [Au2-dppe-L
7
] in the solid state are 
singlet in nature and therefore not a result of aurophilic interactions. 
Cytotoxicity measurements were carried out for the naphthalene-based complex 
{[Au(PPh3)]2L
15
} and its ligand, L
15
. No sensitivity to the ligand was seen in any of the cell 
lines tested. The only cell line to show sensitivity to the complex {[Au(PPh3)]2L
15
} was that 
of MCF-7. The absence of sensitivity to the ligand suggests the toxicity of the complex is 
attributed to the gold unit. MCF-7’s are high in mitochondria, given that the mitochondria are 
believed to be the key intracellular target of gold agents (see the earlier discussion of TrxR), 
this is a promising route for the synthesis of a gold-based therapeutic agent. The dual 
functionality of complexes of this type (cellular and therapeutic agents) could not be assessed 
as the excitation wavelength of the malonate based complex is of high energy and therefore 
would damage the cells if used.   
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4.7. Experimental 
 
4.7.1. Crystallography 
{[Au(PPh3)]2L
3
}: C62H62Au2F6N2O10P2S2, M = 1629.13, 0.10  0.04  0.04 mm
3
, monoclinic, 
space group P21/n (No. 14), a = 12.0014(15), b = 27.888(4), c = 19.133(2) Å, = 
104.048(7)°, V = 6212.2(14) Å
3
, Z = 4, Dc = 1.742 g/cm
3
, F000 = 3208, MoK radiation, = 
0.71073 Å,  T = 293(2)K, 2max = 38.0º, 9107 reflections collected, 4906 unique (Rint = 
0.0864). Final GooF = 1.355, R1 = 0.1565, wR2 = 0.3030, R indices based on 3666 reflections 
with I >2sigma(I) (refinement on F
2
), 321 parameters, 46 restraints. Lp and absorption 
corrections applied, = 4.913 mm-1. 
 
Au cluster: C56H47Au3Cl2F3O4P3S, M = 1627.71, 0.12  0.10  0.10 mm
3
, triclinic, space 
group P-1 (No. 2), a = 12.7242(2), b = 14.5427(2), c = 16.2111(3) Å, = 63.8380(10), = 
81.6950(10), = 89.6090(10)°, V = 2658.75(7) Å3, Z = 2, Dc = 2.033 g/cm
3
, F000 = 1548, 
MoK radiation, = 0.71073 Å,  T = 150(2)K, 2max = 55.0º, 17979 reflections collected, 
12118 unique (Rint = 0.0367). Final GooF = 1.033, R1 = 0.0453, wR2 = 0.1065, R indices 
based on 10074 reflections with I >2sigma(I) (refinement on F
2
), 650 parameters, 9 restraints.  
Lp and absorption corrections applied, = 8.544 mm-1. 
 
{[Au(PPh3)]2L
7
}  C49H44Au2O4P2, M = 1152.71, colourless plate, 0.40 × 0.28 × 0.12 mm
3
, 
monoclinic, space group P21/a (No. 14), a = 18.3922(7), b = 12.7687(4), c = 22.6554(8) Å, b 
= 112.362(2)°, V = 4920.4(3) Å
3
, Z = 4, Dc = 1.556 g/cm
3
, F000 = 2232, KappaCCD, MoKa 
radiation, l = 0.71073 Å, T = 150(2)K, 2qmax = 49.1º, 14715 reflections collected, 8086 unique 
(Rint = 0.0670). Final GooF = 1.035, R1 = 0.1107, wR2 = 0.2657, R indices based on 5461 
reflections with I >2sigma(I) (refinement on F
2
), 444 parameters, 7 restraints.  Lp and 
absorption corrections applied, m = 6.060 mm
-1
. 
 
{[Au(PPh3)]2L
9
} C55H56Au2O4P2, M = 1236.87, 0.25  0.15  0.02 mm
3
, monoclinic, space 
group P21/a (No. 14), a = 18.6917(16), b = 12.9506(13), c = 22.7648(12) Å, = 110.571(4)°, 
V = 5159.3(7) Å
3
, Z = 4, Dc = 1.592 g/cm
3
, F000 = 2424, MoK radiation, = 0.71073 Å,  T = 
293(2)K, 2max = 41.8º, 9411 reflections collected, 5271 unique (Rint = 0.1260).  Final GooF = 
1.394, R1 = 0.1535, wR2 = 0.3603, R indices based on 2885 reflections with I >2(I) 
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(refinement on F
2
), 198 parameters, 37 restraints.  Lp and absorption corrections applied, = 
5.785 mm
-1
. 
 
{[Au(PPh3)]2L
15
} C67H52Au2O4P2, M = 1376.96, 0.53  0.34  0.02 mm
3
, triclinic, space 
group P-1, a = 13.3177 (12), b = 13.2371 (11), c = 17.0686 (18) Å, = 77.650 (6)°, V = 
2772.1 (4) Å
3
, Z = 2, Dc = 1.650 Mg/m
3
, F000 = 1348, MoK radiation, = 0.71075 Å,  T = 
120(2)K, 2max = 41.8º, 29975 reflections collected, 11299 unique (Rint = 0.1704).  Final 
GooF = 0.975, R1 = 0.1424, wR2 = 0.1846,  
  
4.7.2. Synthesis of ligands: 
L
1
: Ethylene glycol (4 mL, 7 mmol) was added to a solution of nicotinoyl chloride (0.5 g, 3.5 
mmol) in chloroform (30 mL) and TEA (1.6 mL, 11 mmol). The solution was left at stir at 60 
˚C for 3 h. The solution was washed using sat. aq. sodium bicarbonate (3 × 10 mL) and sat. 
aq. ammonium chloride (2 × 10 mL). The organic layer was dried and the solvent evaporated 
to dryness, yielding a cream solid. Yield: 1.3 g, 68 %. 
1
H NMR (CDCl3, 300 MHz, 298 K) δH: 
4.61 (4H, s, (H5)), 7.32-7.35 (2H, m, (H3)), 8.11-8.19 (2H, m, (H4)), 8.63-8.68 (2H, m, 
(H2)), 9.13 (2H, s, (H12)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 164, 152.6, 
149.9, 136.2, 122.4, 61.9 ppm. MS (ES
+
) m/z: 272.08 [M+H]
+
. IR (nujol) υ: 1651 (CO) cm-1. 
 
L
2
: 1,6 hexan-diol (0.380 g, 3.23 mmol) was added to a solution of nicotinoyl chloride (1 g, 
7.07 mmol) in chloroform (50 mL) and TEA (3.23 mL, 22 mmol). The solution was left at stir 
at 60 ˚C for 3 h. The solution was washed using sat. aq. sodium bicarbonate (3 × 10 mL) and 
sat. aq. ammonium chloride (2 × 10 mL). The organic layer was dried and the solvent 
evaporated to dryness, yielding a white solid. Yield: 0.831 g, 78 %. 
1
H NMR (CDCl3, 300 
MHz, 298 K) δH: 1.38-1.45 (4H, m, (H8, H9)), 1.7 (2H, t, (H7)), 2.42-2.48 (2H, m, (H6)), 
3.61 (2H, t, (H10)), 4.34 (2H, t, (H5)), 7.38-7.42 (2H, m, (H3)), 8.28 (2H, dd, (H4)). 8.68-
8.72 (2H, m, (H2)). 9.18 (2H, m, ((H1)) ppm.   
 
L
4
: To a solution of propargyl alcohol (2.085 g, 37.24 mmol) and TEA (12.3 mL, 89.4 mmol) 
in DCM (15 mL) was added malonyl chloride (2.5 g, 17.73 mmol) drop wise. The solution 
was left to stir at room temperature for 15 mins. The solution was washed using sat. aq. 
sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 × 10 mL). The organic 
layer was dried and the solvent evaporated to dryness, yielding orange oil. Yield: 1.3 g, 41 %. 
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1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.5 (2H, t, (H1)), 3.41 (4H, s, (H3)), 4.59 (4H, t, 
(H2)) ppm. 
 
L
5
:
 
To a solution of benzaldehyde (0.112 mL, 1.11 mmol) in DMSO (5 mL) was added 
proline (0.128 g, 1.11 mmol). L
4
 (0.200 g, 1.11 mmol) was added after 5 minutes. The 
solution was stirred at room temperature for 24 h. EtOAc (20 mL) was added and then the 
solution was washed with water (2 × 10mL). The organic layer was dried and the solvent 
evaporated to dryness, yielding light orange oil. The crude product was purified using column 
chromatography eluting with DCM. Yield: 0.063 g, 21 %. 
1
H NMR (CDCl3, 400 MHz, 298 
K) δH: 2.41-2.46 (2H, t, 
3
JHH = 2.5 Hz, (H1)), 4.74 (4H, d, 
3
JHH = 2.8 Hz, (H2)), 7.2-7.43 (3H, 
m, (H3, H4)), 7.38-7.43 (2H, m, (H5)), 7.71 (1H, s, (H6)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 
MHz, 298 K) δC: 53.1, 75.2, 124, 129, 130, 131.2, 132.3, 144.6, 163.1, 165.4 ppm. MS (ES
+
) 
m/z: 213.05 [M-C3H3O]
+
, 268.07 [M]
+
. HRMS (ES
+
) found m/z 268.0730; [C16H12O4]
+  
requires 268.0730. IR (nujol) υ: 1626 (CO), 1735 (CO), 2130 (CC) cm-1. UV-vis λmax (ε / M
-
1
cm
-1
) (MeCN) λmax : 280 (4874) nm.  
 
L
6
: To a solution of anisaldehyde (0.126 mL, 1.11 mmol) in DMSO (5 mL) was added 
proline (0.128 g, 1.11 mmol). L
4
 (0.200 g, 1.11 mmol) was added after 5 minutes. The 
solution was stirred at room temperature for 24 h. Work-up as before. Yield: 0.108 g, 33 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.43-2.59 (2H, t, 
3
JHH = 2.6 Hz, (H1)), 3.76 (3H, s, 
(H6)), 4.71-4.85 (4H, d, 
3
JHH = 2.4 Hz, (H2)), 6.73 (2H, d, 
3
JHH = 8.8 Hz, (H4)), 7.78 (2H, d, 
3
JHH = 8.8 Hz (H5)), 7.62 (1H, s, (H3)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 
51.9, 52, 54.4, 74.7, 75.9, 76.1, 113.4, 120, 123.7, 131.1, 143.1, 161.1, 162.4, 164.8 ppm. MS 
(ES
+
) m/z: 243.05 [M-C3H3O]
+
, 298.07 [M]
+
, HRMS (ES
+
) found m/z 298.0775; [C17H14O5]
+  
requires 298.0836. IR (nujol) υ: 1651 (CO),1737 (CO), 2129 (CC) cm-1. UV-vis λmax (ε / M
-
1
cm
-1
) (MeCN) λmax : 311 (18419) nm.  
 
L
7
: To a solution of diethyl malonate (4.74 mL, 31.2 mmol), potassium tertiary butoxide (8.4 
g, 74.88 mmol), in ethanol (200 mL) was added propargyl bromide (9.8 mL, 74.99 mmol) 
slowly. The solution was stirred at room temperature, under N2(g) for 5 h. The solution was 
washed with water (3 × 50 mL). The organic layer was dried and the solvent evaporated to 
dryness, yielding orange oil. Yield: 4.21 g, 82 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.22 
(6H, t, 
3
JHH = 7.25 Hz, (H1)), 1.99 (2H, t, 
3
JHH = 2.6 Hz, (H4)), 2.92 (4H, d, 
3
JHH = 2.6 Hz, 
(H3)), 4.17 (4H, q, 
3
JHH = 7.1 Hz, (H2)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 
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53.1, 75.2, 124, 129, 130, 131.2, 132.3, 144.6, 163.1, 165.4 ppm. MS (ES
+
) m/z: 163 [M-H]
+
. 
IR (nujol) υ: 1740 (CO), 1995 (CC) cm-1. 
 
Ligand precursor L
8/9
: To a solution octanol (0.716 g, 5.5 mmol) and TEA (1.17 mL, 9 
mmol) in DCM (15 mL) was added ethyl malonyl chloride (0.750 g, 5 mL) drop wise. The 
solution was left to stir at room temperature for 15 mins. The solution was washed using sat. 
aq. sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 × 10 mL). The 
organic layer was dried and the solvent evaporated to dryness, yielding colourless oil. Yield: 
0.434 g, 36 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.82 (3H, t, 
3
JHH=6.7 Hz, (H11)), 1.18-
1.32 (13H, m, (H1,H6-H10)), 1.53-1.72 (2H, m, (H5)), 3.32 (2H, s, (H3)), 4.01-4.18 (4H, m, 
(H2, H4)) ppm. L
8/9 
To a solution of ligand precursor (0.167 g, 0.684 mmol), potassium 
tertiary butoxide (0.183 g, 1.64 mmol), in ethanol (50 mL) was added propargyl bromide 
(0.18  mL, 2.05 mmol) slowly. The solution was stirred at room temperature, under N2(g) for 
5 h. The solution was washed with water (3 × 50 mL). The organic layer was dried and the 
solvent evaporated to dryness, yielding a colourless oil. Yield L
8 
: 0.029 g, 15 %. 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 0.82 (3H, t, (H11)), 1.12-1.34 (13H, m, (H1, H6-H10)), 1.62-
1.66 (2H, m, (H5)), 2.08 (1H, t, (H3b)), 2.72-2.75 (1H, m, (H3)), 2.98 (2H, d, (H3a)), 4.12-
4.29 (4H, m, (H2,H4)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 14.1, 14.2, 18.6, 
22.7, 25.9, 28.6, 19.2, 29.3, 31.9, 52.3, 56.5, 61.8, 62.2, 70.5, 71.8, 78.6, 168.8, 168.9 ppm. 
MS (ES
+
) m/z: 282 [M+H]
+
. Yield L
9
: 0.129 g, 59 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 
0.82 (3H, t, (H11)), 1.18-1.43 (13H, m, (H1, H6-H10)), 1.52-1.68 (2H, m, (H5)), 2.08 (2H, t, 
3
JHH = 2.4 Hz, (H3b)), 2.98 (4H, d, 
3
JHH = 2.6 Hz, (H3a)), 4.12-4.29 (4H, m, (H2,H4)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 14.0, 14.1, 22.5, 22.6, 25.7, 28.4, 29.1, 29.2, 
31.6, 31.8, 40.1, 56.3, 62.1, 66.2, 71.7, 76.6, 78.4, 168.6, 168.7 ppm. MS (ES
+
) m/z: 321.2 
[M]
+
. HRMS (ES
+
) found m/z 321.2063; [C19H29O4]
+  
requires 321.2065. IR (nujol) υ: 1739 
(CO), 2124 (CC) cm
-1
. 
 
Ligand precursor L
10
: To a solution octanol (2.35 mL, 14.9 mmol) and TEA (2.29 mL, 21.2 
mmol) in DCM (15 mL) was added malonyl chloride (0.750 g, 5 mL) drop wise. The solution 
was left to stir at room temperature for 15 mins. The solution was washed using sat. aq. 
sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 × 10 mL). The organic 
layer was dried and the solvent evaporated to dryness. Excess octanol was removed via 
distillation. Yield: 0.987 g, 42 % 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.85 (6H, t, 
3
JHH= 
Hz, (H1)), 1.39-1.98 (20H, m, (H2-H6)), 1.65-1.78 (4H, m, (H7)), 3.33 (2H, s, (H9)), 4.13 
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(4H, t, (H8)) ppm.
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 14.1, 22.7, 25.8, 28.5, 29.2, 
29.7, 31.8, 41.7, 65.6, 166.7 ppm. IR (nujol) υ:1651 (CO) 1737 (CO) cm-1. UV-vis λmax (ε / 
M
-1
cm
-1
) (MeCN) λmax : 253 (3489) nm.  L
10
: To a solution of ligand precursor (0.400 g, 1.22 
mmol), potassium tertiary butoxide (0.328 g, 2.92 mmol), in ethanol (50 mL) was added 
propargyl bromide (0.32 mL, 3.65 mmol) slowly. The solution was stirred at room 
temperature, under N2(g) for 5 h. The solution was washed with water (3 × 50 mL). The 
organic layer was dried and the solvent evaporated to dryness, yielding orange oil. Yield: 
0.168 g, 36 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.82 (6H, t, 
3
JHH = 6.8 Hz, (H1)), 1.32-
1.43 (20H, m, (H2-H6)), 1.58 (4H, m, (H7)), 2.06 (2H, t, 
3
JHH = 2.6 Hz, (H10)), 2.98 (4H, d, 
3
JHH = 2.6 Hz, (H9)), 4.18 (4H, t, 
3
JHH = 4.7 Hz, (H8)) ppm. 
 
 
Ligand precursor L
11 /12
: To a solution ligand precursor A (0.560 g, 1.7 mmol) and TEA 
(0.037 mL, 2.3 mmol) in DCM (25 mL) was added ethyl malonyl chloride (0.231 g, 1. 5 
mmol) drop wise. The solution was left to stir at room temperature for 15 mins. The solution 
was washed using sat. aq. sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 
× 10 mL). The organic layer was dried and the solvent evaporated to dryness, yielding a dark 
orange oil. Yield: 0.972 g, 69 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.14-1.44 (19H, m, 
(H1,H6-H13)), 1.55-1.69 (2H, m, (H5)), 1.67-1.72 (2H, m, (H14)), 3.27 (2H, s, (H3)), 4.0-
4.18 (4H, m, (H2, H4)), 4.26 (2H, t, 
3
JHH = 6.5 Hz, (H15)), 7.29-7.32 (1H, m, (H17)), 8.17-
7.24 (1H, m, (H16)), 8.69 (1H, d, (H18)), 9.17 (1H, s, (H19)) ppm. 
13
C{
1
H} NMR (CDCl3, 
101 MHz, 298 K) δC: 12.3, 25.8, 26.0, 26.2, 26.5, 27.0, 28.1, 28.5, 28.8, 29.3, 29.6, 31.2, 
34.3, 42.0, 65.8, 122.9, 137.1, 149.1, 152.3 ppm. MS (ES
+
) m/z: 422.25 [M+H]
+
,
 
444.23 
[M+Na]
+
,
 
460.21 [M+K]
+
. HRMS (ES
+
) found m/z 422.2535; [C23H36O6N]
+  
requires 
422.2357. IR (nujol) υ:1591 (CO), 1658 (CO), 1728 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) 
λmax: 254 (5214) nm. L
11/12 
To a solution of ligand precursor (0.560 g, 1.7 mmol), potassium 
tertiary butoxide (0.04 g, 4.08 mmol), in ethanol (50 mL) was added propargyl bromide (0.8 
mL, 4.08 mmol) slowly. The solution was stirred at room temperature, under N2(g) for 5 h. 
The solution was washed with water (3 × 50 mL). The organic layer was dried and the solvent 
evaporated to dryness, yielding a dark orange oil. Yield L
11
: 0.021 g. 
 1
H NMR (CDCl3, 400 
MHz, 298 K) δH: 1.18-1.39 (22H, m, (H1,H6-H13,H18)), 1.55-1.73 (4H, m, (H5,H14)), 1.97-
2.08 (2H, m, (H3b, H16b)), 2.70-2.81 (2H, m, (H3, H16)), 2.92-2.98 (4H, m, (H3a,H16a)), 
4.08-4.29 (8H, m, (H2,H4,H15,H17)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 
14.0, 14.1, 18.5, 22.6, 25.8, 28.5, 29.1, 29.2, 29.5, 29.6, 51.2, 56.4, 61.8, 61.9, 62.2, 66.0, 
66.3, 70.5, 70.6, 71.8, 78.5, 78.5, 168.0, 168.9 ppm. MS (ES
+
) m/z: 507.1 [M+H]
+
, 529 
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[M+Na]
+
, 545 [M+K]
+
. HRMS (ES
+
) found m/z 524.3216; [C28H46O8N]
+ 
requires 524.3218. 
IR (nujol) υ: 1591 (CO), 1658 (CO), 1735 (CO), 2124 (CC) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 263 (3215), 302 (1653), 352 (528) nm. Yield L
12
: 0.060 g, 7 %. 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 1.18-1.39 (19H, m, (H1, H6-H13)), 1.55-1.73 (2H, m, (H5)), 
1.68-1.75 (2H, m, (H14)), 1.97 (2H, t, (H3a)), 2.92-2.98 (4H, m, (H3b)), 4.0-4.18 (4H, m, 
(H2, H4)), 4.26 (2H, t, 
3
JHH = 6.5 Hz, (H15)), 7.29-7.32 (1H, m, (H17)), 8.18-8.24 (1H, m, 
(H16)), 8.69 (1H, d, (H18)), 9.17 (1H, s, (H19)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 
K) δC: 53.1, 75.2, 124, 129, 130, 131.2, 132.3, 144.6, 163.1, 165.4 ppm. MS (ES
+
) m/z: 
498.28 [M+H]
+
, 520.26 [M+Na]
+
. HRMS (ES
+
) found m/z  498.2844 [M+H]
+
; [C29H40O6N]
+  
requires 498.2850. IR (nujol) υ: 1591 (CO), 1727 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) 
λmax: 262 (3827) nm.  
 
Ligand Precursor L
13
: To a solution ligand precursor A (1 g, 3.26 mmol) and TEA (0. 69 
mL, 4.89 mmol) in DCM (15 mL) was added malonyl chloride (0.230 g, 1.63 mmol) drop 
wise. The solution was left to stir at room temperature for 15 mins. The solution was washed 
using sat. aq. sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 × 10 mL). 
The organic layer was dried and the solvent evaporated to dryness, yielding orange oil. Yield: 
0.136 g, 12 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.15-1.29 (28H, m, (H7-H13)), 1.29-
1.41 (4H, m, (H14)), 1.53-1.62 (4H, m, (H6)), 1.68-1.77 (4H, m, (H15)), 3.31 (2H, s, (H17)), 
4.08 (4H, t, 
3
JHH = 6.8 Hz, (H16)), 4.29 (4H, t, 
3
JHH = 6.7 Hz, (H5)), 7.27-7.36 (2H, m, (H3)), 
8.18 (2H, dd, (H4)), 8.13-8.25 (2H, m, (H2)), 9.11-9.19 (2H, m, (H1)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δC: 25.6, 25.8, 26.2, 26.8, 27.1, 28.5, 28.9, 28.6, 29, 29.3, 29.6, 
42.3, 65.7,  123.3, 137.1, 151.2, 153.4, 164.6 ppm. MS (ES
+
) m/z: 682.41 [M]
+
. HRMS (ES
+
) 
found m/z  682.4181 [M]
+
; [C30H58O8N2]
+  
requires 682.4188. IR (nujol) υ: 1751 (CO), 1756 
(CO) cm
-1
. UV-vis λmax (ε / M
-1
cm
-1
) (MeCN) λmax : 261 (6067), 363 (610) nm. L
13
 To a 
solution of ligand precursor (0.100 g, 0.146 mmol), potassium tertiary butoxide (0.05 g, 0.439 
mmol), in ethanol (50 mL) was added propargyl bromide (0.1 mL, 0.439 mmol) slowly. The 
solution was stirred at room temperature, under N2(g) for 5 h. The solution was washed with 
water (3 × 50 mL). The organic layer was dried and the solvent evaporated to dryness, 
yielding orange oil. Yield: 0.04 g, 37 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.12-1.31 
(28H, m, (H7-H13)), 1.49-1.56 (4H, m, (H14)), 1.62-1.73 (8H, m, (H6, H15)), 1.92 (2H, t, 
3
JHH = 2.3 Hz, (H17b)), 2.81 (4H, d, 
3
JHH = 2.2 Hz, (H17a)), 4.08 (4H, t, 
3
JHH = 6.6 Hz, (H16)), 
4.27 (4H, t, 
3
JHH = 6.7 Hz, (H5)), 7.25-7.36 (2H, m, (H3)), 8.18 (2H, dd, (H4)), 8.13-8.25 (2H, 
m, (H2)), 9.11-9.19 (2H, m, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 21.5, 
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24.7, 24.9, 27.4, 27.6, 28.1, 28.2, 28.5, 29.3, 55.4, 64.5, 65.2, 70.7, 77.5, 122.3, 125.3, 136, 
149.9, 152.3, 164.3, 167.6 ppm. MS (ES
+
) m/z: 758.45 [M]
+
. HRMS (ES
+
) found m/z  
758.4507 [M+H]
+
; [C45H62O8N2]
+  
requires 758.4501. IR (nujol) υ: 1724 (CO), 1735 (CO) cm-
1
. UV-vis λmax (ε / M
-1
cm
-1
) (MeCN) λmax : 261 (10356) nm.  
 
Ligand Precursor L
14
: To a solution benzyl-alcohol (1 g, 9.25 mmol) and TEA (1.86 mL, 
13.8 mmol) in DCM (15 mL) was added malonyl chloride (0.620 g, 4.39 mmol) drop 
wise. The solution was left to stir at room temperature for 15 mins. The solution was 
washed using sat. aq. sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 
× 10 mL). The organic layer was dried and the solvent evaporated to dryness, yielding a 
colourless oil. Yield: 0.840 g, 68 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 3.39 (2H, s, 
(H5)), 5.05 (4H, s, (H4)), 7.11-7.32 (10H, m, (H1-H3)) ppm. L
14
:To a solution of ligand 
precursor (0.840 g, 2.96 mmol), potassium tertiary butoxide (1.16 mL, 10.35 mmol), in 
ethanol (50 mL) was added propargyl bromide (1.34 mL, 14.8 mmol) slowly. The solution 
was stirred at room temperature, under N2(g) for 5 h. The solution was washed with water 
(3 × 50 mL). The organic layer was dried and the solvent evaporated to dryness, yielding a 
colourless oil. Yield: 0.625 g, 37 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.98 (2H, t,
 
3
JHH = 2.65 Hz, (H6)), 2.92 (4H, d,
 3
JHH = 2.6 Hz (H5)), 5.03 (4H, s, (H4)), 7.08-7.29 
(10H, m, (H1-H3)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 21.5, 29.3, 65.1, 
70.9, 75.5, 77.1, 122.4, 124.1, 124.5, 124.9, 125.5, 126.5, 127.6, 128.4, 129.3, 130.4, 
132.5, 167.2 ppm. MS (ES
+
) m/z: 461.18 [M+H]
+
, 478.20 [M+NH4]
+
, 483.16 [M+Na]
+
, 
499.13 [M+K]
+
, HRMS (ES
+
) found m/z 483.1561 [M+Na]
+
; [C31H24O4Na]
+ 
requires 
483.1567. IR (nujol) υ: 1739 (CO) cm-1. UV-vis λmax (ε / M
-1
cm
-1
) (MeCN) λmax : 281 
(3510) nm.  
 
Ligand Precursor L
15
: To a solution naphthol (1 g, 6.32 mmol) and TEA (1.27 mL, 9.03 
mmol) in DCM (15 mL) was added malonyl chloride (0.424 g, 3.01 mmol) drop wise. The 
solution was left to stir at room temperature for 15 mins. The solution was washed using 
sat. aq. sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 × 10 mL). The 
organic layer was dried and the solvent evaporated to dryness, yielding a pale orange oil. 
Yield: 0.900 g, 78 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 3.43 (2H, s, (H9)), 5.03 
(4H, s, (H8)), 7.31-7.55 (8H, m, (H3-H6)), 7.72-7.9 (6H, m, (H1, H2, H7)) ppm. L
15
: To a 
solution of ligand precursor (0.579 g, 1.5 mmol), potassium tertiary butoxide (0.592 mL, 
5.29 mmol), in ethanol (50 mL) was added propargyl bromide (0.88 mL, 7.5 mmol) 
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slowly. The solution was stirred at room temperature, under N2(g) for 5 h. The solution 
was washed with water (3 × 50 mL). The organic layer was dried and the solvent 
evaporated to dryness, yielding a colourless oil. Yield: 0.110 g, 16 %.  
1
H NMR (CDCl3, 
400 MHz, 298 K) δH: 1.81 (2H, t,
 3
JHH = 2.3 Hz (H10)), 2.92 (4H, d,
 3
JHH = 2.3 Hz (H9)), 
5.38 (4H, s, (H8)), 7.21-7.28 (2H, m, (H4)), 7.23-7.37 (4H, m, (H3, H5)), 7.53-7.78 (8H, 
m, (H1, H2, H6, H7)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 21.5, 29.3, 65.1, 
70.9, 75.5, 77.1, 122.4, 124.1, 124.5, 124.9, 125.5, 126.5, 127.6, 128.4, 129.3, 130.4, 
132.5, 167.2 ppm. MS (ES
+
) m/z: 461.18 [M+H]
+
, 478.20 [M+NH4]
+
, 483.16 [M+Na]
+
, 
499.13 [M+K]
+
, HRMS (ES
+
) found m/z  483.1561 [M+Na]
+
; [C31H24O4Na]
+  
requires 
483.1567. IR (nujol) υ: 1739 (CO) cm-1. UV-vis λmax (ε / M
-1
cm
-1
) (MeCN) λmax: 281 
(3510) nm.  
 
4.7.3. Synthesis of Complexes: 
{[Au(PPh3)2L
7
}:  To a round bottom flask encase in aluminium foil L
7 
(0.044 g, 0.184 mmol), 
[AuClPPh3] (0.200 g, 0.404 mmol), potassium tertiary butoxide (0.062 g, 0.552 mmol) and 
ethanol (2 mL) were added and stirred under nitrogen for 12 h. The solution was concentrated 
in vacuo, re-dissolved in DCM and filtered. The orange solid was recrystallized from THF 
and diethyl ether. Yield: 0.097 g, 50 %.  
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.22 (6H, t, 
(H1)), 3.21 (4H, s, (H3)), 4.18 (4H, q, (H2)), 7.30-7.62 (30H, m, (H4)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δC: 14.1, 24.2, 61.4, 129.0, 129.1, 131.4, 134.3, 134.5 ppm. δ 
31
P 
42.73 ppm. IR (nujol) υ: 1732 (CO), 1771 (CO), 2168 (CC) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 250 (14608), 271 (4939), 297 (1497) nm. 
 
[Au2dppe-L
7
]: To degassed toluene (10 mL) was added [[Au(PPh3)]2L
7
] (0.076 g, 0.07 
mmol), degassed, and dppe (0.026 g, 0.07 mmol) added. The degassed solution was left to stir 
under N2(g) for 72 h. The solution was concentrated in vacuo and the cream solid was 
recrystallized from THF and diethyl ether. Yield: 0.027 g, 40 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.25 (6H, t, (H1)), 2.55 (4H, s, (H4)), 3.25 (4H, s, (H3)), 4.18 (4H, q, (H2)), 7.36-
7.70 (20H, m, (H5)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 14.3, 24.1, 61.6, 77.3, 
129.6, 131.9, 133.5, 169.4 ppm. δ 31P 39.67 ppm. IR (nujol) υ: 1621 (CC), 1732 (CO), 2166 
(CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 241.5 (11788), 285 (6106), 351.5 (1246) nm. 
 
{[Au(PPh3)]2L
9
}: To a round bottom flask encase in aluminium foil L
9 
(0.021 g, 0.07 mmol),  
[AuClPPh3] (0.072 g, 0.07 mmol), potassium tertiary butoxide (0.026 g, 0.023 mmol) and 
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ethanol (2 mL) were added and stirred under nitrogen for 12 h. Work-up as before. Yield: 
0.012 g, 48 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 0.78 (3H, t, (H11)), 1.06-1.32 (10H, 
m, (H6-H10)), 3.17 (4H, s, (H3a)), 4.02-4.18 (4H, m, (H2, H4)), 7.21-7.56 (30H, m, (H3b)) 
ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 14.1, 22.7, 24.2, 44.1, 25.8, 25.9, 37.5, 39, 
39.2, 31.8, 62.4, 129.0, 129.1, 129,4, 131.4, 134.3, 134.5 ppm. δ 31P 42.71 ppm. MS (ES) m/z: 
721 [Au(PPH3)2]
+
. IR (nujol) υ: 1732 (CO), 1771 (CO), 2168 (CC) cm-1. UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 250 (14608), 271 (4939), 297 (1497) nm.   
 
{[Au(PPh3)]2L
10
}: To a round bottom flask encase in aluminium foil L
10 
(0.012 g, 0.032 
mmol),  [AuClPPh3] (0.034 g, 0.069 mmol), potassium tertiary butoxide (0.011 g, 0.095 
mmol) and ethanol (2 mL) were added and stirred under nitrogen for 12 h. Work-up as before 
Yield: 0.073 g, 57 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 1.32 (6H, t, 
3
JHH = 8.3 Hz 
(H1)), 1.12-1.27 (20H, m, (H2-H6)), 1.49-1.61 (4H, m, (H7)), 3.21 (4H, s, (H9), 4.05 (4H, t, 
3
JHH = 6.7 Hz, (H8)), 7.22-7.41 (30H, m, (H10)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 
K) δC: 14.2, 22.4, 22.7, 24.8, 28.5, 29.3, 31.8, 33.2, 65.7, 128.9, 129.1, 131.4, 134.8, 134.5. 
ppm. δ 31P 42.75 ppm. IR (nujol) υ: 1724 (CO), 1735 (CO), 2182 (CC) cm-1. UV-vis λmax (ε / 
M
-1
cm
-1
) (MeCN) λmax : 251 (20779), 306 (5000), 326 (4429) nm.  
 
{[Au(PPh3)]2L
15
}: To a round bottom flask encase in aluminium foil L
15 
(0.033 g, 0.071 
mmol), [AuClPPh3] (0.080 g, 0.162 mmol), potassium tertiary butoxide (0.024 g, 0.213 
mmol) and ethanol (2 mL) were added and stirred under nitrogen for 12 h. Work-up as before. 
Yield: 0.071 g, 74 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 3.26 (4H, s, (H9)), 5.41 (4H, s, 
(H8)), 7.22-7.52 (38H, m, (H2, H3, H4, H6, H10)), 7.62 (2H, d, (H5)), 7.68 (2H, d, (H7)), 
7.93 (2H, d, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) , δC: 65.2, 76.3, 125.7, 
126.7, 126.9, 128.8, 129, 129.1, 131.4, 134.3, 134.5, 169.4 ppm. δ 31P 42.75 ppm.  IR (nujol) 
υ: 1736 (CO), 2329 (CC) cm-1.UV-vis (ε / M-1 cm-1) (MeCN) λmax: 253 (1076), 273 (831) nm.   
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Chapter 5. Luminescent Mono- and Di-Metallic Au(I) Complexes 
Incorporating Anthraquinone-Based Ligands Towards Dual-
Functional Therapeutic And Cellular Imaging Applications. 
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5.1.    Introduction 
Despite the increasing interest in Au(I) species as therapeutic and cellular imaging 
agents, limited research has been dedicated to combining these properties within a single 
entity. Following on from the series of alkyl and aryl Au(I) alkyne based complexes discussed 
in Chapter 4, this chapter looks at the synthesis of a  series of aromatic, mono- and di-metallic 
Au(I) alkyne based complexes for suitability as both therapeutic and cellular imaging agents. 
Through varying the nature of the aromatic functional groups attached to the alkyne Au(I) 
units, a novel series of complexes was synthesised and their synthesis, photophysical and 
cytotoxic properties, as well as their cellular imaging properties are reported herein. 
5.1.1.   Heterocycles in therapeutics and luminescence 
The addition of Au(I) and Au(III) to existing antitumor agents can lead to enhanced 
antitumor activity, however, there exists several reports highlighting the cytotoxic behaviour 
of aromatic compounds in the absence of Au(I). Bair et al.
1
 reported the synthesis of a series 
of polyaromatic propane diol derivatives which displayed a dependency of antitumor activity 
on the shape of the aromatic system.
 
A more detailed discussion by Becker et al.
2
 reporting a 
series of lipophilic aromatic amines, discussed the effects of varying, aliphatic chain length, 
aromatic ring size and the terminal heterocyclic ring on the cytotoxicity of the compounds. 
The more interesting observation within the series was seen with the nature of the linkers, 
amine and amide. The amines (which were formed via a reduction of the amides) displayed 
increased cytotoxic activity when compared to their precursors. Additionally, this series of 
complexes reported that the functional groups incorporated inside the heterocyclic ring and 
the ring size did affect the cytotoxic profile, however the length of the aliphatic chain and the 
incorporation of a double bond did not.
2
 
5.1.2. Anthraquinone 
O
O
 
Figure 5.1 Anthraquinone. 
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Anthraquinones, otherwise referred to as anthracenedione, are used as the building 
blocks of many important organic compounds; anthraquinones and their derivatives can be 
found in dyes, as a bird repellent in seeds, but more importantly they are found in abundance 
in pharmaceuticals.
3 
Although anthraquinone based compounds have been extensively 
studied, studies on their photophysical and therapeutic properties have been conducted 
separately.  
5.1.2.1.Cytotoxic studies of anthraquinones 
Cytotoxic studies on anthraquinone based complexes have been conducted with 
several reports on DHAQ suggesting their potential to act as antitumor agens.
4,5,6 
Reports by 
Ahn et al. have documented good antitumor activity for a range of derivatives of 
anthraquninones including 2-(1-hydroxyalkynyl)- and 2-(1-alkoxy-alkynyl)- 1,4-
dihydroxyalkynyl complexes
5 
and 2-(1-hydroxyalkyl)-anthracene-1,4,9,10-tetraones 
complexes.
6 
Additionally, this group have reported the incorporation of chlorambucil, a 
known chemotherapy drug,  into a 1,4-DHAQ unit (via an ester unit) with varying aliphatic 
chain lengths and substituents in the 2 position of the aromatic ring (Figure 5.2). From the 12 
new complexes investigated, 2 esters (R=H and R=phenyl) gave cytotoxic values higher than 
that of unmodified chlorambucil. The complexes followed a trend that indicated that the 
toxicity of compounds of this nature was dependent on the size of the alkyl group.
7  
The anti-
tumor activity of anthraquinones is thought to be due to the intercalation of the planar ring 
system between the base pairs of the DNA, resulting in an inhibition of DNA transcription 
and replication.  
 
O
O
Chlorambucil
ROH
OH
O
OH
N
Cl
Cl
Chlorambucil
 
Figure 5.2 1,4 DHAQ incorporating chlorambucil and the structure of chlorambucil (RHS). 
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5.1.2.2.Luminescent properties of anthraquinones 
DHAQ, unlike AQ is a coloured chromophore. The presence of the hydroxyl groups 
on DHAQ allows intramolecular hydrogen bonding to occur between the donor group (OH) 
and the accepter group (CO). In the excited state the phenolic OH is more acidic and the 
carbonyl oxygen is more basic which results in proton transfer. This proton transfer leads to 
significant changes in the electronics and fluorescent properties of the molecule. Therefore the 
dual fluorescence properties exhibited by molecules of this type are attributed to ESIPT 
(excited state, intramolecular proton transfer) from the S1 states of the two tautomer forms, 
the enol and keto forms (Figure 5.3)
 
The energy barrier for ESIPT increases with polarity of 
the solvent and varies with the position of the OH; ESIPT does not occur with 1-4-DHAQ.
8,9
 
O
O O
H
O
H
O
O O
O
H
H
 
Figure 5.3 1,5 DHAQ, intramolecular hydrogen bonding displayed; enol form (LHS), keto form (RHS). 
5.1.3.    Cell imaging with Au(I) species 
The application Au(I) complexes as cellular imaging agents, when compared to their 
application as therapeutic agents (discussed in detail in Chapter 1 and Chapter 4), has 
received considerably less attention with only a few examples to date having been reported, 
some of which are discussed below.  
Ott et al.
10
 have reported a series of four Au(I) complexes based on the lipophilic, cell growth 
inhibiting compound, naphthalimide. The four complexes varied via the substituent bound to 
the phosphine (Figure 5.4). All four complexes gave an IC50 value in the range of 1.1-3.7 μM. 
Low cell uptake was observed for the toxic [AuClPPh3] precursor complexes. Cellular 
biodistribution studies were carried out on the two complexes inclusive of R = P(CH2CH3)3 
and R=PPh3 and uptake into the  nuclei was observed.
 10
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S Au(PR3)
O
N
O
NCH3
CH3
R = CH3  / CH2CH3  / C(CH)3  / C6H5
 
Figure 5.4 Complexes reported by Ott et al.
10 
Aswell as reporting a mechanistic explanation for the favourable antitumor properties 
of Au(I) phosphine complexes (discussed in detail in Chapter 4), Berners-Price et al.
11
 have 
reported the first example of an Au(I) NHC based complex in cellular imaging (Figure 5.5); in 
compound A and B the Au(I) centres are ‘locked’ with a separation for A of 3.0484 (3) Å and 
B 3.79417 (4) Å. The emissive nature of compound A was attributed to the shorter Au-Au 
distance, however, its luminescence properties are such that they would damage the cells if 
imaged since high energy irradiation was required; λex = 260 nm, λem = 400 nm. Compound C 
gave the smaller Au-Au distance of 2.9582 (4) Å with the more favourable luminescence 
properties, λex = 355 nm, λem = 496 nm for cell imaging. Compound C was incubated with 
RAW264.7 cells (a mouse macrophage cancer cell line) and co-localisation studies with both 
a lysosomal and mitochondrial dye were carried out showing clear localisation of Compound 
C in lysosomes only (Figure 5.6).
11 
The cellular distribution of a series of Au(I) alkynyls has 
also been reported with the distribution of the Au(I)-alkyne complex throughout the cells 
rather than limited to one area.
11 
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Figure 5.5 Complex  A (top LHS), B (top RHS) and C (bottom). Reproduced from ref 11.
11 
 
Figure 5.6 Cell imaging with Compound C. Bright field image (LHS), luminescence image (centre) and 
lysosome stain (RHS). Reproduced from ref. 11.
 
The cellular imaging and distribution studies of the highly cytotoxic Au(I) complexes 
discussed above highlight an inconsistency with the proposed mitochondrial pathway to 
apoptosis in cancer cells discussed in Chapter 4; none of the complexes discussed above 
reveal mitochondrial staining. As these are only a few examples of cellular imaging with 
therapeutic agents (allowing the cellular distribution of a complex to be viewed) a noticeable 
rise in the need for this new method of analysis for the apoptosis mechanism is realised. 
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5.2.    Overview 
The exploitation of aurophillic interactions (and thus the luminescent properties which 
result) can allow the cellular distribution of therapeutic agents to be viewed, but to date, 
compounds of this type are yet to be fully explored. Taking into account previous reports 
where-by Au(I) units were added onto already known antitumor aromatics, the initial aromatic 
compounds chosen for co-ordination onto the Au(I) alkyne unit was coumarin (Chapter 3 
reports cytotoxic nature of Re(I)-coumarin to MCF-7 cells) and anthracene. Thereafter, 
anthraquinones were investigated. The successful synthesis of Au(I)-alkyne based complexes 
in Chapter 4 resulted in its continued use throughout this chapter. Herein, the synthesis of a 
novel series of aromatic, mono- and di-metallic Au(I) complexes are reported and their dual 
suitability as therapeutic and cellular imaging agents discussed. 
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5.3.     Results and discussion 
5.3.1.    Synthesis and characterisation of ligands 
Despite L
1
-L
4 
being reported previously in research, their photophysical data has been 
reported herein for easy referral when discussing the novel Au(I) complexes of L
1
, L
2 
and L
4
. 
The
 
Au(I) complex of L
3 
has also been reported previously, however, the cellular imaging 
properties of the complex have yet to be investigated. 
O O
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Figure 5.7 Synthesis of ligands: L
1 
and L
2
, reagents; acid chloride,  propargyl alcohol,  TEA, CHCl3, 61 ˚C, 
3 h: L
3-8 ; propargyl bromide, excess carbonate, acetone, Δ, 2-5 days. 
L
1 
and L
2
 were synthesised via the production of coumarin-3- and anthracene-9- acyl 
chlorides, respectively. These syntheses were achieved by heating coumarin-3-carboxylic acid 
or anthracen-9-carboxylic acid in excess thionyl chloride (2 mL) and catalytic DMF at 71 ˚C 
for 3 hours. The precursors were dried thoroughly and added to propargyl alcohol and TEA in 
chloroform. Purification of the ligands was achieved using column chromatography 
producing L
1 
and L
2 
in good-to-excellent yields of 71 % and 86 % respectively.  
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L
3
 to L
8 
were synthesised following literature methodology. The relevant phenolic 
starting materials, which are all commercially available, were reacted with  propargyl 
bromide, in the presence of excess potassium carbonate via an SN2 nucleophilic substitution 
reaction. Both the reaction time and the base used had an influence on the nature and yields of 
the products formed. Since literature reports the use of potassium carbonate as the base, this 
was incorporated into the production of L
3 
and L
4
 both of which were formed in moderate 
yields, 29 % and 40 % respectively, and required no further purification. When changing the 
base from potassium to sodium carbonate the yields of L
6
, L
7
, and L
8
 were increased and 
these yields are reported herein.  
The observation of a shift downfield for the peak in the 
1
H NMR spectra between 
+4.51 and +5 ppm corresponding to the CH2CCH unit for L
1
-L
8 
confirmed the formation of 
the ether/ester units. MS and HRMS analysis for each of the ligands showed peaks 
corresponding to the parent [M]
+
 for L
5
-L
8 
and [M+H]
+
 for L
4
. L
5
 also
 
showed a peak 
corresponding to [M-C3H2] and both L
6
 and L
8
 showed peaks corresponding to [M-C3H3]
+
 
resulting from the loss of a propargyl radical. Both the IR and UV-Vis data for each ligand are 
reported in Table 5.4. 
Different isomers of di-hydroxy anthraquinone, when reacted with propargyl bromide, 
showed varying results with respect to the nature and the yields of the products formed. These 
results are summarised in Table 5.1. The di-alkyne ligand of the 1,2-isomer, L
4
, required no 
purification as only the dimer was produced. However, the production of di-alkyne, 1,4- and 
1,8- isomer of L
6
 and L
8
 respectively, under the same conditions 
 
produced a mixture of 
products (using either sodium or potassium carbonate) and so further purification via column 
chromatography was required. Column chromatography isolated both mono- and di-alkyne 
ligands, in poor yields in both cases. Increasing the reaction time by an additional 48 hours 
resulted in a yield increase for the production of the di-alkyne ligands, L
6 
and L
8
 (L
6
 3 days: 
5.6 %, 5 days: 31 %) (L
8
 3 days: 14.3 %, 5 days: 54 %). The synthesis of mono- and di-alkyne 
ligands based around the 1,5-dihydroxy anthraquinone isomer produced L
9
 and L
10
, however, 
due to the poor yields obtained (L
9
, 4 % and L
10
, 3 %) it was decided the synthesis of the 
complexes would not be attempted. The difference in the reactivity of the di-hydroxy 
anthraquinones can be attributed to the electronic properties of the compounds and the 
reactivity of the phenoxide groups.   
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Table 5.1 Reactivity of anthraquinones; percentage yields varied with time. 
 Di-hydroxy 
anthraquinone 
% after 
3 days 
% after 
5 days 
 1, 2 Dimer 40    
 1, 4 Monomer 
Dimer 
15 
5.6 
- 
Dimer 
 
31 
 1, 5 Monomer 
- 
4 Monomer 
Dimer 
4 
3 
 1, 8 Monomer 13.4 - 
Dimer 
 
54  Dimer 14.3 
5.3.2.    Synthesis and characterisation of the complexes 
The alkynes were reacted following the same method as Chapter 4, however, the work 
up was slightly modified in the cases where a di-metallic Au(I) complex was produced as a 
result of a precipitate being formed; the precipitate was filtered, dissolved in DCM and re-
filtered to remove the salt. Each complex was purified by recrystallization using vapour 
diffusion of diethyl ether into a concentrated THF solution. Again, the use of THF proved 
necessary as prolonged exposure to chlorinated solvents resulted in the breakdown of 
complexes to the Au(I)- starting material [AuClPPh3]. The soluble complexes were 
characterised by 
1
H and 
31
P NMR and IR spectroscopies. 
CH2
O
O
O
Au(PPh3)
Au(PPh3)
O
O
O
O
CH
CH
 
Figure 5.8 Synthesis of {[Au(PPh3)]2L
4
}. Reagents: [AuClPPh3], K
+t
BuO
-
, ethanol, N2(g), RT. 
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1
H NMR spectra were obtained for each complex in CDCl3. For each complex there 
was an absence of the terminal alkyne proton CH2CCH peak seen in the free ligand and a shift 
of propargyl CH2, H2CC-, to higher frequency. The latter peak was seen as a singlet in the 
region +4.5 to +5.0 ppm. For [Au(PPh3)L
1/2
] a shift in the aromatic protons adjacent to the 
ester gold unit to lower frequency was also displayed. The tri-phenyl phosphine proton 
resonances were typically broad and in most cases superimposed with the co-ordinated ligand 
aromatic protons. For [Au(PPh3)L
5
] and {[Au(PPh3)]2L
6/8
}
 
broad proton resonances were seen 
in the region of  +7.23 to +7.5 ppm integrating to 15H and 30H respectively. 
31
P{
1
H} NMR spectra for [Au(PPh3)L
1/2
] gave a signal in the range of +29 to +30 
ppm. For the mono-metallic, [Au(PPh3)L
5
] and the di-metallic {[Au(PPh3)]2L
3,4,6,8
} 
complexes a shift of +42 ppm was displayed. All of the complexes gave a single peak in the 
31
P NMR spectra indicating the symmetrical nature of the di-metallic Au(I) complexes. The 
difference in 
31
P NMR  shifts can be explained in terms of the donating ability of the alkyne; 
[Au(PPh3)L
1/2
] displayed  peaks at a lower frequency, which are attributed to the ester oxygen 
being more electron withdrawing (when compared to the ether unit for L
3-6,8
) which leads to 
strengthening of the CC bond. This was confirmed through IR studies where both 
[Au(PPh3)L
1/2] displayed an increase in the value of ν(CC) upon co-ordination with 
enhancements of 190 cm
-1
 and 55 cm
-1
 respectively.
  
 
Solid state IR studies were carried out for all complexes which showed subtle changes 
in the ν(CC) when compared to the free ligand. The ligands display an IR stretch similar to 
the precursor, propargyl alcohol with a shift at 2120 cm
-1 
whereas the complexes displayed a 
weaker IR absorption band ranging from 2132-2252 cm
-1 
for the alkyne stretch. This slight 
shift to a higher wavenumber
 
corresponds to a decrease in the difference of electronegativity 
between the terminal proton and the Au(I) unit and thus an increase in the strength of the 
alkyne bond was observed (Table 5.4). Similarly to the complexes discussed in Chapter 4, MS 
analysis for each of the complexes gave a peak at 721 only 
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5.3.3.   Single crystal X-ray diffraction studies 
Re-crystallisation of complexes [Au(PPh3)L
2
] and {[Au(PPh3)]2L
3/8
}
 
by vapour 
diffusion of diethyl ether into a concentrated THF solution yielded pale orange crystals 
suitable for X-ray diffraction studies. {[Au(PPh3)]2L
3
} 
 
has been reported previously but is 
included herein for comparison. 
 
  
                                           
Figure 5.9 Structural representations of complexes [Au(PPh3)L
2
] (top) and {[Au(PPh3)]2L
3/8
} (bottom LHS 
and bottom RHS respectively)
 
 (H atoms omitted for clarity).  
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The parameters associated with the data collections of the complexes [Au(PPh3)L
2
] 
and {[Au(PPh3)]2L
3/8
}
  
(Table 5.3) and the selected bond lengths and bond angles (Table 5.2) 
are shown below. As the {[Au(PPh3)]2L
3
} has been reported previously it is not discussed in 
greater detail herein.
  
 
For the anthracene based structure of [Au(PPh3)L
2
], the C-Au-P bond angle does not 
show substantial deviations from linearity, 177 ˚. The Au-P bond length of 2.27 Å and the Au-
C bond length of 2.025 Å, were both consistent with other gold(I)-acetylide complexes 
reported, additionally, both bond lengths were longer than those of the [AuClPPh3] starting 
material, consistent with the stronger trans influence of the acetylene group when compared 
to the chloride.
12-14 The C≡C bond length for complex, 1.15 Å, was again normal for 
complexes of this type. No evidence of intermolecular contacts between the Au(I) units was 
observed.
15,16  
 
 Similarly to the [Au(PPh3)L
2
] structure, the average C-Au-P bond angle does not 
deviate from linearity for {[Au(PPh3)]2L
8
}
 
with both the Au-P and Au-C bond lengths in 
agreement with the literature values for gold(I)-acteylide complexes. The structure for 
{[Au(PPh3)]2L
8
}
 
is however, slightly more interesting than that of [Au(PPh3)L
2
] with the 
anthraquinone unit showing deviation for the planar unit expected. The structure of the non-
planar anthraquinone unit shows an open-book conformation with an angle between the two 
terminal rings of approximately 161˚. No evidence of intra- or intermolecular contacts 
between any Au(I) units can be seen but π-stacking was observed between the aromatic units 
in the packing of the asymmetric units; close contacts (closer than van der Waals radii) 
between adjacent molecules involving the phenyl units of the phosphine ligands and the 
anthraquinone rings reveal intra- and intermolecular π stacking which resulted in the 
unexpected conformation of the anthraquinone unit. 
Table 5.2 Selected bond lengths and bond angles for the complexes: [Au(PPh3)L
2
], {[Au(PPh3)]2L
3
} and 
{[Au(PPh3)]2L
8
}. 
               [Au(PPh3)L
2
]                             {[Au(PPh3)]2L
3
}                           {[Au(PPh3)]2L
8
}                    
C36H26AuO2P   C58H38Au2Cl6O4P2 
   Bond Lengths (Å)  
Au-P             2.266 (2)                    Au-P              2.227                     Au-P              2.277 (4)                    
Au-C            2.025 (7) Au-C             2.034  Au-C             2.01 (2) 
C-C               1.15 (1) C-C               1.16 C-C                1.13 (3) 
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Table 5.3 Crystal data collection and refinement details for the crystal structures of                                    
[Au(PPh3)L
2
] and {[Au(PPh3)]2L
8
}. 
                                                                  [Au(PPh3)L
2
]                          {[Au(PPh3)]2L
8
}                    
 
 
 
Empirical formula C36H26AuO2P C58H38Au2Cl6O4P2 
Formula weight 718.50 1467.46 
Temperature 150(2) K 293 K 
Wavelength 0.71013 Å 0.71013 Å 
Crystal system Orthorhombic Monoclinic 
Space group P b c a (61) P2(1)/n (14) 
Unit cell dimensions a = 9.974 (2) Å 
α = 90.00 ˚ 
b = 17.5178 (3) Å 
β = 90.00˚ 
c = 32.8694 (8) 
ϒ =90.00˚ 
a = 18.4561 (9) Å 
α = 90.00 ˚ 
b = 11.6603 (5) Å 
β = 98.614 (2)˚ 
c = 26.6071 (7) Å 
ϒ =90.00˚ 
Volume 5743.08 (3) Å
3 
5661.4 Å
3
 
Z 8 4 
Density (calculated) 
F(000) 
1.662 g/cm
3 
2816 
1.722 g/cm
3 
2832 
Crystal size 0.25 × 0.25 × 0.20  
Theta range for data 
collection 
55.8 55.1 
All reflections 12222 22508 
Independent reflections 6652 12700 
Observed reflections 4564 6204 
Goodness-of-fit on F 
Rint 
1.096 
0.0613 
1.018 
0.1312 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0695 
wR2 = 0.1027 
R1 = 0.0999 
wR2 = 0.2248 
R indices (all data)   
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5.3.4.   UV-Vis absorption spectroscopy  
 The UV-Vis data are summarised in Tables 5.4 and 5.5. The high energy transitions 
around 250 nm are attributed to 
1IL (ππ*) or metal perturbed 1IL transitions. The low energy 
absorptions in the regions of 330 nm are indicative of ligand to ligand charge transfer 
(
1LLCT) transitions from the π orbital on the alkyne ligands. The anthraquinone based ligands 
and their complexes show an additional absorption in the region of 375-448 nm, this 
transition is assigned to a charge transfer transition with substantial ππ*character.  
Table 5.4 Photophysical data for the ligands. 
Compound Abs ε dm3 mol-1  cm-1 Em(MeCN) Lifetimes (MeCN) ns CC (Cm-1) 
      
L
1
 - - 395 
 
- 2062 
 
L
2
 - - 460 
 
- 2129 
 
L
3
 - - 345 
 
- 2117 
 
 
L
4
 276 
359 
 
 
3437 
1050 
398 - 2129 
L
5
 270 
326 
432 
2448 
1501 
1252 
409 
532-560 
 
- 2115 
 
      
L
7
 
 
L
8
 
 
254 
408 
 
254 
374 
2432 
11951 
 
29230 
10428 
- 
 
 
505 
- 
 
 
- 
2034 
 
 
2130 
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Table 5.5 Photophysical data for the complexes. 
Compound Abs ε dm3 mol-1  cm-1 Em(MeCN) Lifetimes (MeCN) ns CC (Cm-1)   
[Au(PPh3)L
1
]                                          220 
286 
 
10017 
7154 
 
434-494 5.65 2252   
[Au(PPh3)L
2
]                                          224 
251 
 
10071 
4173 
 
452 6.7 2184   
{[Au(PPh3)]2L
3
}                                          228
329 
 
17519 
2860 
369 < 2 2132   
{[Au(PPh3)]2L
4
}                                          212
273 
375 
 
15998 
5542 
1430 
 
415 
435 
5.4 2184 
 
  
[Au(PPh3)L
5
]                                          272 
448 
 
24360 
10639 
 
406 
538-566 
 
2 <  2133 
 
 
  
{[Au(PPh3)]2L
6
}                                          250
406 
12700 
1790 
411-438 
524 
 
4.08 2246 
2133 
  
{[Au(PPh3)]2L
8
}                                          257
397 
19593 
4700 
491 2.53 2239   
 
5.3.5.   Luminescence spectroscopy 
There have been a number of reports discussing the luminescent properties of hydroxy 
anthraquinone compounds; however, there have been no reports on the properties of alkynyl 
anthraquinones. Luminescence spectra were obtained in aerated acetonitrile following 
irradiation at λex 340 nm and 405 nm. The luminescence data for the Au(I) complexes and 
their ligands are shown in Tables 5.4 and 5.5 respectively and are discussed in the following 
sections. 
 
5.3.5.1.Luminescence properties of [Au(PPh3)L
1/2
] and {[Au(PPh3)]2L
3
}
 
Upon excitation at 340 nm {[Au(PPh3)]2L
3
}
 
displayed a single broad emission band 
around 380 nm, this was a blue-shifted emission when compared to that of [Au(PPh3)L
1/2
] and 
can be attributed to reduced conjugation within the ligand (Figure 5.10). Both 
{[Au(PPh3)]2L
1/2
}
 
displayed emission around 480 nm in solution. [Au(PPh3)L
2
] emission 
bands can be attributed to the chromophoric unit as these wavelengths are similar to those of 
their ligands, i.e. 
1IL (ππ*). [Au(PPh3)L
1
] displayed a red-shifted emission when compared 
to the ligand (L
1
, 395 nm, [Au(PPh3)L
1
], 434-494 nm), indicating an effect of the [AuPPh3]
+
 
unit, and is attributed to 
1
IL/
1LLCT possibly with mixed character of CC (ππ*) and Au-P 
(σπ*) CC.   
Chapter 1. 
 
182 
 
 
Figure 5.10 Emission spectra of [Au(PPh3)L
1/2
] and {[Au(PPh3)]2L
3
}
 
(λexc = 340 nm). 
 The lifetime measurements for all three complexes were recorded with an excitation 
of 295 nm and detection wavelengths of 380 nm for {[Au(PPh3)]2L
3
} and 480 nm for 
[Au(PPh3)L
1/2
]. A decay profile best fitting a single-exponential decay provided 
corresponding short-lived lifetimes for each complex in solution of < 5 ns, and thus emission 
was assigned as a short-lived 
1IL (ππ*) fluorescence. 
5.3.5.2.Luminescence properties of [Au(PPh3)L
5
]
  
 Following excitation at 340 nm, [Au(PPh3)L
5
] displayed dual emission with a band ca. 
430 nm and a broader band at ca. 550 nm. The lower energy band was attributed to AQ 
chromophore, whilst the higher energy band may be 
1IL (CC ππ*). The ligand-centred 
nature was confirmed through very short-lived lifetime values, < 2 ns. In order to probe the 
charge transfer nature of the low-energy band, different polarity solvents were used, revealing 
significant changes in the intensity of the band (Figure 5.11). 
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Figure 5.11 Emission spectra of [Au(PPh3)L
5
] in different solvents (λexc = 340 nm) 
5.3.5.3. Luminescence properties of [Au(PPh3)L
5
] and {[Au(PPh3)]2L
4/6/8
}
   
 Following excitation at 340 nm for the complex {[Au(PPh3)]2L
6
}, two emission bands 
were seen, at 411-438 nm, and 524 nm, but the emission profile for {[Au(PPh3)]2L
6
} is very 
different to its free ligand where only one emission band was seen with λmax at 487 nm 
(Figure 5.12). The spectrum of {[Au(PPh3)]2L
6
} showed the appearance of a new band at 411-
438 nm, and a red-shifted emission at 524 nm. The similarity of the di-metallic complex, 
{[Au(PPh3)]2L
6
}, to the mono-metallic complex, [Au(PPh3)L
5
], indicated the ligand based 
emission was effected by the presence of the [AuPPh3]
+ 
, the presence of the [AuPPh3]
+
 units 
in the dimer influence the electronics of the ligand in a similar fashion to the OH group on the 
monomer (Figure 5.12). This emission pattern is indicative of 
1
ILCT / 
1 
LLCT possibly with 
mixed character of CC (ππ*) and Au-P (σπ*) CC. The lifetime of the di-metallic Au(I) 
complex was larger than the monomer, however with a lifetime of < 10 ns only singlet 
character, 
1ILCT (π-π*) / 1LLCT, can be assigned  with certainty.    
Chapter 1. 
 
184 
 
 
Figure 5.12 Emission spectra of L
5
 with [Au(PPh3)L
5
], L
6
 with and {[Au(PPh3)]2L
6
}
  
and 
 
[Au(PPh3)L
5
] 
with {[Au(PPh3)]2L
6}. (λexc = 340 nm). 
5.3.5.4. Luminescence properties of {[Au(PPh3)]2L
4/8
}
   
For the remaining two complexes, {[Au(PPh3)]2L
4/8
}, excitation at 340 nm resulted in 
the emission spectra displaying a single broad structure-less emission band with λmax values 
similar to the free ligand 
1
ILCT attributed to the chromophoric anthraquinone unit (Table 5.6). 
The contribution of phosphorescence (
3ILCT (ππ*)) has been negated due to the short-lived 
lifetimes, < 10 ns. 
 For this series of isomeric phosphinogold di-alkyne complexes, the position of the 
substituents on the anthraquinone has a profound effect on the positions of bands in the 
electronic spectra (Table 5.5). The 1,2 isomer, {[Au(PPh3)]2L
4
}, 
 λmax  of 415-435nm is blue-
shifted when compared to the 1,4 and the 1,8 isomers or {[Au(PPh3)]2L
6/8
} with
 λmax  of 
524nm and 491 nm respectively. A blue-shifted emission was also seen with the napthyl-ether 
based complex, {[Au(PPh3)]2L
3}, with a λmax  of 369 nm. The blue shift can be attributed to 
interaction between the two substituents (which are closer together in the naphthyl-ether and 
1, 2 isomers) resulting in an increase in the HOMOLUMO energy gap and therefore a 
higher energy emission was observed. The 1,4 isomer,{[Au(PPh3)]2L
6
}, was the only one of 
the three dimers to exhibit a two band emission spectra, this, again, was attributed to the 
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position of the alkyne units however the effect was only seen when the [AuPPh3]
+ 
 unit was 
introduced presumably for steric reasons.  
 
Table 5.6 The emission data for the isomeric di-alkyne ligands and their complexes, MeCN, λexc 340  (nm). 
 
 
 
 
 
5.3.5.5. Aurophillic interactions 
Both solution and solid state emission spectra were recorded for [Au(PPh3)L
5
] and 
{[Au(PPh3)]2L
6/8
} (Figure 5.13). All three complexes show a red-shift in emission maxima in 
the solid state when compared to the spectra recorded in solution. This red-shift could be 
indicative of intramolecular aurophilic interactions occurring between the Au(I) centres. 
However, for [Au(PPh3)L
5
], where only one Au(I) unit is present within the complex, red-shift 
was also observed. Given that the crystal structure of {[Au(PPh3)]2L
8
} (Table 5.5) showed no 
evidence to suggest Au(I)-Au(I) contacts, it is more likely that the red-shift is simply due to 
packing effects in the solid state. 
 
 
 
Ligand 
 
Em(MeCN) Compound Em(MeCN)   
4 398 {[Au(PPh3)]2L
4
} 
 
 415-435 
 
 
6 487 {[Au(PPh3)]2L
6
} 411-438 
524 
 
  
8 505 {[Au(PPh3)]2L
8
} 
 
 491   
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Figure 5.13 Emission spectra of [Au(PPh3)L
5
] and {[Au(PPh3)]2L
6/8
} in solid and solution. (λexc = 340 nm). 
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5.4.    Cytotoxicity investigation 
A preliminary study of the cytotoxicity was undertaken for L
5
, L
6
 and L
8 
and their 
corresponding complexes [Au(PPh3)L
5
] and {[Au(PPh3)]2L
6/8
} using the MTT assay with four 
different cancer cell lines: MCF-7 (breast adenocarcinoma), A549 (lung adenocarcinoma), 
PC3 (prostate adenocarcinoma) and LoVo (colon adenocarcinoma). For the MTT assay, the 
compounds were initially dissolved in DMSO, and doses of 0.1, 1, 10 and 100 μm were tested 
to analyse the activity of different concentrations and then compared to a control medium 
with no treatment. The approximate IC50 values for these compounds are shown in Table 5.7. 
 
Table 5.7 Cytotoxicity data for the ligands and complexes  
Ligand / Complex IC50 MCF-7 IC50 PC3 IC50 A549 IC50 LoVo 
L
5
 80 >100 >100 >100 
[Au(PPh3)L
5
] 5 50 100 100 
L
6
 >100 >100 >100 70 
{[Au(PPh3)]2L
6
}
 5 50 >100 80 
L
8
 >100 >100 >100 >100 
{[Au(PPh3)]2L
8
} 5 >100 >100 >100 
 
A comparison of the IC50 values in Table 5.7 shows that the Au(I) complexes are 
dramatically more toxic than their corresponding free ligands. The increase in the cytotoxicity 
of the Au(I) complexes is attributed to the presence of the Au(I) alkynyl unit. 
The MCF-7 cell line is apparently a more sensitive cell line to this type of complex with all 
three Au(I) complexes displaying an IC50 value of 5 μM. The complex of the 1,4-isomer, 
[Au(PPh3)L
5
] and {[Au(PPh3)]2L
6
}, displayed increased cytotoxicity in the PC3 cell line with 
the relatively high IC50 values of 50 μM. L
6 
and its corresponding complex, {[Au(PPh3)]2L
6
}, 
show increased toxicity towards the LoVo cell line when compared to the other compounds 
looked at with IC50 values of 70 μM and 80 μM respectively. The A549 cell line shows no 
sensitivity to any of the compounds in this series.  
Despite the increased sensitive nature of the MCF-7 cell line to complexes of this type, 
when compared to the IC50 value of cis-platin (IC50 = 2.0 μM) these values are not sufficiently 
active to suggest applications solely as a therapeutic agent. However, given that the 
mitochondria are believed to be the key intracellular target of gold agents (Chapter 4’s 
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discussion of TrxR), having established that these complexes display toxicity towards MCF-
7s their therapeutic application and cellular distribution can be investigated via fluorescence 
microscopy. 
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5.5.    Cellular imaging 
 Despite the short lived lifetimes exhibited by each of the complexes, preliminary 
cellular imaging experiments were carried out. For the complexes, [Au(PPh3)L
2
]
 
and 
{[Au(PPh3)]2L
3
} the cellular imaging results displayed ligand based fluorescence / auto-
fluorescence only. For [Au(PPh3)L
1
], apoptosis was observed immediately upon radiation 
which indicated that the coumarin moiety is toxic to cells.  
 For the anthraquinone based compounds: the di-alkyne ligand, L
6
, and the mono and 
di-metallic Au(I) complexes, [Au(PPh3)L
5
] and {[Au(PPh3)]2L
6
}, were chosen for further 
studies as the compounds are analogous which made comparisons easy.  
 The ligand, L
6
, and the mono and di-metallic gold complexes, [Au(PPh3)L
5
] and 
{[Au(PPh3)]2L
6
} were each incubated with MCF-7 cells over a 30 minute period at 4 ˚C. The 
low temperature allows energy-dependent uptake processes, such as endocytosis, to be 
repressed.
 
Following the removal of excess agent, the cells were allowed to warm to room 
temperature. At room temperature the cells functions normalise; energy-dependent pathways 
are no longer repressed allowing the accumulation and toxicity of the investigated complexes 
to be viewed.  
 The samples were imaged by confocal microscopy using an excitation of 405 nm and 
a detection range between 530-580 nm in accordance to the 
3
MLCT emission reported in 
Table 5.5 thus eliminating autofluorescence. All three of the compounds viewed show 
successful uptake with > 80 % of cells showing good uptake. Initially good cell morphology 
was maintained for each sample, additional details are discussed in detail in the following 
sections 
5.5.1.   Cellular imaging properties of L
6 
 The 1,4 di-alkyne ligand showed good uptake whilst maintaining good cell 
morphology throughout the entire confocal session. Variable ligand based emission 
throughout the cytoplasm was observed. The presence of intense spots within the cytoplasm 
would suggest specific organelle localisation (Figure 5.14).  
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               A           B             C        D 
Figure 5.14 Imaging with L
6
 in MCF-7 cells showing: (A) & (C) cytoplasmic distribution; (B) & (D) 
transmitted light only. 
5.5.2.   Cellular imaging properties of [Au(PPh3)L
5
] 
 
 The mono-metallic Au(I) complex, [Au(PPh3)L
5
], again showed good cell uptake 
whilst maintaining good cell morphology throughout the entire confocal session. 
[Au(PPh3)L
5
]  showed very similar cellular distribution to L
6
 but with increased luminescence 
intensity; increased luminescence was observed throughout the entire cytoplasm with intense 
spots for specific organelle distribution (Figure 5.15). The increase in intensity for 
[Au(PPh3)L
5
] was attributed to the increased lipophilicity of the complex provided by the 
PPh3 unit.  
    
A           B             C        D 
Figure 5.15 Imaging with [Au(PPh3)L
5
] in MCF-7 cells showing: (A) & (C) cytoplasmic distribution; (B) & 
(D) transmitted light only. 
5.5.3.   Cellular imaging properties of {[Au(PPh3)]2L
6
}
  
The di-metallic Au(I) complex, {[Au(PPh3)]2L
6
}, despite the additional PPh3 unit, 
displayed similar luminescent intensity when compare to the mono-metallic Au(I) complex, 
[Au(PPh3)L
5
] with both complexes displaying similar luminescence distribution to L
6
. Unlike 
L
6 
and the mono-metallic complex, the di-metallic complex exhibited photobleaching with 
toxic effects seen upon irradiation. As the sample was irradiated, the appearance of large 
Chapter 1. 
 
191 
 
vacuoles within the cells as well as a decrease in the luminescence intensity was apparent 
(Figure 5.16). The exact mechanism of photobleaching is unknown but with the apparent 
toxic effects of the di-metallic Au(I) complex there is the possibility it is linked as 
photobleaching which often involves the generation of toxic species (O2 radicals). 
 
    
             A          B                C       D 
Figure 5.16 Imaging with {[Au(PPh3)]2L
6
} in MCF-7 cells showing: (A) cytoplasmic distribution (overlaid 
luminescence and transmitted light); (B) appearance of vacuoles upon irradiation (transmitted light only);  
(C) & (D) photobleaching (luminescence only). 
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5.6.   Conclusion  
Several mono- and di-metallic Au(I)-alkyne aromatic complexes were synthesised 
successfully. The ligand synthesis has shown that the choice of anthraquinone isomer has an 
effect on the nature and yield of the product formed. Favourable photophysical and cytotoxic 
properties were shown for this family of compounds, L
5
, [Au(PPh3)L
5
], L
6
, {[Au(PPh3)]2L
6
}, 
L
8 
and {[Au(PPh3)]2L
8
} suggesting suitability for applications as dual therapeutic and cellular 
imaging agents. The cellular imaging properties of L
6
, [Au(PPh3)L
5
], {[Au(PPh3)]2L
6
} was 
investigated and all three compounds showed staining of the general cytoplasm with some 
intense staining of organelles. The increased lipophilicity on changing from the ligand to the 
mono-metallic complex resulted in increased uptake, as judged by emission intensity. 
However, no increase in intensity was observed from the mono-metallic to the di-metallic 
complex. Interestingly, upon irradiation, the di-metallic complex showed photobleaching with 
apparent toxic effects; the appearance of large vacuoles from within the cell was observed 
upon continual irradiation.  
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5.7. Experimental 
5.7.1. Crystallography 
[Au(PPh3)L
2
]: C36H26AuO2P, M = 718.50, 0.25  0.25  0.20 mm
3
, orthorhombic, space 
group Pbca (No. 61), a = 9.9741(2), b = 17.5178(3), c = 32.8694(6) Å, V = 5743.08(18) Å
3
, Z 
= 8, Dc = 1.662 g/cm
3
, F000 = 2816, MoK radiation, = 0.71073 Å,  T = 150(2)K, 2max = 
55.8º, 12222 reflections collected, 6652 unique (Rint = 0.0613).  Final GooF = 1.096, R1 = 
0.0695, wR2 = 0.1027, R indices based on 4564 reflections with I >2sigma(I) (refinement on 
F
2
), 361 parameters, 6 restraints.  Lp and absorption corrections applied, = 5.210 mm-1. 
{[Au(PPh3)]2L
8
}: C58H38Au2Cl6O4P2, M = 1467.46, monoclinic, space group P21/n (No. 14), 
a = 18.4561(9), b = 11.6603(5), c = 26.6072(7) Å, = 98.614(2)°, V = 5661.4(4) Å3, Z = 4, Dc 
= 1.722 g/cm
3
, F000 = 2832, MoK radiation, = 0.71073 Å,  T = 293(2)K, 2max = 55.1º, 
22508 reflections collected, 12700 unique (Rint = 0.1312).  Final GooF = 1.018, R1 = 0.0999, 
wR2 = 0.2248, R indices based on 6204 reflections with I >2sigma(I) (refinement on F
2
), 686 
parameters, 57 restraints.  Lp and absorption corrections applied, = 5.561 mm-1. 
5.7.2. Synthesis of ligands 
L
1 
Coumarin acid chloride (0.5 g, 2.63 mmol) in chloroform (10 mL) and TEA (0.56 mL, 3.95 
mmol) was added slowly to a solution of propargyl alcohol (0.14 mL, 2.39 mmol) in 
chloroform (5 mL). The solution was left to stir at 60 ˚C for 3 h. The solution was washed 
using sat. aq. sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 × 10 mL). 
The organic layer was dried and the solvent evaporated to dryness, yielding an orange solid. 
The crude product was purified using column chromatography eluting with DCM.  Yield: 
0.387 g, 71 %. 
1
H NMR (CDCl3, 300 MHz, 298 K) δH: 2.54 (1H, t, (H7)), 4.94-4.96 (2H, m, 
(H6)), 7.29-7.33 (2H, m, (H2,H3)), 7.65-7.7  (2H, m, (H1,H4)), 7.72 (1H, s, (H5)) ppm.   
L
2 
Anthracene chloride (0.5 g, 2.25 mmol) in chloroform (10 mL) and TEA (0.49 mL, 3.48 
mmol) was added slowly to a solution of propargyl alcohol (0.12 mL, 2.05 mmol) in 
chloroform (5 mL). The solution was left to stir at 60 ˚C for 3 h. The solution was washed 
using sat. aq. sodium bicarbonate (3 × 10 mL) and sat. aq. ammonium chloride (2 × 10 mL). 
The organic layer was dried and the solvent evaporated to dryness, yielding a pale orange 
solid. The crude product was purified using column chromatography eluting with DCM.  
Yield: 0.485 g, 86 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.5 (1H, t, 
3
JHH = 2.4 Hz, (H6)), 
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5 (2H, d, 
3
JHH = 2.4 Hz, (H5)), 7.28-7.39 (2H, m, (H3)), 7.39-7.46 (2H, m, (H4)), 7.73 (2H, d,
 
3
JHH = 8.4 Hz (H2)), 7.98 (2H, d, 
3
JHH = 8.8 Hz (H5)), 8.38 (1H, s, (H1)) ppm.  
L
3 
To an excess of potassium carbonate in acetone (40 mL) was added bis-2-naphthol (0.5 g, 
1.75 mmol) and propargyl bromide (0.42 mL, 3.69 mmol). The solution was left to stir at 65 
˚C for 15 h. The solution was filtered and filtrate concentrated in vacuo to produce a cream 
solid. Yield: 0.557 g, 89 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.22 (2H, t, 
3
JHH = 2.25 
Hz (H8)), 4.51 (4H, d, (H7)), 7.05-7.17 (6H, m, (H3, H5, H6)), 7.22 (2H, t, 
3
JHH = 7.6 Hz, 
(H4)), 7.72 (2H, d, 
3
JHH = 8.2 Hz, (H2)), 7.83 (2H, d, 
3
JHH = 9.05 Hz, (H1)) ppm.  
L
4 
To an excess of potassium carbonate in acetone (40 mL) was added alizarin (0.5 g, 2.08 
mmol) and propargyl bromide (0.32 mL, 4.37 mmol). The solution was left to stir at 65 ˚C for 
15 h. The solution was filtered and filtrate concentrated in vacuo to produce a brown solid. 
Yield: 0.260 g, 40 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.52-2.54 (1H, m, (H8a)), 2.61-
2.65 (1H, m, (H8b)), 4.84-4.96 (4H, m, (H7)), 7.42 (1H, d, (H6)), 7.73-7.85 (2H, m, 
(H2,H3)), 8.18-8.30 (3H, m, (H1, H4,H6)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 
56.9, 61.0, 75.2, 77.2, 118.0, 118.4, 125.6, 126.8, 127.4, 127.9, 128.2, 132.9, 133.7, 133.8, 
134.1, 135.0, 147.3, 157.1, 182.3, 182.6 ppm. MS (ES
+
) m/z: 316.01 [M-H]
+
, HRMS (ES
+
) 
found m/z 317.0812; [C20H13O4]
+  
requires 317.0808. IR (nujol) υ: 1568 (CO), 1673 (CO), 
2129 (CC) cm
-1
. 
L
5 
To an excess of potassium carbonate in acetone (40 mL) was added 1,4 dihydroxy 
anthraquinone (0.5 g, 2.08 mmol) and propargyl bromide (0.499 mL, 4.37 mmol). The 
solution was left to stir at 65 ˚C for 15 h. The solution was filtered and filtrate concentrated in 
vacuo. The crude product was purified using column chromatography eluting with DCM. 
Yield: 0.085 g, 15 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.49 (1H, t, (H8)), 4.73 (2H, d, 
3
JHH = 2.4 Hz, (H7)), 7.18 (1H, d, (H1)), 7.43 (1H, d, (H4)), 7.63-7.81 (2H, m, (H2, H3)), 
8.13-8.24 (2H, m, (H5, H6)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δc: 58.4, 77.8, 
115.5, 121.5, 126, 126.5, 126.5, 127.5, 128.1, 128.2, 133.6, 134.9, 135.0, 151.8, 158.7, 181.8, 
188.9 ppm. MS (ES
+
) m/z: 240 [M-C3H2]
+
, 278 [M]
+
. HRMS (ES
+
) found m/z 278.0574; 
[C17H10O4]
+  
requires 278.0574. IR (nujol) υ: 1593 (CO), 1663 (CO), 1666 (CO), 2115 (CC) 
cm
-1
.
 
UV-vis (ε / M-1 cm-1) (MeCN) λmax: 270 (2700), 326 (552), 432 (1382) nm.   
L
6
 To an excess of potassium carbonate in acetone (40 mL) was added 1,4 dihydroxy 
anthraquinone (0.5 g, 2.08 mmol) and propargyl bromide (0.499 mL, 4.37 mmol).  The 
solution was left to stir at 65 ˚C for 5 days. The solution was filtered and filtrate concentrated 
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in vacuo. The crude product was purified using column chromatography eluting with DCM. 
Yield 0.205 g, 31 %. 
1 
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.52 (2H, t, 
3
JHH = 2.4 Hz, 
(H5)), 4.79 (4H, d, 
3
JHH = 2.4 Hz, (H4)), 7.41 (2H, s, (H3)), 7.59-7.66 (2H, m, (H2)), 8.0-8.19 
(2H, m, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K): δc: 58.3, 77.4, 123.8, 126.6, 
133.6, 155.8 ppm. MS (ES
+
) m/z: 277.05 [M-C3H3]
+
, 316 [M]
+
. HRMS (ES
+
) found m/z 
316.0746; [C20H12O4]
+ 
requires 316.0730. IR (nujol) υ: 1582 (CO), 1671 (CO), 2119 (CC) cm-
1
.
 
UV-vis (ε / M-1 cm-1) (MeCN) λmax: 302 (1192), 394 (1029) nm. 
L
7 
To an excess of potassium carbonate in acetone (40 mL) was added 1,8 dihydroxy 
anthraquinone (0.5 g, 2.08 mmol) and propargyl bromide (0.499 mL, 4.37 mmol).  The 
solution was left to stir at 65 ˚C for 15 h. The solution was filtered and filtrate concentrated in 
vacuo. The crude product was purified using column chromatography eluting with DCM. 
Yield: 0.078 g, 13 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.52 (1H, t, (H8)), 4.91 (2H, d, 
(H7)), 7.2 (1H, d, (H3)), 7.42 (1H, d, (H4)), 7.51-7.53 (1H, m, (H2)), 7.57-7.65 (2H, m, (H1, 
H5)), 7.94 (1H, d, (H6)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 39.8, 57.2, 77.3, 
118.9, 120.5, 121.2, 124.8, 135.8, 138.1, 161.0, 163.9 ppm. MS (ES
+
) m/z: 252 [M-C2H3]
+
. 
HRMS (ES
+
) found m/z 279.0651; [C17H10O4]
+  
requires 279.0652. IR (nujol) υ: 1584 (CO), 
1643 (CO), 1675 (CO), 2034 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 254 (24321), 408 
(11951) nm.  
L
8 
 To an excess of potassium carbonate in acetone (40 mL) was added 1,8 dihydroxy 
anthraquinone (0.5 g, 2.08 mmol) and propargyl bromide (0.499 mL, 4.37 mmol).  The 
solution was left to stir at 65 ˚C for 5 days. The solution was filtered and filtrate concentrated 
in vacuo. The crude product was purified using column chromatography eluting with DCM. 
Yield: 0.354 g, 54 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.52 (2H, t, 
3
JHH = 2.34 Hz, 
(H5)), 4.88 (4H, d, 
3
JHH = (H4)), 7.42 (2H, d, 
3
JHH = 8.3 Hz, (H1)), 7.51 (2H, t, 
3
JHH = 8 Hz, 
(H2)), 7.82 (2H, d, 
3
JHH = 7.8 Hz (H3)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K): δc: 
57.3, 77.5, 120.4, 121.1, 133.8, 157.2 ppm. MS (ES
+
) m/z: 277.04 [M-C3H3]
+
. HRMS (ES
+
) 
found m/z 316.0707; [C20H12O4]
+  
requires 316.0730. IR (nujol) υ: 1585 (CO), 1658 (CO), 
1671 (CO), 2130 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 254 (29230), 374 (10428) 
nm.  
L
9 
To an excess of potassium carbonate in acetone (40 mL) was added 1,5 dihydroxy 
anthraquinone (0.5 g, 2.08 mmol) and propargyl bromide (0.499 mL, 4.37 mmol).  The 
solution was left to stir at 65 ˚C for 15 h. The solution was filtered and filtrate concentrated in 
vacuo. The crude product was purified using column chromatography eluting with DCM. 
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Yield: 0.025 g, 4 %. 
1
H NMR (CDCl3, 400MHz, 298K) δH: 2.49 (1H, t, (H1)), 4.97 (2H, d, 
7.23 (1H, d, (H2)), 7.48 (2H, d, (H6)), 7.65-7.73 (2H, m, (H4, H5)), 7.7-7.82 (2H, m, (H3, 
H7)), 7.98 (2H,d, (H8)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298K): δc: 57.3, 77.6, 119, 
121.2, 121.8, 123.5, 132.9, 135.8, 138.1, 163.4 ppm. MS (ES
+
) m/z: 239.21 [M-C3H3]
+
. 
HRMS (ES
+
) found m/z 279.0652; [C17H11O4]
+  
requires 279.0652. IR (nujol ) υ:1583 (CO), 
1634 (CO), 1664 (CO), 2112 (CC) cm
-1
.
 
UV-vis (ε / M-1 cm-1) (MeCN) λmax: 254 (1945), 274 
(1035), 394 (568) nm.   
L
10
 To an excess of potassium carbonate in acetone (40 mL) was added 1,5 dihydroxy 
anthraquinone (0.5 g, 2.08 mmol) and propargyl bromide (0.499 mL, 4.37 mmol).  The 
solution was left to stir at 65 ˚C for 5 days. The solution was filtered and filtrate concentrated 
in vacuo. The crude product was purified using column chromatography eluting with DCM. 
Yield: 0.012 g, 3 %. 
1
H NMR (CDCl3, 400MHz, 298K) δH: 2.48 (1H, t, (H1)), 4.82 (2H, d, 
(H2)), 7.37 (2H, d, (H5)), 7.64 (2H, t, (H4)), 7.91 (2H, d, (H3)) ppm.
 
5.7.3. Synthesis of complexes
 
[Au(PPh3)L
1
]: To a round bottom flask encase in aluminium foil L
1 
(0.019 g, 0.84 mmol),  
[AuClPPh3] (0.050 g, 0.1 mmol), potassium tertiary butoxide (0.013 g, 0.1 mmol) and ethanol 
(2 mL) were added and stirred under nitrogen for 12 h. The solution was concentrated in 
vacuo, re-dissolved in DCM and filtered. The filtrate was concentrated in vacuo and the 
orange solid was recrystallized from THF and diethyl ether. Yield: 0.016 g, 28 %. 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 4.42 (2H, s, (H4)), 7.2-7.8 (19H, m, (H2, H3, H5)), 8.55 (1H, s, 
(H1)) ppm. δ 31P 29.98 ppm. IR (nujol) υ: 1609 (CO), 1761 (CO), 2252 (CC) cm-1. UV-vis (ε / 
M
-1 
cm
-1
) (MeCN) λmax: 220 (10017), 286 (7164), 386 (4208) nm.  
[Au(PPh3)L
2
]: To a round bottom flask encase in aluminium foil L
2 
(0.024 g, 0.84 mmol),  
[AuClPPh3] (0.050 g, 0.1 mmol), potassium tertiary butoxide (0.013 g, 0.1 mmol) and ethanol 
(2 mL) were added and stirred under nitrogen for 12 h. The solution was concentrated in 
vacuo, re-dissolved in DCM and filtered. The filtrate was concentrated in vacuo and the 
orange solid was recrystallized from THF and diethyl ether. Yield: 0.024 g, 36 %. 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 5.38 (2H, s, (H6)), 7.21-7.67 (17H, m, (H3, H7)), 7.71-7.75 
(2H, m, (H2)), 8 (2H, d, (H4)), 8.19 (2H, d, (H1)), 8.52 (1H, s, (H5)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δC: 77.4, 125.5, 127, 127.9, 129.2, 129.3, 131.9, 134.2, 134.4 ppm. 
δ31P 29.86 ppm. MS (ES+) m/z: 721.15 [Au(PPh3)2]
+
. HRMS (ES
+
) found m/z 721.1475; 
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[AuC36H26PO2H]
+  
requires 719.1409. IR (nujol) υ: 1720 (CO), 2184 (CC) cm-1. UV-vis (ε / 
M
-1 
cm
-1
) (MeCN) λmax: 224 (10071), 251 (4173) nm.  
{[Au(PPh3)]2L
3
}: To a round bottom flask encase in aluminium foil L
3 
(0.019 g, 0.84 mmol),  
[AuClPPh3] (0.050 g, 0.1 mmol),  potassium tertiary butoxide (0.011 g, 0.1 mmol) and 
ethanol (2 mL) were added and stirred under nitrogen for 12 h. Same work up as before. 
Yield: 0.035 g, 60 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 4.78 (4H, s, (H7)), 7.05-7.21 
(6H, m, (H4, H5, H6)), 7.22-7.42 (30H, m, (H8)), 7.71-7.92 (6H, m, (H1, H2, H3)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 58. 8, 117.1, 123.4, 126.1, 127.8, 129.2, 129.3, 
131.7, 134.2, 134.2, 134.4, 154.5 ppm. MS (ES
+
) m/z: 721.29  [Au(PPh3)2]
+
, 1301.48 
[M+Na]
+
. δ 31P 42.6 ppm. IR (nujol) υ: 2017 (CO), 2132 (CC) cm-1.UV-vis (ε / M-1 cm-1) 
(MeCN) λmax: 228 (17519), 326 (2860) nm.  
{[Au(PPh3)]2L
4
}: To a round bottom flask encase in aluminium foil L
4 
(0.022 g, 0.073 
mmol),  [AuClPPh3] (0.050 g, 0.1 mmol),  potassium tertiary butoxide (0.011 g, 0.1 mmol) 
and ethanol (2 mL) were added and stirred under nitrogen for 12 h. Same work up as before. 
Yield: 0.043 g, 48 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 4.99-5.07 (4H, m, (H7)), 7.31-
7.58 (32H, m, (H2, H5, H8)), 7.61-7.66 (1H, m, (H4)), 8.1-8.3 (3H, m, (H1, H3, H6)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC 77.2, 128.9, 129.1, 131.5, 134.3, 134.6 ppm. δ
31
P 
42.46 ppm. MS (ES
+
) m/z: 721.15 [Au(PPh3)2]
+
. IR (nujol) υ:1720 (CO), 2184 (CC) cm-1. UV-
vis (ε / M-1 cm-1) (MeCN) λmax: 212 (15998), 273 (5542), 375 (1430) nm.  
[Au(PPh3)L
5
]: To a round bottom flask encase in aluminium foil L
5
 (0.020 g, 0.0735 mmol),  
[AuClPPh3] (0.040 g, 0.08 mmol) and potassium tertiary butoxide (0.009 g, 0.80 mmol) and 
ethanol (2 mL) were added and stirred under nitrogen for 12 h. Same work up as before. 
Yield: 0.015 g, 28 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 5.01 (2H, s, (H7)), 7.16-7.23 
(2H, m, (H2, H3)), 7.3-7.42 (15H, m, (H8)), 7.62-7.79 (2H, m, (H1,H4)) 8.12-8.19 (2H, m, 
(H5, H6)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC 76.2, 129.1, 129.3, 131.6, 134.2, 
134.4, 134.5, 154.2 ppm. MS (ES
+
) m/z: 721.15 [Au(PPh3)2]
+
. δ31P 42.4 ppm. IR (nujol) υ: 
1593 (CO), 1664 (CO), 1665 (CO), 2133 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 272 
(24360), 448 (10639) nm. 
{[Au(PPh3)]2L
6
}:  To a round bottom flask encase in aluminium foil L
6
 (0.016 g, 0.05 mmol),  
[AuClPPh3] (0.060 g, 0.12 mmol),  potassium tertiary butoxide (0.011 g, 0.1 mmol) and 
ethanol (2 mL) were added and stirred under nitrogen for 12 h. Same work up as before. 
Yield: 0.022 g, 36 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 5.01 (4H, s, (H4)), 7.23-7.45 
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(15H, m, (H5)), 7.52-7.55 (2H, m, (H2)), 7.68 (2H, s, (H1)), 8.1-8.15 (2H, m, (H3)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC 58.2, 123.2, 123.5, 125.3, 129.2, 129.3, 131.7, 
133.5, 134.3, 134.4 ppm. δ31P 42.46 ppm. MS (ES+) m/z: 721.15 [Au(PPh3)2]
+
.IR (nujol) υ: 
1666 (CO), 1898 (CO), 2021 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 250 (12700), 406 
(1790) nm. 
{[Au(PPh3)]2L
8
}: To a round bottom flask encased in aluminium foil L
8
 (0.010 g, 0.03 
mmol),  [AuClPPh3] (0.035 g, 0.07 mmol), potassium tertiary butoxide (0.023 g, 0.2 mmol) 
and ethanol (2 mL) were added and stirred under nitrogen for 12 h. Work up as before to yield 
an orange solid. Yield: 0.018 g, 50 %. 
1
H NMR (CDCl3, 300 MHz, 298 K) δH: 5.08 (4H, s, 
(H4)), 7.33-7.52 (15H, m, (H5)), 7.63 (2H, t, (H1)), 7.79-7.81 (2H, m, (H2)), 7.83 (2H, m, 
(H3)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC 77.3, 129.2, 129.3, 131.6, 134.3, 
134.5 ppm. MS (ES
+
) m/z: 721.29 [Au(PPh3)2]
+
. δ31P 42.48 ppm. IR (nujol) υ: 1584 (CO), 
1667 (CO), 2129 (CC), 2239 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 257 (19593), 397 
(4700) nm. 
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Chapter 6. Luminescent Multi-Metallic Complexes Incorporating 
an Au(I) Alkyne Unit Towards Dual-Functional In Therapeutic 
And Cellular Imaging Applications. 
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6.1.   Introduction 
The synthesis and applications of emissive hetero-metallic complexes is an area of 
growing research interest. In many of the hetero-metallic systems inclusive of d
6 
and/or d
10
 
TM ions, reported to date, either alkynyls and or polydentates have been applied in the 
development of the ligand systems.
1-3
As an extension of the previous work on Re(I) diimines 
(Chapters 2 and 3) and Au(I) alkynyl complexes (Chapters 4 and 5) attempts have been made 
to synthesize novel hetero-metallic complexes based around both d
6 
and d
10 
TM ions 
combining the use of both alkyne and diimine units.  
6.1.1. Requirements for the co-ordination of low spin d
6 
metals 
Heavy transition metals with a d
6 
configuration, such as Re(I), Ru(II) and Ir(III), when 
bonded to one or more aromatic bidentate ligands show the ideal photophysical and redox 
properties required to be useful luminophores. The reducibility of the bidentate ligand make 
them fitting candidates for allowing the dππ* 3MLCT to occur. Therefore, when 
synthesising a ligand suitable for co-ordinating metal ions such as Re(I), Ru(II) and Ir(III), in 
order to display the desirable luminescence properties, it is usually necessary to include a 
bidentate unit. 
6.1.2.   Requirements for the co-ordination of Au(I) 
In recent years the interest in Au(I) complexes has increased owing to the intriguing 
photophysical properties which are dependent on: the nature of the ligand, geometry of the 
gold and more interestingly, the presence of Au(I)-Au(I) aurophilic interactions. Since the 
first report on the rich luminescent properties of Au(I) alkynes in 1993
4
, Au(I) alkynyls have 
been used to synthesise a range of mono and hetero-metallic complexes inclusive of a Au(I) 
alkyne unit.
1
 The versatile nature of the TM alkynyl has led to several different studies on the 
reactivity of alkynes toward TM ions.
1,5-8
  
Various attempts to synthesise luminescent gold complexes were discussed in the 
earlier chapters; the latter half of Chapter 4 and then Chapter 5 reported the successful co-
ordination of a [AuPPh3]
+
 unit to a series of varying alkyne units. Therefore when considering 
the design of a ligand system suitable for the synthesis of a hetero-metallic complex inclusive 
of an Au(I) unit, it was decided to include an alkyne unit. 
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6.1.3.   The addition of an alkyne unit to an aromatic ring 
Alkynes are one of the most important structural building blocks in organic chemistry, 
and can be found in a variety of applications including pharmaceuticals and in molecular 
material applications in nanomaterials.
9,10 
The versatile palladium catalyzed cross coupling 
reaction between a terminal alkyne and an organic halide for the synthesis of a new sp
2
-C and 
sp-C carbon-carbon bond was first reported in 1975 by Heck,
11
 Cassar
12
 and Sonogashira.
13
 
The former two reactions are based on an extension of the well-known Heck reaction of 
alkenes.  
6.1.4.   Palladium catalyzed coupling 
Several variations of palladium catalyzed cross and homo coupling reactions exist for 
the formation of new carbon-carbon bonds in organometallic chemistry, including: Heck:- 
alkene and aryl halide coupling, Suzuki:- aryl halide and boronic acid coupling, Sonogashira:-
aryl halide and alkyne coupling and Negishi:- organo-halide and organo-zinc coupling. 
Palladium is a key component in these reactions with a zero valent palladium generally being 
the active catalyst; Pd(II) is more stable than Pd(0) over long periods of time and so some 
coupling reactions use Pd(II) as the catalyst precursor as it is known to reduce in the presence 
of amines/phosphines to Pd(0) under the reaction conditions.
14,15 
Palladium catalysts commonly used in these coupling reactions include, Pd(PPh3)4, 
[tetrakis(triphenylphosphine)palladium(0)] and Pd2(dba)3, tris-
[(dibenzylideneacetone)dipalladium(0)]. The inclusion of strong σ donor ligands on the 
palladium increases the electron density on the palladium and thus increases the rate of the 
oxidative insertion (often the rate determining step), whilst the presence of bulky groups on 
the palladium relates to the Tolman angle (sterics), dictating the strength of the bonds and the 
orientation of the ligands around the palladium centre (PdL2 is favoured over PdL/PdL3).
16 
6.1.4.1. Sonogashira coupling of alkynes 
Sonogashira demonstrated the use of a palladium-copper co-catalyst for the successful 
coupling of an alkyne unit and a halide under more favorable and milder conditions than the 
previously used Castro-Stephens coupling; a Castro-Stephens coupling is carried out at high 
temperatures in the absence of a catalyst.
17 ‘Sonogashira’ coupling reactions have been 
reported in the absence of copper (discussed in detail below), the absence of palladium, in 
nickel-copper co-catalysed ‘Sonogashira’ couplings,18 and in the absence of both copper and 
palladium in a gold catalyzed ‘Sonogashira’ coupling using Au/CeO2.
19,20
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6.1.4.1.1. Copper-free Sonogashira couplings 
The presence of the copper co-catalyst in a Sonogashira coupling reaction increases 
the reactivity of the alkyne unit allowing the coupling reaction to be carried out under milder 
conditions. Sonogashira couplings can be carried out in the absence of a copper co-catalyst 
but the exact mechanism for coupling is still under debate. The absence of a copper co-
catalyst does eliminate the potential of any homo-coupling side-reactions of the alkyne, this 
coupling is referred to as Glaser coupling and involves the coupling of two alkyne units in the 
presence of a copper(I) halide salt and oxygen forming an alkyne dimer.
21-23 
However, 
carrying out a Sonogashira coupling in the presence of a copper-co catalyst and in an inert 
atmosphere can negate Glaser homo-coupling reactions.  
Alkynyl silanes are well documented in Sonogashira reactions; the presence of a TMS 
group on the alkyne allows more control over reactivity by minimizing side reactions. 
Additionally, both the starting materials and products of TMS-based reactions are generally 
non-toxic.
24
  
6.1.4.1.2. Catalytic Cycle 
The formation of the new C-C bond proceeds via the activation of the organo-halides 
by Pd(0). Pd(0) activates the organo-halide by oxidative addition into the carbon halogen 
bond forming Pd(II). The copper halide reacts with the terminal alkyne to produce copper(I) 
acetylide which acts as an activated species for the coupling reaction. Transmetallation then 
occurs followed by reductive elimination to give the coupling product (Figure 6.1). 
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Figure 6.1 Outline of the reaction scheme for Pd–Cu catalyzed cross-coupling of sp2-C halides with 
terminal acetylenes. Reproduced from ref. 25.
 
6.1.5.   Hetero-metallic complexes including Au(I) alkynyls 
The photophysical properties of a series of novel mono- and di-metallic alkynyl Au(I) 
complexes were discussed in detail in chapters 4 and 5. A discussion of varying hetero-
metallic complexes inclusive of an Au(I)-alkyne unit takes place in the following section. 
6.1.5.1. Au(I)-M (M=Cu(I)/Ag(I)) alkynyl complexes   
Koshevoy et al.
26,27
 reported a series of novel hetero-metallic alkynyl coinage cluster 
complexes inclusive of an Au(I) unit. Unique photophysical properties were observed for 
complexes of this type and the potential to form hetero-metallic supramolecular complexes 
due to of the mixed M-M interactions between the closed-shell d
10
 ions was recognised. Self-
assembled cluster complexes of this type arranged with the Au(I) phosphine alkynyl in a 
‘belt’ formation; the Au(I) σ-bonded to the alkynyl groups ‘wraps’ the Cu(I)/Ag(I) units 
which interact with the centred Au(I) units (Figure 6.2). Both solid and solution state 
luminescence measurements for the Au/Ag complex resulted in roughly the same emission 
maxima for both complexes being observed with the maxima within the range of 526-641 nm. 
A bathochromic shift and a decrease in emission intensity was seen when Cu(I) was 
exchanged for Ag(I) within the cluster core.
27 
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Figure 6.2 Au = Ph-C2-Au-C2-Ph. R = PPh2. M = M2 = Cu(I) / Ag(I).
27 
A second report by Koshevoy et al.
26
 discussed the properties of a tetra-nuclear Au(I)-
Cu(I) tppm-based cluster complex, (tppm = tri(diphenylphosphine)methane). Unlike the 
previous examples by this group, these novel complexes displayed π-bonding of the Cu(I) unit 
to the alkyne. Complexes of this type gave emission in the range of 550-680 nm and lifetimes 
in the μs range which were attributed to the phosphorescent nature of the emission.26 
Ph2P PPh2
PPh2
Au
+
Au
+
Au
+
M
 
Figure 6.3 Complex structure omitting Au(I)-Au(I) interaction.
26 
Yam et al.
28
 also reported Au(I) alkynyl-Cu(I)/Ag(I) type complexes where the Au(I) 
was, σ-bonded and the Cu(I)/Ag(I) units were π- bonded to the alkynyl group. In the absence 
of Cu(I) and Ag(I), the luminescence of the Au(I) complex was centred on 454 nm. On 
addition of the Cu(I) metal centre, the π* C≡C orbital (alkyne) was lowered giving rise to a red 
shifted emission between 606-664 nm.
28 
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Figure 6.4 R = Ph / p-Tol, M = Cu(I) / Ag(I).
28 
6.1.5.2. Au(I)-Re(I) alkynyl complexes 
There are only a few examples of Au(I)-Re(I) hetero-metallic complexes reported to 
date. The first Au(I)-Re(I) hetero-metallic complex was reported by Yamamoto et al.
29
 in 
2004
 
where the effect of the two luminescent centres on the photophysical properties of was 
reported for the following complexes (Figure 6.5).
29 
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Figure 6.5 Re(I) and Au(I)-Re(I) complexes.
29 
The mono- and di-metallic Au(I) precursor complexes (not shown in Figure 6.5) 
displayed intense phosphorescence at room temperature with an excitation wavelength of 450 
nm. The emission profiles of the hetero-metallic complexes (RHS Figure 6.5) were similar to 
those of the mono-metallic Re(I) complexes (LHS Figure 6.5) with a broad structure-less 
emission around 650 nm being observed only (absence of the Au(I) ligand based emission 
seen in pre-cursor). A higher quantum yield was observed for the hetero-metallic complexes 
when compared to the mono-metallic Re(I) complexes and this increase was attributed to 
intra-molecular energy transfer from the Au(I) to the Re(I) unit.
29
 
Zuo et al.
30 
reported the synthesis of a second tri-hetero-metallic complex, Au(I)2-
Re(I), with 1,2-dithiolene units included as the Au(I)-binding moieties. Little change was 
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observed between solid and solution state emission for all three complexes (Figure 6.6). 
When compared to the mono-metallic Re(I) complex, the 
3
MLCT emission of the tri-metallic 
complex was significantly red-shifted; Re(I) 530 nm, Au(I)2-Re(I) 597 nm. The red-shift in 
emission maxima was attributed to the presence of increased conjugation via the Au(I) units 
which reduced the HOMO-LUMO separation. A peak at 468 nm in both the di-metallic 
Au(I)2 complex and the Au(I)2-Re(I) tri-hetero-metallic complex is indicative of perturbed 
Au(I)- ligand based emission of the dithiolene.
30 
No quantum yield measurements  were 
reported for these complexes. 
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Figure 6.6 Re(I) mono-metallic (LHS), Au(I)2 di-metallic (centre) and Re(I)-Au(I)2 tri-metallic (RHS) 
complexes.
30 
Yam et al.
31 
reported the synthesis of a novel series of Au(I)-Re(I) hetero-metallic 
complexes based on [Re(CO)3(bipy)]
+ 
fragments substituted with the 4-ethynylpyridine Au(I) 
binding unit (Figure 6.7). With an excitation wavelength of >350 nm, emission ranging from 
510-580 nm for each of the complexes was observed with little change in the maxima 
between solid and solution state emission.
31
 Similarly to the emission profile of the hetero-
metallic complex reported by Yamamoto et al. (but unlike the hetero-metallic complex 
reported by Zuo et al.) there was an absence of the alkyl based Au(I) emission, present in the 
precursor, indicating efficient intramolecular energy transfer from the Au(I) to the Re(I) unit. 
No quantum yield measurements were recorded for this series of complexes.  
Chapter 1. 
 
208 
 
Re
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CO
X
X
Au(PR3)  
Figure 6.7 X = H / 
t 
Bu, R = PPh3 / P(p-Tol)3.
31 
Following on from the previously discussed Au(I)-Re(I) hetero-metallic complex by 
Yam et al.
31
, Ferrer et al.
32
 attempted to synthesise a Au(I)-Re(I)2 tri-metallic type complex 
based on the same structure (Figure 6.8), using a similar procedure. However, a di-metallic 
Re(I) cation was produced from this reaction which indicated a transmetallation process had 
occurred; the ethynylpyridine group was transferred from the Au(I) to the Re(I).
32
This was the 
only report to highlight the importance in the order of metal addition in the synthesis of a 
hetero-metallic complex. 
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Figure 6.8 Target compound (LHS), actual compound (RHS).
32 
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With only a few reports to date, little research has been devoted to hetero-metallic complexes 
inclusive of both Re(I) and Au(I) units. From the complexes that have been reported, no 
general predictions can be made in terms of the synthesis or photophysical properties and so 
in any attempt to synthesise complexes of this type it is necessary to start with simple ligand 
systems.  
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6.2.   Overview 
This chapter reports the synthesis of novel hetero-metallic complexes based around an 
Au(I)-alkyne unit. The hetero-metallic complexes investigated include: Au(I)-Re(I), Au(I)-
Ru(II) and Au(I)-Ir(III). The first half of this chapter is devoted to investigating the synthesis 
and luminescent properties of a hetero-tri-metallic complex consisting of both Au(I) and Re(I) 
ions. Additionally, reported herein is the first application of a complex of this type in cellular 
imaging and a discussion of its potential use as a therapeutic agent is also included. The latter 
half of this chapter reports the synthesis of an analogous pair of novel ligands (varying in 
linking groups) and a discussion of both the successes and failures encountered during the 
attempts to synthesise the hetero-metallic species based on Au(I)-Re(I), Au(I)-Ru(II) and 
Au(I)-Ir(III) complexes which followed.  
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6.3.    Results and discussion (part 1) 
6.3.1.  Synthesis of a bi-functional ligand   
The simplest synthetic route to a ligand which will allow the incorporation of the two 
different metal ions (discussed above) is via a diimine central unit, however, commercially 
available diimines with additional functionality are costly. Various synthetic routes were 
therefore explored in an attempt to synthesise a functionalised diimine from low costing 
starting materials and these routes are discussed in detail below.  
2,6-dibromopyridine is a commercially available, cheap organo-halide starting 
material with the functionality to undergo a coupling reaction. A homo-coupling reaction of 
the aryl halide would provide a cheap, synthetic route to the commercially available 
functionalised diimine ligand, 6,6’-dibromo-2,2’-bipyridine, a ligand equipped with halides 
permitting further reactivity (Figure 6.9). There are numerous reports on the synthesis of the 
target compound with yields varying from 10% to 79%,
33 
however, when following literature 
precedent much smaller yields were obtained.  
NN
Br Br 
Figure 6.9 Target compound, 6,6’-dibromo-2,2’-bipyridine. 
There are several coupling reagents andcoupling catalysts known which could assist in 
the formation of the target compound (Figure 6.9), including Gilman reagent, a ‘turbo’ 
Grignard reagent and Negishi coupling. All three methods of coupling were explored. 
6.3.1.1 Synthesis of L
1 
Gilman reagent coupling proceeds via the formation of an organocuprate, R2CuI, 
where R is an organic radical. They are typically prepared at low temperatures as 
organocuprates are thermally labile. Organocuprates react well with organo-halides to form a 
new carbon-carbon bond.
16 
This methodology was followed and 6,6’-dibromo-2,2’-
bipyridine, L
1
,was formed with an 18 % yield.  
 
An alternative reagent in a coupling reaction is the turbo Grignard reagent. An aryl 
Grignard compound couples with an aryl-halide to form the new carbon-carbon bond. 
However, when this methodology was followed there was no evidence of product formation. 
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The inclusion of a catalyst, for example nickel or zinc chloride can enhance the reactivity and 
selectivity in Grignard coupling reactions.
5 
Negishi coupling is a Pd catalysed cross-coupling reaction between an organo-halide 
and an organo-zinc compound to form a new carbon-carbon bond. This was the more 
favourable coupling route out of the three discussed with L
1
 being formed in the highest yield 
of 42 % (Figure 6.10). 
NN
Br Br
i , ii
 iii                                                                          
N BrBr
 
Figure 6.10 Synthesis of L
1
. Reagents: (i) BuLi; (ii) ZnCl2; (iii) Pd(PPh3)4, 2,6 dibromopyridine. 
Negishi coupling was carried out via the lithiation of 2,6 dibromopyridine (0.5 eq.) 
using BuLi (1.6 M) at -78 ˚C. ZnCl2 was then added to the reaction mixture to form the more 
reactive organo-zinc precursor required for coupling. The addition of both the Pd(PPh3)4 
catalyst and the second 0.5 eq. of 2,6 dibromopyridine (organo-halide) followed after 20 
minutes. Product formation was confirmed using 
1
H NMR spectroscopy; L
1 
was formed in a 
moderate yield of 42 %. Co-ordination of L
1 
to Re(I) was now achievable, but further 
adaptation was required to allow successful co-ordination of a Au(I) moiety.  
6.3.1.2. Synthesis of L
2 
and L 
3 
Despite L
2
 and L
3 
being reported previously
5
 they are included herein as they provide 
a synthetically pleasing route for the synthesis of a novel, hetero-metallic complex. Following 
literature precedent for a Sonogashira cross-coupling reaction, two equivalents of 
trimethylsilyethylene were coupled to L
1
, forming L
2 
(Figure 6.12). The removal of the TMS 
groups was achieved using potassium fluoride or potassium carbonate under mild conditions 
to produce L
3
 in low and moderate yields; 19 % and 78 % respectively. 
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Figure 6.11 L
1 
(LHS), L
2
 (centre) and L
3 
(RHS). Reagents: (i) CuI, Pd(OAc)2, PPh3; (ii) TMS ethylene; (iii) 
KF. 
6.3.1.3. Attempts to further functionalise the ligands 
The small number of hetero-metallic complexes inclusive of Re(I) and Au(I) units to 
date are generally based around a single diimine and an alkyne unit. In an attempt to expand 
the functionality within the complexes in question, a series of coupling reactions were carried 
out using L
1
 and L
3
, as well as a mono-alkyne bipyridine (Figure 6.12) to extend the number 
of diimine units within the ligand systems. 
NN
Br
NN
SiMe3
NN
CH
i                                                                        iii
ii
 
Figure 6.12 Synthesis of 2-ethynylbipyridine from commercially available 6-bromo-2,2’-bipyridine.  
Reagents: (i) CuI, Pd(OAc)2, PPh3; (ii) TMS ethylene; (iii) KF. 
 
Sonogashira coupling reactions were carried out between L
1
 with L
3 
and L
1
 with the 
newly formed 2-ethynylbipyridine (Figure 6.13). The reactions were carried out following the 
same procedure as above, but in both cases there was little evidence of the product forming. 
Both the ratio of catalyst used and the nature of the catalyst (Pd(OAc)2 and Pd(PPh3)4 were 
varied for both reactions with little visible effect. With little change expected in the 
1
H NMR 
spectra for the complexes MS were carried out for initial characterisation; MS data for L
1 
with 
L
3 
showed evidence of product formation but no pure products were obtained despite attempts 
at purification by chromatography and crystallisation. 
Chapter 1. 
 
214 
 
NN
Br Br
NN
CH
NN
CH
CH
N
N
Br
NN
N
N
Br
NN
CH3
N
N
Br
 
Figure 6.13 Predicted possible outcomes from the coupling reactions of L
1
 with L
3
 and 2-
ethynylbipyridine. 
A Sonogashira coupling of L
1
 with 4-bromopyridine was also attempted using 
Pd(OAc)2 following the same coupling procedure as above but an unexpected compound was 
recovered [C12H8BrPdCl2] (Figure 6.14). The nature of the complex formed indicated, with 
the presence of C-Br bond, that the catalytic cycle did not work and so an alternative synthetic 
approach was taken to functionalise the aromatics. 
 
Figure 6.14 Unexpected product. 
6.3.1.4. Synthesis and reactivity of L
4 
and L
5
  
L
4 
and L
5
 were synthesised by heating hydrazine with 6-bromo-2-2’-bipyridine and L1 
respectively (Figure 6.15). Although the syntheses of ligands of this type are known,
34
 the 
nature of the products formed seemed to be dependent on the scale of the reaction. In large 
scale reactions the reduction of both 6-bromo-2,2’-bipyridine and 6,6-dibromo-2,2’-
bipyridine to bipyridine and/or 6-hydroxy-2,2’-bipyridine was evident in the 1H NMR spectra 
with the absence of the expected peak at +6.5 ppm for the predicted product and the presence 
of only four peaks in the aromatic region. This result was confirmed using IR spectroscopy 
and MS spectrometry. Small scale reactions provided L
4 
and L
5 
in moderate yields. 
NN
NHNH2
NN
NHNHNH2 NH2 
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Figure 6.15 L
4 
(LHS) and L
5
 (RHS) 
Mimicking the conditions required for the formation of L
4 
and L
5
 (high temperatures 
and small scale), L
4
 was reacted with L
1, but again, 2,2’-bipyridine was recovered. It was 
suspected that the reduction of L
1
 results from the presence of palladium, left over from the 
Sonogashira coupling, since the presence of palladium and hydrazine will act as a reducing 
agent rather than a nucleophile. L
1 
was subsequently washed with EDTA and the reaction was 
repeated. Although a number of attempts were made to further functionalise the diimine unit 
whilst still maintaining the ability to add an alkyne unit, no successful route was found. 
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6.3.2.   Synthesis and characterisation of the complexes 
The synthesis, together with the photophysical properties of the di-metallic gold 
complex, {[Au(PPh3)]2L
3
}, has been reported previously
5
 but is discussed herein for easy 
referral when discussing the novel tri-hetero-metallic complex 
{Re(CO)3{[Au(PPh3)]2(L
3
)Br}. The synthesis of the following mono-, di- and tri-metallic 
complexes of L
1-3 
was achieved following literature precedent. The pure complexes were 
isolated in moderate yields ranging from 30 % for [Re(CO)3(L
2
)Br]
 
to 76 % for 
{[Au(PPh3)]2L
3
}. 
NN
Br Br
ReOC
OC CO
Br
NN
(Ph3P)Au Au(PPh3)
ReOC
OC CO
Br
NN
SiMe3SiMe3
ReOC
OC CO
Br
NN
(Ph3P)Au Au(PPh3)
        Re(I)-L1                                                                            Re(I)-L2                                                                                                                                 
      Au(I)2-L3                                                                          Re(I)-Au(I)2-L3                                                           
 
Figure 6.16 The complexes discussed herein. 
Characterisation of the complexes was achieved using a variety of spectroscopic and 
spectrometric techniques the analysis of which is discussed in more detail in this section. 
1
H 
NMR spectra were obtained for each complex in CDCl3 or CD3CN, comparison to the free 
ligand confirmed the successful co-ordination of the ligands to the Re(I) and or Au(I) units. 
6.3.2.1. The synthesis and characterisation of [Re(CO)3(L
1-3
)Br] 
In the 
1
H NMR spectrum of [Re(CO)3(L
1
)Br] a shift of the four aromatic protons in 
positions 4,4’- and 3,3’-, to higher frequency (+7.42 ppm and +7.61 ppm to +7.88 ppm 
respectively) was observed; for [Re(CO)3(L
2
)Br],
 
a shift of the aromatic proton, in positions 
5,5
’
-, to lower frequency, (+8.43 ppm to +7.68 ppm), was observed.
  
The contrasting nature of 
this NMR data is attributed to the co-ordination of the [Re(CO)3Br] unit; the difference in the 
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electron density at the 5,5- position is enhanced for L
2 
> L
1
 upon co-ordination of the 
[Re(CO)3Br].  
An attempt was made to synthesise the analogous mono-metallic complex of 
[Re(CO)3(L
1/2
)Br]
 
using L
3 
but an insoluble, non-fluorescent compound resulted. The 
presence of un-protected alkynes within L
3
 adds additional co-ordination sites suitable for co-
ordination of the Re(I) units, this can lead to the formation of a coordination polymer (Figure 
6.17). The formation of a polymer, either through coordination chemistry or through metal-
induced polymerisation of the alkynes could account for the limited solubility and the non-
fluorescent nature of the compound.  
ReOC
OC CO
Br
NN
L
3
(CO)3Re Re(CO)3L
3
 
Figure 6.17 Potential polymer type compound. 
An alternative synthetic route to form [Re(CO)3(L
3
)Br] was carried out using 
[Re(CO)3(L
2
)Br] and KF following the same procedure for the synthesis of L
3
 but again an 
insoluble product resulted.  
6.3.2.2. Synthesis of rhenium alkynes 
The reactivity of alkynes toward TM ions has been subject of many studies, however, 
little research has been devoted to Re(I) alkyne bonding. Insight regarding the nature of the 
polymer formed in the reaction between L
3
 and [Re(CO)5Br] requires an understanding of the 
requirements necessary to form Re(I) alkyne bonds, and the tolerance of the reactions to 
various functional groups. To further probe these conditions, a series of reactions were carried 
out between [Re(CO)3(bipy)MeCN]
+
 and the following commercially available alkynes: 
phenyl acetylene, propargyl alcohol and ethyl propiolate (Figure 6.18).  
 
CH
O
CH
O
CH3
OH
CH
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Figure 6.18 phenylacetylene (LHS), propargyl alcohol (centre) and ethylpropiolate (RHS). 
The first reaction was carried out following literature precedent
35
 using thallium 
hexafluorophosphate for the formation of a Re(I) acetylene compound (Figure 6.19).
  
Re
+
NN
OC CO
CO
 
Figure 6.19 [Re(CO)3(bipy)phenylacetylene]
+ 
The Re(I) acetylene compound was successfully formed, however, following the same 
method, using propargyl alcohol and ethylpropiolate, there was no evidence of a reaction 
occurring; starting material was recovered only. With no further understanding on the 
conditions required to form the Re(I)-alkyne units, the synthesis of [Re(CO)3(L
3
)Br] using L
3
 
was unlikely. 
6.3.2.3. Synthesis of the hetero-metallic complex 
The order of metal ion addition has proven important in the synthesis of hetero-
metallic complexes of this nature and so both the protected and the unprotected alkyne 
ligands, L
2 
and L
3
, were used to synthesis the di-metallic complex {[Au(PPh3)]2L
3
}. Similarly 
to the reported synthesis of {[Au(PPh3)]2L
3
}, little change in the 
1
H NMR spectra of the 
ligand was seen upon co-ordination of the gold to the terminal alkynes (except the loss of the 
terminal proton). The 
31
P{
1
H} NMR spectra of the complexes gave a signal in agreement to 
the literature, with a single peak at +42.66 observed. 
The successful co-ordination of [Re(CO)3Br] was achieved following literature 
precedent forming a novel tri-hetero-metallic complex, {Re(CO)3{[Au(PPh3)]2L
3
}Br}, in a 62 
% yield (no transmetallation was seen). In the 
1
H NMR spectrum of the complex, one broad 
peak in the aromatic region, equating to all thirty six protons, was observed. The 
31
P{
1
H} 
NMR spectrum consisted of a single peak with a chemical shift which had moved to a lower 
frequency, from +42.66 to +35.6 ppm.
 
The difference in 
31
P NMR shifts between the di-
metallic and tri-hetero-metallic complex can be explained in terms of the donating ability; the 
presence of Re(I) lowers the electron density on the diimine which in-turn lowers the electron 
density at the Au(I)-P unit. This was also confirmed through IR studies; {[Au(PPh3)]2L
3
}, 
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C≡C 2116 cm-1 and {[Re(CO)3{Au(PPh3)]2L
3}Br}, C≡C 2151 cm-1; the introduction of the 
Re(I) unit induces a ‘pull’of electron density from the diimine unit, and this results in the 
strengthening of the C≡C unit (observed through an increase in the ν(CC) of 35 cm-1) and a 
decrease in the electron density at the Au(I)-P unit. MS analysis for the complexes gave a 
peak at 721 only, and this peak has been reported by Schmidbaur et al.
36 
and attributed to the 
breakdown of complex within the mass spectrometer and then recombination to form 
[Au(PPh3)2]
+
. 
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6.3.2.4. Single crystal X-ray diffraction studies 
Re-crystallisation of complexes [Re(CO)3(L
1
)Br] and [Re(CO)3(L
2
)Br] 
 
yielded pale 
orange crystals suitable for X-ray diffraction studies. The crystals were obtained via vapour 
diffusion of diethyl ether into a concentrated dichloromethane solution. 
 
Figure 6.20 Structural representations of complexes [Re(CO)3(L
1
)Br] and [Re(CO)3(L
2
)Br] (H atoms 
omitted for clarity). 
The parameters associated with the data collections of the novel complexes, 
[Re(CO)3(L
1
)Br] and [Re(CO)3(L
2
)Br]
  
(Table 6.2), and the selected bond lengths and bond 
angles (Table 6.1) are shown below. 
Table 6.1 Selected bond lengths and bond angles for the complexes: Re(CO)3(L
1
)Br] and [Re(CO)3(L
2
)Br]. 
                                                  [Re(CO)3(L
1
)Br]                [Re(CO)3(L
2
)Br]  
C13H6Br3N2O3Re C23H24BrN2O3ReSi2 
                          Bond Lengths (Å) 
Re-Br  2.619    (2)             
Re-N   2.204    (6) 
C-Br   1.879     (8) 
Re-Br  2.614   (1)                 
Re-N   2.19     (9)                                     
C-Si    1.87      (1)                  
C-C     1.19      (2) 
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Table 6.2 Crystal data refinement details for the crystal structures of [Re(CO)3(L
1
)Br] and 
[Re(CO)3(L
2
)Br]. 
                                                                     [Re(CO)3(L
1
)Br]                     [Re(CO)3(L
2
)Br]  
Empirical formula C13H6Br3N2O3Re C23H24BrN2O3ReSi2 
Formula weight 664.13 698.73 
Temperature 150(2)K 150(2)K 
Wavelength 0.71013Å 0.71013Å 
Crystal system Monoclinic Monoclinic 
Space group P2(1)/m P2(1)/a 
Unit cell dimensions a = 6.4833 (4) Å 
α = 90.00 ˚ 
b = 14.3775 (10) Å 
β = 105.961(4) ˚ 
c = 9.0151 (5) Å 
ϒ =90.00˚ 
a = 13.5076 (4) Å 
α = 90.00 ˚ 
b = 13.9248 (4) Å 
β = 107.145(2) ˚ 
c = 14.3606 (3) 
ϒ =90.00˚ 
Volume 807.93  Å
3 
2581.06  Å
3 
Z 2 4 
Density (calculated) 
 F(000) 
2.730 g/cm
3 
604 
1.798 g/cm
3 
1352 
Crystal size 0.20 × 0.20 × 0.20 0.20 × 0.20 × 0.20 
Theta range for data 
collection 
55.1 ˚ 56.6 
All reflections 3204 22858 
Independent reflections 1915 6356 
Observed reflections 1701 4903 
Goodness-of-fit on F 1.050 1.204 
Rint 0.0415 0.1201 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0456 
wR2 = 0.1117 
R1 = 0.0959 
wR2 = 0.1500 
R indices (all data)   
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6.3.3.   UV-Vis absorption spectroscopy  
The UV-Vis data are summarised in Table 6.3. The high energy transitions around 250 
nm are attributed to 
1IL (ππ*) or metal perturbed 1IL transitions. The moderately low 
energy absorptions in the regions of 330 nm are indicative of ligand to ligand charge transfer 
(
1LLCT) transitions from the π orbital on the alkyne ligands. The transitions in the region of 
340-400 nm are assigned to the spin allowed transfer (
1MLCT) (d ππ*). 
Table 6.3 Photophysical data for the complexes (part 1).  λexc = 340 nm.  
Compound Abs  
(nm) 
      ε  
(dm3 mol-1  cm-1) 
Em(MeCN) 
    (nm)      
Lifetimes (MeCN) 
         (ns) 
 
Re(CO)3(L
1
)Br] 
258 
324 
397 
 
8248 
7757 
1380 
 
625 
 
< 2 
Re(CO)3(L
2
)Br] 253 
280 
335 
1450 
914 
709 
 
480 
619 
 
 
 
29.4 
 {[Au(PPh3)]2L
3
} 
 
 {Re(CO)3{[Au(PPh3)]2L3}Br} 
 
228 
329 
 
268 
309 
375 
17519 
2860 
 
11149 
6351 
3038 
477 
 
 
475 
588 
< 2 
 
 
 
1.59 
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6.3.4.   Luminescent spectroscopy
 
Luminescence spectra were obtained in aerated acetonitrile and dichloromethane 
following irradiation at λex: 340 nm, 370 nm and 405 nm. DCM was included for ease of 
comparison to the literature values recorded. The data and spectra recorded in acetonitrile at 
405 nm are shown in Table 6.3 and Figure 6.21. 
 
Figure 6.21 Steady state emission spectra recorded in acetonitrile (λexc  405 nm). 
 Neutral complexes, [Re(CO)3(L
1
)Br]
 
and Re(CO)3(L
2
)Br], differ only in the functional 
group appended to the aromatic chromophore, bromide and trimethylsilylethylene 
respectively. Both
 
display an emission band around 620 nm which is attributed to a 
3
MLCT 
transition. The only appreciable difference between the spectra (λexc 405 nm) was the presence 
of an additional emission band centred on 480 nm for [Re(CO)3(L
2
)Br], this broad emission 
band was present in both {[Au(PPh3)]2L
3
} and {Re(CO)3{[Au(PPh3)]2L
3
}Br}. The absence of 
the gold units in [Re(CO)3(L
2
)Br] indicated the emission present at 480 nm in all three 
complexes, [Re(CO)3(L
2
)Br], {[Au(PPh3)]2L
3
} and {Re(CO)3{[Au(PPh3)]2L
3
}Br},  was likely 
to be perturbed, 
1IL fluoresecence, CC (ππ*).  
 Neutral Re(I) diimine complexes generally show lifetimes in the order of hundreds of 
ns but the luminescence lifetime of [Re(CO)3(L
1
)Br] was too short to be reliably measured 
(Figure 6.22), for [Re(CO)3(L
2
)Br] 
 
a lifetime of 29.4 ns was observed. The unexpectedly 
short lifetimes for these complexes can be attributed to non-radiative quenching.  
Chapter 1. 
 
224 
 
 
Figure 6.22 Lifetime spectrum of [Re(CO)3(L
1
)Br]. (λexc  = 295 nm). 
6.3.4.1. Luminescent properties of {Re(CO)3{[Au(PPh3)]2L
3
}Br} 
 {Re(CO)3{[Au(PPh3)]2L
3
}Br} is a dual emissive complex with ligand-based emission 
observed at 475 nm and 
3
MLCT based emission at 588 nm. Similarly to its precursor 
complex, {[Au(PPh3)]2L
3
}, {Re(CO)3{[Au(PPh3)]2L
3
}Br} showed no evidence of Au(I)-
based phosphorescence in solution (Figure 6.23). The 
3
MLCT based emission for the hetero-
metallic complex was blue-shifted by ca. 30 nm when compared to the analogous complexes 
[Re(CO)3(L
1
)Br] and [Re(CO)3(L
2
)Br]. Both the presence of the ligand-based emission peaks 
in the luminescent spectra and the short luminescence lifetime of the tri-metallic-complex 
suggest that there was no intramolecular transfer of energy from the ligand based states to the 
MLCT levels, but the very low lifetime of the neutral complex (Table 6.3) does indicate 
quenching of the luminescent lifetime and so the possibility of RET cannot be completely 
ruled out. 
 
 
 
 
 
Figure 6.23 Steady state emission spectra recorded in acetonitrile for {[Au(PPh3)]2L
3
} and 
{Re(CO)3{[Au(PPh3)]2L
3}Br} (λ exc  345 nm). 
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6.4.   Cytotoxicity investigation 
A preliminary study of the cytotoxicity of the tri-hetero-metallic complex was 
undertaken using the MTT assay with four different cancer cell lines: MCF7 (breast 
adenocarcinoma), A549 (lung adenocarcinoma), PC3 (prostate adenocarcinoma) and LoVo 
(colon adenocarcinoma). For the MTT assay, the compound was initially dissolved in DMSO, 
and doses of 0.1, 1, 10 and 100 μm were tested to analyse the activity of different 
concentrations and then compared to a control medium with no treatment. The approximate 
IC50 values for the compound is shown in in Table 6.4. 
 
Table 6.4 Cytotoxicity results for {Re(CO)3{[Au(PPh3)]2L
3
}Br}   
Complex IC50 MCF7 IC50 PC3 IC50 A549 IC50 Lovo 
{Re(CO)3{[Au(PPh3)]2L
3
}Br}         5     70       5      5 
 
 A comparison of the IC50 values in Table 6.4, shows that the tri-hetero-metallic 
complex, {Re(CO)3{[Au(PPh3)]2L
3
}Br}, is apparently more toxic than the di-homo-metallic, 
type complexes {[Au(PPh3)]2L} reported in Chapter 4. The tri-hetero-metallic complex shows 
considerably less cytotoxicity to PC3 (prostate) than the other three cell lines tested with an 
IC50 value 14 times higher. The cytotoxicity values in MCF-7, A549 and LoVo were 
considerably higher than that of cisplatin (IC50 = 2.0 μM)
37
 and so applications solely as a 
therapeutic agent is unlikely. Similarly to the complexes discussed in Chapter 4, the MCF-7 
cell line showed sensitivity to the tri-hetero-metallic complex and so its therapeutic 
application and cellular distribution were investigated via confocal fluorescence microscopy.
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6.5. Cell imaging of {Re(CO)3{[Au(PPh3)]2L
3
}Br}
 
 With the 
3
MLCT based emission preferable to an excitation wavelength of 405 nm, the 
novel tri-hetero-metallic complex, {Re(CO)3{[Au(PPh3)]2L
3
}Br}, was investigated for its 
suitability as a cellular imaging agent or sensor. {Re(CO)3{[Au(PPh3)]2L
3
}Br} was incubated 
with MCF-7 cells over a 30 minute period at 4 ˚C. The low temperature allows energy-
dependent uptake processes, such as endocytosis, to be omitted.
 
Following the removal of 
excess agent, the cells were allowed to warm to room temperature. At room temperature the 
cells functions normalise and energy-dependent pathways are no longer omitted allowing the 
accumulation and toxicity of the investigated complexes to be viewed.  
 The sample was imaged by confocal microscopy using an excitation wavelength of 
405 nm and a detection range between 560-610 nm, in accordance with the 
3
MLCT emission 
reported in Table 6.3 (thus eliminating autofluorescence). The complex showed successful 
uptake with > 90 % of cells showing rhenium based emission whilst maintaining good cell 
morphology.  
 The hetero-metallic complex, {Re(CO)3{[Au(PPh3)]2L
3
}Br}, showed variable levels 
of intensity of rhenium based emission throughout the entire cell. The cytoplasm and nucleus 
exhibit background emission with the presence of intense spots indicative of specific-
localisation; the presence of intense spots/regions (hot spots) within the cytoplasm indicates 
accumulation of the complex within certain organelles. The intense spots in the centre of the 
nucleus are similar to the di-rhenium ester complex discussed in Chapter 3 which was 
indicative of nucleolar staining. Further studies are required for this complex with incubation 
at lower temperature and a co-localisation experiment.  
    
A                    B                                   C                 D 
Figure 6.24 Imaging with {Re(CO)3{[Au(PPh3)]2L
3
}Br} in MCF-7 cells showing: (A) & (C) cytoplasmic & 
necleolar distribution; (B) & (D) transmitted light only. 
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6.6. Conclusion 
The first half of this chapter highlighted the investigation into the synthesis of a 
novel tri-hetero-metallic complex, {Re(CO)3{[Au(PPh3)]2L
3
}Br}, and the additional attempts 
to add further functionality to ligands of this nature through a variety of coupling reactions. 
The cytotoxicity studies on the tri-hetero-metallic complex demonstrated its cytotoxic profile 
for four different tumour cell lines; MCF-7, PC3, A459 and LoVo. The IC50 values for MCF-
7, A549 and LoVo were identical with an IC50 value of 5 μM. For PC3 an IC50 value fourteen 
times higher was observed. The cellular uptake and localisation potential of the hetero-
metallic complex in MCF-7 cells was also investigated. The complex shows good cellular 
uptake with both specific and non-specific localisation throughout the entire cell. Both the 
cytotoxic and photophysical properties confirm the complex suitability as both an imaging 
and or a therapeutic agent. Additional investigations into the selectivity towards cancer cells 
over healthy cells for this complex could be performed as well as the additional confocal 
microscopy experiments discussed previously. 
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6.7.   Di-hetero-metallic complexes  
The first half of this chapter was based around a tri-hetero-metallic complex inclusive 
of one rhenium unit and two gold units and promotes its suitability as both a therapeutic and 
cellular imaging agent. The latter half of this chapter is dedicated to the synthesis of di-hetero-
metallic complexes inclusive of different d
6 
TM and a Au(I) moiety and discusses their 
potential future applications. 
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6.8.   Results and discussion (part 2)  
6.8.1.   Synthesis of pre-cursor ligands for the formation of di-hetero-metallic complexes 
The simplest synthetic route to a ligand suitable for the synthesis of a di-hetero-
metallic complex is via a diimine unit with one additional functional moiety only. Omitting 
the commercially available 6-bromo-2,2’-bipyridine (due to expense) two synthetic 
procedures for a ligand of this type were carried out. 2-(2-4-methyl pyrimidine) pyridine 
(Figure 6.25) and 5-methyl-2,2’-bipyridine (Figure 6.26) were produced via two-step 
synthesis following literature precedent in yields of 74 % and 58 % respectively.
38  
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Figure 6.25 Synthesis of 2-(2-4-methyl pyrimidine) pyridine Reagents; (i) K
t 
BuO, MeOH, 4,4 dimethoxy-
2-butanone; (ii) K
t 
BuO, 4,4 dimethyl oxybutan-2-one Δ. 
 
NN
CH3
N
N
+
O
I
-
N
CH3
O
      i                                                                                ii 
 
 
Figure 6.26 Synthesis of 5-methyl-2,2’bipyridine. Reagents; (i) iodine, pyridine, N2(g), Δ; (ii) methacrolein, 
ammonium acetate, formamide, Δ. 
2-(2-4-methyl pyrimidine) pyridine and 5-methyl-2,2’-bipyridine differ in the position 
of the methyl group (6 and 5 respectively) which can affect their reactivity. To form a hetero-
metallic complex, both precursors require the addition of an alkyne unit for the successful co-
ordination to a gold moiety. The alkyne unit can be added in one of two ways; the first is via 
the formation of an alkyl bromide and then the addition of an alkyne unit (via a Sonogashira 
coupling reaction); the second is via the formation of an acid group (oxidation of the methyl) 
followed by the addition of the alkyne unit via a condensation reaction. Both routes were 
carried out on 2-(2-4-methyl pyrimidine) pyridine and 5-methyl-2,2-bipyridine. 
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6.8.2.   Reactivity of 2-(2-4-methyl pyrimidine) pyridine 
6.8.2.1.Bromination of 2-(2-4-methyl pyrimidine) pyridine 
Azobisisobutyronitrile (AIBN) is a radical initiator commonly used as a photo initiator 
in the production of vinyl-based polymers such as PVC. It can be used as a catalyst in radical 
bromination when using N-bromosuccinimide (NBS). The formation of 2-(2-4-bromo methyl 
pyrimidine) pyridine was attempted following literature precedent using AIBN
38 
however, 
only starting material remained. 
 
N
NN
OH
O
N
NN
CH3
i
N
NN
Br
ii+
 
Figure 6.27  Reagents; (i) N-bromosuccinimide, benzoyl peroxide, CCl4; (ii) Na2CO3, KMNO4, Δ. 
6.8.2.2. Oxidation of 2-(2-4-methyl pyrimidine) pyridine 
Organic oxidations of aromatic methyl groups using selenium oxide have also been 
reported, but when attempted there was no evidence of any reaction having occurred.
39
An 
alternative oxidation reaction using an excess of potassium permanganate in the presence of 
sodium carbonate was carried out which produced the desired product, albeit in a low yield.
40 
6.8.3.   Reactivity of 5-methyl-2,2
’
-bipyridine 
6.8.3.1.Bromination of 5-methyl-2,2
’
-bipyridine 
The formation of 5-bromomethyl-2,2
’
-bipyridine was attempted following literature 
precedent using AIBN
37 
however, only starting material remained. With both 2-(2-4-methyl 
pyrimidine) pyridine and 5- methyl-2,2’-bipyridine having resulted in no reaction, the quality 
of the AIBN initiator was suspected to be poor and so benzoyl peroxide was used as an 
alternative radical initiator. 5-bromomethyl-2,2’-bipyridine was subsequently formed in a 24 
% yield. Despite the successful formation of 5-bromomethyl-2,2’-bipyridine, no further 
reactions were carried out with this ligand precursor as low levels of stability were observed 
when the compound was left over short periods of time at room temperature. The decreased 
stability of the complex is believed to result from the occurrence of intermolecular reactions 
between the bipyridine nitrogen and the alkyl bromide.  
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Figure 6.28  Reagents; (i) N-bromosuccinimide, benzoyl peroxide, CCl4; (ii) Na2CO3, KMNO4, Δ. 
6.8.3.2. Oxidation of 5-methyl-2,2’-bipyridine 
Organic oxidation using an excess of potassium permanganate in the presence of 
sodium carbonate was carried out on 5-methyl-2,2’-bipyridine which produced 5-carboxylic 
acid-2,2’-bipyridine in a 54 % yield.40 Having produced a suitably functionalised bipyridine in 
a moderate yield, further work with this ligand precursor was carried out. The addition of an 
alkyne unit to 5-carboxylic acid,-2,2’-bipyridine via a condensation reaction was then carried 
out using two different functionalised alkynes. 
6.8.4.   N-methyl propargyl amine 
N-propargyl amines are heavily used as MAO-inhibitors. MAO is an acronym for 
monoamine oxidase; it is an enzyme found on the outer membrane of the mitochondria in 
most cells in the body and catalyses the deamination of monoamines.
41-43
MAO inhibitors can 
act as an anti-depressant and can also be used in the treatment of Alzheimers and Parkinsons 
disease. Too much or too little MAO activity can lead to psychiatric and neurological 
disorders.
43,44 
There have been numerous studies on the structure-activity relationship of N-
propargyl amines inclusive of N-methyl propargyl amine which have concluded that the 
structure of the propargyl amine is essential in their inhibitor function.
45-48 
The presence of N-
methyl propargyl amine within a complex adequate for cellular imaging promotes an 
innovative method for investigating its inhibiting function. 
Propargyl alcohol and N-methyl propargyl amine were used to produce novel ligands, 
L
6
 and L
7
 in excellent yields of 83 % and 84 % respectively. The position of the alkyne 
protons, CH2 and CH, in the 
1
H NMR spectra were used to distinguish the products from 
starting material. 
 
NN
O
O
CH
NN
N
O
CH
CH3
NN
O
OH
 
Figure 6.29  L
6 
(RHS) & L
7 
(LHS) 
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6.8.4.1. Characterisation of L
7 
The 
1
H NMR spectra of L
6 
was very similar to its pre-cursor, 5-carboxylic acid-2,2’-
bipyridine differing only in the appearance of a doublet and triplet of the alkyne unit in the 
aliphatic region of the spectrum. The 
1
H NMR spectra of L
7 
suggested the product consists of 
interconverting rotational isomers, resulting from the diastereotopic nature of the CH2 unit 
within the molecule. The integration of peaks within the aliphatic region of the spectrum 
indicated the presence of the isomers in a 50:50 ratio, 2.32-2.37 and 2.48-2.57 ppm, 3.02-3.23 
ppm, 3.91-3.98 and 4.22 and 4.42 ppm are assigned to CH alkyne, CH3 and CH2 alkynes of 
the two rotamers respectively. The presence of two isomers was less obvious in the aromatic 
region of the spectrum with only the two aromatic protons closest to the aliphatic chain 
(ortho. and meta. to the nitrogen) displaying less structured, broad peaks at 7.82-7.98 and 
8.61-8.74 ppm.  
NN
N
O
CH
CH3
 
 
               Figure 6.30 L
7 
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6.8.5.   Synthesis and characterisation of the complexes 
6.8.5.1. Synthesis and characterisation of [Re(CO)3(L
6
)Br] and [Re(CO)3(L
7
)Br]
 
The successful co-ordination of a [Re(CO)3Br] unit to L
6
and L
7
 was achieved 
following literature precedent forming a novel mono-metallic complexes in low yields of 25 
% and 20 % respectively. The 
1
H NMR spectra for both complexes were recorded in CDCl3 
and displayed changes in the aromatic region of the spectrum only. The comparison to the 
free ligand confirmed the successful co-ordination of the ligands to Re(I). A shift in the 
aromatic protons to higher frequency was evident with the number of signals and their 
intensities fitting well for the target compounds. For [Re(CO)3(L
7
)Br] the presence of 
rotational isomerism was also evident.  
Solid state IR studies were carried out for the complexes which show little change in 
the ν(CC) when compared to the ligands; the ligands display an IR stretch similar to their 
precursors, propargyl alcohol with a shift at 2120 cm
-1
, the complexes display a weaker IR 
absorption band ranging from 2105-2152 cm
-1 
for the alkyl stretch. Three strong CO bonds 
ranging from 1665-2032 cm
-1
 were also displayed. MS analysis for each of the complexes 
gave a parent peak suitable for the loss of the [C3H2]
+
 alkyne only. 
6.8.5.2. Synthesis and characterisation of [Ir(PPy)2(L
6
)]
+
 and [Ir(PPy)2(L
7
)]
+ 
The complex, [Ir(PPy)2(L
6
)]
+
, was synthesised following literature methodology
50
 
with a yield of 23 %.
49
 L
6 
was heated with {[Ir(PPy)2Cl]2} in methoxyethanol at 110 ˚C for 
3.5 hours. Sodium tetrafluoroborate was then added to the solution and after stirring for 5 
minutes the product was extracted into DCM. The 
1
H NMR spectra were recorded in CDCl3 
and again displayed changes in the aromatic region only. The comparison to the free ligand 
confirmed the successful co-ordination of the [Ir(PPy)2] unit with both a shift in the aromatic 
protons of the ligand to higher frequency and the presence of additional aromatics whose 
number and signal integrations fit well. Solid state IR studies were carried out for the 
complexes which show little change in the ν(CC) when compared to the ligand with a shift at 
2124 cm
-1
. MS analysis for the complex gave a parent peak at 739.17 with an isotope pattern 
consistent with the predicted product. 
The same reaction conditions were carried out for L
7
, however, despite the absence of 
starting material in the crude 
1
H NMR spectra, no product was successfully isolated. The 
difference in the reactivity of the two ligands can only be attributed to the nature of the linker 
units (the ester/amide linking units). The presence of an amide on the bipyridine presumably 
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leads to increased reactivity when compared to the ester; L
7 is presumably more ‘activated’ 
upon co-ordination of the Ir(III) unit and this activation could suggest decomposition. 
6.8.5.3. The attempted synthesis of [Ru(bipy)2(L
6
)]
2+
 and [Ru(bipy)2(L
7
)]
2+ 
L
6/7 
were reacted with {[Cl2Ru(bipy)2](H2O)2} following the same method used for 
the synthesis of the iridium complexes. The reactions were monitored by TLC and after 
heating for 48 hours work-up was conducted. The products were purified using column 
chromatography where both L
6 
and L
7 
were recovered along with a product consisting of 
aromatic protons only.  Further characterisation of the unpredicted product by XRD presented 
a structure for a ruthenium biproduct (Figure 6.31). The reaction with L
6/7 
was repeated using 
the more reactive [(H2O)2Ru(bipy)2]
2+
 complex as a precursor, however, in both cases the 
ruthenium biproduct and ligand starting material was recovered.  
 
Figure 6.31  Structural representations of the ruthenium biproduct (H atoms omitted for clarity).  
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6.8.6.   UV-Vis absorption spectroscopy  
The UV-Vis data for the compounds are summarised in Table 6.5. A high energy band 
(below 330nm) typically assigned to spin-allowed intra ligand (IL) (ππ*) transitions was 
noted for all complexes. The transitions in the region of 340-400nm are assigned to the spin 
allowed 
1MLCT (d ππ*). 
Table 6.5 Photophysical and IR data for the ligands and the complexes (part 2). λexc = 340/360 nm, IR recorded in solid state. 
Compound Abs ε dm3 mol-1  cm-1 Em(MeCN) Lifetimes (MeCN) ns CC (Cm-1) 
      
L6 251 
293 
553 
992 
365 - 2112 
 
      
L7 252 
305 
2678 
698 
356 
 
- 2116 
 
      
[Re(CO)3(L
6
)Br] 252 
298 
18382 
14645 
401 
525 
 
27.8 2152 
 
 
[Re(CO)3(L
7
)Br] 297 
379 
 
 
13527 
23034 
463 30 2105 
[Ir(PPy)2(L
6
)]
+ 259 
281 
316 
376 
21015 
18382 
9349 
2706 
445 
602 
15 
60 
2124 
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6.8.7.   Luminescence spectroscopy 
Luminescence spectra were obtained in aerated acetonitrile following irradiation at λex 
350-430 nm. The luminescence data for these complexes are shown in Table 6.5 and are 
discussed in detail in the following sections. 
6.8.7.1. Luminescent properties of [Re(CO)3(L
6
)Br] and [Re(CO)3(L
7
)Br]
 
The emission of L
6 
appears to be one major transition centred around 365 nm. L
7
 has a 
two peaks centred emission at 356 nm which can be attributed to rotational isomers and/or 
presumably ππ* for mixed alkyne and bipyridine (Figure 6.33). Both the emission and 
excitation spectra obtained for [Re(CO)3(L
6
)Br] and [Re(CO)3(L
7
)Br] can be viewed in Figure 
6.32. In the emission spectra of the complexes, the major transition is now 
3
MLCT at 525 nm 
for the ester, [Re(CO)3(L
6
)Br], and at 463 nm for the amide, [Re(CO)3(L
7
)Br]. The defined 
structure of [Re(CO)3(L
6
)Br] can be attributed to the alkyne-based emission presumed to be 
obscured by 
3
MLCT. For [Re(CO)3(L
7
)Br], despite the observation of rotational isomers in 
the 
1
H NMR, only one peak is visible in the emission spectra indicating similarity of the 
3
MLCT energy of the two isomers. The emission peak in [Re(CO)3(L
7
)Br] is red-shifted when 
compared to L
7
, 356 nm and 463 nm respectively, and attributed to the presence of rhenium. 
The lifetimes of the two neutral rhenium based complexes are within the expected timescale. 
  Figure 6.32 Steady state excitation and emission spectra of [Re(CO)3(L
6
)Br]
 
(LHS) and [Re(CO)3(L
7
)Br]
 
(RHS). (λexc = 350 nm) 
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Figure 6.33 Steady state emission spectra of L
6
, [Re(CO)3(L
6
)Br], L
7 
and [Re(CO)3(L
7)Br] (λexc = 350 nm) 
6.8.7.2. Luminescent properties of [Ir(PPy)2(L
6
)]
+
 
The Ir(III) complex, [Ir(PPy)2(L
6
)]
+
, displayed broad emission with peaks centred at 
445 nm and 602 nm tentatively assigned to red-shifted ligand based emission (upon co-
ordination) and 
3
MLCT to the bipyridine, however, contribution from the phenylpyridine 
transitions cannot be excluded.
50
 The lifetime of this complex was lower than predicted for 
complexes of this type suggesting quenching of the excited state may be occurring. 
 
Figure 6.34. Steady state excitation and emission spectra of [Ir(PPy)2(L
6
)]
+. (λexc = 360 nm) 
 
The synthesis of the novel complexes: [Re(CO)3(L
6
)Br], [Re(CO)3(L
7
)Br] and [Ir(PPy)2(L
6
)]
+
 
is a suggested route to the synthesis of novel, hetero-metallic systems with potential to act as 
both cellular imaging and therapeutic agents. However, due to the time restriction of the PhD, 
the hetero-metallic complexes inclusive of these starting materials have yet to be synthesised. 
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6.9.    Conclusion 
The aim of the second half of this chapter was to synthesise a series of di-hetero-
metallic complexes inclusive of a d
6 
TM ion and a Au(I) moiety to determine their potential 
applications. The successful synthesis of two ligands, L
6 
and L
7
, was achieved with excellent 
yields of 83 % and 84 % respectively. The successful synthesis of three novel mono-metallic 
complexes; [Re(CO)3(L
6
)Br], [Re(CO)3(L
7
)Br] and [Ir(PPy)2(L
6
)]
+
 in low-moderate yields 
was also achieved.  
The photophysical properties of both [Re(CO)3(L
6
)Br] and [Ir(PPy)2(L
6
)]
+
, promote 
their potential suitability as imaging agents. With small changes within a complex having 
already proved to have major effects in both the photophysical properties and cellular 
localisation observed, a confocal microscopy experiment could be performed. Additionally, 
all three complexes could be used as starting material for the synthesis of a variety of di-
hetero-metallic complexes. Following on from the first half of this chapter, where-by a tri-
hetero-metallic complex inclusive of Au(I)2-Re(I) displayed suitability as both an imaging 
and/or therapeutic agent, all three mono-metallic complexes show promising potential. 
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6.10. Experimental 
6.10.1. Crystallography 
[Re(CO)3(L
1
)Br] C13H6Br3N2O3Re, M = 664.13, 0.2 ×  0.2 ×  0.2 mm
3
, monoclinic, space 
group P21/m (No. 11), a = 6.4833(4), b = 14.3775(10), c = 9.0151(5) Å,  = 105.961(4)°, V 
= 807.93(9) Å
3
, Z = 2, Dc = 2.730 g/cm
3
, F000 T = 
150(2)K, 2 max = 55.1º, 3204 reflections collected, 1915 unique (Rint = 0.0415).  Final GooF 
= 1.050, R1 = 0.0456, wR2 = 0.1117, R indices based on 1701 reflections with I >2(I) 
(refinement on F
2
), 107 parameters, 0 restraints.  Lp and absorption corrections applied,  = 
14.949 mm
-1
. 
[Re(CO)3(L
2
)Br] C23H24BrN2O3ReSi2, M = 698.73,  0.2 ×  0.2 ×  0.2 mm
3
, monoclinic, space 
group P21/a (No. 14), a = 13.5076(4), b = 13.9248(4), c = 14.3606(3) Å, b = 107.145(2)°, V = 
2581.06(12) Å
3
, Z = 4, Dc = 1.798 g/cm
3
, F000 = 1352, MoKa radiation, l = 0.71073 Å,  T = 
150(2)K, 2qmax = 56.6º, 22858 reflections collected, 6356 unique (Rint = 0.1201).  Final GooF 
= 1.204, R1 = 0.0959, wR2 = 0.1500, R indices based on 4903 reflections with I >2sigma(I) 
(refinement on F
2
), 295 parameters, 0 restraints.  Lp and absorption corrections applied, m = 
6.375 mm
-1
. 
6.10.2. Synthesis of the ligands 
L
1 
To a solution of 2,6 dibromopyridine (2 g, 8.44 mmol) in anhydrous ether (45 mL) at -78 
˚C was added BuLi (5.28 mL, 8.44 mmol) and the solution left to stir for 2 h.  Zinc chloride 
(9.3 mL, 9.3 mmol) was then added followed by the addition of dry 2,6 dibromo pyridine (2 
g, 8.44 mmol) and the palladium tetrakis catalyst (0.94 g, 10 %) 20 minutes later. The 
solution was allowed to reach room temperature and left for an additional 15 h. H2O (50 mL) 
was added to the solution and product extracted into DCM. The organic layer was dried and 
the solvent evaporated to dryness, yielding a white solid. Yield: 2.22 g, 42 %. 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 7.42 (2H, d, 
3
JHH =7.7 Hz, (H1)), 7.61 (2H, t, 
3
JHH  =7.8 Hz 
(H2)),  8.32 (2H, d, 
3
JHH  =7.6 Hz (H3)) ppm.    
L
2 
To a solution of L
1 
(0.6 g, 1.92 mmol) in diisopropylamine and THF (10 mL) under N2(g) 
was added CuI (10 mg), Pd(OAc)2 (10 mg) and PPh3 (30 mg) and stirred at 50 ˚C for 20 
minutes. To the resulting solution was added trimethylsilylethylene (0.824 g, 8.4 mmol) and 
the reaction left at 25 ˚C for 20 h. The solution was cooled, filtered and filtrate evaporated to 
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dryness, yielding a white solid. Yield: 126 mg, 19 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 
0.28 (18H, s, (H4)), 7.42 (2H, d, (H3)), 7.82 (2H, t, (H2)), 8.43 (2H, d, (H1)) ppm.  
L
3 
L
2
 (110 mg, 0.316 mmol) and KF (40 mg, 0.695 mmol) in MeOH (20 mL) were stirred at 
RT for 2 h. The resulting solution was filtered through a plug of silica and filtrate evaporated 
to dryness, yielding a cream solid. Yield: 62 mg, 58 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) 
δH: 3.22 (2H, s, (H4)), 7.57 (2H, d, (H3)),  7.88 (2H, t, (H2)), 7.53  (2H, d, (H1)) ppm.    
L
6 
5-COOH-2,2 bipyridine chloride (200 mg, 1 mmol) was added to a solution of TEA (0.281 
mL, 2 mmol) and propargyl alcohol (62 mg, 1.1 mmol) in chloroform (30 mL) and stirred for 
3 hours 60 ˚C. Aqueous work up followed by the organic solvent being evaporated to dryness, 
yielding a cream solid. Yield: 162 mg, 83 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 2.53 
(1H, t,
 3
JHH = 2.4 Hz, (H9)), 4.91 (2H, d,
 3
JHH = 2.4 Hz (H8)), 7.25-7.44 (1H, m, (H3)), 7.72-
7.86 (1H, m,
 
(H5)), 8.33-8.51 (3H, m, (H2, H4, H6)), 8.61 (1H, d, 
3
JHH = 4.7 Hz, (H1)), 9.21 
(1H, s, (H7)) ppm.
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 52.8, 76.7, 120.6, 122, 124.7, 
125, 137.2, 138.3, 149.5, 150.8, 155, 160 ppm. MS (ES
+
) m/z: 238.07 [M]
+
. IR (nujol) 1727 
(CO), 2122 (CO) cm
-1
.UV-vis (ε / M-1 cm-1) (MeCN) λmax: 251 (555), 293 (992) nm.   
L
7 
5-COOH-2,2 bipyridine chloride (200 mg, 1 mmol) was added to a solution of TEA (0.281 
mL, 2 mmol) and N-methyl propargyl amine (76 mg, 1.1 mmol) in chloroform (30 mL) and 
stirred for 3 hours 60 ˚C. Aqueous work up followed by the organic solvent being evaporated 
to dryness, yielding a cream solid. Yield: 210 mg, 84 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) 
δH: 2.22-2.31 (1H, m, (H10a)), 2.32-2.42 (1H, m, (H10b)), 3.02-3.23 (6H, m,
 
(H8a, H8b)), 
3.91-4.04 (2H, m, (H9a)), 4.33-4.42 (2H, m,
 
(H9b)), 7.42-7.34 (2H, m, (H3a, H3b)), 7.72-
7.80 (2H, m, (H5a, H5)), 7.82-7.98, 2H, m, (H6a, H6b)), 8.32-8.43 (4H, m, (H2a, H2b, H4a. 
H4b)), 8.61-8.64 (2H, m, (H1a,H1b)), 8.67-8.78 (2H, m,
 
(H7a, H7b)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δC: 29.7, 336.8, 77.7, 120.7, 121.5, 124.4, 131, 136.2, 137.1, 
147.8, 149.4, 155.2,157.4, 168.9 ppm. MS (ES
+
) m/z: 251.1 [M]
+
.
 
IR (nujol) 1588.57 (CO), 
1633.89 (CO), 2117.94 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 213 (1840), 253 
(2678), 305 (698) nm.   
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6.10.3. Synthesis of the complexes 
fac-[Re(CO)3(L
1
)Br] Re(CO)5Br (48 mg, 0.12 mmol) and L
1 
(41 mg, 0.132 mmol) were 
heated at 70 ˚C in toluene (5 mL) for 12 h. The resultant precipitate was filtered, washed with 
toluene and dried in vacuo to yield an orange solid. The crude product was purified using 
column chromatography eluting with DCM. Yield: 58 mg, 73 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 7.88-7.99 (2H, m, (H2, H3)), 8.29 (1H, d, (H1)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 
MHz, 298 K) δC: 123.2, 131.1, 140.9, 146.4, 158.8, 161.6 ppm. MS (ES
+
) m/z: 666.76 [M]
+
, 
HRMS (ES) found m/z 686.6081 [M+H]
+
; [
185
ReNaC13H6O3N2Br3]
+  
requires 686.7341. IR 
(nujol) υ: 1892 (CO), 1995 (CO), 2022 (CO) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 258 
(8248), 324 (7757), 397 (1380) nm.  
fac-[Re(CO)3(L
2
)Br] Re(CO)5Br (160 mg, 0.4 mmol) and L
2 
(150 mg, 0.43 mml) were 
heated at 70 ˚C in toluene (5 mL) for 12 h. The resultant precipitate was filtered, washed with 
toluene and dried in vacuo to yield an orange solid. The crude product was purified using 
column chromatography eluting with DCM. Yield: 75 mg, 30 %. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δH: 1.19 (18H, s, (H4)), 7.51 (2H, d, (H3)), 7.72 (2H, t, (H2)), 7.93 (2H, d, (H1)) ppm. 
13
C NMR ((CDCl3) 300 MHz, 298K) δc: 30.13, 122.5, 130, 130.4, 138.5, 159.2 ppm. MS 
(ES
+
) (%) m/z: 734.99 [M+Cl
-
]
+
. HRMS (ES) found m/z 619.0886 [M-Br]
+
; 
[ReC23H24O3N2Si1]
+  
requires 619.0876. IR (nujol) υ: 1923 (CO), 2022 (CO) cm-1. UV-vis (ε / 
M
-1 
cm
-1
) (MeCN) λmax: 253 (1450), 280 (914), 335 (709) nm.  
fac-{Re(CO)3{[Au(PPh3)]2L
3
}Br} Re(CO)5Br (11 mg, 0.026 mmol) and [[AuPPh3]2L
3
]
 
(30 
mg, 0.0267 mmol) were heated at 70 ˚C in toluene (5 mL) for 12 h. The resultant precipitate 
was filtered, washed with toluene and dried in vacuo to yield a dark orange solid. Yield: 24 
mg, 62 %. 
1
H NMR (CDCl3, 400 MHz, 298 K) δH: 7.29-7.68 (36H, m, (H1-H4)) ppm. 
13
C{
1
H} NMR (CDCl3, 101 MHz, 298 K) δC: 77.2, 129.2, 129.4, 132, 134.1, 134.9 ppm. δ
31
P 
35.9 ppm. MS (ES
+
) m/z: 721.15 [Au(PPh3)2]
+
. IR (nujol) υ: 1908 (CO), 1995 (CO), 2034 
(CO), 2151 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax: 268 (11149), 309 (6351), 375 
(3038) nm. 
fac-[Re(CO)3(L
6
)Br]: Re(CO)5Br (75 mg, 0.185 mmol) L
4 
(48 mg, 0.203 mmol) were heated 
at 70 ˚C in toluene (5 mL) for 12 h. The resultant precipitate was filtered, washed with 
toluene and dried in vacuo to yield a dark orange solid. Yield: 27 mg, 25 %.  
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 2.59 (1H, t,
 3
JHH = 2.4 Hz, (H9)), 4.91 (2H, d,
 3
JHH = 2.4 Hz 
(H8)), 7.49-7.58 (1H, m, (H3)), 7.96-8.04 (1H, m, (H5)), 8.20-8.32 (2H, m, (H4, H6)), 8.49-
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8.54 (1H, m,
 
(H2)), 8.99 (1H, d, 
3
JHH = 4.5 Hz, (H1)), 9.51 (1H, s, (H7)) ppm. 
13
C{
1
H} NMR 
(CDCl3, 101 MHz, 298 K) δC: 53.9, 76.4, 122.5, 124.6, 128.1, 128.2, 139.3, 140, 153.7, 
154.4, 159, 177.6 ppm. MS (ES
+
) m/z: 550 [M-C3H2]
+ 
, 587.93 [M]
+
. IR (nujol) υ: 1735 (CO), 
1900 (CO), 2022 (CO), 2152 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) λmax:  218 (42428), 
252.5 (18382.3), 298 (14645)) nm.  
fac-[Re(CO)3(L
7
)Br]: Re(CO)5Br (80 mg, 0.197 mmol) L
5 
(54 mg, 0.217 mmol) were heated 
at 70 ˚C in toluene (5 mL) for 12 h. The resultant precipitate was filtered, washed with 
toluene and dried in vacuo to yield a dark orange solid. Yield: 24 mg, 20 %.  
1
H NMR 
(CDCl3, 400 MHz, 298 K) δH: 2.31 (1H, d, (H10a)), 2.42 (1H, d, (H10b)), 3.08-3.23 (6H, m,
 
(H8a,Hb)), 3.88-3.94 (2H, m, (H9a)), 4.2-4.44 (2H, m, (H9b)), 7.48-7.51 (2H, m, (H4a, 
H4b)), 7.96-7.81 (2H, m, (H5a, H5b)), 8.11-8.22 (6H, m, (H3a,H3b, H5a,H5b, H7a, H7b)), 
8.98-9.02 (3H, m, (H2a, H2b, H1a), 9.12 (1H, m, (H1a)) ppm. 
13
C{
1
H} NMR (MeOD, 101 
MHz, 298 K) δC: 27.8, 31.8, 35.1, 76.2, 114.5, 121.2, 122, 125.7, 136.1, 137.3, 149.7,151.4, 
151.6, 153, 154.7, 163.7, 186.4, 194.7 ppm. MS (ES
+
) m/z: 564.08 [M-C3H2]
+
. IR (nujol) υ: 
1664.5 (CO), 1902.43 (CO), 2023.44 (CO), 2105.4 (CC) cm
-1
. UV-vis (ε / M-1 cm-1) (MeCN) 
λmax:  297 (13527), 379.5 (23034) nm. 
 [Ir(PPy)2(L
6
)]: [Ir(PPy)2Cl]2 (50 mg, 0.063 mmol) and L
4 
(30 mg,0.12 mmol) were heated at 
110 ˚C in methoxy ethanol (5 mL). The resultant solution was dried in vacuo, re-dissolved in 
acetonitrile (10 mL) and a spatula of NaPF6 added. The resultant precipitate was filtered and 
filtrate dried in vacuo to yield an orange solid. Yield 21 mg, 23 %.
 1
H NMR (CDCl3, 400 
MHz, 298 K) δH: 2.49 (1H, t,
 3
JHH = 2.4 Hz, (H9)), 4.71 (2H, d,
 3
JHH = 2.4 Hz (H8)), 6.18-6.28 
(2H, m, (H15)), 6.81-7.02 (6H, m, (H3, H4, H12, H16)), 7.32-7.43 (3H, m, (H6, H14)), 7.56-
7.75 (4H, m,
 
(H13, H17)), 7.8-7.88 (3H, m, (H2, H11)), 8.18-8.27 (1H, m, (H6)), 8.49 (1H, s, 
(H1)),  8.62-8.74 (1H, m, (H7)), 9.61-9.82 (2H, m, (H10)) ppm. MS (ES
+
) m/z: 739.17 [M]
+
, 
IR (nujol) υ: 1734 (CO), 2124 (CC) cm-1. UV-vis (ε / M-1 cm-1) (MeCN) λmax:  258.5 (21015), 
280.5 (18382.3), 316 (9349), 375.5 (2706) nm. 
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